{
  "paragraphs": [
    {
      "title": "Import Clinical Trials (Rawdata)",
      "text": "%pyspark\n\nrawdata \u003d sc.textFile(\"/clinicaltrials.txt\")\n\nheader  \u003d rawdata.take(1)\n\nprint \"\\r\\n\" + \"#\"*150\nprint \"\\r\\nTotal Number of Clinical Trials: \" + str(rawdata.count())\nprint \"Number of variables in dataset:  \" + str(len(header[0].split(\"|\")))\nprint header\nprint \"\\r\\n\" + \"#\"*150\n",
      "dateUpdated": "Dec 4, 2016 7:14:42 PM",
      "config": {
        "colWidth": 12.0,
        "graph": {
          "mode": "table",
          "height": 300.0,
          "optionOpen": false,
          "keys": [],
          "values": [],
          "groups": [],
          "scatter": {}
        },
        "enabled": true,
        "editorMode": "ace/mode/scala",
        "title": true,
        "editorHide": false
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "jobName": "paragraph_1480857042553_620533906",
      "id": "20161204-131042_1856155362",
      "result": {
        "code": "SUCCESS",
        "type": "TEXT",
        "msg": "\r\n######################################################################################################################################################\n\r\nTotal Number of Clinical Trials: 4681\nNumber of variables in dataset:  12\n[u\u0027rank|status|study|conditions|interventions|study_type|phase|funder_type|outcome_measures|number_enrolled|nct_number|start_date\u0027]\n\r\n######################################################################################################################################################\n"
      },
      "dateCreated": "Dec 4, 2016 1:10:42 PM",
      "dateStarted": "Dec 4, 2016 6:42:29 PM",
      "dateFinished": "Dec 4, 2016 6:42:29 PM",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "title": "Format and Structure Dataframe",
      "text": "%pyspark\n\ndf \u003d rawdata.filter(lambda x: x not in header)      \\\n        .map(lambda x: x.split(\u0027|\u0027))                \\\n        .toDF(header[0].split(\"|\"))\n\ndf.registerTempTable(\"table_df\")\ndf.cache()\n",
      "dateUpdated": "Dec 4, 2016 6:43:32 PM",
      "config": {
        "colWidth": 12.0,
        "graph": {
          "mode": "table",
          "height": 300.0,
          "optionOpen": false,
          "keys": [],
          "values": [],
          "groups": [],
          "scatter": {}
        },
        "enabled": true,
        "editorMode": "ace/mode/scala",
        "title": true
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "jobName": "paragraph_1480857863474_-711789485",
      "id": "20161204-132423_1796173164",
      "result": {
        "code": "SUCCESS",
        "type": "TEXT",
        "msg": "DataFrame[rank: string, status: string, study: string, conditions: string, interventions: string, study_type: string, phase: string, funder_type: string, outcome_measures: string, number_enrolled: string, nct_number: string, start_date: string]\n"
      },
      "dateCreated": "Dec 4, 2016 1:24:23 PM",
      "dateStarted": "Dec 4, 2016 6:43:32 PM",
      "dateFinished": "Dec 4, 2016 6:43:32 PM",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "title": "Explore Raw Clinical Data",
      "text": "%sql\n\nselect * from table_df where study_type\u003d\"${study_type\u003dInterventional,Interventional|Observational|Expanded Access}\" and phase\u003d\"${phase\u003dPhase 0,Phase 0|Phase 1|Phase 2|Phase 3|Phase 4}\"",
      "dateUpdated": "Dec 4, 2016 8:44:28 PM",
      "config": {
        "colWidth": 12.0,
        "graph": {
          "mode": "table",
          "height": 300.0,
          "optionOpen": true,
          "keys": [
            {
              "name": "rank",
              "index": 0.0,
              "aggr": "sum"
            }
          ],
          "values": [
            {
              "name": "status",
              "index": 1.0,
              "aggr": "sum"
            }
          ],
          "groups": [],
          "scatter": {
            "xAxis": {
              "name": "rank",
              "index": 0.0,
              "aggr": "sum"
            },
            "yAxis": {
              "name": "status",
              "index": 1.0,
              "aggr": "sum"
            }
          }
        },
        "enabled": true,
        "editorMode": "ace/mode/sql",
        "editorHide": false,
        "title": true
      },
      "settings": {
        "params": {
          "study_type": "Interventional",
          "phase": "Phase 4",
          "study": "Diabetes",
          "": "",
          "study in \"\"": "",
          "study in": ""
        },
        "forms": {
          "phase": {
            "name": "phase",
            "defaultValue": "Phase 0",
            "options": [
              {
                "value": "Phase 0"
              },
              {
                "value": "Phase 1"
              },
              {
                "value": "Phase 2"
              },
              {
                "value": "Phase 3"
              },
              {
                "value": "Phase 4"
              }
            ],
            "hidden": false
          },
          "study_type": {
            "name": "study_type",
            "defaultValue": "Interventional",
            "options": [
              {
                "value": "Interventional"
              },
              {
                "value": "Observational"
              },
              {
                "value": "Expanded Access"
              }
            ],
            "hidden": false
          }
        }
      },
      "jobName": "paragraph_1480858046672_1684086244",
      "id": "20161204-132726_987647264",
      "result": {
        "code": "SUCCESS",
        "type": "TABLE",
        "msg": "rank\tstatus\tstudy\tconditions\tinterventions\tstudy_type\tphase\tfunder_type\toutcome_measures\tnumber_enrolled\tnct_number\tstart_date\n21\tNot yet recruiting\tComparison of PIEB vs CEI for Labor Analgesia\t\tOther:ProgrammedIntermittentEpiduralBolus;  Other:ContinuousEpiduralInfusion;  Drug:Ropivacaine;  Drug:Fentanyl\tInterventional\tPhase 4\tOther\tVolume of local anesthetic received through Patient Controlled Epidural Analgesia (PCEA) per hour-computerized information;  Total required local anesthetic required per hour- computerized information;  Time to first patient controlled epidural analgesia (PCEA) bolus- computerized information;  Laborpainscores-patientquestionnaire;  Degree of motor blockade measured as lowest recorded modified Bromage score;  Modeofdelivery;  Patient controlled epidural analgesia (PCEA) attempts-computerized information;  Patient controlled epidural analgesia (PCEA) ratio of successful attempts to unsuccessful attempts - computerized information;  Frequencyofhypotension-physiologicalparameter;  Durationoffirstandsecondstagesoflabor;  Level of patient satisfaction- patient questionnaire\t120\tNCT02949271\tNovember 2016\n23\tNot yet recruiting\tOptimal Volume Rate and Interval of Bolus Nerve Catheters for Shoulder Surgery\t\tDrug:Ropivacaine\tInterventional\tPhase 4\tOther\tOptimal Volume of Ropivacaine 0.2% bolus via interscalene catheter;  Optimal Rate of Ropivacaine 0.2% administration bolus via interscalene cathter\t99\tNCT02946268\tNovember 2016\n33\tRecruiting\tAssessment of Infection Control Practice Efficiency and Health Economics of Sheathed Versus Standard Cystoscopy\t\tDevice:EndoSheathCST-5000Scope;  Device:OlympusViseraEliteOTV-S190Scope\tInterventional\tPhase 4\tOther / Industry\tTheChangeinBacteriuria\t60\tNCT02922868\tMarch 2016\n46\tRecruiting\tComparison of 1000 Hertz (Hz) Burst and Standard Spinal Cord Stimulation in Chronic Pain Relief\t\tDevice:Spinalcordstimulator\tInterventional\tPhase 4\tOther\tNPRS;  OswestryDisabilityIndex;  PatientsGlobalImpressionofChange;  PreferabilitySurvey\t22\tNCT02902796\tSeptember 2016\n59\tRecruiting\tSpironolactone After Liver Transplant\t\tDrug:Spironolactone\tInterventional\tPhase 4\tOther\tGFR\t36\tNCT02883400\tDecember 2014\n67\tRecruiting\tAccelerated Invisalign Therapy in Conjunction With Acceledent Aura\t\tDevice:AcceleDentAura;  Device:AcceleratedInvisaligntherapy\tInterventional\tPhase 4\tOther / Industry\tRate of orthodontic tooth movement [Little\u0026apos;s Irregularity Index mm/day percent];  Activity of Bone Turnover Markers (BTMs) during Orthodontic Tooth Movement [Quantitative Polymerase Chain Reaction (qPCR) Cycle threshold values (Ct)];  Patient Discomfort [Visual Analog Scale in conjunction with Faces Pain Scale 1-10]\t30\tNCT02868554\tAugust 2016\n87\tRecruiting\tA Volumetric Analysis of Soft and Hard Tissue Healing for Ridge Preservation and Socket Seal After Tooth Extraction\t\tBiological:Xenograftbonesubstitute;  Biological:Collagendressing;  Biological:3D-collagenmatrix\tInterventional\tPhase 4\tOther / Industry\tThicknessofthebuccalplate;  Heightofthealveolarridge;  Softtissuevolume;  Bonevolume;  Woundhealingassessment\t24\tNCT02844569\tJuly 2016\n142\tRecruiting\tAnalgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery\t\tProcedure: Interscalene plus PECS \u0026quot;Pectoralis\u0026quot; 1 and 2 Blocks;  Procedure:InterscaleneplusShamBlock\tInterventional\tPhase 4\tOther\tPost-operativeAxillaryPain;  NumericalRatingScalePainScoresatrest;  NauseaorVomiting;  TotalOpioidUsage;  TimetoReturnofAxillaryPain\t40\tNCT02741713\tApril 2016\n149\tCompleted\tEfficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis\t\tDrug:InvestigationalOTCCream;  Other:CosmeticEczemaCream;  Drug:0.05%DesonideCream;  Other:PlaceboCream\tInterventional\tPhase 4\tIndustry\tSCORAD(SeverityScoringofAtopicDermatitis)\t53\tNCT02732314\tMarch 2016\n151\tNot yet recruiting\tRejuvesol\u0026#174; Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions\t\tDrug:Rejuvesol;  Procedure:Bloodtransfusion\tInterventional\tPhase 4\tOther\tPercenthemoglobin(HbA)decrement;  Actual HbA decrement (g/dl) with indexing to calculated circulating blood volume;  Actual HbA decrement (g/dl) without indexing to calculated circulating blood volume;  ChangeinRBCmicroparticles(MP)counts;  ChangeinRBC/RBC-MP-mediatedthrombingeneration;  Changeinp50pre-andpost-transfusion\t4\tNCT02731157\tMay 2016\n160\tRecruiting\tComparison of Two Gingival Displacement Procedures\t\tDevice:AquasilUltraCordlessDentsply;  Device:UltrapakUltradentcord\tInterventional\tPhase 4\tOther\tPercentage of errors in impressions made for indirect restorations;  Timerequiredtomaketheimpression;  Patientdiscomfort\t60\tNCT02716727\tOctober 2016\n171\tRecruiting\tTACE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma\t\tProcedure:TransarterialChemoembolization;  Procedure:MicrowaveAblation\tInterventional\tPhase 4\tOther\tIntrahepaticdisease-freesurvival;  Overallsurvival;  Postoperativemorbidity;  Postoperativemortality\t100\tNCT02704130\tMarch 2016\n183\tRecruiting\tPredicting Understanding and Speeding Recovery After TKA\t\tDrug:Gabapentin;  Drug:Placebo\tInterventional\tPhase 4\tOther / NIH\tChanges in daily worst-pain score after discharge from hospital\t300\tNCT02685735\tFebruary 2016\n197\tRecruiting\tInternet Surveys and Their Impact on Adherence to Brimonidine Topical Gel and QOL in Patients With Rosacea\t\tOther:internetsurvey;  Drug:brimonidinetopicalgel0.33%\tInterventional\tPhase 4\tOther\tChange from baseline Disease severity measure: Clinician Erythema Assessment (CEA) to month 6.;  Change from baseline Disease severity measure: Patient Severity Assessment (PSA) to month 6.;  Change from baseline Disease severity measures: Investigator Visual Analogue Scale (VAS) to month 6.;  Change from baseline Disease severity measure: Lesion Count (Performed by investigator) to month 6.;  Change from baseline Subjective Symptom Improvement: Quality of Life Survey to month 6.;  Subject survey to identify factors that affect adherence to rosacea treatment\t20\tNCT02659670\tJanuary 2016\n219\tRecruiting\tBilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times\t\tDrug:AminolevulinicAcid(ALA);  Device:EnvironCosmeticRoller;  Device:BLU-UIIlluminator\tInterventional\tPhase 4\tOther\tEfficacy-Percentage of treatment areas with \u0026gt;75% reduction in lesion count as compared to baseline;  Efficacy-Percentage of treatment areas with 100% cure rate as compared to baseline\t10\tNCT02622594\tOctober 2015\n232\tRecruiting\tCelestone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosyovitis\t\tDrug:Celestone;  Drug:Ketorolac\tInterventional\tPhase 4\tOther\tVisualanalogscaleofpainwithfinklesteintest;  Visual analog scale of pain with tenderness over tendon;  Visual analog scale of pain on radial side of wrist;  The Disabilities of the Arm Shoulder and Hand Score (DASH);  Veterans-Rand12(VR-12);  PinchStrength;  GripStrength\t64\tNCT02604537\tNovember 2015\n241\tActive not recruiting\tFoot and Ankle Clinic Application for Liposomal Related Anesthetic\t\tDrug:Exparel\tInterventional\tPhase 4\tOther / Industry\tAmountofNarcoticUse;  VisualAnalogScaleofpain(0-10);  Anti-emeticuse;  Patient Satisfaction Questionnaire regarding post surgical pain relief;  Complications\t36\tNCT02586077\tFebruary 2014\n261\tCompleted                  Has Results\tLazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints\t\tDrug:Lazanda\tInterventional\tPhase 4\tOther / Industry\tSafety and Tolerability as Measured by the Number of Adverse Events;  Pain Score Differences Using the DVPRS (Defense and Veterans Pain Rating Scale) Tool.;  Patient Satisfaction Using a Likert Satisfaction Survey;  AdverseEvents;  SedationLevelAssessedbyPOSSTool\t23\tNCT02571634\tMay 2015\n311\tRecruiting\tRejuvenated Washed Packed Red Blood Cells in Pediatric Cardiac Surgery\t\tDrug:Rejuvesol;  Procedure:Cardiacsurgery\tInterventional\tPhase 4\tOther\tChange in tissue oxygenation/perfusion during cardiac surgery measured by whole blood lactate concentration;  Change in ischemic organ injury during cardiac surgery measured by urinary neutrophil gelatinase associated lipocalin (NGAL);  Change in hemolysis during cardiac surgery as measured by plasma free hemoglobin levels\t15\tNCT02485366\tJune 2015\n324\tNot yet recruiting\tTolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders\t\tDrug:tolvaptan;  Other:Placebo\tInterventional\tPhase 4\tOther\tChangeinbodyweightat48hours;  Changes in congestion (patient reported and investigator assessed);  Changeinbodyweightatday8;  Clinicalcompositeofmorbidity\t40\tNCT02476409\tJuly 2015\n338\tRecruiting\tSystemic Steroids for Peripheral Nerve Blocks\t\tDrug:Dexamethasone;  Drug:Bupivacaine;  Drug:Epinephrine;  Procedure:LumbarPlexusNerveBlock;  Drug:Saline\tInterventional\tPhase 4\tOther\tDurationofSensoryBlockade;  Timetofirstanalgesicrequest;  TotalOpioidConsumption;  VerbalNumericPainScoreComparisons\t115\tNCT02464176\tJune 2015\n341\tRecruiting\tPerineural Steroids for Peripheral Nerve Blocks\t\tDrug:Dexamethasone;  Drug:Bupivacaine;  Drug:Epinephrine;  Procedure:SaphenousPeripheralNerveBlock\tInterventional\tPhase 4\tOther\tDurationofSensoryNerveBlock;  VerbalPainScores;  RateofPostOperativeNauseaandVomiting;  NeurologicComplications;  PostOperativeOpioidUseandConsumption;  Timetofirstopioidanalgesicrequest\t115\tNCT02462148\tJuly 2015\n358\tWithdrawn\tPreoperative Antibiotic Dosing for Total Knee Arthroplasty\t\tDevice:NewIntraosseous;  Drug:Cefazolin\tInterventional\tPhase 4\tOther\trateofacutesurgicalsiteinfection;  correlation of clinical comorbidities to acute infection rates;  numberofcomplications;  tourniquettime;  bloodloss\t0\tNCT02433704\tMay 2015\n360\tCompleted\tEovist vs. Dotarem Healthy Volunteer MRI\t\tDrug:gadoxetatedisodium;  Drug:gadoteratedimeglumine;  Drug:Saline\tInterventional\tPhase 4\tOther\tSubject breath hold capacity as measured by number of seconds a subject can hold his/her breath;  Subject-reported dyspnea a measured by questionnaire;  ChangesinO2saturation;  Changesinpulserate;  Presence of motion artifacts at arterial phase imaging;  Severity of motion artifacts at arterial phase imaging measured on a 1-5 scale\t48\tNCT02431598\tJune 2015\n367\tRecruiting\tEfficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries\t\tDrug:Ranolazine;  Drug:Placebo\tInterventional\tPhase 4\tOther / Industry\tCardiacMRI(CMR)strain;  Dobutaminewallmotionscoringindex(WMSI);  QualityofLife/burdenofangina;  TreadmillECGexercisedistance;  Time to ECG changes (ST depression) on exercise ECG\t30\tNCT02423265\tJune 2015\n393\tRecruiting\tCilostazol After Lower Extremity Arterial Revascularization Trial\t\tDrug:Cilostazol\tInterventional\tPhase 4\tOther\tDifference in quality of life in relation to use of cilostazol after lower extremity revascularization;  Patency of the graft/stent and re intervention rate after initial procedure\t30\tNCT02374957\tFebruary 2015\n406\tRecruiting\tPerampanel in Seizure Patients With Primary Glial Brain Tumors\t\tDrug:Perampanel\tInterventional\tPhase 4\tOther\tPercentage of patients with \u0026#8805;50% seizure reduction during the maintenance period compared with seizure frequency before initiation of perampanel;  Percentage of patients who experience a adverse event possibly probably or definitely attributable to perampanel treatment\t71\tNCT02363933\tFebruary 2015\n416\tRecruiting\tLiposomal Bupivacaine in Simultaneous Bilateral Total Knee Arthroplasty\t\tDrug:Liposomalbupivacaine\tInterventional\tPhase 4\tOther\tAdverseEvents;  Plasmabupivacainelevels\t15\tNCT02349542\tJanuary 2015\n457\tRecruiting\tIntravesicular Onabotulinumtoxin A in Interstitial Cystitis\t\tDrug:OnabotulinumtoxinA;  Procedure: injections upper aspect of trigone of urinary bladder;  Procedure: injections on posterior bladder wall excluding the trigone\tInterventional\tPhase 4\tOther / Industry\tThe primary outcome will be assessing change in a measurement of subjective patient pain using the Pelvic Pain and Urinary Urgency Frequency (PUF) questionnaire and the O\u0026apos;Leary-Sant Symptom and Problem Indexes.;  Secondary outcomes will be assessing change in patient performance in uroflowmetry.\t40\tNCT02297100\tDecember 2014\n460\tCompleted\tThoracoabdominal Arortic CTA Study\t\tDrug:Isovue\tInterventional\tPhase 4\tOther\tRadiationdose;  Noise;  Signaltonoiseratio;  Hounsfieldunitattenuationvalues;  Contrasttonoiseratio\t150\tNCT02291718\tJanuary 2014\n461\tCompleted                  Has Results\tReducing Pain of Lidocaine Injection\t\tDrug:1%Lidocaine;  Drug:1%Lidocaineplussodiumbicarbonate\tInterventional\tPhase 4\tOther\tPain\t88\tNCT02288364\tDecember 2014\n469\tCompleted\tDexamethasone and Pain Following Total Knee Arthroplasty\t\tDrug:Dexamethasone;  Other:Placebo\tInterventional\tPhase 4\tOther\tChangeinVisualanaloguepainscore;  ChangeinOpioidconsumption;  ChangeinChronicPain;  ChangeinFunctionalstatus;  ChangeinInterleukin6and10levels;  ChangeinMacrophageproliferation\t45\tNCT02271698\tDecember 2014\n476\tCompleted                  Has Results\tHigh Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System\t\tOther:Highfrequencystimulation;  Other:Lowfrequencystimulation\tInterventional\tPhase 4\tOther\tNumericPainRatingScale(NPRS);  OswestryDisabilityIndexQuestionnaire(ODI).;  Patient\u0026apos;sGlobalImpressionofChange(PGIC)\t22\tNCT02265848\tOctober 2014\n484\tRecruiting\tPerimenopausal Effects of Estradiol on Reward Responsiveness\t\tDrug:Estradiol;  Drug:Progesterone\tInterventional\tPhase 4\tOther / NIH\tChange in frontostriatal reactivity to reward during the MID fMRI task;  Change in neural connectivity measured during resting-state fMRI;  Change in response latency to reward versus non-reward during the MID fMRI task;  Change in Inventory of Depression and Anxiety Symptoms (IDAS) scores;  Change in the Positive and Negative Affect Schedule (PANAS);  Change in Mood and Anxiety Symptom Questionnaire--Anhedonic Depression subscale (MASQ-AD)\t50\tNCT02255175\tOctober 2015\n510\tRecruiting\tSurgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain\t\tDrug:Lidocaine;  Drug:LidocainewithDexamethasone\tInterventional\tPhase 4\tOther\tavoidanceofnecksurgery;  Disability;  Pain;  PatientSatisfaction\t60\tNCT02226159\tAugust 2014\n521\tCompleted\tThe Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine\t\tDrug:AcetaminophenArm;  Drug:PlaceboArm;  Drug:IbuprofenArm\tInterventional\tPhase 4\tOther / U.S. Fed\tSeroconversion;  Seroprotection;  GeometricmeanHAItiter\t104\tNCT02212990\tSeptember 2014\n536\tRecruiting\tMultimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study\t\tOther:MultimodalAnalgesiaTreatment;  Other:StandardofCarePainManagementProtocol\tInterventional\tPhase 4\tOther\tPatient reported pain level using a verbal numeric pain scale (NPS);  Patientsatisfaction;  Narcoticconsumption;  Lengthofstay;  Dischargedestination;  OswestryDisabilityIndex(ODI);  TheVeteransRand12(VR-12)\t124\tNCT02202369\tFebruary 2015\n564\tRecruiting\tComparison of Combigan BID Versus Simbrinza TID\t\tDrug:CombiganBID;  Drug:SimbrinzaTID\tInterventional\tPhase 4\tOther / Industry\tIntraOcularPressure;  Tolerability\t40\tNCT02167035\tAugust 2014\n573\tSuspended\tEffect of a Multimodal Pain Regimen on Pain Control Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients\t\tDrug:Gabapentin;  Drug:Acetaminophen;  Drug:Celecoxib;  Drug:Dexamethasone;  Drug:Oxycodone\tInterventional\tPhase 4\tOther\tPain;  NarcoticUse;  PatientSatisfaction;  Patientfunction;  FractureUnion;  Adverseevents\t160\tNCT02160301\tNovember 2017\n576\tRecruiting\tPain Expectations in Subjects With Osteoarthritis\t\tDrug:Modafinil;  Drug:Gabapentin;  Drug:Placebo\tInterventional\tPhase 4\tOther\tRestingpupildiameter\t30\tNCT02155257\tJuly 2014\n604\tRecruiting\tLNG-IUS at 2 Weeks Postpartum\t\tDrug: Levonorgestrel Intrauterine System (LNG-IUS)\tInterventional\tPhase 4\tOther\tTo report the acceptability of receiving an LNG-IUS two-weeks postpartum.;  To estimate the expulsion rate (complete or partial) at six months of LNG-IUS placed at two-weeks postpartum.;  To assess the pain experience of LNG-IUS insertion.\t50\tNCT02121067\tSeptember 2014\n606\tWithdrawn\tA Randomized Comparison of AmnioClear\u0026#8482; Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds\t\tBiological: AmnioClear\u0026#8482; Human Allograft Amniotic Membrane\tInterventional\tPhase 4\tIndustry\tReductioninWoundSize\t0\tNCT02120755\t\n643\tCompleted\tEfficacy of Belatacept in Reducing DSA\t\tDrug:Belatacept\tInterventional\tPhase 4\tOther\tReductionofDonorSpecificAntibodies(DSA);  AssessingSafety\t3\tNCT02078193\tNovember 2013\n663\tRecruiting\tIntravenous Exenatide in Patients With Acute Brain Injury\t\tDrug:Exenatide\tInterventional\tPhase 4\tOther / Industry\tFeasibility defined as the proportion of patients 1) experiencing severe hypoglycemia (\u0026lt;40 mg/dL); 2) achieving glucose measurements within goal (110-180 mg/dL); and 3) experiencing nausea requiring discontinuation of exenatide therapy;  Mean glucose concentration during exenatide infusion;  Number of glucose measurements within goal (110-180 mg/dL)/total number of glucose measurements;  Mean time to reach glucose measurements within goal (110-180 mg/dL);  Glycemic variability defined as the standard deviation of glucose;  Meaninsulinuse(units/kgbodyweight);  Proportion of subjects requiring rescue insulin infusion protocol;  Number of hypoglycemic episodes (\u0026lt;80 mg/dL)/total number of glucose measurements;  Number of subjects with \u0026gt;1 episode of hypoglycemia (\u0026lt;80 mg/dL)/total number of subjects;  Proportion of patients experiencing metabolic crisis defined as cerebral microdialysate glucose concentration \u0026lt;0.7 mmol/L in combination with lactate pyruvate ratio \u0026gt;40;  Mean daily intracranial and cerebral perfusion pressures;  Number of hypotensive episodes (SBP\u0026lt;100 mmHg)/total number of blood pressure measurements;  Proportion of patients experiencing serious adverse events;  Pharmacokinetics of exenatide infusion defined as the correlation of exenatide concentrations with creatinine clearance\t24\tNCT02058940\tAugust 2015\n670\tCompleted                  Has Results\tA Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions\t\tDrug:3%BenzoylPeroxide;  Drug:3%BenzoylPeroxidePlacebo;  Drug:NeutrogenaRapidClear\u0026#174;\tInterventional\tPhase 4\tIndustry\tTo Assess the Percentage Change in Acne Lesion Swelling (Height) of the Target Lesion for 3% Benzoyl Peroxide (BPO) Gel Test Product Relative to the Vehicle Gel After 4 Once-daily Applications.;  To Assess the Percentage Change in Acne Lesion Swelling (Height) for the 3% Benzoyl Peroxide Gel Test Product and Positive Control Relative to the Vehicle Gel.;  To Assess the Change in Acne Lesion Redness (Erythema) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.;  To Assess the Percentage Change in Acne Lesion Diameter (Size) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.;  To Assess the Change in Facial Skin Clarity for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel;  To Assess the Change in Perceptions of the Overall Appearance of Their Skin for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel\t90\tNCT02052752\tFebruary 2014\n693\tRecruiting\tTXA vs. Amicar in Total Knee and Hip Arthroplasty\t\tDrug:Amicar;  Drug:TXA\tInterventional\tPhase 4\tOther\tBloodLoss;  NumberofTransfusions;  Preoperative and lowest postoperative hematocrit and hemoglobin;  Lengthofhospitalizationstay;  CostofHospitalization\t400\tNCT02030821\tJanuary 2015\n700\tRecruiting\tPhenylephrine Versus Ephedrine in Pre-eclampsia\t\tDrug:Phenylephrine;  Drug:Ephedrine\tInterventional\tPhase 4\tOther\tCerebraltissueoxygensaturation;  Cardiacoutput\t40\tNCT02025426\tSeptember 2012\n702\tCompleted\tEfficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude\t\tDrug:Riociguat\tInterventional\tPhase 4\tOther\tChangefromBaselineinPulmonaryArteryPressure;  ChangefromBaselineinRadialArterialPressure;  Change from Baseline in Arterial Oxygen Saturation (PaO2);  ChangefromBaselineinVentilationRate;  ChangefromBaselineinWorkRateatExhaustion;  ChangefromBaselineinCardiacOutput\t28\tNCT02024386\tJanuary 2014\n720\tRecruiting\tBone Marrow Aspirate Concentrate (BMAC) Supplementation for Osteochondral Lesions\t\tProcedure: ankle arthroscopy with debridement and microfracture of the OLT;  Other:BoneMarrowAspirateinjection\tInterventional\tPhase 4\tOther\tChangeinPainAssessment;  ChangeinFunctionalAssessment;  MRIAssessment\t30\tNCT02011295\tDecember 2013\n731\tCompleted\tThe Role of Estrogen in Luteinizing Hormone Surge and Ovulation\t\tDrug:Letrozole\tInterventional\tPhase 4\tOther\tIncreaseinProgesteronelevel;  ChangeinLHlevel;  FollicularDevelopment\t10\tNCT01999569\tApril 2007\n740\tRecruiting\tMarkers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care\t\tDrug:Totalintravenousanesthesiawithpropofol;  Drug:Generalanesthesiawithisoflurane\tInterventional\tPhase 4\tOther\tAssess the correlation between perioperative change in CSF Markers of Alzheimers Disease and perioperative cognitive change.;  Continuouscognitiveindexscorechange;  AssessCSFMarkersofAlzheimersDisease;  PerioperativeCSFTau/Abetaratiochange\t140\tNCT01993836\tNovember 2013\n766\tCompleted\tThe Role of Massage in Increasing Total Motile Sperm Count of IUI\t\tBehavioral:Massage\tInterventional\tPhase 4\tOther\tTotalMotileSpermCount;  Pregnancy\t40\tNCT01969825\tDecember 2005\n767\tCompleted\tTolerability and Satisfaction With Evie\t\tDevice:EvieSlow-releaseInseminationDevice;  Other:TraditionalIntrauterineInsemination\tInterventional\tPhase 4\tOther\tPatienttolerabilityandsatisfaction;  Cramping;  PregnancyRates\t20\tNCT01969812\tJanuary 2014\n773\tActive not recruiting\tAn Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)\t\tBiological:RV5(PentavalentRotavirusVaccine)\tInterventional\tPhase 4\tOther / Industry\tG1serum-neutralizingantibody;  G2serum-neutralizingantibody;  G3serum-neutralizingantibody;  G4serum-neutralizingantibody;  P[8]serum-neutralizingantibody\t60\tNCT01960725\tFebruary 2014\n775\tCompleted\tSexual Absorption of Vaginal Progesterone\t\tDrug:Crinonevaginalprogesteronegel;  Drug:Placebovaginalgel\tInterventional\tPhase 4\tOther\tMalechangeinprogesterone;  Femalechangeinprogesterone\t20\tNCT01959464\tNovember 2008\n790\tActive not recruiting\tEffects of Ranolazine and Exercise on Daily Physical Activity Trial\t\tDrug:Ranolazine;  Behavioral:AerobicExercise;  Drug:Placebo\tInterventional\tPhase 4\tOther / Industry\tChangeinpeakoxygenconsumption;  Change in treatment satisfaction as measured by the seattle angina questionnaire;  Changeintotaldailyenergyexpenditure\t38\tNCT01948310\tDecember 2013\n793\tCompleted\tClinical Immunization Safety Assessment (CISA) Project: Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After IIV\t\tOther:Acetaminophen;  Other:Placebo\tInterventional\tPhase 4\tOther / U.S. Fed\tCompletionofstudyprocedures;  ImmuneResponsetoIIV\t41\tNCT01946594\tOctober 2013\n815\tCompleted                  Has Results\tShort-Term Effects \u0026amp; Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure\t\tDrug:Sodiumferricgluconate\tInterventional\tPhase 4\tOther\tSerumHemoglobinConcentration;  TransferrinSaturation;  SerumFerritinLevel\t13\tNCT01925703\tApril 2011\n818\tCompleted                  Has Results\tThe Effect of Anticholinergics on Cognitive Function in the Elderly\t\tDrug:TrospiumChloride;  Drug:Placebo\tInterventional\tPhase 4\tOther\tHopkinsVerbalLearningTest-Revised;  Mini-MentalStateExamination;  OveractiveBladderQuestionnaire\t59\tNCT01922115\tJune 2013\n898\tCompleted                  Has Results\tControl of Tourniquet Pain With an Axillary Ring of Subcutaneous Local Anesthetic\t\tDrug:BupivacainewithEpinephrine;  Drug:NormalSaline\tInterventional\tPhase 4\tOther\tTimeinMinutesThatTqRemainedInflated;  PainScoreatTimeofTqDeflation\t24\tNCT01829399\tApril 2013\n905\tCompleted\tDuration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis\t\tDrug:Doxycycline;  Drug:Azithromycin;  Drug:Augmentin\tInterventional\tPhase 4\tOther\tNumber of patients recommended for sinus surgery after 3 weeks of antibiotic therapy;  Number of patients recommended for sinus surgery after 6 weeks of antibiotic therapy;  Change in Quality of Life after 3 weeks of antibiotics;  Change in Quality of Life after 6 weeks of antibiotics;  Change in Nasal endoscopy scores after 3 weeks of antibiotics;  Change in Nasal Endoscopy Score following 6 weeks of antibiotics;  ChangeinCTScoreafter3weeksofantibiotics;  ChangeinCTScoreafter6weeksofantibiotics;  Number of patients with antibiotic side effects after a 3 week course of antibiotics;  Number of subjects with antibiotic side effects after a 6 week course of antibiotics\t37\tNCT01825408\tFebruary 2013\n906\tActive not recruiting\tAmniotic Membrane as an Adjunct Treatment for Hallux Rigidus\t\tProcedure: Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation;  Procedure: Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation\tInterventional\tPhase 4\tOther\tAmerican Orthopedic Foot and Ankle Society (AOFAS) score\t60\tNCT01825356\tApril 2013\n930\tCompleted\tDexamethasone for Post-cesarean Delivery Pain\t\tDrug:Dexamethasone;  Drug:Placebo\tInterventional\tPhase 4\tOther\tMorphineconsumptionat24hourspost-op;  Painscoresbetweenthegroupsat2hours.;  Time to first rescue analgesic request between the groups.;  Cumulative opioid consumption at 48 hours between the groups;  Painscoresbetweenthegroupsat24hours.;  Painscoresbetweenthegroupsat48hours.\t48\tNCT01812057\tDecember 2012\n935\tCompleted                  Has Results\tDoes Oral Micronized Progesterone Shorten Time of Symptoms From Concussion\t\tDrug:Progesterone;  Drug:Placebo\tInterventional\tPhase 4\tOther\tTime (in Days) That a Patient Reports Symptoms From Their Concussion.\t25\tNCT01809639\tJune 2013\n954\tTerminated                  Has Results\tA Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women\t\tDrug:Placebo;  Drug:Escitalopram\tInterventional\tPhase 4\tOther\tReductioninDepressiveSymptoms\t5\tNCT01797380\tJanuary 2008\n983\tCompleted                  Has Results\tOpen-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)\t\tDrug:Open-labelflexiblydosedmilnacipran\tInterventional\tPhase 4\tOther\tChangeinPainVisualAnalogueScale(VAS).;  ChangeinKneeSocietyScore(KSS).;  GlobalRatingofChange;  Change in Total Score of Multidimensional Fatigue Inventory (MFI-20);  ChangeintheBeckDepressionInventory(BDI-II);  Change in the Montgomery Asberg Depression Rating Scale;  Change in Total Score of State Trait Anxiety Inventory (STAI);  Change in Total Score of Short Form-36 (SF-36) Measuring Perceived Quality of Life\t5\tNCT01780389\tOctober 2010\n995\tCompleted\tImmediate vs. Delayed Postpartum Etonogestrel Implant\t\tDrug:Etonogestrelimplant\tInterventional\tPhase 4\tOther\tContinuationrate;  Rateofintercourse;  ContinuationRate\t60\tNCT01767285\tJanuary 2013\n1040\tCompleted\tRanolazine for the Treatment of Chest Pain in HCM Patients\t\tDrug:Ranolazine\tInterventional\tPhase 4\tOther / Industry\tSafetyofRanolazinewithregardtoQTinterval;  Safety of Ranolazine with regard to adverse events;  Safety of Ranolazine with regard to drug tolerability;  Improvement in number of episodes of angina per week;  Improvementindyspnea;  Improvementinqualityoflife\t14\tNCT01721967\tNovember 2012\n1061\tCompleted                  Has Results\tTime of Intravenous Acetaminophen Administration\t\tDrug:Acetaminophen\tInterventional\tPhase 4\tOther\tChangesinPostoperativePainScores;  PainMedicationConsumptionRates\t126\tNCT01699815\tOctober 2012\n1062\tRecruiting\tReverse Shoulder Arthroplasty With or Without Concomitant Latissimus and Teres Major Transfer for Shoulder Pseudoparalysis With Teres Minor Dysfunction\t\tProcedure:Transfergroup;  Procedure:Controlgroup\tInterventional\tPhase 4\tOther\tADLERScore;  DASHScore;  ASESscore;  SF-12Score;  RangeofMotion;  X-RayMeasurements\t42\tNCT01697865\tOctober 2012\n1086\tUnknown\u0026nbsp;\u0026#8224;\tPostpartum Etonogestrel Implant for Adolescents\t\tDrug:Contraceptiveimplant\tInterventional\tPhase 4\tOther\tContinuationat1year;  Satisfaction;  Rapidrepeatpregnancy\t96\tNCT01666912\tAugust 2012\n1100\tCompleted\tStudy of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics\t\tDrug:Liraglutide;  Drug:Insulin\tInterventional\tPhase 4\tOther\tChangefrombaselineinHbA1catsixmonths;  Hypoglycemia;  TotalDailyInsulinDose(TDID);  Weight;  GlycoMark\t36\tNCT01654120\tDecember 2011\n1107\tCompleted                  Has Results\tReinfusion Drains vs Tranexamic Acid in Total Joint Arthroplasty\t\tProcedure:Hemovacdrain;  Procedure:Re-infusiondrain;  Procedure:Tranexamicdrain\tInterventional\tPhase 4\tOther\tBloodTransfusion;  ChangeinHemoglobinLevel\t204\tNCT01636414\tMay 2012\n1127\tUnknown\u0026nbsp;\u0026#8224;\tManagement of Chronic Pain in Military Patients With Injuries Sustained During Active Duty\t\tDevice:Spinalcordstimulator\tInterventional\tPhase 4\tOther / Industry\tChangeinpainscore;  changeinrelatedpain;  changeinmeandailypainscore;  changeinmeanpainpertreatmentgroup;  changeinMPQpertreatmentgroup;  changeinspinerelatedpain;  changeinneuropathicpain;  analgesicefficacy;  painreliefusingacategoricalscale;  changeinmood;  changeinemotionalstatus;  changeinanxiety;  changeinqualityoflife;  effectivenessofintervention;  Functionaleffectivenessofintervention;  Functional effectiveness of interventions via activity scores;  changeinsleep;  urinedrugtests;  Effectofdemographiccharacteristics;  predictive value of the change in NPRS average pain scores;  Analgesicbenefit;  Safety and tolerability of analgesic interventions;  Tolerabilityofanalgesicinterventions\t180\tNCT01616342\tDecember 2011\n1137\tUnknown\u0026nbsp;\u0026#8224;\tCombinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding\t\tDrug:Liraglutide;  Drug:Orlistat;  Drug:Liraglutide+Orlistat\tInterventional\tPhase 4\tOther\tType2diabetesremission;  Wholebodyinsulinsensitivity;  GLP-1response;  FirstPhaseInsulinsecretion\t9\tNCT01597531\tJune 2012\n1145\tActive not recruiting\tPalliative Care in Heart Failure\t\tBehavioral: Usual heart failure care + interdisciplinary palliative care\tInterventional\tPhase 4\tOther / NIH\tIs there an impact on quality of life with the addition of a palliative care intervention?;  Is there an impact on depression and anxiety with the addition of a palliative care intervention?;  Is there an impact on caregiver satisfaction and perception of subject quality of life with the addition of a palliative care intervention?;  Is there an impact on spiritual well-being with the addition of a palliative care intervention?;  Is there an impact on cost and resource utilization with the addition of a palliative care intervention?\t200\tNCT01589601\tAugust 2012\n1167\tCompleted                  Has Results\tPostpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding\t\tDrug: Levonorgestrel-releasing intrauterine system\tInterventional\tPhase 4\tOther\tBreastfeeding;  LNG-IUSExpulsionorRemoval\t61\tNCT01555931\tMarch 2012\n1172\tCompleted                  Has Results\tOnce-Daily Asenapine for Schizophrenia\t\tDrug:Asenapine10mgdailyintheevening;  Drug:Asenapine5mgtwicedaily\tInterventional\tPhase 4\tOther / Industry\tPatientAcceptance;  Change in Brief Psychiatric Rating Scale (BPRS) Total Score\t30\tNCT01549041\tApril 2012\n1177\tCompleted                  Has Results\tImmediate Postplacental Insertion of IUDs at Time of Cesarean Delivery: A Randomized Clinical Trial\t\tDevice: Immediate Postplacental Placement of an IUD during cesarean delivery\tInterventional\tPhase 4\tOther\tIUDUse;  IUDExpulsion;  Women\u0026apos;sSatisfactionWithIUDs\t112\tNCT01539759\tMarch 2012\n1196\tTerminated\tA Prospective Randomized Study Evaluating the Effect of Biliary Stenting on EAU-FNA in Patients With Suspected Malignant Biliary Obstruction\t\tProcedure: EUS-FNA first followed by CRCP with bilinary stenting;  Procedure: ERCP with stent placement followed by EUS-FNA\tInterventional\tPhase 4\tOther\tCytological yield (adequate versus inadequate for diagnosis) of EUS-FNA prior to stent placement vs post stent placement\t8\tNCT01514058\tNovember 2011\n1245\tCompleted                  Has Results\tSuppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)\t\tDrug:Nitrofurantoin;  Drug:Placebo\tInterventional\tPhase 4\tOther\tUrinaryTractInfections;  OtherRiskFactorsforUTI\t163\tNCT01450800\tAugust 2011\n1246\tCompleted                  Has Results\tThe Use of the Prevena\u0026#8482; Incision Management System on Post-Surgical Cesarean Section Incisions\t\tDevice: Prevena\u0026#8482; Incision Management System (PIMS);  Device:Standard-of-careDressing\tInterventional\tPhase 4\tIndustry\tIncidence of Postoperative Surgical Site Occurrences (SSOs) up to Day 42 (+/- 10 Days) Post Cesarean Section Surgery.;  Incidence Rate of Surgical Incision Intervention (SII) up to Day 42 (+/- 10 Days) Post Cesarean Section Surgery.\t92\tNCT01450631\tFebruary 2012\n1247\tTerminated                  Has Results\tRight Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventricular Assist Device (LVAD)\t\tDevice: Implantable Cardioverter-Defibrillator (subject\u0026apos;s pre-existing ICD)\tInterventional\tPhase 4\tOther / Industry\tLengthofHospitalization;  Post-operative Need for Hemodynamic / Respiratory Support;  RightVentricularFunction;  FunctionalCapacityandSymptoms\t3\tNCT01446796\tSeptember 2011\n1276\tUnknown\u0026nbsp;\u0026#8224;\tComparison of Meal Replacements Versus Protein Supplements and Utilizing the Protein Digestibility Corrected Amino Acid Score (PDCAAS) Method\t\tDietarySupplement:Group1MealReplacement;  DietarySupplement:Group2ProteinSupplement;  DietarySupplement:Group3\tInterventional\tPhase 4\tOther\tProteinAbsorption;  PatientCompliancewithProteinSupplement;  Patient tolerability and satisfaction of protein supplement\t60\tNCT01399333\tJanuary 2010\n1288\tCompleted\tAnkle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures\t\tProcedure:electiveforefootsurgery\tInterventional\tPhase 4\tOther\tConversion to general anesthesia following either a single shot popliteal fossa block or ankle block;  VisualAnalogPainScale(VAS);  PatientSatisfaction;  LengthofPostAnesthesiaCareUnit(PACU)stay;  NarcoticUse\t202\tNCT01376960\tJune 2011\n1289\tCompleted\tAnatomic Reconstruction of the Patellofemoral Joint\t\tProcedure: Measured Resection of patellofemoral joint;  Procedure:Measuredresectionofpatella\tInterventional\tPhase 4\tOther\tAnteriorkneePain;  Knee Injury and Osteoarthritis Outcome Score (KOOS);  RangeofMotionofknee\t52\tNCT01375231\tJune 2011\n1290\tCompleted\tEfficacy and Satisfaction Comparing Two Braces in the Treatment of Developmental Dysplasia of the Hip (DDH) in Infants\t\tOther:PavlikBrace;  Other:PlastizoteBrace\tInterventional\tPhase 4\tOther\tResolutionofinstability\t30\tNCT01375218\tJune 2011\n1314\tCompleted\tPilot Study of Using Copeptin to Predict Response to Tolvaptan\t\tDrug:tolvaptan\tInterventional\tPhase 4\tOther / Industry\tUrineoutput;  Bodyweight\t21\tNCT01346072\tApril 2011\n1327\tWithdrawn\tDaily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis\t\tDrug:tadalafil\tInterventional\tPhase 4\tOther / Industry\timprovement in Gastric Emptying Study residual tracer amount\t0\tNCT01326117\tApril 2011\n1341\tCompleted                  Has Results\tTissueLink Study During Multi-Level Spine Surgery\t\tDevice:Tissuelinkdevice\tInterventional\tPhase 4\tOther / Industry\tHemoglobinMeasurementg/dl\t60\tNCT01300559\tApril 2006\n1342\tCompleted                  Has Results\tOpen Label Use Of RiaStap During Aortic Reconstruction\t\tDrug:RiaSTAP\tInterventional\tPhase 4\tOther / Industry\tFibrinogenLevelChange;  PackedRedBloodCellTransfusion;  FreshFrozenPlasmaTransfusion;  PlateletTransfusion;  CryoprecipitateTransfusion\t23\tNCT01300286\tDecember 2010\n1343\tActive not recruiting\tLong-Acting Reversible Contraception\t\tDrug:DMPA;  Drug:oralcontraceptives;  Drug:Implanon\u0026#174;;  Drug:ParaGard\u0026#174;;  Drug:Mirena\u0026#174;\tInterventional\tPhase 4\tOther\tContraceptivemethoddiscontinuation;  Unintendedpregnancy;  ParticipantattitudestoLARCvsSARC\t916\tNCT01299116\tDecember 2011\n1368\tCompleted\tA PK/PD Study of Fospropofol Disodium Compared With Propofol Injectable Emulsion\t\tDrug:Fospropofoldisodiumpropofol\tInterventional\tPhase 4\tIndustry\t\u0026#8226; The primary objective of the study is to characterize the PK and PD properties of 3 dose levels of fospropofol disodium in comparison with 3 estimated equivalent dose levels of propofol\t36\tNCT01260142\tNovember 2010\n1408\tCompleted\tInuniv and Working Memory\t\tDrug:extendedreleaseguanfacine\tInterventional\tPhase 4\tOther / Industry\tCentralNervousSystem-VitalSigns(CNS-VS);  Wide Range Assessment of Memory and Learning(WRAML)\t18\tNCT01177306\tJuly 2010\n1432\tCompleted\tCan E-cadherin Found in Tissue/Blood be Valuable in Identifying \u0026amp; Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn\t\tDrug:Dexlansoprazole\tInterventional\tPhase 4\tOther\tDexlansoprazole\t40\tNCT01149395\tJune 2010\n1501\tWithdrawn\tMilk-only Lactation Study for Patients on Eltrombopag\t\tDrug:eltrombopag\tInterventional\tPhase 4\tIndustry\tBreast milk eltrombopag concentrations collected from nursing mothers taking eltrombopag;  AEs in infant reported during the 24 hour breast milk collection period;  Plasma eltrombopag concentrations from infant as data permit (optional)\t0\tNCT01055600\tMarch 2013\n1511\tCompleted                  Has Results\tA Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis\t\tDrug:FluocinonideCream0.1%\tInterventional\tPhase 4\tOther / Industry\tChange in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 2/3.;  Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 14.\t20\tNCT01049243\tMarch 2009\n1513\tCompleted                  Has Results\tAdherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris\t\tDrug: clindamycin phosphate 1.2% and tretinoin 0.025%;  Drug:clindamycin1%gel;  Drug:tretinoin0.025%cream\tInterventional\tPhase 4\tOther / Industry\tMeasured Adherence to ZIANA Gel or Generic Topical Clindamycin 1% Gel Each Morning Plus Generic Topical Tretinoin 0.025% Cream Each Evening in Subjects With Mild to Moderate Acne;  The Change (Dynamic Assessment) From Baseline to Week 12 (or End of Treatment) in Total Acne Lesion Count\t26\tNCT01047189\tMarch 2009\n1514\tUnknown\u0026nbsp;\u0026#8224;\tPilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery\t\tDrug:Lovazagroup\tInterventional\tPhase 4\tOther / Industry\tSpecific Aim 1: To determine if Lovaza treatment reduces markers of inflammation and improves mitochondrial function in atrial myocardium;  Specific Aim 2: To determine if Lovaza treatment alters the biophysical and biochemical organization of cardiac mitochondrial membranes. The following questions will be addressed using the blood and cardiac tissue samples collected as described above:\t24\tNCT01046604\tJanuary 2010\n1515\tCompleted                  Has Results\tReducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)\t\tDrug:MyforticEscalation\tInterventional\tPhase 4\tOther / Industry\tPercent Change in Mean Fluorescence Index (MFI) of Donor Specific Antibodies (DSA) With Increasing Doses of Enteric-Coated Mycophenolate Sodium (EC-MPS);  To Assess the Rate of Rejection Infection and Renal Function as Mycophenolic Acid Dose is Increased.\t32\tNCT01044303\tJanuary 2010\n1526\tTerminated                  Has Results\tMemantine and Postoperative Pain\t\tDrug:Memantine;  Drug:Placebo\tInterventional\tPhase 4\tOther\t24hrOpioidConsumption;  PainScores;  OpioidRelatedSideEffects;  OpioidRelatedSideEffects:Pruritus;  Hyperalgesia;  PatientSatisfaction;  ChronicPost-surgicalPain\t77\tNCT01032759\tDecember 2009\n1548\tTerminated                  Has Results\tVyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity\t\tDrug:Lis-dexamphetamine\tInterventional\tPhase 4\tOther / Industry\tPre and Post Study Fasting Blood Sugar and Two Hour Post Prandial.\t14\tNCT01017263\tDecember 2009\n1550\tTerminated                  Has Results\tDexmedetomidine Sedation With Third Molar Surgery\t\tDrug:Dexmedetomidine;  Drug:Midazolam;  Drug:Ketamine\tInterventional\tPhase 4\tOther\tAmnesia: Lack of Picture Recall Shown Prior to Sedation.;  Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown Prior to Sedation.;  Amnesia: Lack of Picture Recall Following Dexmedetomidine Infusion Plus Midazolam.;  Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown Following Dexmedetomidine Infusion Plus Midazolam.;  Amnesia: Lack of Picture Recall Shown 15 Minutes Into Surgery;  Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown 15 Minutes Into Surgery.;  Amnesia: Lack of Picture Recall Shown 30 Minutes Into Surgery;  Primary Title: Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown 30 Minutes Into Surgery.;  Amnesia: Lack of Picture Recall at Surgery End Time.;  Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown at Surgery End Time.;  RespiratoryParameters:RespiratoryRate;  RespiratoryParameters:OxyhemoglobinSaturation;  RespiratoryParameters:End-tidalCarbonDioxide;  MeanArterialBloodPressure;  HeartRate;  SurgeonSatisfactionWithSedationTechnique;  PatientSatisfactionWithSedationTechnique;  RamseySedationScaleScore;  BispectralIndexScore(BIS)\t18\tNCT01017237\tJuly 2009\n1551\tTerminated                  Has Results\tModerate to Persistent Asthma in the Obese Subject\t\tDrug:Montelukast;  Other:Sugarpill\tInterventional\tPhase 4\tOther\tDetermine the Effect of Montelukast / Moderate Dose ICS Versus High Dose ICS on Asthma Control as Measured by the Asthma Control Questionnaire.;  Serum Adiponectin Leptin Tumor Necrosis Alpha (TNF-\u0026#945;) and Interleukin 6 (IL6) Levels;  Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1);  Change in Trends in Asthma Control Questionnaire (ACQ ACTQ) Scores Over Duration of the Study;  AsthmaExacerbation;  SputumCellCountsandDifferentials\t38\tNCT01016847\tJanuary 2010\n1560\tTerminated\tDysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen\t\tDrug:Baclofen;  Drug:PlaceboComparator:Placebo\tInterventional\tPhase 4\tOther\tEfficacy of baclofen vs. placebo on dysfunctional voiding as measured with uroflometry and EMG; patients\u0026apos; symptoms score questionnaires and diaries.;  Efficacy of baclofen vs. placebo on the external anal sphincter muscle dysfunction via patient symptoms and questionnaire.;  The safety of baclofen in patients with dysfunctional voiding (urinary and defecatory).\t12\tNCT01003249\tSeptember 2009\n1569\tCompleted\tA Pilot Study of Early Postpartum Intrauterine Contraception\t\tDevice:MirenaIntrauterineContraceptiveSystem\tInterventional\tPhase 4\tOther\tIUDexpulsion;  Feasibilityofenrollment\t40\tNCT00997932\tJune 2009\n1578\tCompleted\tEffects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction\t\tDrug:aliskiren;  Drug:placebo\tInterventional\tPhase 4\tOther / Industry\tThe primary objective of this study is to determine whether treatment with aliskiren (300 mg) compared to placebo will improve treadmill exercise time in older (age \u0026#8805; 55 years) patients with heart failure and normal ejection fraction (HFNEF).;  Determine whether aliskiren (300mg) compared to placebo will improve other measures of exercise performance including peak exercise oxygen consumption (VO2peak) ventilatory anaerobic threshold (VAT) and 6-minute walk distance.;  Determine whether treatment with aliskiren (300 mg) compared to placebo will improve left ventricular diastolic function assessed via tissue Doppler imaging (early diastolic mitral annular velocity);  Evaluate the safety and tolerability of aliskiren in older patients with HFNEF\t52\tNCT00982033\tJuly 2009\n1609\tTerminated                  Has Results\tMotorized Continuous Cold Therapy Versus Standard Post-op Icing Protocol for Two Foot and Ankle Procedures\t\tDevice:Iceman\u0026#174;ColdTherapyunit(djOrtho);  Other:Ice\tInterventional\tPhase 4\tOther / Industry\tVisualAnalogScale(VAS)PainScores;  NarcoticPainMedicationUsage;  PatientSatisfaction;  SurgicalComplications;  PostoperativeComplications\t36\tNCT00950183\tFebruary 2007\n1610\tCompleted\tChronic Insertional Achilles Tendonitis Treated With or Without Flexor Hallucis Longus Tendon Transfer\t\tProcedure:Achillesdecompression\u0026amp;debridement;  Procedure: Achilles decompression and debridement with FHL transfer\tInterventional\tPhase 4\tOther\tankle plantar flexion strength measured using a handheld dynamometer;  American Orthopaedic Foot and Ankle Society(AOFAS) Ankle-Hindfoot score;  Visualanalogpainscale(VAS);  Hallux plantarflexion strength using the dynamometer;  PatientSatisfaction;  Surgicalcomplications;  Postoperativecomplications\t52\tNCT00950053\tDecember 2008\n1611\tWithdrawn\tComparison Study of Biofoam Porous Metal Versus Allograft to Treat Adult Acquired Flatfoot\t\tDevice:Biofoam;  Other:IliacCrestAllograftwithlockedplate\tInterventional\tPhase 4\tOther / Industry\tThe degree of correction as measured by talonavicular coverage angle which is used to quantify the degree of deformity. Degree of correction is defined as the difference between the preoperative and postoperative talonavicular coverage angle.;  American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Score;  FootFunctionIndex(FFI)Score;  PainVisualAnalogScale(VAS);  Implantfailure\t0\tNCT00949897\tMarch 2009\n1617\tCompleted                  Has Results\tEvaluate Inflammation Caused by Gingivitis in Adults\t\tDrug:Triclosan/Copolymer/fluoridetoothpaste;  Drug:sodiummonofluorophosphatetoothpaste\tInterventional\tPhase 4\tIndustry\tLevel of Gingival Crevicular Fluid Interleukin - 1 (GCF IL-1) at 2 Hours;  Level of Gingival Crevicular Fluid Interleukin - 6(GCF IL-6) at 2 Hours\t49\tNCT00941668\tJanuary 2007\n1635\tCompleted                  Has Results\tContinuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)\t\tDrug:ContinuousOC(EE/DROS);  Drug:IntermittentOC(EE/DROS);  Drug:placebo\tInterventional\tPhase 4\tOther / NIH\tPre-PostChangeinPremenstrualSymptomSeverity\t67\tNCT00927095\tJuly 2008\n1644\tCompleted                  Has Results\tOptima: Optimizing Prograf Therapy in Maintenance Allografts II\t\tDrug:cyclosporine;  Drug:Prograf(Tacrolimus)\tInterventional\tPhase 4\tOther / Industry\tRenal Function in Patients Converted From Cyclosporine to Prograf;  Optimal Dose/Blood Level of Prograf in Long-term Maintenance Kidney Transplant Patients;  Change in Risk Factors for Cardiovascular Morbidity and Chronic Graft Dysfunction as Evidenced by Blood Levels of Homocysteine and Transforming Growth Factor Beta (TGF-B)\t63\tNCT00905515\tAugust 2003\n1645\tCompleted\tImpact of Myfortic on Gastrointestinal (GI) Prophylaxis in Maintenance Renal Transplant Patients\t\tDrug:GImedication\tInterventional\tPhase 4\tOther / Industry\tTo determine the success (% of patients) in discontinuing GI medications over the 90-day period or also % of patients able to maintain reduced doses of GI medications over the 90-day period.;  To evaluate the cost effectiveness of discontinuing GI medications in transplant recipients.\t61\tNCT00905242\tMarch 2006\n1646\tRecruiting\tOral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure\t\tDrug: Intravenous Bolus Furosemide and Oral Metolazone;  Drug:IntravenousContinuousInfusionFurosemide\tInterventional\tPhase 4\tOther\tDailynetfluidoutput;  PatientGlobalAssessmentScale;  Daily urine output (mL urine out per mg furosemide received);  Need for additional or alternative diuretic (crossover) or IV vasoactive therapy (study failure);  Death rehospitalization and unscheduled visit for HF to an emergency department or outpatient clinic;  Critically low potassium (\u0026lt; 3.5 mmol/L) and magnesium (\u0026lt; 1.6 mg/dL) concentrations;  Changeinbloodureanitrogenorcreatinine;  Number of hypotensive episodes defined as systolic blood pressure below 85 mmHg or greater than 10 mmHg below baseline (whichever is greater);  Total number of times antihypertensive doses are held due to low blood pressure\t160\tNCT00904488\tOctober 2008\n1665\tCompleted                  Has Results\tComparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)\t\tDrug:Methylphenidatetransdermalsystem;  Drug:Lisdexamfetaminedimesylate;  Drug: Osmotic-release oral system methylphenidate (OROS MPH);  Drug:Mixedamphetaminesaltsextendedrelease\tInterventional\tPhase 4\tOther / NIH\tDichotomized Clinical Global Impression-Effectiveness (CGI-E) Scale;  Clinical Global Impressions-Improvement (CGI-I) Scale;  Clinical Global Improvements-Acceptability (CGI-A) Scale\t228\tNCT00889915\tApril 2009\n1698\tCompleted                  Has Results\tA Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis\t\tDrug:Olux-EFoam;  Drug:Clobexlotion\tInterventional\tPhase 4\tIndustry\tAt Least a One Grade Improvement for the Target Psoriasis Lesion on the Elbow or Knee (Psoriasis Grading Scale);  At Least 1 Grade Improvement Psoriasis Grading Scale;  At Least a 2 Grade Improvement Psoriasis Grading Scale;  At Least a 3 Grade Improvement Psoriasis Grading Scale;  At Least 1 Grade Improvement in the Psoriasis Global Assessment;  At Least a 2 Grade Improvement in the Psoriasis Global Assessment;  At Least a 3 Grade Improvement in the Psoriasis Global Assessment;  At Least 1 Grade Improvement in Subject\u0026apos;s Global Assessment;  At Least a 2 Grade Improvement in Subject\u0026apos;s Global Assessment;  At Least a 3 Grade Improvement in Subject\u0026apos;s Global Assessment;  MedianChangeinPsoriasisGradingScale;  Dermatology Quality of Life - Symptoms and Feelings;  DermatologyQualityofLife-DailyActivities;  DermatologyQualityofLife-Leisure;  DermatologyQualityofLife-WorkandSchool;  Dermatology Quality of Life - Personal Relationships;  DermatologyQualityofLife-Treatment;  TotalDermatologyLifeQualityIndex(DLQI)Score;  DermatologyLifeQualityIndex(DLQI)Categories\t34\tNCT00852761\tMarch 2009\n1763\tCompleted\tVascular Improvement With Olmesartan Medoxomil Study\t\tDrug: olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure;  Drug: atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure\tInterventional\tPhase 4\tIndustry\tSubcutaneous gluteal fat arteriole measurements prior to and after 52 weeks of therapy;  Resultsofvascularfunctiontests;  Measurement of serum lipid and markers of atherosclerosis;  Retinalarteriolemeasurements;  Calculationofinsulinsensitivitymeasurement;  24 hour urine creatinine and thromboxane B2 measurements;  Calculation of albumin-to-creatinine ratio and sodium-to-creatinine ratio\t100\tNCT00772499\tNovember 2002\n1770\tTerminated\tComparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)\t\tDrug:RegadenosonDobutamine\tInterventional\tPhase 4\tOther / Industry\tDurationofprocedures;  Ease of Administration of regadenoson versus intravenous dobutamine.\t40\tNCT00763035\tJanuary 2009\n1771\tCompleted                  Has Results\tCompare Anti-inflammatory Dentifrices\t\tDrug:Triclosan/Copolymer/fluoridetoothpaste;  Drug:Sodiummonofluorophosphatetoothpaste\tInterventional\tPhase 4\tIndustry\tGingivalIndex(GI);  ProstaglandinE2(PGE2);  Interleukin-1Beta(IL-\u0026#223;);  Interleukin-6(IL-6);  NuclearFactorKappaBLigand(RANK-L);  8-iso-prostaglandinF2\u0026#945;(8-iso-PGF2\u0026#945;);  DentalPlaqueIndex(PI);  BleedingonProbing(BOP)\t49\tNCT00762528\tFebruary 2009\n1773\tCompleted\tBivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients\t\tDrug:bivalirudin\tInterventional\tPhase 4\tIndustry\tPlateletcounts\t150\tNCT00759083\tSeptember 2008\n1780\tTerminated\tIntraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb\u0026#174; Compared to Placebo Control\t\tDrug:Pancrelipase\tInterventional\tPhase 4\tIndustry / Other\tPeak levels of three enzymes - lipase amylase and protease - each measured in U/ml will be outcomes\t3\tNCT00744250\tAugust 2008\n1781\tTerminated                  Has Results\tEffect on Bleeding When Using FloSeal Matrix\u0026#8482; in Subjects Undergoing Endoscopic Vein Harvest (EVH)\t\tBiological:FloSealMatrix\tInterventional\tPhase 4\tOther / Industry\tNumberofParticipantsWithDecreasedBleeding\t50\tNCT00742313\tJune 2009\n1788\tTerminated                  Has Results\tMetformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)\t\tDrug:Glucophage(Metformin);  Drug:Placebo\tInterventional\tPhase 4\tOther\tStudy Endpoints Will Include Measurements of Insulin Sensitivity Hepatic Insulin Clearance and Altered Parameters of Lipid Metabolism Changes in the Histological Features That Define NAFLD and Quantitative Measurements of Visceral and Peripheral Fat.;  Tests the Postulate That Metformin Will Improve Insulin Sensitivity in NAFLD. Also Test the Postulate That Improving IR (Insulin Resistance) With an Insulin Sensitizing Agent Will Improve Biochemical and Histological Features of NAFLD.;  Determine if Metformin Improves the Altered Parameters of Lipid Metabolism as Compared to Placebo.;  Measure the Differential Effects of IR and Lipid Metabolism on Peripheral Mononuclear Cell (PBMC) Inflammatory Response and the Associated Hepatocyte Mitochondrial Ultrastructure and Measures of Oxidative Stress\t11\tNCT00736385\tApril 2009\n1798\tCompleted                  Has Results\tAprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy\t\tDrug:Aprepitant+Dexamethasone;  Drug:Ondansetron+Dexamethasone\tInterventional\tPhase 4\tOther / Industry\tCumulativeIncidenceofEmesis;  IncidenceofNausea;  IncidenceofVomiting;  UseofRescueAntiemetics;  Number of Participants With a Complete Response Rate;  AverageNauseaScore;  NumberofVomitingEpisodes;  TimetoFirstVomiting;  Number of Participants Who Rated Their Satisfaction With Antiemetic Management as \u0026quot;Very Satisfied\u0026quot;\t115\tNCT00734929\tSeptember 2007\n1819\tTerminated\tEffects of Capsaicin on the Structure Distribution and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin\t\tDrug:Capsaicin\tInterventional\tPhase 4\tOther\tTo assess the effect of capsaicin on small nerve fiber function in psoriasis\t12\tNCT00697034\tJune 2006\n1820\tCompleted\tMeasuring Adherence To Topical 5-Fluorouracil in a Clinic Population\t\tDrug:Fluorouracil0.5%\tInterventional\tPhase 4\tOther\tAdherence to Carac\u0026#174; in subjects with moderate to severe actinic keratosis.\t20\tNCT00696488\tApril 2007\n1821\tUnknown\u0026nbsp;\u0026#8224;\tAnalysis of Adherence in Subjects Undergoing Differin Gel 0.1% Treatment of Moderate to Severe Acne Vulgaris\t\tDrug:Adapalene\tInterventional\tPhase 4\tOther\tPercent change from baseline in total lesions counts;  GlobalAssessmentofimprovementfrombaseline.\t80\tNCT00696449\tJune 2006\n1823\tCompleted\tClinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy\t\tDrug:Biafine\tInterventional\tPhase 4\tOther\tThe change of the target lesions from Baseline to or end of treatment in the IGA\t20\tNCT00695578\tOctober 2006\n1824\tUnknown\u0026nbsp;\u0026#8224;\tAdherence to Topical Hydrocortisone 17-Butyrate 0.1% (Locoid\u0026#174;) Using Different Vehicles in Adults With Atopic Dermatitis\t\tDrug: hydrocortisone 17-butyrate 0.1% preparation ointment;  Drug: hydrocortisone 17-butyrate 0.1% preparation cream;  Drug: hydrocortisone 17-butyrate 0.1% preparation lipocream\tInterventional\tPhase 4\tOther\tThechangeovertreatmentintheIGA.\t30\tNCT00693693\tNovember 2006\n1825\tUnknown\u0026nbsp;\u0026#8224;\tComparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients\t\tDrug:Sarna;  Drug:Cetaphil\tInterventional\tPhase 4\tOther\tThe primary outcome is investigator assessment of pruritus score and response to treatment using an itch questionnaire;  The secondary outcome is the effect of treatment on skin moisturization and quality of life at baseline and end of treatment.\t30\tNCT00693654\tNovember 2006\n1837\tCompleted\tEfficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis\t\tDrug:topicaldesonidehydrogel0.05%\tInterventional\tPhase 4\tOther\tThe change from Baseline to Week 4 (or end of treatment) in the IGA\t41\tNCT00690833\tAugust 2007\n1852\tCompleted\tSelf System Therapy and Chronic Low Back Pain Trial\t\tBehavioral:Self-SystemTherapy;  Behavioral:Education;  Other:StandardCare\tInterventional\tPhase 4\tOther\tDepressionlevels\t137\tNCT00672880\tOctober 2003\n1877\tCompleted\tMeasuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne\t\tDrug:BenzoylPeroxide\tInterventional\tPhase 4\tOther\tAdherence;  Efficacy\t20\tNCT00658112\tJuly 2006\n1878\tCompleted\tEthnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects\t\tDrug:Capsaicin\tInterventional\tPhase 4\tOther\tTo assess ethnic differences in burning pain induced by topical capsaicin;  To assess ethnic differences on the effects of topical capsaicin on thermal sensory thermal thresholds\t40\tNCT00655811\tFebruary 2008\n1879\tCompleted                  Has Results\tLong-Term One Year Use of Alefacept (Amevive\u0026#174;) in Moderate to Severe Chronic Plaque Type Psoriasis\t\tDrug:Alefacept\tInterventional\tPhase 4\tOther\tEfficacy of Continuous Use of Alefacept as Defined as a 75% Reduction in Psoriasis Area and Severity Index (PASI);  Safety of Alefacept Using CD4 Counts and Adverse Event Reporting\t15\tNCT00655564\tMay 2008\n1881\tUnknown\u0026nbsp;\u0026#8224;\tMeasuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit\t\tDrug:tacrolimusointment\tInterventional\tPhase 4\tOther\tMeasured adherence to topical therapy in children via MEMS cap in a \u0026quot;real-life\u0026quot; clinic population;  The change from Baseline to Week 4 (or end of treatment) in the IGA.;  The change from Baseline to Week 4 (or end of treatment) in the calculated EASI score.\t30\tNCT00654355\tApril 2008\n1889\tTerminated                  Has Results\tRapid Switch From Flolan to Remodulin in the Outpatient Clinic\t\tDrug:treprostinilsodium\tInterventional\tPhase 4\tIndustry\tChangeinSixMinuteWalkDistance;  ChangeinWHOFunctionalClassification;  Change in Borg Dyspnea Score Immediately After Six Minute Walk;  Change in Score on Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR);  Change in Score on Treatment Satisfaction Questionnaire for Medication;  Change in Total Weekly Time Spent With the Specific Activities Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol;  ChangeinPAHSignsandSymptoms-Fatigue;  ChangeFrominSignsandSymptomsofPAH-Edema;  ChangeinSignsandSymptomsofPAH-Dyspnea;  ChangeinSignsandSymptomsofPAH-Orthopnea;  ChangeinSignsandSymptomsofPAH-Dizziness;  ChangeinSignsandSymptomsofPAH-Syncope;  ChangeinSignsandSymptomsofPAH-ChestPain;  PatientImpressionofChangeQuestionnaire\t7\tNCT00643604\tMarch 2008\n1896\tCompleted                  Has Results\tRapid Sternal Closure System (TALON)\t\tDevice:RapidSternalClosureSystem;  Device:Conventionalwireclosure\tInterventional\tPhase 4\tOther\tPercentage Change of Preoperative Incentive Spirometry (IS) Volume Achieved;  Number of Participants With Sternal Wound Infection or Sternal Instability/Non-union\t51\tNCT00638014\tMarch 2008\n1931\tCompleted                  Has Results\tThe Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty\t\tOther:Placebosalineinjection;  Drug:Ropivicaine0.5%\tInterventional\tPhase 4\tOther / Industry\tNumericPainScore;  Total Fentanyl Patient-Controlled Anesthesia (PCA) Narcotic Consumption;  Postoperative Day 1 Physical Therapy Outcome - Ambulation Distance;  Postoperative Day 1 Physical Therapy Outcome- Knee Extension and Flexion;  Postoperative Day 1 Physical Therapy Outcome - Straight Leg Raise\t67\tNCT00620828\tMay 2007\n1964\tCompleted\tParoxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)\t\tDrug:ParoxetineCR;  Drug:Placebo\tInterventional\tPhase 4\tOther / Industry\tChange from baseline in: Changes in Mean composite pain scores (on IVRS);  Change from baseline in Associated symptoms of IBS (diarrhea constipation incomplete emptying etc.) scores IBS Quality of Life scores Clinical Global Impression scores of 1 or 2 Beck Depression Inventory II Beck Anxiety Inventory;  Recording of spontaneous adverse events throughout the screening run-in and treatment phases of the study Conducting the DOTES at defined points during the study\t60\tNCT00610909\tJanuary 2002\n1976\tCompleted                  Has Results\tU-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod\t\tDrug: U-500 Insulin delivered by Omnipod (disposable insulin pump)\tInterventional\tPhase 4\tOther\tImprovement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c);  PercentageofTimeSpentinHypoglycemia;  Patient Satisfaction With Insulin Delivery Method Via Insulin Delivery Rating System Questionnaire (IDRSQ)\t21\tNCT00606034\tDecember 2007\n1998\tCompleted                  Has Results\tMulti Center Prospective Registry of Infliximab Use for Childhood Uveitis\t\tDrug:infliximab\tInterventional\tPhase 4\tOther\tEffects of Infliximab on Uveitis Disease Activity.\t13\tNCT00589628\tSeptember 2007\n2021\tCompleted                  Has Results\tResponses of Myocardial Ischemia to Escitalopram Treatment\t\tDrug:Escitalopram;  Drug:Placebo\tInterventional\tPhase 4\tOther / NIH\tPercentage of Participants With an Absence of Mental Stress-induced Myocardial Ischemia (MSIMI) During the 3 Mental Stressors;  Percentage of Participants With Overall Mental Stress-induced Myocardial Ischemia (MSIMI);  Mental Stress Induced Change of Systolic Blood Pressure;  Mental Stress Induced Change of Diastolic Blood Pressure;  PercentageofParticipantsWithAdverseEvents;  BeckDepressionInventory;  MentalStressInducedChangeinHeartRate;  5HTTSerotoninTransporterProtein;  PlateletSerotoninBindingAffinityKd_100;  PerceivedStressScale;  Cook-MedleyHostility(Ho)Scale;  Cook-Medley Hostility (Ho) Hostile Affect Sub-scale;  Spielberger State-Trait Anxiety Inventory Scales (STAI);  Exercise Stressed-induced Myocardial Ischemia (ESIMI)\t127\tNCT00574847\tSeptember 2006\n2024\tCompleted                  Has Results\tA Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy\t\tDrug:Pregabalin;  Drug:Placebo\tInterventional\tPhase 4\tOther / Industry\tAssessing the Change in Resting Blood Pressure Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy.;  Assessing the Change in Heart Rate by Means of the LifeShirt System Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy.;  Assessing the Change in Heart Rate Variability by Means of the LifeShirt System Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy.;  Assessing the Change of Parameters of Autonomic Nerve Function Such as Heart Rate Variability by Means of the LifeShirt System Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy.;  To Assess the Change of Pain Symptoms Upon Treatment of Pregabalin in Comparison to Placebo.;  To Assess the Change of Anxiety Symptoms Upon Treatment of Pregabalin in Comparison to Placebo.;  To Assess the Change of Depressive Symptoms Upon Treatment of Pregabalin in Comparison to Placebo.;  To Assess the Change in Disability Scale Upon Treatment of Pregabalin in Comparison to Placebo.\t40\tNCT00573261\tMarch 2006\n2025\tTerminated                  Has Results\tA Pilot Study of Daptomycin for Antimicrobial Prophylaxis\t\tDrug:daptomycin6mg/kgIV\tInterventional\tPhase 4\tOther / Industry\tRate of Patients Receiving Antimicrobial Prophylaxis Within the Appropriate Timeframe Before Incision\t11\tNCT00572260\tJanuary 2008\n2034\tCompleted\tSynera\u0026#8482; for Epidural Needle Insertion\t\tDrug:Synera(TM);  Other:Placebopatch\tInterventional\tPhase 4\tOther\tSubject VRS (0 - 11) with epidural needle insertion;  AnesthesiaproviderperceivedVRS;  Needfordeepinfiltrationwithlocalanesthesia\t33\tNCT00564785\tFebruary 2007\n2038\tCompleted                  Has Results\tSecondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)\t\tDrug:Paroxetine;  Drug:Placebo\tInterventional\tPhase 4\tU.S. Fed\tClinicianAdministeredPTSDScale(CAPS);  ShortPTSDRatingInterview;  ConnorDavidsonResilienceScale;  HospitalAnxietyandDepressionScale;  Clinical Global Impressions of Severity and of Improvement Scales;  SymptomChecklist90;  SheehanDisabilityScale(SDS)\t12\tNCT00560612\tJanuary 2006\n2044\tCompleted                  Has Results\tRe-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment\t\tDrug:0.59mgFluocinoloneAcetonideimplant\tInterventional\tPhase 4\tOther / Industry\tNumberofEyesWithInflammationRecurrence;  Percentage of Eyes With Improvement in Visual Acuity;  Number of Participant\u0026apos;s Eye Requiring Adjunctive Therapy;  Number of Eyes With Increased Intraocular Pressure\t21\tNCT00543296\tMarch 2004\n2050\tTerminated\tCombining Observational and Physiologic Sedation Assessment Tools\t\tOther:RamsayScale;  Device:Bispectralindexmonitor\tInterventional\tPhase 4\tOther / Industry\tHowmuchsedativewasinfused;  Howquicklythesubjectrecoveredfromsedation;  Thenumberofundersedationevents\t67\tNCT00538369\tNovember 2006\n2053\tCompleted                  Has Results\tHow Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis\t\tDrug:doxercalciferol\tInterventional\tPhase 4\tOther / Industry\tChangeinEndothelialCellFunction\t24\tNCT00528788\tSeptember 2007\n2069\tWithdrawn\tVitamin D and Carboxy PTH Fragments in Coronary Calcification\t\tDrug:Doxercalciferoladministration;  Drug:Doxercalciferoladministeredby1-84-7-84\tInterventional\tPhase 4\tOther\tPercent Change in Hounsfield units of coronary calcification between baseline and after one year of therapy;  Mean dose of Vitamin D2 administered over 12 months\t0\tNCT00502268\tFebruary 2008\n2079\tCompleted                  Has Results\tEffect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery\t\tDrug:StandardCare;  Drug:nepafenac\tInterventional\tPhase 4\tOther\tCentral Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups);  Pre-operativeBestCorrectedVisualAcuity(BCVA);  FovealThickness;  Macular Volume (Difference in Mean Pre-post Changes by the Two Treatment Groups);  Post-operative Best Corrected Visual Acuity (BCVA)\t82\tNCT00494494\tJune 2007\n2094\tCompleted\tImproving Care for Primary Care Patients With Diabetes and Poor Literacy and Numeracy Skills\t\tBehavioral: Literacy/Numeracy oriented educational intervention;  Behavioral:ControlGroup\tInterventional\tPhase 4\tOther / Industry\tA1C;  Patientself-managementbehaviors;  Patientknowledge;  Patientsatisfaction\t110\tNCT00469105\tDecember 2006\n2101\tCompleted                  Has Results\tThe Treatment of Insomnia in Patients With HIV Disease\t\tDrug:Doxepin;  Drug:Temazepam;  Drug:Placebo\tInterventional\tPhase 4\tOther\tResponse: Change in Insomnia Severity Rating Scale at 3 Months.;  ChangeinPiperFatigueScaleat3Months\t44\tNCT00465972\tMarch 2007\n2116\tCompleted\tZylet vs TobraDex in Blepharokeratoconjunctivitis\t\tDrug: Loteprednol etabonate and tobramycin ophthalmic suspension;  Drug: Tobramycin and dexamethasone ophthalmic suspension\tInterventional\tPhase 4\tIndustry\tThe primary efficacy endpoint for this study is the change from baseline to Day 15 in the signs and symptoms composite score;  The distribution of Investigator global assessment at each visit.;  The percentage of eyes that were considered improved or cured at each visit based on the Investigator global assessment.;  The change from baseline to Day 7 (Visit 3) and to Day 3 (Visit 2) in the signs and symptoms composite score.;  The change from baseline to each visit in the signs composite score and the symptoms composite score.;  The change from baseline to each visit in the Blepharitis signs composite score the conjunctivitis signs composite score and the Keratitis signs composite score.;  The change from baseline to each visit in individual signs and symptoms.;  VA Biomicroscopy and IOP assessments at each visit;  AdverseEvents\t276\tNCT00447577\tJanuary 2007\n2122\tCompleted\tAnalysis of Adherence \u0026amp; Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin\u0026#174; Gel 0.1%\t\tOther:Morefrequentthannormalofficevisits;  Other: Electronic reminders (voice e-mail text messages);  Other: Parenteral involvement / intervention reminders;  Other:Nointerventionorreminders\tInterventional\tPhase 4\tIndustry\tEfficacy - Percent adherence calculated from MEMS Caps readings;  Efficacy - lesion counts; percent adherence as calculated by product weights and by Subject\u0026apos;s Diary; Global Severity Assessment; Global Assessment of Improvement; Subject questionnaire;  Safety-tolerabilityandadverseeventreporting\t61\tNCT00437151\tJune 2006\n2127\tCompleted\tChanges in Cerebral Blood Flow in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain\t\tOther: Precision Spinal Cord Stimulation and PET Scan\tInterventional\tPhase 4\tIndustry\tCumulative frequency of adverse events and events per subject;  Cerebral blood flow and VAS with optimal paresthesia coverage compared with SCS off;  Cerebral blood flow and VAS with partial paresthesia coverage and subthreshold stimulation compared with optimal coverage and with SCS off\t15\tNCT00418301\tJanuary 2007\n2129\tCompleted\tLifestyle Modification for Obesity-Related Type 2 Diabetes\t\tBehavioral:Lowcarbohydrateketogenicdiet;  Behavioral: Low glycemic index reduced calorie diet\tInterventional\tPhase 4\tOther\tHemoglobinA1c;  Bodyweight;  Serumlipoproteins\t90\tNCT00415688\tJuly 2004\n2164\tTerminated\tFunctional Brain Imaging of Medication Treatment Response in Mild Alzheimer\u0026apos;s Disease Patients\t\tDrug:RazadyneER;  Drug:Aricept\tInterventional\tPhase 4\tOther / Industry\tBrain activity patterns as collected via functional magnetic resonance imaging (fMRI) at rest and associated with task performance after 4 weeks of low-dose treatment and after 8-weeks of higher-dose treatment.;  Differences in cognitive testing and functional status at pre-treatment baseline and after completion of the 12-week treatment trial.\t4\tNCT00369603\tOctober 2006\n2167\tCompleted                  Has Results\tStudy of the Insomnia in Patients With Low Back Pain\t\tDrug:Eszopiclone;  Drug:Placebo\tInterventional\tPhase 4\tOther / Industry\tMean Subjective Sleep Diary Derived Total Sleep Time (TST);  VisualAnalogScalePainRatings(VAS);  MeanSleepOnsetLatency(SOL);  WakeTimeAfterSleepOnset;  NumberofAwakenings;  SleepQualityRatings;  InsomniaSeverityIndex(ISI);  PatientGlobalImpressionofPainRatings;  RolandMorrisLowBackPainInventory(RMLBPI);  HamiltonDepressionRatingScale(HAM-D-24);  ShortForm36HealthSurveyQuestionnaire(SF-36);  State-TraitAnxietyInventory(STAI)\t58\tNCT00365976\tAugust 2006\n2175\tCompleted\tEffect of Revival Soy on Weight Loss and Skin Hair and Nails in Premenopausal Women\t\tBehavioral:RevivalSoyDietarySupplement\tInterventional\tPhase 4\tIndustry / Other\tInvestigator assessed appearance of skin (roughness wrinkling dyspigmentation and redness) at baseline and after 3 and 6 months;  Investigator assessed appearance of hair (roughness dullness lack of manageability and scalp flaking) at baseline and after 3 and 6 months;  Investigator assessed appearance of finger nails (roughness ridging flaking and splitting) at baseline and after 3 and 6 months.;  Bodyweightatmonthlyintervals;  Body mass index (BMI) at the baseline and study completion;  Subject-perceived changes in appearance of skin hair and finger nails at baseline and after 3 and 6 months\t40\tNCT00352157\tJuly 2006\n2176\tCompleted\tEfficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy\t\tDrug:CyclosporineRefreshPlus\tInterventional\tPhase 4\tIndustry\tDryEyeSymptoms;  Dryeyesigns\t93\tNCT00349440\tSeptember 2006\n2198\tWithdrawn\tEffect of Dexmedetomidine Upon Sleep Postoperatively\t\tDrug:Dexmedetomidine;  Drug:Propofol;  Drug:Midazolam;  Drug:Fentanyl;  Drug:Isoflurane\tInterventional\tPhase 4\tOther\tMeasurements of sleep quality during postoperative period:Epworth Sleepiness Scale;  Completionofsleeplog;  Subjects will also be asked to complete Visual Analogue Scales (VAS) of sleep and daytime sleepiness.;  The quality of postoperative recovery (QoR) and the presence of fatigue (Brief Fatigue Inventory);  Subjects will also be asked to complete Visual Analogue Scale (VAS) of fatigue.\t0\tNCT00333632\tJune 2006\n2202\tActive not recruiting\tStudy of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation\t\tDrug:Alemtuzumab;  Drug:Anti-ThymocyteGlobulin\tInterventional\tPhase 4\tOther\tPatientsurvival;  Graftsurvival;  AcuteRejection;  Hematologicadverseevents;  Infectiousadverseevents;  Otheradverseevents;  Cost;  Healthstatusandqualityoflife\t275\tNCT00331162\tFebruary 2005\n2214\tCompleted                  Has Results\tOptimizing Body Composition for Function in Older Adults\t\tDrug:Pioglitazone;  Behavioral: Resistance exercise training to maximize muscle power;  Behavioral:Hypocaloricdiet;  Drug:Placebo\tInterventional\tPhase 4\tOther / Industry\tAppendicularNon-boneLeanMass;  LeanBodyMass\t88\tNCT00315146\tApril 2006\n2216\tCompleted\tTreatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage\t\tDrug:imiquimod\tInterventional\tPhase 4\tOther\thistologicclearanceofbasalcellcarcinoma\t15\tNCT00314756\tMarch 2005\n2222\tTerminated\tA Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)\t\tDrug:Pegaptanibsodium\tInterventional\tPhase 4\tIndustry\t\t262\tNCT00312351\tApril 2006\n2248\tCompleted\tSleep Disorders and Gastroesophageal Reflux Disease (GERD)\t\tDrug:Rabeprazole\tInterventional\tPhase 4\tOther / Industry\tThe percentage of: subjects with non-OSA sleep disturbances who demonstrate esophageal reflux night-time arousals which are accompanied by a reflux event.\t20\tNCT00287391\tSeptember 2004\n2252\tCompleted                  Has Results\tThe Utility of Nexium in Chronic Cough and Reflux Disease\t\tDrug:Esomeprazole;  Drug:Placebo\tInterventional\tPhase 4\tOther / Industry\tChange in Cough-Specific Quality of Life Questionnaire\t40\tNCT00287339\tSeptember 2005\n2278\tUnknown\u0026nbsp;\u0026#8224;\tImproving Sleep and Psychological Functioning in People With Depression and Insomnia\t\tDrug:Eszopiclone;  Drug:Fluoxetine;  Drug:Placebo\tInterventional\tPhase 4\tOther / NIH\t\u0026quot;Role Functioning\u0026quot; and \u0026quot;Relation to Self/Others\u0026quot; Basis-32 subscale ratings;  Quality of life ratings as measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q);  Subjective sleep symptoms (perceived sleep onset latency perceived total sleep time number of awakenings final rising time and the presence and duration of any naps the prior day);  Insomnia symptoms as measured by the Insomnia Severity Index (ISI)\t96\tNCT00247624\tOctober 2005\n2292\tCompleted\tDetermining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence\t\tDrug:DepotRisperidoneMicrosphere(Consta)\tInterventional\tPhase 4\tOther / Industry\t\t64\tNCT00215579\tApril 2004\n2309\tCompleted\tEARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis\t\tDrug:Avonex/Zocor\tInterventional\tPhase 4\tOther\tThe primary objective of this study is to determine whether combination therapy with IFNb-1a plus simvastatin when compared to IFNb-1a plus placebo decreases or delays additional clinical or MRI activity.;  Wewillusethefollowingoutcomemeasures:;  Relapse rates Time to first relapseNumber of new T2 lesions Number of new Gd-enhancing lesions\t30\tNCT00146068\tSeptember 2004\n2437\tUnknown\u0026nbsp;\u0026#8224;\tEffectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment\t\tDrug:Ritonavir;  Drug:Abacavirsulfate;  Drug:Amprenavir;  Drug:Efavirenz;  Drug:Lamivudine;  Drug:Stavudine\tInterventional\tPhase 4\tIndustry\t\t300\tNCT00005017\t\n2514\tTerminated\tComparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.\t\tDrug:Oxybutyninextendedrelease;  Device:PosteriorTibialNerveStimulation;  Drug:Placebo\tInterventional\tPhase 4\tOther\tChangeinmeannumberofUUIepisodesperday;  Changein24hrpadweight\t36\tNCT02176642\tAugust 2014\n2536\tActive not recruiting\tDonepezil Compared to Placebo in Patients With Chronic Neuropathic Pain\t\tDrug:Donepezil;  Drug:Placebo\tInterventional\tPhase 4\tOther / NIH\tPainIntensity\t33\tNCT01743976\tDecember 2012\n2563\tCompleted                  Has Results\tFMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders\t\tDrug:Aripiprazole\tInterventional\tPhase 4\tOther / NIH\tBaseline and Week 8scores on Children\u0026apos;s Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version;  TotalRepetitiveBehaviorScale-Revised(RBS_R)\t13\tNCT01028820\tAugust 2009\n2569\tCompleted\tTreatment of Acute HIV With Emtricitabine Tenofovir and Efavirenz (CID 0805)\t\tDrug:Atripla\tInterventional\tPhase 4\tOther / Industry\tTo determine the safety and tolerability and the virologic and immunologic efficacy of FTC/TDF and efavirenz or the fixed-dose combination of efavirenz/FTC/TDF (Atripla) given once daily to patients with acute HIV infection.;  To assess impact of once daily therapy combined with a standardized adherence program on treatment adherence virologic suppression and rate of viral load decline in blood and infectious fluids (cerebrospinal fluid semen and vaginal secretions).;  To define the prevalence of genotypic and phenotypic resistance to antiretroviral agents among persons diagnosed with acute HIV infection in the Southeastern United States.\t90\tNCT00924898\tJanuary 2005\n2572\tCompleted\tStudy to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Na\u0026#239;ve Patients Treated With Darunavir/Ritonavir and Etravirine\t\tDrug:Darunavir/RitonavirandEtravirine\tInterventional\tPhase 4\tOther / Industry\tTo measure virologic and immunologic response in AHI with DRV/R \u0026amp; ETR (absolute values and change from baseline plus slope of change).;  To measure drug levels in various compartments with replication in cellular compartments and immunological outcome.\t15\tNCT00855413\tMarch 2009\n2576\tWithdrawn\tCardio Risk of Acute Schizophrenia Olanzapine Duke\t\tDrug:Olanzapine;  Drug:Metformin;  Drug:Simvastatin\tInterventional\tPhase 4\tOther\tTo compare added metformin and/or added simvastatin versus no intervention in reducing or eliminating increased cardiovascular risk (as estimated by elevation in non-HDL cholesterol levels) during the treatment of schizophrenia with olanzapine.;  To compare added metformin and/or added simvastatin versus no intervention in reducing or eliminating increased cardiovascular risk during the treatment of schizophrenia with olanzapine.\t0\tNCT00672464\tApril 2008\n2577\tCompleted\tRaltegravir as Early Therapy in African-Americans Living With HIV Study\t\tDrug:Raltegravir+Truvada\tInterventional\tPhase 4\tOther / Industry\tAssess Raltegravir tolerability acceptability and adherence among African-American men and women initiating HIV therapy. 2. Determine the pharmacokinetics of Raltegravir in African-American men and women.;  Determine the pharmacokinetics of Raltegravir in African-American men and women.\t43\tNCT00667433\tJune 2008\n2594\tTerminated\tFunctional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal\t\tDrug:Antipsychotic/RisperidoneConsta\tInterventional\tPhase 4\tOther / Industry\t\t30\tNCT00314613\tApril 2006\n2599\tTerminated\tTesting Pharmacological Therapies for Pregnant Smokers\t\tBehavioral: Motivational interviewing for smoking cessation;  Behavioral:Cognitivebehaviorstherapy;  Drug:CBT+NRT\tInterventional\tPhase 4\tOther / NIH\tBiochemically-validatedsmokingcessation\t181\tNCT00224419\tJune 2003\n2615\tRecruiting\tPK and Safety Study of XARTEMIS\u0026#174; XR (7.5 mg Oxycodone HCl/325 mg APAP) in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain\t\tDrug:XARTEMISXR\tInterventional\tPhase 4\tIndustry\tTimetoreachsteadystate;  Areaunderthecurve;  Peakexposure;  Half-life;  Timetopeakexposure\t60\tNCT02508935\tJune 2015\n2648\tCompleted                  Has Results\tPreventing Hypotension in Parturients With an Elevated Body Mass Index (BMI)\t\tDrug:Phenylephrinebolus;  Drug:phenylephrineinfusion\tInterventional\tPhase 4\tOther\tIncidenceofNauseaandVomiting;  IncidenceofHypotension;  NeonatalAcidosis\t170\tNCT01481740\tNovember 2010\n2687\tCompleted\tParoxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome\t\tDrug:ParoxetineCR;  Drug:Placebo\tInterventional\tPhase 4\tOther / Industry\tTwenty five percent change from baseline in Fibromyalgia Impact Questionnaire (FIQ) total scores;  Change from baseline in FIQ Number of tender points Beck Depression Inventory II Beck Anxiety Inventory Visual Analog Scale for pain;  Recording of spontaneous adverse events throughout the screening run-in and treatment phases of the study\t120\tNCT00610610\tJanuary 2002\n2696\tCompleted                  Has Results\tStudy of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic\t\tDrug:Acamprosate(Campral)\tInterventional\tPhase 4\tOther\t%Dropout;  PercentDaysAbstinent;  Retention;  PercentWithCompleteAbstinence;  %HeavyDrinkingDaysDuringTrial;  ClinicalGlobalImpressionScale;  %CompliantWithMedication\t100\tNCT00381043\tAugust 2006\n2735\tCompleted                  Has Results\tAlternate Dosing Schedules Study for HPV Vaccine\t\tBiological:ReceivedHPVvaccinefirst;  Biological:Receivedconcomitantvaccinesfirst\tInterventional\tPhase 4\tOther / U.S. Fed\tPainFollowingHPVVaccine\t72\tNCT00862810\tMarch 2009\n2746\tRecruiting\tMEtformin and Lorcaserin for WeighT Loss in Schizophrenia\t\tDrug:Lorcaserin;  Drug:Metformin;  Drug:Placebo\tInterventional\tPhase 4\tOther / NIH\tMean Difference in Body Weight Change Between Participants Assigned to lorcaserin/metformin combination treatment and placebo;  Mean Difference in Body Weight Change Between Participants Assigned to lorcaserin monotherapy treatment and placebo;  Change in HDL Cholesterol From Baseline to 52 Weeks;  Change in LDL Cholesterol From Baseline to 52 Weeks;  ChangeinTriglyceridesFromBaselineto52Weeks;  Change in Total Cholesterol From Baseline to 52 Weeks;  Change in Hemoglobin A1c From Baseline to 52 Weeks;  Change in Fasting Glucose From Baseline to 52 Weeks\t110\tNCT02796144\tSeptember 2016\n2749\tNot yet recruiting\tA Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD\t\tDrug:AptensioXR;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tADHD-RS-IVTotalScore;  CGI-Iscore;  CGI-Sscore\t150\tNCT02683265\tMarch 2016\n2750\tNot yet recruiting\tA 12-Month Open Label Safety Study of Aptensio XR\u0026#174; in Children Ages 4-5 Years Diagnosed With ADHD\t\tDrug:AptensioXR\tInterventional\tPhase 4\tIndustry\tTreatment-emergentadverseevents(TEAEs);  ColumbiaSuicideSeverityRatingScale(C-SSRS);  Vitalsigns;  12-leadelectrocardiogram;  ADHD-RS-IVPreschoolVersion;  Clinical Global Impressions-Severity Scale (CGI-S);  Connors Early Childhood Behavior-Parent Short [ConnorsEC BEH-P(S)]\t120\tNCT02677519\tSeptember 2016\n2756\tRecruiting\tPharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD\t\tDrug:MethylphenidateHClERCapsules\tInterventional\tPhase 4\tIndustry\tCmax;  AUC(0-t);  AUC(0-inf);  AUC/D;  CL/F;  V(dss)/F;  Cmax/dose;  Tmax;  T1/2;  Eliminationrateconstant(Kel)\t60\tNCT02470234\tFebruary 2016\n2772\tRecruiting\tEfficacy and Safety of Expandable Spacer in the Treatment of Degenerative Disc Disease Using the Minimally Invasive Transforaminal Lumbar Interbody Fusion Surgical Approach\t\tDevice:CALIBER\tInterventional\tPhase 4\tIndustry / Other\tFusionanddischeightmaintenance;  PatientSelfAssessment\t75\tNCT02075554\tJuly 2012\n2783\tCompleted\tYoung Hearts Strong Starts\t\tOther:Intervention;  Other:Control\tInterventional\tPhase 4\tOther\tSummary composite measure of practice performance and exposure;  Measures of guideline adherence for BMI blood pressure and tobacco use and exposure\t32\tNCT01893593\tNovember 2011\n2796\tCompleted\tCombination Treatment Study for Memory Impairment and Depression\t\tDrug:Donepezil;  Drug:Placebo\tInterventional\tPhase 4\tOther / NIH\tSelectiveRemindingTest(SRT);  ADAS-Cog\t86\tNCT01658228\tSeptember 2011\n2808\tCompleted                  Has Results\tSafety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)\t\tDrug:AztreonamLysineforInhalation(AZLI);  Procedure:StatusPostLungTransplant\tInterventional\tPhase 4\tOther / Industry\tChange in Pulmonary Function as Measured by Serial Forced Expiratory Volume in 1 Second (FEV1) on Spirometry;  Change in Global Health Related Quality of Life Measured by Serially Self-administered Short Form 36 Health Survey Questionnaire (SF-36) at Baseline (Prior to AZLI First Dose) and During AZLI Therapy at Month 1;  Change in Global Health Related Quality of Life Measured by Serially Self-administered Short Form 36 Health Survey Questionnaire (SF-36) at Baseline (Prior to AZLI First Dose) and During AZLI Therapy at Month 1 and Month 5.;  Change in Respiratory-specific Health Related Quality of Life Measured by Serially Self Administered St. George\u0026apos;s Respiratory Questionnaire (SGRQ) at Baseline (Prior to AZLI First Dose) and During AZLI Therapy at Month 1;  Change in Respiratory-specific Health Related Quality of Life Measured by Serially Self Administered St. George\u0026apos;s Respiratory Questionnaire (SGRQ) at Baseline (Prior to AZLI First Dose) and During AZLI Therapy at Month 5.;  Change in Pulmonary Function as Measured by Serial Forced Expiratory Flow (FEF25-75) on Spirometry at Baseline (Prior to AZLI First Dose) and During AZLI Therapy at Month 5.;  Change in Pulmonary Function as Measured by Serial Forced Expiratory Flow (FEF25-75) on Spirometry at Baseline (Prior to AZLI First Dose) and During AZLI Therapy at Month 1;  ChangeinFEV1OffAZLITherapy;  ChangeinHRQOLOffAZLITherapy.;  Among Patients Colonized With Pseudomonas Aeruginosa Change in Infection Burden as Measured by the Culture Final Report (01+ 2+ 3+ 4+) of in Pseudomonas Aeruginosa Sputum or Bronchoalveolar Fluid.;  Bronchoalveolar Lavage Fluid (BALF) Neutrophilia After Treatment When Performed as Part of Clinical Care (SOC).\t30\tNCT01469364\tMarch 2013\n2828\tRecruiting\tLymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection\t\tProcedure:TourniquetUse\tInterventional\tPhase 4\tOther\tLymphedema15%changefrompre-postingirth;  Wound assessmentPatient Satisfaction (on a scale of 0-10Surgical and postoperative complications\t206\tNCT00984269\tSeptember 2009\n2839\tCompleted                  Has Results\tContralateral Comparison of Three Excimer Laser Systems in Performing LASIK\t\tDevice:ExcimerLaser;  Device:AMO/VISXCustomVue\u0026#8482;;  Device:LADARVision4000excimerlaser\tInterventional\tPhase 4\tOther / Industry\t1 Day Postoperative Lasik Uncorrected Visual Acuity;  1 Week Postoperative Lasik Uncorrected Visual Acuity;  1MonthPostoperativeLasikVisualAcuity\t40\tNCT00821236\tJanuary 2009\n2840\tCompleted                  Has Results\tPatient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension\t\tDrug:TimololMaleateinSorbate;  Drug:Timololhemihydrate;  Drug:Timololmaleategelformingsolution\tInterventional\tPhase 4\tIndustry\tStingingonInstillation;  ConjunctivalHyperemia;  TearFilmBreak-upTime;  CornealStainingGrade;  CornealStainingCount;  IntraoclularPressure;  BasicSchirmer\u0026apos;s;  ConjunctivalStaining-NasalGrade;  ConjunctivalStaining-NasalCount;  ConjunctivalStaining-TemporalGrade;  ConjunctivalStaining-TemporalCount;  VisualAcuity\t30\tNCT00804648\tNovember 2008\n2841\tTerminated                  Has Results\tQuetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder\t\tDrug:QuetiapineXR;  Drug:Placebo\tInterventional\tPhase 4\tOther\tThe Continuous Performance Test-Identical Pairs Version;  Brief Assessment of Cognition for Affective Disorders (BAC-A)\t32\tNCT00746421\tJanuary 2010\n2845\tCompleted                  Has Results\tAn Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease\t\tBiological:AlglucosidaseAlfa;  Drug:Methotrexate;  Drug:Rituximab\tInterventional\tPhase 4\tIndustry\tChange From Baseline in Number of Patients With Anti-Recombinant Human Acid Alfa-glucosidase (Anti-rhGAA) Immunoglobulin G (IgG) Antibody at End of Study;  Number of Patients With Recombinant Human Acid Alfa-glucosidase (rhGAA) Inhibitory Antibody at End of Study;  NumberofPatientsWhoSurvivedatEndofStudy;  Number of Patients With Normal/Abnormal Left Ventricular Mass (LVM) Z-Score and LVM Index at End of Study;  Number of Patients With Ventilator Use at End of Study;  Gross Motor Disability Assessed by Gross Motor Function Measure-88 (GMFM-88) at End of Study;  Motor Development Status Assessed by Alberta Infantile Motor Scale (AIMS) at End of Study;  Disability Index Assessed by the Pompe Pediatric Evaluation of Disability Inventory (Pompe PEDI) at End of Study\t4\tNCT00701129\tOctober 2009\n2883\tCompleted                  Has Results\tCombination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder\t\tDrug:ContinuedParoxetineCR;  Drug:Quetiapine;  Drug:Placebo\tInterventional\tPhase 4\tOther\tHamilton Anxiety Scale (HAM-A) Score at Study Endpoint.;  Remission(HAM-A\u0026#8804;7);  Response Clinical Global Impression of Improvement (CGI-I);  Depressive Symptoms Montgomery-Asberg Depression Rating Scale (MADRS);  The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).\t50\tNCT00113295\tFebruary 2004\n2917\tCompleted                  Has Results\tResearch Evaluating a PDE5 Inhibitor for Erectile Dysfunction\t\tDrug:Placebo;  Drug:Avanafil100mg;  Drug:Avanafil200mg\tInterventional\tPhase 4\tIndustry\tPer-subject Proportion of Sexual Attempts That Had an Erectogenic Effect Within Approximately 15 Minutes Following Dosing\t440\tNCT01698684\tSeptember 2012\n2973\tCompleted                  Has Results\tLearning Impairments Among Survivors of Childhood Cancer\t\tDrug:Methylphenidate\tInterventional\tPhase 4\tOther / NIH\tBrain White Matter Volume for Patients Versus Sibling Controls;  Brain White Matter Volume for Patients With Acute Lymphoblastic Leukemia Versus Brain Tumors;  Brain White Matter Volume for Treatment Intensity Groups and Sibling Controls;  Change From Methylphenidate (MPH) Home Maintenance Phase Baseline to Completion of Phase as Measured by Conners\u0026apos; Teacher Rating Scale (CTRS: ADHD T Score);  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Conners\u0026apos; Teacher Rating Scale (CTRS: Cognitive Problem T Score);  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Conners\u0026apos; Parent Rating Scale (CPRS: ADHD T Score);  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Conner\u0026apos;s Parent Rating Scale (CPRS: Cognitive Problem T Score);  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Social Skill Rating System (SSRS-P);  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Reading: Composite Standard Score;  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Spelling: Standard Score;  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Math: Composite Standard Score;  Best Weekly Score Measured by Conners\u0026apos; Parent Rating Scale (CPRS: ADHD T Score) During the 3-week Home Crossover Phase.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by The Conners\u0026apos; Parent Rating Scale (CPRS) Cognitive Problem/Inattention Scale.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by The Conners\u0026apos; Parent Rating Scale (CPRS) Hyperactivity Scale.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by The Conners\u0026apos; Parent Rating Scale (CPRS) ADHD Index.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by The Conners\u0026apos; Teacher Rating Scale (CTRS) Cognitive Problem/Inattention Scale.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by The Conners\u0026apos; Teacher Rating Scale (CTRS) Hyperactivity Scale.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by The Conners\u0026apos; Teacher Rating Scale (CTRS) ADHD Index.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by Social Skills Rating System - Parent (SSRS-P) - Social Skill.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by Social Skills Rating System - Parent (SSRS-P) - Problem Behavior.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by Social Skills Rating System - Teacher (SSRS-T) - Social Skill.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by Social Skills Rating System - Teacher (SSRS-T) - Problem Behavior.;  Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention Reaction Time and Impulsivity Using Conner\u0026apos;s Continuous Performance Test (CPT) for Omission Errors.;  Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention Reaction Time and Impulsivity Using Conner\u0026apos;s Continuous Performance Test (CPT) for Commission Errors.;  Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention Reaction Time and Impulsivity Using Conner\u0026apos;s Continuous Performance Test (CPT) for Hit Reaction Time.;  Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention Reaction Time and Impulsivity Using Conner\u0026apos;s Continuous Performance Test (CPT) for d\u0026apos; (Sensitivity).;  Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention Reaction Time and Impulsivity Using Conner\u0026apos;s Continuous Performance Test (CPT) for Beta (Risk Taking).;  Establish the Effectiveness of MPH on Laboratory Measures of Learning and Recall Using California Verbal Learning Test (CVLT) Over Five Learning Trials.;  Establish the Effectiveness of MPH on Laboratory Measures of Learning and Recall Using California Verbal Learning Test (CVLT) for Short Delay Free Recall.;  Establish the Effectiveness of MPH on Laboratory Measures of Learning and Recall Using California Verbal Learning Test (CVLT) for Long Delay Free Recall.;  Establish the Effectiveness of MPH on Laboratory Measures of Interference Impulsivity Cognitive Flexibility and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Word Naming Time.;  Establish the Effectiveness of MPH on Laboratory Measures of Interference Impulsivity Cognitive Flexibility and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Color Naming Time.;  Establish the Effectiveness of MPH on Laboratory Measures of Interference Impulsivity Cognitive Flexibility and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Ink Color Naming Time.;  Establish the Effectiveness of MPH on Laboratory Measures of Interference Impulsivity Cognitive Flexibility and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Interference Score.\t469\tNCT00576472\tJanuary 2000\n2986\tRecruiting\tTolerability Safety and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)\t\tDrug:Naloxegol;  Drug:Placebo\tInterventional\tPhase 4\tOther / Industry\tAdverseEvents;  Numerical Rating Scale (NRS) for Pain change from Baseline;  DailyOpioidUsechangefromBaseline;  Adverse Events associated with Blood Laboratory result changes from Baseline;  Electrocardiogram (ECG) Interval and Rate Change from Baseline;  VitalSignschangesfromBaseline;  RescueFreeBowelMovements(RFBM)ResponderRate;  TimetoFirstPost-doseRescueFreeLaxation;  BristolStoolScale(BSS)Score;  Patient Assessment of Constipation Symptoms (PAC-SYM);  Patient Assessment of Constipation Quality of Life (PAC-QOL);  Degree of Straining question with each Bowel Movement;  Complete Evacuation question with each Bowel Movement\t44\tNCT02839889\tSeptember 2016\n2988\tRecruiting\tSafety of Simultaneous Tdap and IIV in Pregnant Women\t\tBiological: Tetanus Diphtheria and Pertussis Vaccine;  Biological: 2016-2017 Quadrivalent Inactivated Influenza Vaccine\tInterventional\tPhase 4\tOther / U.S. Fed\tProportion of Injection-site Reactions post Tdap and Flu administration;  Proportions of Systemic Reactions post Tdap and Flu administration;  Pertussis Serum Antibody Levels as measured by Geometric mean titers;  Diphtheria Serum Antibody Levels as measured by the proportion of subjects with seroprotection (defined as \u0026gt; 0.1 IU/mL);  Tetanus Serum Antibody Levels as measured by the proportion of subjects with seroprotection (defined as \u0026gt; 0.1 IU/mL);  Flu Serum Antibody Levels as measured by proportion of subjects with seroprotection (pre- and post-immunization) and seroconversion (4-fold rise from baseline);  feasibility as measured by number of participants recruited;  feasibility as measured by participant retention (percentage of participants who complete all visits);  feasibility reported as percentage of adequate data collected;  feasibility reported as percentage of adequate biospecimens collected;  feasibility reported as percentage of timely collected biospecimens;  feasibility reported as percentage of timely collected data;  Proportion of adverse maternal outcomes based on medical record review;  Proportion of adverse infant outcomes based on medical record review;  Proportionofclinicalchorioamnionitis;  Proportion of histologic chorioamnionitis on surgical pathology examination of placental tissue;  feasibility as measured by percentage of blood samples in testable condition;  feasibility as measured by percentage of blood samples in with sufficient volume for testing;  feasibility as measured by percentage of testable blood samples completed\t50\tNCT02783170\tSeptember 2016\n3011\tEnrolling by invitation\tEnhanced Algorithm for Crohn\u0026apos;s Treatment Incorporating Early Combination Therapy\t\tOther:EnhancedTreatmentAlgorithm;  Other:ConventionalStep-careAlgorithm\tInterventional\tPhase 4\tOther\tRisk of CD-related complications at one-year measured at the practice level;  RiskofCD-relatedcomplicationsat6months.\t1200\tNCT01698307\tMarch 2014\n3014\tCompleted\tNAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness\t\tDrug:Natalizumab(Tysabri)\tInterventional\tPhase 4\tOther / Industry\tChange in parameters of sleep as measured by polysomnography and multi-sleep latency test over 6 months of Natalizumab treatment.;  Change in neurocognition parameters over 6 months of Natalizumab treatment and correlation with changes in sleep efficiency.;  Change in subjective measures of fatigue sleepiness and mood over 6 months of Natalizumab treatment and correlation with changes in sleep efficiency.\t37\tNCT01591551\tMarch 2012\n3024\tTerminated                  Has Results\tTreatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy\t\tDrug:Photodynamictherapy;  Drug:Imiquimod\tInterventional\tPhase 4\tOther / Industry\tActinicKeratosisCount;  CompleteClearance;  CosmeticAppearance\t21\tNCT01203878\tSeptember 2010\n3026\tCompleted\tPredictors of Response to Augmentation With Ziprasidone (Geodon\u0026#174;) in Major Depressive Disorder\t\tDrug:ziprasidone;  Drug:Sugarpill\tInterventional\tPhase 4\tOther\tThe primary outcome of this study is to determine if predictors of response can select a population of patients with MDD that is effectively treatable by augmentation with ziprasidone.\t64\tNCT01168674\tFebruary 2010\n3042\tUnknown\u0026nbsp;\u0026#8224;\tEarly Versus Late Bronchoscopy in Bone Marrow Transplantation (BMT) Patients\t\tProcedure: Variation in the time for performing bronchoscopy\tInterventional\tPhase 4\tOther\tChange in therapy due to results obtained from bronchoscopy.;  In-Hospitalandthreemonthmortality;  Durationofantibiotictherapy\t100\tNCT00846352\tJanuary 2009\n3051\tCompleted                  Has Results\tEffect of Orlistat in Body Composition\t\tDrug:Orlistat;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tChange From Baseline to Week 24 in Abdominal VAT Mass;  Change From Baseline to Week 12 in Abdominal VAT Mass;  ChangeFromBaselinetoWeek24inBodyWeight;  ChangeFromBaselinetoWeek24inTotalFatMass;  Change From Baseline to Week 24 in Percentage Body Fat;  Change From Baseline to Week 24 in Waist Circumference;  Change From Baseline to Week 24 in Percentage Liver Fat;  ChangeFromBaselinetoWeek24inLiverFat;  Change From Baseline to Week 24 in Total Calories Expended for Physical Activity;  Change From Baseline to Week 24 in Quality of Life (QoL) Scores.;  SelectivityIndexatWeek24\t131\tNCT00752726\tSeptember 2008\n3054\tCompleted                  Has Results\tA Preference Study Comparing Kristalose\u0026#174; and Liquid Lactulose\t\tDrug:lactulose(Kristalose\u0026#174;);  Drug:liquidlactulose\tInterventional\tPhase 4\tIndustry\tPatient Preference in Terms of Overall Preference and Preference of Taste Consistency and Portability.\t50\tNCT00712543\tJune 2009\n3061\tTerminated                  Has Results\tNaratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction\t\tDrug:naratriptanHCl\tInterventional\tPhase 4\tOther / Industry\tHeadacheDays;  HeadacheImpactTest-6(HIT-6)Score;  Mental Efficiency Workload Test (MEWT) Performance Index Score;  OverallSatisfactionWithMedicationScore;  QualityofLifeScores;  SustainedTreatmentEffect\t12\tNCT00487578\tOctober 2006\n3085\tRecruiting\tEfficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use\t\tDrug:Eluxadoline;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tPercentageofPrimaryCompositeResponders;  PercentageofStoolConsistencyResponders;  PercentageofPainResponders;  PercentageofMonthlyCompositeResponders\t340\tNCT02959983\tOctober 2016\n3089\tRecruiting\tA Multicenter 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar\u0026#174; Gel in Subjects With Rheumatoid Arthritis\t\tDrug:Acthar;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tProportion of subjects with Disease Activity Score with 28 joint count and Erythrocyte Sedimentation Rate (DAS28-ESR);  ProportionofsubjectswhomaintainedDAS28-ESR\t232\tNCT02919761\tOctober 2016\n3106\tCompleted\tHPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)\t\tDrug:FTC/TDF\tInterventional\tPhase 4\tOther\tInitiationofPrEP;  AdherencetoPrEP;  Adverseevents;  STIs;  Changesinsexualrisk-takingbehavior;  InitiateordeclinePrEP;  IncidentHIV-seroconversions/characteristics;  Participantperceptionofcareandreferralplan\t225\tNCT01808352\tAugust 2013\n3111\tTerminated\tEffect of Including Synera\u0026#174; in Discussions on Dialysis Access Conversion in Patients With Needle Phobias\t\tOther:EnhancedNeedlePhobiaIntervention;  Other:StandardNeedlePhobiaIntervention\tInterventional\tPhase 4\tIndustry\tProportion of patients achieving a score of 3 or 4 on the stages of change questionnaire;  Proportion of patients for whom the intervention was successful\t10\tNCT01623583\tApril 2014\n3119\tUnknown\u0026nbsp;\u0026#8224;\tMegadyne Ace Incision/Dissection Study\t\tDevice:E-ZCleanACEBlade\tInterventional\tPhase 4\tIndustry\tEvaluateWoundHealing/ScarFormation;  Evaluate patient satisfaction relating to wound healing\t52\tNCT01175889\tAugust 2010\n3123\tActive not recruiting\tThe FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.\t\tProcedure:Focusedultrasound(MRgFUS);  Procedure:Uterinearteryembolization(UAE)\tInterventional\tPhase 4\tOther / NIH\tSymptomatic outcomes measured by validated instruments;  Adverseeventsfollowingtreatment;  Biologicpredictorsofoutcome\t180\tNCT00995878\tOctober 2009\n3151\tCompleted                  Has Results\tAtomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children\t\tDrug:Atomoxetine;  Drug:Placebo;  Behavioral:ParentTraining\tInterventional\tPhase 4\tOther / NIH\tChangeinADHD-IVRatingScaleTotalScore;  ChangeinTotalADHD-IVTeacher\t93\tNCT00254462\tOctober 2005\n3153\tCompleted\tConservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot\t\tProcedure:PackedRedBloodCellTransfusion\tInterventional\tPhase 4\tOther / U.S. Fed\tIn-hospitaldeath;  Recurrentmyocardialinfarction(MI);  Neworworseningheartfailure;  CriticalCareUnit(CCU)lengthofstay;  Lengthofhospitalization;  Death or recurrent MI at hospital discharge and 30 days;  Death or recurrent MI or new or worsening congestive heart failure (CHF) at 30 days;  Deathat30days;  In-hospitalrecurrentischemia;  In-hospital death or recurrent MI or new or worsening CHF or recurrent ischemia;  Acute renal insufficiency (increase in serum creatinine of \u0026#8805; 0.5mg/dL);  Numberoftransfusionsreceivedperpatient;  Proportion of patients receiving at least one transfusion;  Meandailyhematocrit;  Transfusion-relatedreactions\t45\tNCT00126334\tApril 2003\n3162\tRecruiting\tPREA PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects\t\tDrug:ivpantoprazole\tInterventional\tPhase 4\tIndustry\ttime to peak plasma concentration (Tmax) of iv pantoprazole;  peak plasma concentration (Cmax) of iv pantoprazole;  area under the concentration-time curve from time zero to last concentration (AUClast) of iv pantoprazole;  area under the concentration-time curve from time zero to extrapolated infinite time (AUCinf) of iv pantoprazole;  steady state volume of distribution (Vss) of iv pantoprazole;  terminal phase half-life (T1/2) of iv pantoprazole;  clearance(CL)ofivpantoprazole;  CYP2C19genotyping\t24\tNCT02401035\tDecember 2016\n3170\tTerminated\tThe Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations\t\tBiological: Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy);  Biological: Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy);  Biological:Placebo\tInterventional\tPhase 4\tOther\tLimb function: AMA disability rating score of envenomated limb time to recovery of 100% of premorbid function Kaplan-Meier analysis;  Limb function: AAOS Normative Outcome Study scoring for envenomated limb;  Limb function: AAOS Normative Outcome Study scoring for envenomated limb time to recovery of 100% of premorbid function Kaplan-Meier analysis;  Pain:visualanalogscore;  Painmedicationuse:Mgofmorphineequivalents;  Swelling: percentage (%) of limb spread proximal from bite site;  Swelling: % increase in volume compared to contralateral (non-envenomated) limb;  Limbfunction:returntowork;  Limb function: physical or occupational therapy sessions attended;  Hematological: Clotting studies and platelet counts;  Complicationsoftherapy\t25\tNCT00303303\tApril 2005\n3175\tRecruiting\tReducing Suicidal Ideation Through Insomnia Treatment\t\tDrug:Zolpidem-CR;  Drug:Placebo\tInterventional\tPhase 4\tOther / NIH\tSuicideSeverityIndex(SSI);  DysfunctionalBeliefsandAttitudesAboutSleep;  Disturbing Dreams and Nightmares Severity Index (DDNSI);  BeckHopelessnessScale(BHS);  HamiltonRatingScaleforDepression(HAM-D);  InsomniaSeverityIndex(ISI)\t138\tNCT01689909\tSeptember 2012\n3190\tCompleted                  Has Results\tAntidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression\t\tDrug:Asenapine5-20mgdaily;  Drug:Placebo1-4tabletsdaily\tInterventional\tPhase 4\tOther / Industry\tChangeinMADRSTotalScore;  StudyCompletionRate;  ClinicalResponseRate;  ClinicalRemissionRate;  RatesofSustainedRemission\t46\tNCT01670019\tOctober 2012\n3194\tRecruiting\tPermanent Versus Absorbable Colpopexy Trial\t\tDevice: polytetrafluoroethylene Gore-Tex permanent suture;  Device: 2-0 polydioxanone PDS delayed absorbable monofilament suture\tInterventional\tPhase 4\tOther\tvaginalmeshandsutureexposurerates\t200\tNCT02277925\tDecember 2014\n3213\tEnrolling by invitation\tInfluenza Vaccine Feasibility Study in Children With Persistent Asthma\t\tDrug:ccIIV4;  Drug:IIV4\tInterventional\tPhase 4\tOther / U.S. Fed\tTo assess the feasibility of conducting a randomized prospective safety study of LAIV4 versus IIV4 during the 42 days after vaccination in children aged 5-11 years with persistent asthma of varied severity (ccIIV4 will be used as a surrogate for LAIV4);  Local and Systemic reactogenicity events during the 14 days post-vaccination;  UnsolicitedandSeriousAdverseEvents;  Proportionsofasthmaexacerbations\t50\tNCT02967393\tOctober 2016\n3252\tCompleted\tDrug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients\t\tDrug:Atazanavir/Ritonavir;  Drug:Atazanavir/Ritonavir+Famotidine;  Drug: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine\tInterventional\tPhase 4\tIndustry\tAtazanavirplasmadrugconcentrations;  Ritonavirplasmadrugconcentrations;  Safetymeasures:Physicalexaminations;  ECGs;  laboratory tests including liver and renal function;  CD4count;  HIVviralload\t40\tNCT00384904\tDecember 2006\n3260\tCompleted                  Has Results\tTreatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)\t\tDrug:Risperidone;  Drug: Olanzapine (enrollment closed in this treatment);  Drug:Molindone\tInterventional\tPhase 4\tOther / NIH\tChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 8 Weeks;  Change From Baseline in PANSS Positive Symptom Subscale Score at 8 Weeks.;  Change From Baseline in PANSS Negative Symptom Subscale at Week 8;  ChangeFromBaselineinWeightatWeek8;  Change From Baseline in Barnes Akathisia Scale at Week 8;  Change From Baseline in Body Mass Index Change kg/m2 at Week 8\t116\tNCT00053703\tFebruary 2002\n3278\tCompleted\tPopulation Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients\t\tDrug:Ceftolozane/Tazobactam\tInterventional\tPhase 4\tOther / Industry\tCeftolozaneClearance;  CeftolozaneVolumeofDistribution;  TazobactamClearance;  TazobactamVolumeofDistribution;  CeftolozaneProbabilityofTargetAttainment;  Safety and Tolerability (changes in serum chemistry hematology and hepatic lab values as well as reported adverse events)\t20\tNCT02421120\tSeptember 2015\n3307\tCompleted                  Has Results\tA Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval\t\tDrug:lapatinib;  Drug:placebomatchinglapatinib\tInterventional\tPhase 4\tIndustry\tTreatment Difference in Duration of Cardiac Ventricular Depolarization and Repolarization Interval (QT) in Fridericia-corrected QT Interval (QTcF) Values Between Placebo and Lapatinib 2000mg;  Change From Baseline in the Holter ECG Parameters of QT Interval Corrected QT Interval (QTc) Bazett Corrected QTc Interval (QTcB) Individual-corrected QT Interval (QTcI) RR Interval PR Interval and QRS Duration at Indicated Time Points;  Number of Participants With 12-lead Holter ECG Findings at the Indicated Time Points;  Number of Participants With the Worst-case Post-Baseline 12-lead Holter ECG Findings With Significant ST T Wave and U Wave Abnormalities;  Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE);  Mean Albumin and Hemoglobin at the Indicated Time Points;  Mean Alkaline Phosphatase (ALP) Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) at the Indicated Time Points;  Mean Direct Bilirubin Total Bilirubin and Creatinine at the Indicated Time Points;  Mean Calcium Chloride Carbon Dioxide (CO2) Potassium Sodium Magnesium and Urea at the Indicated Time Points;  Mean Total Neutrophils (ANC [Absolute Neutrophil Count]) Platelets and Leukocyte Count at the Indicated Time Points;  Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points;  Change From Baseline in Heart Rate at the Indicated Time Points;  Number of Participants With 12-lead ECG Findings at Indicated Time Points;  Mean Area Under the Plasma Drug Concentration-time Curve (AUC) From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC[0-t]) and From Time Zero (Pre-dose) to 24 Hours Post Dose (AUC[0-24]) for Lapatinib;  Mean Maximum Plasma Concentration (Cmax) and Observed Plasma Concentration at 24 Hours Post-dose (C24) of Lapatinib;  Median Time to Cmax (Tmax) and the Time Prior to the First Quantifiable (Non-zero) Lapatinib Plasma Concentration (Tlag) Following the Last (3rd) Lapatinib Dose\t58\tNCT01328054\tDecember 2011\n3331\tTerminated\tInfergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin\t\tDrug:Infergenandribavirin\tInterventional\tPhase 4\tIndustry\tTo evaluate the proportion of patients with a sustained viral response (SVR) defined as undetectable serum HCV RNA at the end of the 24 week post-treatment follow-up period.;  Compare proportion of patients with SVR after switching treatment with Infergen/Ribavirin for 48 weeks versus those treated for 36 weeks\t5\tNCT00456248\tFebruary 2007\n3346\tCompleted\tOptimizing Electroconvulsive Therapy for Depression\t\tProcedure:Highdosageelectroconvulsivetherapy;  Drug:Nortriptyline;  Drug:Venlafaxine;  Drug:Lithium;  Procedure:Lowdosageelectroconvulsivetherapy\tInterventional\tPhase 4\tOther / NIH\tNeurocognitivebattery;  Clinical evaluations side effect evaluations and blood level determinations;  Memoryfunction\t340\tNCT00045916\tFebruary 2001\n3361\tTerminated\tTrial of High Dose Vitamin D in Patient\u0026apos;s With Crohn\u0026apos;s Disease\t\tDrug:Cholecalciferol10000IU;  Drug:Cholecalciferol400IU\tInterventional\tPhase 4\tOther\tPrimaryCompositeOutcome;  Hypercalcemia;  Incidenceofnephrolithiasis;  Crohn\u0026apos;srelatedhospitalizations;  Steroidprescriptions;  Crohn\u0026apos;srelatedsurgeries;  change in modified Harvey-Bradshaw Index (HBI without examination);  ChangeinC-reactiveprotein;  Changesinfecalcalprotectin;  Percentwithescalationoftherapy;  QualityofLifemeasurechanges;  Changeinfatiguemeasurements;  Crohn\u0026apos;srelatedEmergencyDepartment(ED)visits\t11\tNCT02208310\tApril 2015\n3387\tCompleted\tReducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics\t\tDrug:AripiprazoleorPerphenazine;  Drug:Metformin;  Drug: Olanzapine quetiapine risperidone ziprasidone aripiprazole asenapine iloperidone lurasidone paliperidone or olanzapine/fluoxetine\tInterventional\tPhase 4\tOther / NIH\tBodymassindex(BMI)z-scorechange;  Bodyfatmass;  Wholebodyinsulinsensitivityindex;  Triglyceridelevels;  Lowdensitylipoprotein(LDL)-cholesterollevel;  Metabolicsyndrome\t127\tNCT00806234\tJanuary 2009\n3394\tCompleted                  Has Results\tDePuy Trochanteric (ATN) Nailing Clinical Outcomes Trial\t\tDevice:Intramedullarynailing\tInterventional\tPhase 4\tIndustry\tSuccessinTermsoftheMerleD\u0026apos;AubigneScore;  LowerExtremityMeasure(LEM);  MedicalImaging;  SixItemScreenerandAmbulatoryStatus;  SF-12;  Merled\u0026apos;AubigneandPostel\t62\tNCT00546429\tSeptember 2006\n3405\tCompleted\tComparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications\t\tDrug:polyethyleneglycol3350\tInterventional\tPhase 4\tIndustry\tA successful outcome is defined as no longer meeting the definition of constipation using ROME I criteria;  AnalysisofindividualROMEIcriteria;  Safety(adverseeventandlaboratorytesting)\t100\tNCT00153127\tNovember 2001\n3434\tCompleted\tA Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer Severe Infection Related to Bone Marrow Transplantation\t\tDrug:DrotrecoginAlfa(activated)\tInterventional\tPhase 4\tIndustry\tSafety;  Mortality;  Bleedingincidence\t7\tNCT00067730\tMarch 2003\n3447\tRecruiting\tTrial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children\t\tDrug:Amoxicillin;  Drug:Amoxicillin-clavulanate;  Drug:Cefdinir;  Other:Placebo\tInterventional\tPhase 4\tNIH\tDesirabilityofOutcomeRanking(DOOR);  Adequate clinical response rates (a component of DOOR);  Frequencyofsolicitedevents;  Receipt of non-study systemic antibiotics for all causes during medically attended visits;  Receipt of non-study systemic antibiotics for persistent or worsening pneumonia during medically attended visits;  Resolutionofsymptoms(acomponentofDOOR)\t400\tNCT02891915\tOctober 2016\n3451\tUnknown\u0026nbsp;\u0026#8224;\tCT Coronary Angiogram Versus Traditional Care in Emergency Department Assessment of Potential ACS\t\tProcedure:CTCoronaryAngiography;  Procedure:TraditionalStandardofCare\tInterventional\tPhase 4\tOther\tTo estimate the rate of major cardiac events (AMI or cardiac death) within 30 days in participants in Group B who were found not to have stenosis of the main or first order coronary branches greater than or equal to 50% by CT coronary angiography.;  To estimate and compare the rates of significant CAD detected within the index visit in participants across the two study arms.;  To compare hospital length of stay across the two study groups.;  To compare health care utilization and cost incurred by participants in the two study groups during the index hospitalization.;  To compare cardiac health care utilization and cost incurred by participants in the two study groups during 1 year post triage/presentation.;  To compare rates of major cardiac events (cardiac death AMI and revascularization for participants who were not found to have significant CAD at the index visit) among participants in the two study groups within 1 year post triage/presentation.\t1365\tNCT00933400\tJuly 2009\n3467\tCompleted                  Has Results\tTolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study\t\tOther: Favor one of two thiazides for new prescriptions \u0026amp; attempt target dose\tInterventional\tPhase 4\tU.S. Fed\tPrescriptionRates;  FactorsAssociatedWithPrescribingPatterns\t20\tNCT01235377\tSeptember 2011\n3475\tTerminated                  Has Results\tMinimally Invasive Total Knee Replacement - Navigated Versus Non-navigated Study\t\tDevice: Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique;  Device: Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation\tInterventional\tPhase 4\tIndustry\tTo Compare the Precision of the Long Leg Alignment Between the Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare the Proportion of Procedures That Fall Within a Satisfactory Alignment Window Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare the Number of Optimal Implantations Achieved From Pre-op to 6-12 Weeks Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare American Knee Society Knee Score Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare Oxford Knee Scores Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare WOMAC Scores Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare VAS Pain Scores Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare Interface Radiographic Appearance Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare the Change From 6-12 Weeks \u0026amp; 5 Years on Long Leg Alignment.;  To Compare 6 Minute Walk Test Scores Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.\t86\tNCT00733330\tJanuary 2005\n3477\tRecruiting\tImmune Tolerance Induction Study\t\tBiological:Myozyme(alglucosidasealfa)\tInterventional\tPhase 4\tIndustry\tEvaluate the efficacy of ITI regimens as assessed by anti-recombinant human acid \u0026#945;-glucosidase (anti-rhGAA) antibody titers and antibodies that inhibit the enzymatic activity and/or uptake of Myozyme;  Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by overall survival.;  Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by respiratory function.;  Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by Left ventricular mass index (LVMI).;  Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by motor function.;  Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by disability index.;  Evaluate the safety of the 2 ITI regimens as assessed by the incidence of adverse events (AEs) serious adverse events (SAEs) and clinical laboratory abnormalities.\t9\tNCT00701701\tDecember 2008\n3487\tTerminated\tEffect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett\u0026apos;s Esophagus With Radiofrequency Ablation\t\tDrug:Dexlansoprazole;  Drug:DexlansoprazolePlacebo\tInterventional\tPhase 4\tIndustry\tPercentage of Participants with Recurrence of Intestinal Metaplasia (IM) at 12 months;  Percentage of Participants with Recurrence of Intestinal Metaplasia (IM) with Dysplasia at 12 months;  The percentage of participants demonstrating Erosive Esophagitis (EE) during the 12 month treatment phase of the study.;  Mean change from baseline in quality of life (GERD-HRQL) at 12 months\t6\tNCT02162758\tJuly 2014\n3488\tCompleted                  Has Results\tIndacaterol 75 \u0026#956;g Compared to Placebo Assessing Time to Patient\u0026apos;s Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease\t\tDrug:indacaterol;  Drug:placebo\tInterventional\tPhase 4\tIndustry\tTime (in Minutes) to Patient\u0026apos;s Perception of Onset of Effect\t40\tNCT01543828\tJanuary 2012\n3490\tCompleted                  Has Results\tA Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition\t\tDrug:Oxybutynintransdermalsystem\tInterventional\tPhase 4\tIndustry\tAverage Number of Catheterizations Without Leaking Per Day;  PatchAdhesion;  UrodynamicMeasurements;  UrinaryLeakageandCatheterizationData\t24\tNCT00224029\tDecember 2004\n3491\tWithdrawn\tRapid Assessment of Cardiac Markers for the Evaluation of Acute Coronary Syndrome (RACE-ACS)\t\tDevice: Triage CardioProfilER (Troponin I Myoglobin CK-MB BNP)\tInterventional\tPhase 4\tOther\tSensitivity and specificity of the three-marker versus the four-marker panelDetermine the added benefit of BNP in the diagnosis of patients with ACS;  Determine the economic and resource utilization benefit of the POC platform vs. standard lab testing\t0\tNCT00206817\tOctober 2003\n3501\tCompleted\tPhase IV O2 Consumption Study in COPD Patients\t\tDrug: Budesonide 160 mcg and formoterol fumarate dehydrate 4.5 mcg Inhalation aerosol;  Drug:MatchingPlacebopMDI160/4.5\u0026#956;g\tInterventional\tPhase 4\tIndustry\tChange from pre-dose (Visit 2) to post-dose (Visit 5) assessment in oxygen consumption (VO2; obtained via a metabolic cart);  Change from pre-dose (Visit 2) to post-dose (Visit 5) assessment in oxygen pulse (defined as VO2/heart rate [HR]; VO2 is obtained via a metabolic cart; used as a surrogate for stroke volume);  Change from pre-dose (Visit 2) to post-dose (Visit 5) assessment in gas exchange parameters (HR VCO2 and SaO2);  Change from pre-dose (Visit 2)to post-dose (Visit 5) assessment in spirometry.;  Change from pre-dose (Visit 2) to post-dose (Visit 5) assessment in mean inspiratory flow (tidal volume [Vt]/inspiratory time [Ti]);  Change from pre-dose (Visit 2) to post-dose (Visit 5) assessment in the Modified Borg Scale for dyspnea\t122\tNCT02533505\tAugust 2015\n3530\tCompleted                  Has Results\tComparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis\t\tDevice:EpiCeramSkinBarrierEmulsion;  Drug:DesonideCream0.05%\tInterventional\tPhase 4\tIndustry\tChangeFromBaselineinThreeItemSeverityScore\t100\tNCT00828412\tMarch 2009\n3592\tRecruiting\tCase Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery\t\tDevice: Mechanical Thrombectomy by the Indigo System\tInterventional\tPhase 4\tIndustry\tAngiographic assessment of vessel patency at immediate post-procedure as measured by TIMI scores;  Proceduralseriousadverseevents\t100\tNCT02085551\tMarch 2014\n3628\tCompleted                  Has Results\tRituximab in Progressive Immunoglobulin A (IgA) Nephropathy\t\tDrug:IntravenousRituximab;  Drug:ACE/ARB;  Dietary Supplement: Omega-3 Fatty Acid Fish Oil Supplement\tInterventional\tPhase 4\tOther / Industry\tChangeinProteinuriaat12Months;  BiochemicalMarkerIgAat12Months;  Biochemical Marker Gd-Immunoglobulin A Subclass 1 (IgA1) at 12 Months;  Biochemical Marker Immunoglobulin G (IgG) AutoAb at 12 Months\t34\tNCT00498368\tFebruary 2009\n3713\tRecruiting\tA \u0026quot;Real World\u0026quot; Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)\t\tDrug:INSULINGLARGINE(U300);  Drug:INSULINGLARGINE(U100);  Drug:Insulindetemir(Levemir)\tInterventional\tPhase 4\tIndustry\t- Proportion of patients with individualized HbA1c target attainment per HEDIS criteria (\u0026lt;8% if age \u0026#8805;65 years or with defined comorbidities or otherwise \u0026lt;7%) at 6 months without documented symptomatic (BG \u0026#8804;70 mg/dL) hypoglycemia;  Change in HbA1c from baseline (obtained at screening visit within one week of study initiation);  Proportion of patients with documented symptomatic (BG \u0026#8804;70 mg/dL) nocturnal (midnight to 5:59 am) hypoglycemia;  Proportion of patients with documented symptomatic (BG \u0026#8804;70 mg/dL) 24-hour hypoglycemia\t3270\tNCT02451137\tJune 2015\n3728\tActive not recruiting\tA Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors\t\tDrug:APD356-Lorcaserinhydrochloride;  Drug:Placebo\tInterventional\tPhase 4\tIndustry / Other\tTime from randomization to first occurrence of Major Adverse Cardiovascular Events (MACE);  Time from randomization to conversion to type 2 diabetes mellitus (T2DM) for subjects without any type of diabetes at Baseline;  Time from randomization to first occurrence of MACE+;  Time from randomization to event of each component of MACE+;  Time from randomization to event of all-cause mortality;  Time from randomization to event of new onset renal impairment or worsening existing renal impairment in subjects with T2DM at Baseline;  Time from randomization to event of improvement in renal function;  Change from Baseline in HbA[1c] at 6 months in subjects with T2DM at Baseline;  The proportion of subjects who meet FDA-defined valvulopathy in echocardiographically determined heart valve changes;  The percent change from Baseline in echocardiographically-determined pulmonary arterial systolic pressure;  Timetoconversiontonormalglucosehomeostasis\t12000\tNCT02019264\tJanuary 2014\n3731\tActive not recruiting\tEvaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.\t\tDrug:AclidiniumBromide;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tTime to first Major Adverse Cardiovascular Event (MACE);  Rate of moderate or severe COPD exacerbations per patient per year during the first year of treatment;  Rate of hospitalizations due to COPD exacerbation per patient per year during the first year of treatment;  Time to first Major Adverse Cardiovascular Event (MACE) or other serious cardiovascular events of interest\t4000\tNCT01966107\tOctober 2013\n3773\tCompleted                  Has Results\tGI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)\t\tDrug:Celecoxib;  Drug: Any commercially available NSAID with the indication for osteoarthritis\tInterventional\tPhase 4\tIndustry\tPercentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs);  Percentage of Participants With Moderate to Severe Abdominal Symptoms;  Percentage of Participants Who Withdrew Due to GI Adverse Events (AEs);  Hemoglobin(Hb)atBaseline;  ChangeFromBaselineHbatWeek24;  Hematocrit(Hct)atBaseline;  ChangeFromBaselineHctatWeek24;  Percentage of Participants With Clinically Significant Decrease in Hct and/or Hb From Baseline;  Percentage of Participants Satisfied With Efficacy of Current Pain Medication Overall;  Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Time to Pain Relief;  Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Amount of Pain Relief;  Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Duration of Pain Relief\t8067\tNCT00373685\tOctober 2006\n3774\tCompleted\tProspective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen\t\tDrug:celecoxib;  Drug:Ibuprofen;  Drug:Naproxen\tInterventional\tPhase 4\tIndustry / Other\tThe first occurrence of cardiovascular death (including hemorrhagic death) non-fatal myocardial infarction or non-fatal stroke (APTC composite endpoint).;  The occurrence of Clinical Significant Gastrointestinal Events (CSGIEs);  Patient\u0026apos;sAssessmentofArthritisPain(VAS);  The first occurrence of a MACE defined as the composite of cardiovascular death (including hemorrhagic death) non-fatal MI non-fatal stroke hospitalization for UA revascularization or hospitalization for TIA\t24222\tNCT00346216\tOctober 2006\n3778\tCompleted\tComparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes\t\tDrug:insulindetemir\tInterventional\tPhase 4\tIndustry\tComparison of the change from baseline to end of treatment;  Spontaneously reported adverse events during the trial;  Incidence of severe hypoglycaemic during the trial nocturnal (11 pm - 6 am);  FPG during the trial (central laboratory) at Visit 2 and Visit 3;  Proportion of subjects achieving HbA1C \u0026lt;\u003d 7.0% at Visit 2 and Visit 3;  InsulindetemirdosesatVisit2andVisit3;  Within-subject variation of before-breakfast SMPG values at Visit 2 and Visit 3\t5652\tNCT00264901\tOctober 2005\n3782\tCompleted\tBipolar Study in Adults at Least 18 Years of Age\t\tDrug:lamotrigine\tInterventional\tPhase 4\tIndustry\tThe primary endpoint will be the rate of rash during 12 weeks.;  Change from baseline in Week 5 and Week 12 Clinical Global Impression-Bipolar version (CGI-BP) Severityand Improvement scores.\t1200\tNCT00067938\tAugust 2003\n3845\tActive not recruiting\tAffordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study\t\tOther:Studyvouchercard\tInterventional\tPhase 4\tIndustry / Other\tMajorAdverseCardiovascularEvents;  LongTermPersistencetoP2Y12receptorinhibitor;  P2Y12receptorinhibitorselection;  HealthcareResourceUtilization\t11000\tNCT02406677\tJune 2015\n3848\tActive not recruiting\tCardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)\t\tDrug:Placebo;  Drug:Linagliptin\tInterventional\tPhase 4\tIndustry\tTime to the first occurence of any of the following adjudicated components of the primary composite endpoint: cardiovascular death non fatal myocardial infarction non fatal stroke and hospitalization for unstable angina pectoris;  Time to first occurence of any of the following adjudicated components: cardiovascular death non fatal myocardial infarction and non fatal stroke;  Time to first occurence of any of the following adjudicated composite renal endpoint: renal death end stage renal disease and a sustained decrease of 50% or more in estimated glomerular filtration rate\t8300\tNCT01897532\tJuly 2013\n3854\tCompleted                  Has Results\tSAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.\t\tDrug:ADVAIR100/50mcg;  Drug:ADVAIR250/50mcg;  Drug:ADVAIR500/50mcg;  Drug:FLOVENT100mcg;  Drug:FLOVENT250mcg;  Drug:FLOVENT500mcg\tInterventional\tPhase 4\tIndustry\tNumber of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization Asthma-related Endotracheal Intubation or Asthma-related Death);  Number of Participants Experiencing at Least One Asthma Exacerbation;  Number of Participants Experiencing at Least One Asthma Related Hospitalization  Endotracheal Intubation and Death;  Number of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation;  Mean Rescue Medication (Albuterol/Salbutamol) Use as Puffs Per 24 Hours\t11751\tNCT01475721\tNovember 2011\n3879\tTerminated\tNaltrexone/Bupropion Cardiovascular Outcomes Study\t\tDrug:NaltrexoneHCl/BupropionHClER;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tTime from Treatment Period Randomization to the First Confirmed Major Adverse Cardiovascular Events (MACE);  Time from Treatment Period Randomization to the First Confirmed Extended MACE;  Time from Treatment Period Randomization to the Occurrence of All-Cause Death;  Time from Treatment Period Randomization to the Occurrence of Cardiovascular (CV) Death\t67\tNCT02638129\tJanuary 2016\n3888\tCompleted                  Has Results\tA 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine\t\tDrug:Fesoterodine8mg;  Drug:Fesoterodine4mg;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tChange From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12.;  Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4.;  Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12.;  Change From Baseline in Percentage of Micturitions Per 24 Hours at Week 4.;  Change From Baseline in Percentage of Micturitions Per 24 Hours at Week 12.;  Change From Baseline in Mean Number of UUI Episodes Per 24 Hours at Week 4.;  Change From Baseline in Percentage of UUI Episodes Per 24 Hours at Week 4.;  Change From Baseline in Percentage of UUI Episodes Per 24 Hours at Week 12.;  Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 4.;  Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 12.;  Change From Baseline in Percentage of Micturition-Related Urgency Episodes Per 24 Hours at Week 4.;  Change From Baseline in Percentage of Micturition-Related Urgency Episodes Per 24 Hours at Week 12.;  Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Week 12.;  Number of Participants With Change From Baseline in Urgency Perception Scale (UPS) at Week 12.;  Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 12.;  Change From Baseline in Health Related Quality of Life (HRQL)-Coping Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.;  Change From Baseline in Health Related Quality of Life (HRQL)-Concern Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.;  Change From Baseline in Health Related Quality of Life (HRQL)-Sleep Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.;  Change From Baseline in Health Related Quality of Life (HRQL)-Social Interaction Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.;  Change From Baseline in Health Related Quality of Life (HRQL)-Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.;  Percentage of Participants Who Became Dry at Week 4.;  Percentage of Participants Who Became Dry at Week 12.\t2012\tNCT01302067\tMay 2011\n3940\tRecruiting\tSafety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis\t\tDrug:tofacitinib;  Biological:adalimumab;  Biological:etanercept\tInterventional\tPhase 4\tIndustry\tMalignancies excluding non-menlanoma skin cancer (NMSC);  Incidence of major adverse cardiovascular events (MACE);  Opportunisticinfections;  Hepaticevents;  CardiovasculareventsotherthanMACE;  Allcausemortality;  Disease Activity Score Based on 28-joints Count (DAS28);  Number of Participants With an American College of Rheumatology 20% (ACR20) Response;  ClinicalDiseaseActivityIndex(CDAI);  SimplifiedDiseaseActivityIndex(SDAI);  ACR-EULARBooleanremission;  Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response;  Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response;  Health Assessment Questionnaire-Disability Index (HAQ-DI)\t4000\tNCT02092467\tMarch 2014\n3947\tCompleted\tRoflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting \u0026#946;2-agonist (LABA) and Inhaled Corticosteroid (ICS)\t\tDrug:Roflumilast;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tRate of moderate or severe COPD exacerbations per subject per year;  Prebronchodilator Forced Expiratory Volume in 1 second (FEV1) in Liters\t2354\tNCT01443845\tSeptember 2011\n3950\tCompleted                  Has Results\tEfficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension\t\tDrug:nebivololandlisinopril(freecombination);  Drug:nebivololmonotherapy;  Drug:lisinoprilmonotherapy;  Drug:placebo\tInterventional\tPhase 4\tIndustry\tThe Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6.;  The Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6.\t664\tNCT01218100\tOctober 2010\n3951\tCompleted                  Has Results\tA 6-month Randomized Open-label Patient OutComes Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis\t\tDrug:Fingolimod;  Drug:StandardMSDMTs\tInterventional\tPhase 4\tIndustry\tChange From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 6;  Number of Patients Who Experienced Adverse Events Serious Adverse Events and Death;  Change From Baseline in Patient-reported Activities of Daily Living (ADL) Using the Multiple Sclerosis Activities Scale (PRIMUS-Activities) at Month 6;  Change From Baseline in Patient-reported Fatigue Using the Fatigue Severity Scale (FSS);  Change From Baseline in the Patient-reported Effectiveness Subscale Using the TSQM v1.4;  Change From Baseline in the Patient-reported Side Effects Subscale Using the TSQM v1.4;  Change From Baseline in the Patient-reported Convenience Subscale Using the TSQM v1.4;  Change From Baseline in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Standard (SF-36 v2);  Change From Baseline in Patient-reported Depression Using the Beck Depression Inventory (BDI-II);  Physician-reported Clinical Global Impression of Improvement (CGI-I)\t1053\tNCT01216072\tAugust 2010\n3982\tRecruiting\tEfficacy in Controlling Glycaemia With Victoza\u0026#174; (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes\t\tDrug:liraglutide;  Drug:alpha-glucosidaseinhibitors;  Drug:DPP-4inhibitors;  Drug:meglitinides;  Drug:SGLT-2inhibitors;  Drug:sulfonylurea;  Drug:thiazolidinediones\tInterventional\tPhase 4\tIndustry\tTime to inadequate glycaemic control defined as HbA1c above 7.0% (53 mmol/mol);  Number of subjects who achieve HbA1c below or equal to 6.5% (48 mmol/mol);  Number of subjects who achieve HbA1c below or equal to 7.0% (53 mmol/mol) without weight gain;  Changeinfastingplasmaglucose(FPG);  ChangeinBodyweight\t1994\tNCT02730377\tMarch 2016\n3984\tCompleted\tA Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia\t\tDrug:Ibandronate\tInterventional\tPhase 4\tIndustry\tPart A: Number of participants who currently use weekly biphosphonate who answer \u0026quot;yes\u0026quot; to any of the questions in Candidate Identification Questionnaire (CIQ);  Part B: Number of participants who demonstrate improvement from their baseline satisfaction score after 6 months of ibandronate;  Part B: Percentage of participants who demonstrate improvement from their baseline satisfaction score after 6 months of ibandronate;  Part B: Percentage of eligible weekly biphosphonate users at screening who elect to enter Part B;  Part B: Percentage of participants who report an improved satisfaction score with monthly ibandronate compared to weekly alendronate or risendronate;  Part B: Percentage of participants who report preference to monthly ibandronate or weekly alendronate or risedronate;  Part B: Percentage of participants who have greater than or equal to (\u0026gt;\u003d) 80 percent (%) compliance;  Part B: Percentage of participants who report an improvement in the gastrointestinal (GI) symptoms;  Part B: Percentage of participants by age and activity level who report high satisfaction according to Osteoporosis Patient Survey satisfaction Questionnaire (OPSAT-Q);  Part B: Individual Domain scores from Osteoporosis Patient Survey satisfaction Questionnaire (OPSAT-Q);  Part B: Number of eligible weekly biphosphonate users at screening who elect to enter Part B;  Part B: Number of participants who report an improved satisfaction score with monthly ibandronate compared to weekly alendronate or risendronate;  Part B: Number of participants who report preference to monthly ibandronate or weekly alendronate or risedronate;  Part B: Number of participants who have \u0026gt;\u003d 80% compliance;  Part B: Number of participants who report an improvement in the GI symptoms;  Part B: Number of participants by age and activity level who report high satisfaction according to Osteoporosis Patient Survey satisfaction Questionnaire (OPSAT-Q)\t1711\tNCT02604836\tJune 2004\n4012\tCompleted                  Has Results\tXIENCE V\u0026#174; USA Dual Antiplatelet Therapy (DAPT) Cohort\t\tDrug:placebo+aspirin;  Drug: clopidogrel + aspirin OR prasugrel + aspirin;  Device: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)\tInterventional\tPhase 4\tIndustry / Other\tIncidence of Composite of All Death MI and Stroke (Defined as MACE);  IncidenceofARCDefiniteorProbableST;  Major Bleeding (GUSTO Classification Severe and Moderate Bleeding Combined);  MACEforITTPopulation;  STforITTPopulation;  MajorBleedingforITTPopulation;  MACEforTreatmentPopulation;  STforTreatmentPopulation;  MajorBleedingforTreatmentPopulation\t870\tNCT01106534\tAugust 2009\n4043\tRecruiting\tEffect of Albiglutide When Added to Standard Blood Glucose Lowering Therapies on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus\t\tBiological:Albiglutide30mg;  Biological:Albiglutide50mg;  Biological:Albiglutidematchingplacebo\tInterventional\tPhase 4\tIndustry / Other\tTime to first occurrence of major adverse cardiovascular events (MACE; cardiovascular death myocardial infarction or stroke) [Non-inferiority];  TimetofirstoccurrenceofMACE[Superiority];  Time to first occurrence of MACE or urgent revascularisation for unstable angina;  Time to first occurrence of the individual components of the primary endpoint;  Time to first occurrence of cardiovascular death or hospitalization due to heart failure;  Allcausemortality;  Time to initiation of insulin of more than 3 months duration for those subjects not treated with insulin at study start;  The proportion of subjects achieving glycemic control (HbA1c \u0026lt;\u003d7.0% at final assessment) with no severe hypoglycemic incidents and weight gain \u0026lt;5% of body weight\t9400\tNCT02465515\tJuly 2015\n4056\tCompleted\tEvaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.\t\tDrug:Fingolimod;  Drug:DiseaseModifyingtherapy\tInterventional\tPhase 4\tIndustry\tRetentionontreatment;  ReasonsforDiscontinuation;  Adverseevents;  Cognitiveimpairment;  Percentchangeinbrainvolume;  Treatmentsatisfaction\t881\tNCT01623596\tJune 2012\n4061\tCompleted                  Has Results\tA Study of Fluzone\u0026#174; High-Dose Vaccine Compared With Fluzone\u0026#174; Vaccine In Elderly Adults\t\tBiological: High Dose Trivalent Inactivated Influenza Vaccine;  Biological: Trivalent Inactivated Influenza Vaccine\tInterventional\tPhase 4\tIndustry\tOccurrences of Culture- or Polymerase Chain Reaction (PCR)-Confirmed Influenza Caused by Any Influenza Viral Types/Subtypes in Association With a Protocol-defined Influenza-like Illness (ILI).;  Occurrences of Culture-confirmed Influenza Caused by Influenza Viral Types/Subtypes That Are Antigenically Similar to Those Contained in the Vaccine Formulations in Association With a Protocol-defined Influenza-like Illness (ILI);  Occurrences of Culture-confirmed Influenza Caused by Any Influenza Viral Types/Subtypes in Association With a Protocol-defined Influenza-like Illness;  Occurrences of Culture-confirmed Influenza Caused by Influenza Viral Types/Subtypes That Are Antigenically Similar to Those Contained in the Vaccine Formulations in Association With a Modified CDC-defined Influenza-like Illness.;  Occurrences of Culture-confirmed Influenza Caused by Any Influenza Viral Types/Subtypes in Association With a Modified CDC-defined Influenza-like Illness;  Occurrences of Culture-confirmed Influenza Caused by Influenza Viral Types/Subtypes That Are Antigenically Similar to Those Contained in the Vaccine Formulations in Association With a Respiratory Illness;  Occurrences of Culture-confirmed Influenza Caused by Any Influenza Viral Types/Subtypes in Association With a Respiratory Illness\t31989\tNCT01427309\tSeptember 2011\n4066\tCompleted\tA Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors\t\tDrug:Etanercept;  Drug:Tocilizumab\tInterventional\tPhase 4\tIndustry\tTime to First Occurrence of Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event Defined as a Composite of CV Death Non-Fatal Myocardial Infarction and Non-Fatal Stroke;  Time to First Occurrence of Expanded Composite Endpoint Defined as a Composite of CV Death Non-Fatal Myocardial Infarction Non-Fatal Stroke Non-Elective Coronary Revascularization Procedures and Hospitalization for Unstable Angina;  Percentage of Participants with Adverse Events (AEs) and Serious AEs (SAEs)\t3080\tNCT01331837\tAugust 2011\n4067\tCompleted                  Has Results\tA Clinical Study in Patients With Overactive Bladder With Leakage of Urine to Find Out if the Medicine Fesoterodine Works in Those Patients Who Did Not Have Enough Response to the Medicine Tolterodine.\t\tDrug:Fesoterodine8mg;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tMean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours;  Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12;  Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12;  Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 12;  Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Week 12;  Number of Participants With Change From Baseline in Urgency Perception Scale (UPS) at Week 12;  Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 12;  Change From Baseline in Health Related Quality of Life (HRQL) Domains and Total HRQL Score of Overactive Bladder Questionnaire (OAB-q) at Week 12;  Percentage of Participants With More Than (\u0026gt;) 50 Percent (%) Reduction in UUI Episodes at Week 12 as Compared to Week -2;  Percentage of Participants With More Than (\u0026gt;) 50 Percent (%) Reduction in UUI Episodes at Week 12 as Compared to Baseline;  Percentage of Participants With No UUI Episodes (Diary Dry Rate)\t990\tNCT01302054\tMay 2011\n4075\tCompleted                  Has Results\tDoes Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications\t\tDrug:Saxagliptin;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tParticipants With Any Event From the Composite of Cardiovascular Death (CV Death) Non-fatal Myocardial Infarction (MI) or Non-fatal Ischaemic Stroke;  Participants With Any Event From the Composite of CV Death Non-fatal MI Non-fatal Ischaemic Stroke Hospitalisation for Heart Failure Hospitalisation for Unstable Angina Pectoris or Hospitalisation for Coronary Revascularisation;  ParticipantsWithEventofDeath\t18206\tNCT01107886\tMay 2010\n4078\tTerminated                  Has Results\tA Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain\t\tDrug:Oseltamivir;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tTimetoCessationofViralShedding;  Percentage of Participants With Viral Shedding by Clinic Visit as Measured by Viral Culture;  Percentage of Participants With Viral Shedding by Clinic Visit as Measured by Reverse Transcriptase Polymerase Chain Reaction;  Change From Baseline in Influenza Titer Measured by Viral Culture;  Number of Participants With Development of Oseltamivir-Resistant Influenza Virus;  TimetoResolutionofFever;  Time to Alleviation of All Clinical Symptoms - Children;  Time to Alleviation of All Clinical Symptoms - Adults;  Number of Participants Who Developed Secondary Illnesses During the Study;  Number of Participants Who Developed Secondary Illnesses That Were Treated With Antibiotics\t102\tNCT01032837\tNovember 2009\n4090\tCompleted                  Has Results\tA Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure\t\tDrug:amlodipineandolmesartanmedoxomiltablets;  Drug:hydrochlorothiazidetablets\tInterventional\tPhase 4\tIndustry\tThe Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (\u0026lt;140 mm Hg for Non-diabetics and \u0026lt;130 mm Hg for Diabetics) From Baseline to 12 Weeks;  The Percentage of Subjects Achieving Seated Diastolic BP Goal (\u0026lt;90 mmHg for Non-diabetics or \u0026lt; 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks;  The Percentage of Subjects Who Achieve BP Goal (\u0026lt;140/90 mmHg for Non-diabetics or \u0026lt;130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks;  Change in Mean Seated Systolic Blood Pressure From Baseline to 4 8 12 16 20 Weeks;  Change in Mean Seated Diastolic Blood Pressure From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals as Measured by Ambulatory Blood Pressure Monitor From Baseline to 12 Weeks;  Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals as Measured by Ambulatory Blood Pressure Monitor From Baseline to 20 Weeks;  Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals as Measured by Ambulatory Blood Pressure Monitor From Baseline to 12 Weeks;  Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals as Measured by Ambulatory Blood Pressure Monitor From Baseline to 20 Weeks;  Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals as Measured by Ambulatory Blood Pressure Monitor From Baseline to 12 Weeks;  Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals as Measured by Ambulatory Blood Pressure Monitor From Baseline to 20 Weeks;  Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values;  Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values;  Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks;  Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks;  Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks;  Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks;  Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks;  Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks;  Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks;  Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks;  Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks;  Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks;  Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks;  Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks\t999\tNCT00791258\tNovember 2008\n4101\tCompleted                  Has Results\tExubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety\t\tDrug: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care\tInterventional\tPhase 4\tIndustry\tNumber of Subjects With Decline in Forced Expiratory Volume (FEV1) Exceeding 20% From Baseline;  Supplemental Definition of Decline in Forced Expiratory Volume in One Second (FEV1): Number of Subjects;  Time to Persistent Decline in FEV1 Exceeding 20% From Baseline;  Change From Baseline in Forced Expiratory Volume in One Second (FEV1);  Pulmonary Serious Adverse Event (SAE) Composite: SAEs of Asthma Chronic Obstructive Pulmonary Disease (COPD) Pneumonia or Acute Bronchitis;  Time to Event for Pulmonary Serious Adverse Event (SAE) Composite: SAEs of Asthma Chronic Obstructive Pulmonary Disease (COPD) Pneumonia or Acute Bronchitis;  All-causeMortality:NumberofDeaths;  TimetoEvent:All-causeMortality;  Cardiovascular SAE Composite: SAEs of Cardiovascular Mortality Non-fatal Myocardial Infarction (MI) or Non-fatal Stroke;  Time to Event for Cardiovascular Serious Adverse Event (SAE) Composite: SAEs of Cardiovascular Mortality Non-fatal Myocardial Infarction or Non-fatal Stroke;  Allergic Response Serious Adverse Event (SAE) Composite: SAEs of Anaphylaxis Angioedema Generalized Allergic Reaction or Allergic Bronchospasm;  Time to Event for Allergic Response Serious Adverse Event (SAE) Composite Including: SAEs of Anaphylaxis Angioedema Generalized Allergic Reaction or Allergic Bronchospasm;  Change in Glycosylated Hemoglobin (HbA1c) From Baseline\t1976\tNCT00359801\tJuly 2006\n4139\tCompleted\tStudy of Safety of Foradil in Patients With Persistent Asthma\t\tDrug:Formoterol;  Drug:Fluticasonepropionate100mcg;  Drug:Fluticasonepropionate250mcg;  Drug:Fluticasonepropionate500mcg;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tCombinedseriousasthmarelatedevents;  Asthma-relatedhospitalization;  Asthma-relatedintubation;  Asthma-relateddeaths;  Rescuemedicationuse;  Symptomandrescue-freedays;  Nighttimeawakenings;  AsthmacontrolQuestionnaire(ACQ-6)score\t827\tNCT01845025\tMay 2013\n4177\tCompleted                  Has Results\tThe Dual Antiplatelet Therapy Study (DAPT Study)\t\tDrug:Placebo\u0026amp;Aspirin;  Drug:Clopidogrel\u0026amp;AspirinPrasugrel\u0026amp;Aspirin\tInterventional\tPhase 4\tOther / Industry\tMACCE (Death Myocardial Infarction or Stroke) - Randomized DES ITT;  Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT;  GUSTO Severe or Moderate Bleeding - Randomized DES ITT;  MACCE (Death Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS;  Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS;  MACCE (Death Myocardial Infarction or Stroke) - Randomized BMS ITT;  Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT;  GUSTO Severe or Moderate Bleeding - Randomized BMS ITT\t25682\tNCT00977938\tOctober 2009\n4194\tCompleted                  Has Results\tA Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet Sumatriptan Tablet and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period\t\tDrug: sumatriptan and naproxen sodium combination tablet;  Drug:sumatriptantablet;  Drug:naproxensodiumtablet\tInterventional\tPhase 4\tIndustry\tMean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen;  Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan and Naproxen;  Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Sumatriptan;  Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Naproxen;  Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating on Average \u0026lt;4 Migraines 4-6 Migraines \u0026gt;\u003d4 Migraines and \u0026gt;6 Migraines Per Month;  Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating on Average \u0026lt;1.3 Times Per Migraine 1.3-1.7 Times Per Migraine and \u0026gt;1.7 Times Per Migraine;  Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating on Average With \u0026lt;6 6-10 \u0026gt;\u003d6 10-14 and \u0026gt;14 Doses Per Month;  Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating With \u0026lt;30 Total Doses 30-60 Total Doses \u0026gt;\u003d30 60-90 Total Doses and \u0026gt;90 Total Doses;  Number of Participants With an Increase of \u0026gt;\u003d5 mmHg From the Baseline Systolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements;  Number of Participants With an Increase of \u0026gt;\u003d3 mmHg From the Baseline Diastolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements;  Number of Participants With a Consecutive 2-day Average Systolic Blood Pressure of \u0026gt;\u003d140 mmHg During the Study;  Number of Participants With a Consecutive 2-day Average Diastolic Blood Pressure of \u0026gt;\u003d90 mmHg;  Time to the First Day With an Average Systolic Blood Pressure Increase of \u0026gt;\u003d5 mmHg From the Baseline Systolic Blood Pressure;  Time to the First Day With an Average Diastolic Blood Pressure Increase of \u0026gt;\u003d3 mmHg From the Baseline Diastolic Blood Pressure;  Number of Participants Withdrawn From the Study Due to Blood Pressure Changes\t407\tNCT00792636\tNovember 2008\n4224\tCompleted\tPatient\u0026apos;s Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder\t\tDrug:Darifenacin\tInterventional\tPhase 4\tIndustry\tChange from baseline in the patient\u0026apos;s perception of outcome at Week 13 using the Patient Perception Bladder Condition questionnaire (PPBC).;  Patient\u0026apos;s perception of outcome using the PPBC questionnaire at Week 7.;  Patient\u0026apos;s satisfaction by using the Patient Satisfaction Treatment Benefits questionnaire (PSTB Part I) at Week 13.;  Assessment of efficacy of darifenacin with respect to change from baseline in:;  NumberofmicturitionsperdayatWeeks7and13;  Number of urgency episodes per day at Weeks 7 and 13;  Number of urge urinary incontinence episodes (UUIE) per week at Weeks 7 and 13;  Assessmentofsafetyandtolerability\t500\tNCT00366002\tJune 2006\n4226\tRecruiting\tVision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo\t\tDrug:Lyrica(pregabalin);  Drug:placebo\tInterventional\tPhase 4\tIndustry\tChanges in vision from baseline to end of study assessed by the Humphrey Visual Field Analzyer.;  Visual acuity will be assessed at the baseline and end of the study.;  Change in mean deviation score on the Humphrey Visual Field at baseline and end of the study.\t284\tNCT00351611\tJuly 2006\n4228\tCompleted\tRosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin\t\tDrug:rosiglitazone\tInterventional\tPhase 4\tIndustry\tHbA1cateachvisit;  FPG at each visit C-peptide at each visit lipids at each visit BNP at each visit CRP at each visit PAI-1 at each visit MMP-9 at each visit\t630\tNCT00329225\tSeptember 2002\n4231\tCompleted\tPROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)\t\tDrug:Telmisartan\u0026amp;Hydrochlorothiazide;  Drug:Losartan\u0026amp;Hydrochlorothiazide;  Procedure:ABPM\tInterventional\tPhase 4\tIndustry\tChange from baseline in the last 6-hour mean (relative to dose time) diastolic blood pressure (DBP) as measured by ABPM (Ambulatory Blood Pressure Monitoring);  Change in the last 6-hour ABPM mean (relative to dosing time) for systolic blood pressure (SBP);  Change in the 24-hour ABPM mean (relative to dosing time) for DBP and SBP;  Change in the ABPM mean DBP and SBP during the morning daytime and night-time periods of the 24-hour dosing interval;  Change in systolic and diastolic blood pressure load during the 24-hour dosing interval of the 24-hour dosing interval;  Change in mean seated trough DBP and SBP as measured by manual in-clinic cuff sphygmomanometer;  Responder rates based on both the 24-hour ABPM mean (relative to dose time) blood pressures and the in-clinic trough cuff measurements\t805\tNCT00274638\tJuly 2002\n4243\tCompleted                  Has Results\tPRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes\t\tDrug:Aggrenox;  Drug:Clopidogrelplacebo;  Drug:Micardis;  Drug:Aggrenoxplacebo;  Drug:Clopidogrel;  Drug:Micardisplacebo\tInterventional\tPhase 4\tIndustry\tNumber of Patients With First Recurrent Stroke of Any Type Fatal or Nonfatal (Antiplatelet Comparison Only);  Number of Patients With First Recurrent Stroke of Any Type Fatal or Nonfatal (Telmisartan vs. Placebo Only);  Composite Outcome of Stroke Myocardial Infarction (MI) or Vascular Death (Antiplatelet Comparison Only);  Composite Outcome of Stroke Myocardial Infarction Vascular Death or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only);  Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)\t20332\tNCT00153062\tAugust 2003\n4305\tRecruiting\tA Study of Apixaban in Patients With Atrial Fibrillation Not Caused by a Heart Valve Problem Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event Such as a Heart Attack or a Procedure to Open the Vessels of the Heart\t\tDrug:Apixaban;  Drug:vitaminKantagonist;  Drug:Acetylsalicylicacid;  Other:Acetylsalicylicacidplacebo\tInterventional\tPhase 4\tIndustry / Other\tTime to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major or Clinically Relevant Non-Major (CRNM) bleeding during the treatment period between Apixaban and VKA;  Time to first occurrence of major or CRNM bleeding during the treatment period between No aspirin and aspirin;  Superiority on major + CRNM bleeding between Apixaban versus VKA;  The composite endpoints of death and ischemic events (stroke myocardial infarction stent thrombosis urgent revascularization) between Apixaban versus VKA;  First re-hospitalization for any cause between Apixaban versus VKA;  The composite endpoints of death and ischemic events (stroke myocardial infarction stent thrombosis urgent revascularization) between aspirin versus placebo;  First re-hospitalization for any cause between aspirin versus placebo\t4600\tNCT02415400\tJune 2015\n4309\tRecruiting\tWorld-wide Randomized Antibiotic Envelope Infection Prevention Trial\t\tDevice:TYRXAbsorbableAntibacterialEnvelope\tInterventional\tPhase 4\tIndustry / Other\tThefirstoccurrenceofamajorCIEDinfection.;  The first occurrence of a major or minor CIED infection;  The first occurrence of a CIED procedure related or system related complication\t7764\tNCT02277990\tJanuary 2015\n4330\tCompleted\tUsing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients\t\tDrug:TERIFLUNOMIDEHMR1726\tInterventional\tPhase 4\tIndustry\tAssessment at 48 weeks of global satisfaction with teriflunomide treatment measured by the Treatment Satisfaction Questionnaire for Medicine (TSQM) version 1.4 score;  Change in Treatment Satisfaction Questionnaire for Medicine (TSQM) from baseline to week 4 (W4) and to week 48 (W48) in patients switching from another Disease Modifying Therapy (DMT);  Change in Treatment Satisfaction Questionnaire for Medicine (TSQM) from W4 to W48 in na\u0026#239;ve patients;  Change in disease progression from baseline to week 24 (W24) and to W48 of teriflunomide treatment measured by the Patient Determined Disease Steps (PDDS);  Change in disease progression from baseline to W24 and to W48 of teriflunomide treatment measured by the Multiple Sclerosis Performance Scale (MSPS) score;  Clinical outcomes: treated relapses time to first treated relapse;  Change in cognition from baseline to W48 of teriflunomide treatment measured by the Symbol Digit Modalities Test (SDMT) score;  Overview of adverse events (AEs) based on AE reporting at each visit;  Adherence (ie compliance) and persistence (ie duration of exposure) to teriflunomide treatment;  Quality of life: change from baseline to W48 of teriflunomide treatment measured by the Multiple Sclerosis International Quality of Life (MusiQoL) score and Stern Leisure Activity Scale;  ExpandedDisabilityStatusScale(EDSS)score\t1001\tNCT01895335\tJune 2013\n4338\tRecruiting\tEfficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)\t\tBiological:Placeboplusstandardtherapy;  Biological: Belimumab 10 mg/kg plus standard therapy;  Drug:Standardtherapy\tInterventional\tPhase 4\tIndustry\tResponse rate at 52 weeks measured by the SLE Responder Index (SRI);  Timetofirstsevereflare(SLEFlareIndex);  Reductioninprednisonedose;  Number of participants who experienced adverse events\t816\tNCT01632241\tFebruary 2013\n4345\tCompleted                  Has Results\t8-week Randomized Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension\t\tDrug:Aliskiren\tInterventional\tPhase 4\tIndustry\tChange From Baseline (Visit 3) to End of Study (Week 8) in Mean 24 Hour Ambulatory Systolic Blood Pressure (maSBP);  Change From Baseline (Visit 3) to End of Study (Week 8) in Mean 24 Hour Ambulatory Diastolic Blood Pressure (maDBP);  Percentage of Patients Achieving Blood Pressure Control;  Change From Baseline (Visit 3) to End of Study (8 Weeks) in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP);  Percentage of Patients Achieving a Successful Response in Systolic Blood Pressure Reduction;  Pharmacokinetic (PK) of Aliskiren: The Observed Maximum Plasma Concentration (Cmax) Following Drug Administration in Fasted vs. Fed;  Pharmacokinetic of Aliskiren: The Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) in Fasted vs. Fed;  Pharmacokinetic of Aliskiren: Time to Reach the Maximum Concentration (Tmax) After Drug Administration in Fasted vs. Fed;  Change From Baseline to Week 8 in Plasma Renin Activity (PRA);  Change From Baseline to Week 8 in Plasma Renin Concentration (PRC);  Number of Patients With Adverse Events Serious Adverse Events and Death\t589\tNCT01570686\tApril 2012\n4354\tCompleted                  Has Results\tStudy of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)\t\tDrug:Nebivolol;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tTroughSeatedDiastolicBloodPressure(DBP);  TroughSeatedSystolicBloodPressure(SBP)\t641\tNCT01415531\tAugust 2011\n4356\tCompleted                  Has Results\tAllopurinol Outcome Study\t\tDrug:Allopurinol\tInterventional\tPhase 4\tIndustry\tSafetyofAllopurinol;  Proportion of Subjects With Serum Urate (sUA) Less Than 6.0 mg/dL;  IncidenceofGoutFlares;  Mean Change From Baseline to Month 6 in SF-36 PCS+MCS\t1735\tNCT01391325\tJuly 2011\n4358\tTerminated                  Has Results\tStudy to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes\t\tDrug:Valturna;  Drug:Amlodipine;  Drug:Chlorthalidone;  Drug:PlaceboofValturnaTablet;  Drug:PlaceboCapsule\tInterventional\tPhase 4\tIndustry\tChange From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) After 12 Weeks of Treatment Ending With the Combination of Valturna and Amlodipine Versus Valturna Alone;  Change From Baseline in MSSBP After 12 Weeks of Treatment Ending With Between the Valturna + Chlorthalidone Combination and Valturna Alone;  Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) After 12 Weeks of Treatment;  PercentageofRespondersAfterTreatment;  Percentage of Patients Achieving Blood Pressure Control After Treatment;  Number of Patients With Adverse Events Serious Adverse Events and Death to Assess Safety and Tolerability of Treatment With Valturna and Chlorthalidone or Valturna and Amlodipine Versus Valturna Alone\t975\tNCT01368536\tMay 2011\n4361\tTerminated                  Has Results\tA Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor\t\tDrug:tocilizumab[RoActemra/Actemra];  Drug:adalimumab;  Drug:placebototocilizumab;  Drug:placebotoadalimumab;  Drug:methotrexate;  Drug:folate\tInterventional\tPhase 4\tIndustry\tPercentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24;  Percentage of Participants With American College of Rheumatology (ACR20) Response at Week 24;  Percentage of Participants With ACR50 Response at Week 24;  Percentage of Participants With ACR70 Response at Week 24;  Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) DAS28 Responses at Week 24;  Percentage of Participants With DAS28 Low Disease Activity (LDAS) at Week 24;  ChangeFromBaselineinDAS28ScoreatWeek24;  Change From Baseline in Swollen Joint Count (SJC) at Week 24;  Change From Baseline in Tender Joint Count (TJC) at Week 24;  Change From Baseline in Patient Assessment of Pain Visual Analog Scale (VAS) at Week 24;  Change From Baseline in the Patient Global Assessment of Disease Activity VAS at Week 24;  Change From Baseline in the Physician Global Assessment of Disease Activity VAS at Week 24;  Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) at Week 24;  Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 24;  Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24;  Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) Score at Week 24;  Change From Baseline in Quality of Life Short Form (SF-36) Score at Week 24;  Change From Baseline in Routine Assessment of Patient Index Data 3 (RAPID3) Score at Week 24;  ChangeFromBaselineinHemoglobinatWeek24;  Number of Participants With Serious Adverse Events (SAEs) Adverse Events (AEs) Discontinuation Due to AEs and Deaths\t96\tNCT01283971\tMay 2011\n4367\tTerminated                  Has Results\tConversion to Embeda With Rescue Trial\t\tDrug: morphine sulfate and naltrexone hydrochloride (EMBEDA)\tInterventional\tPhase 4\tIndustry\tPercentage of Participants Achieving Stable Dose of EMBEDA Within 6 Weeks Titration Phase;  Percentage of Participants Achieving Stable Dose of EMBEDA Within 6 Weeks Titration Phase Stratified by Prior Opioid Therapy;  DurationtoTitrateParticipantstoStableDose;  Duration to Titrate Participants to Stable Dose Stratified by Prior Opioid Therapy;  NumberofTitrationStepstoAchieveStableDose;  Number of Titration Steps to Achieve Stable Dose Stratified by Prior Opioid Therapy;  Percentage of Participants With Rescue Medications Usage During Titration;  Change From Baseline in Brief Pain Inventory (BPI) at Visit 3 (First Visit After Successful Titration);  Investigator\u0026apos;s Level of Satisfaction With the EMBEDA Conversion Guide\t684\tNCT01179191\tAugust 2010\n4372\tCompleted                  Has Results\tChronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study\t\tDrug:ADVAIRDISKUS250/50mgBID;  Drug:SEREVENT50mcgBID\tInterventional\tPhase 4\tIndustry\tNumber of Par. With Chronic Obstructive Pulmonary Disease (COPD) EXs Requiring Hospitalization That Occurred \u0026gt;21 Days Post-discharge/Physician\u0026apos;s Office Visit for a COPD EX Requiring Treatment With Oral Corticosteroids (OCSs) or OCSs and Antibiotics (ABs);  Number of Participants With the Indicated Number of EXs of COPD Requiring Hospitalization That Occurred More Than 21 Days Post-discharge or Physician\u0026apos;s Office Visit for an EX of COPD Requiring Treatment With OCSs or OCSs and ABs;  Number of EXs of COPD Requiring Hospitalization That Occurred More Than 21 Days Post-discharge or Physician\u0026apos;s Office Visit for an EX of COPD Requiring Treatment With OCSs or OCSs and ABs;  Number of Participants With an EX of COPD Requiring Treatment With OCSs Treatment With ABs and/or Hospitalization;  Number of EXs of COPD Requiring Treatment With OCSs Treatment With ABs and/or Hospitalization (Alone and in Combination)\t639\tNCT01110200\tApril 2010\n4390\tCompleted                  Has Results\tA Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency\t\tDrug:Fesoterodine;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tMean Number of Micturition-related Nocturnal Urgency Episodes Per 24 Hours;  Change From Baseline in Mean Number of Micturition-related Nocturnal Urgency Episodes Per 24 Hours at Week 12;  Change From Baseline in Mean Number of Micturition-related Nocturnal Urgency Episodes Per 24 Hours at Week 4;  Percent Change From Baseline in Micturition-related Nocturnal Urgency Episodes Per 24 Hours at Week 4 and 12;  NumberofNocturnalMicturitionsPer24Hours;  Change From Baseline in Number of Nocturnal Micturitions Per 24 Hours at Week 4 and 12;  Percent Change From Baseline in Nocturnal Micturitions Per 24 Hours at Week 4 and 12;  MeanNumberofMicturitionsPer24Hours;  Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4 and 12;  Percent Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12;  Number of Micturition-related Urgency Episodes Per 24 Hours;  Change From Baseline in Number of Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12;  Percent Change From Baseline in Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12;  Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours;  Change From Baseline in Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12;  Percent Change From Baseline in of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12;  Nocturnal Frequency-urgency Sum Rating Per 24 Hours;  Change From Baseline in Nocturnal Frequency-urgency Sum Rating Per 24 Hours at Week 4 and 12;  Frequency-urgencySumRatingPer24Hours;  Change From Baseline in Frequency-urgency Sum Rating Per 24 Hours at Week 4 and 12;  MeanVoidedVolumePerNocturnalMicturition;  Change From Baseline in Mean Voided Volume Per Nocturnal Micturition at Week 12;  MeanVoidedVolumePerMicturition;  Change From Baseline in Mean Voided Volume Per Micturition at Week 12;  Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score;  Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 4 and 12;  Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q);  Change From Baseline in Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 4 and 12\t963\tNCT00911937\tAugust 2009\n4405\tCompleted\tThe Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose\t\tDrug:Nebivolol;  Drug:HCTZ;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tTroughseateddiastolicbloodpressure(DBP);  Plasma glucose level after an oral glucose tolerance test;  Homeostasis Model Assessment of Insulin Resistance;  Troughseatedsystolicbloodpressure(SBP);  FastingBloodGlucose\t543\tNCT00673790\tMay 2008\n4410\tCompleted\tA Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.\t\tDrug:tolterodineextendedrelease\tInterventional\tPhase 4\tIndustry\tChange from baseline to Week 12 in the micturition bladder diary variable related to the primary symptom of the patient at the time of study entry;  OABBotherRatingScaleatbaseline;  Change from baseline to Week 4 and 12 in micturition bladder diary variables;  Change from baseline to Week 4 and 12 in Patient\u0026apos;s Perception of Bladder Condition;  Change from baseline to Week 4 and 12 in AUA Symptom Index;  Change from baseline to Week 4 and 12 in OAB questionnaire;  ClinicalGlobalImpression-ImprovementatWeek12;  Overall Treatment Effect Scale of Overactive Bladder Control at Week 4 and 12;  To asses the safety of tolterodine in patients with OAB\t896\tNCT00645281\tMarch 2004\n4453\tCompleted                  Has Results\tThe DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)\t\tDrug:Insulinglargine;  Drug:LisproLowMix;  Drug:LisproMidMix;  Drug:Lispro\tInterventional\tPhase 4\tIndustry\tINITIATION: 24-Week Endpoint Glycosylated Hemoglobin (HbA1c);  MAINTENANCE: Duration of Time HbA1c Maintained at Goal by Initiation Regimen (Insulin Glargine or Lispro Low Mix);  ADDENDUM:24-WeekEndpointHbA1c;  INITIATION: Change in HbA1c From Baseline to 24 Weeks;  INITIATION: Percentage of Participants With HbA1c \u0026lt; or \u003d 7.0% HbA1c \u0026lt;7.0% and HbA1c \u0026lt; or \u003d 6.5% at Endpoint;  INITIATION:HbA1c;  INITIATION: 7-point Self-monitored Plasma Glucose (SMPG) Profiles and Postprandial Excursions;  INITIATION: Change From Baseline to Endpoint in 15 Anhydroglucitol (15 AG);  INITIATION: Incremental Change From Baseline in Body Weight;  INITIATION:BodyWeight;  INITIATION: Percentage of Participants With Self-reported Hypoglycemic Episodes;  INITIATION: Rate of Self-reported Hypoglycemic Episodes;  INITIATION:InsulinDose;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Age;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Origin;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Homeostasis Model Assessment of Insulin Resistance (HOMA-IR);  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - HbA1c;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Baseline HbA1c Percentage Group;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - 15 AG;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Pre Meals Blood Glucose Post Meals Blood Glucose Average of All Blood Glucose and Fasting Blood Glucose;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal - Oral Diabetes Medication at Baseline;  MAINTENANCE: HbA1c at Specified Visits and Endpoint;  MAINTENANCE: 7-point SMPG Profiles and Postprandial Excursions;  MAINTENANCE:RateofIncreaseinHbA1c;  MAINTENANCE: Percentage of Participants With HbA1c \u0026lt; or \u003d 7.0% HbA1c \u0026lt;7.0 and HbA1c \u0026lt; or \u003d 6.5%;  MAINTENANCE: Incremental Change From Baseline in Body Weight;  MAINTENANCE:BodyWeight;  MAINTENANCE:InsulinDose;  MAINTENANCE: Percentage of Participants With Self-reported Hypoglycemic Episodes;  MAINTENANCE: Rate of Self-reported Hypoglycemic Episodes;  MAINTENANCE: Change From Baseline in 15-Anhydroglucitol;  MAINTENANCE: Change From Baseline to Endpoint in HbA1c;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - 15 AG;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - 15 AG;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose;  ADDENDUM: Change in HbA1c From Point of Second Randomization (Addendum Baseline) to Endpoint;  ADDENDUM: Percentage of Participants With HbA1c \u0026lt; or \u003d 7.0% HbA1c \u0026lt; 7.0% and \u0026lt; or \u003d 6.5%;  ADDENDUM:7-pointSMPGProfiles;  ADDENDUM: Incremental Change From Baseline in Body Weight;  ADDENDUM:BodyWeight;  ADDENDUM:InsulinDose;  ADDENDUM: Percentage of Participants With Self-reported Hypoglycemic Episodes;  ADDENDUM: Rate of Self-reported Hypoglycemic Episodes;  ADDENDUM: Change From Baseline in 15-Anhydroglucitol to Week 24;  ADDENDUM:HbA1catSpecifiedVisitsandEndpoint\t2091\tNCT00279201\tDecember 2005\n4457\tCompleted\tA Randomized Double-blind Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients\t\tDrug:telmisartan80mg/hydrochlorothiazide25mg;  Drug:valsartan160mg/hydrochlorothiazide25mg;  Drug:placebo\tInterventional\tPhase 4\tIndustry\tChange from baseline in mean seated trough cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period;  Percentage of responders based on change from baseline in cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period\t1109\tNCT00240448\tSeptember 2003\n4465\tCompleted\tEfficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy\t\tDrug:Estradiol\tInterventional\tPhase 4\tIndustry\t\t\tNCT00160173\t\n4466\tCompleted\tClinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population\t\tDrug:Amlodipine/Atorvastatin\tInterventional\tPhase 4\tIndustry\tTo evaluate the efficacy of Caduet therapy by assessing the percentage of intent-to-treat subjects achieving both BP and lipid treatment goals (JNC VII and NCEP ATP III);  To assess the percentage of subjects achieving treatment goals(JNC VII and NCEP) stratified by the final BP and lipid therapy doses respectively the change from baseline in lipid profile SBP and DBP\t500\tNCT00150384\tJuly 2004\n4473\tCompleted\tAdvair\u0026#174; DISKUS\u0026#174; Versus Serevent\u0026#174; DISKUS\u0026#174; For Chronic Obstructive Pulmonary Disease Exacerbations\t\tDrug: Fluticasone Propionate/Salmeterol Combination Product;  Drug:Salmeterol\tInterventional\tPhase 4\tIndustry\tRate of moderate/severe exacerbations over a 52 week treatment period;  The time until the first moderate/severe exacerbation; the annual rate of exacerbations requiring oral corticosteroid treatment and breathing tests conducted over one year\t797\tNCT00115492\tDecember 2004\n4476\tCompleted\tStudy Of Asthma In Patients Of African Descent\t\tDrug:fluticasonepropionate/salmeterolpowder;  Drug:fluticasonepropionatepowder\tInterventional\tPhase 4\tIndustry\tAsthmaexacerbationrateperpatientperyear;  Morning peak flow measurement percent of asthma symptom-free days percent of albuterol-free days\t479\tNCT00102765\tNovember 2004\n4489\tCompleted\tEffect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension\t\tDrug:carvedilol;  Drug:metoprolol\tInterventional\tPhase 4\tIndustry\tChangefrombaselineinHbA1cat5months;  Blood pressure at 3 and 5 months Body weight at 3 and 5 months Lab levels (glucose insulin triglycerides cholesterol and albumin:creatinine ratio) at 3 and 5 months.\t501\tNCT00060931\tJune 2001\n4571\tTerminated\tA Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects\t\tDrug:Arformoteroltartrateinhalationsolution;  Drug:Tiotropium\tInterventional\tPhase 4\tIndustry\tThe rate of all-cause hospitalization or Emergency Department visit within 90-days of initiating treatment.\t66\tNCT02275481\tNovember 2014\n4580\tRecruiting\tStudy to Evaluate the Efficacy Safety and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)\t\tDrug:Mirabegron;  Drug:Placebo\tInterventional\tPhase 4\tIndustry\tChange from baseline to the end of treatment in mean number of micturitions/24 hour based on a 3-day micturition diary;  Change from baseline to end of treatment in mean number of incontinence episodes/24 hour based on a 3-day micturition diary;  Change from baseline to the end of treatment in mean volume voided per micturition;  Change from baseline to the end of treatment in symptom bother and total health related quality of life scores as assessed by OAB-q questionnaire;  Change from baseline to the end of treatment in PPBC;  Safety profile assessed by adverse events (AE) and vital signs;  Safety profile assessed by laboratory parameters (serum chemistry hematology and urinalysis);  Change from baseline to end of treatment in Montreal Cognitive Assessment (MoCA) score\t800\tNCT02216214\tSeptember 2014\n4586\tCompleted                  Has Results\tConcomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.\t\tBiological: 13-valent pneumococcal conjugate vaccine;  Biological: Seasonal Inactivated Influenza Vaccine;  Other:Placebo\tInterventional\tPhase 4\tIndustry\tSerotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes;  Hemagglutination Inhibition Assay (HAI) Geometric Mean Titers (GMTs) for Each Influenza Virus Strain in Quadrivalent Influenza Vaccine (QIV);  Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 1;  Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 2;  Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After 13vPnC Vaccination;  Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) at the 6-Month Follow-up;  Percentage of Participants Achieving Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibody Titer Greater Than or Equal to (\u0026gt;\u003d) Lower Limit of Quantitation (LLOQ);  Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 1 to Immediately Before 13vPnC Vaccination 1;  Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 2 to Immediately Before 13vPnC Vaccination 2;  Percentage of Participants Achieving Seroconversion in Hemagglutination Inhibition Assay (HAI) Titers;  Geometric Mean Fold Rise (GMFR) in Hemagglutination Inhibition Assay (HAI) 1 Month After Vaccination 1 to Immediately Before Vaccination 1\t882\tNCT02124161\tSeptember 2014\n4635\tCompleted                  Has Results\t6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old\t\tDrug:ADVAIR100/50mcg;  Drug:ADVAIR250/50mcg;  Drug:FLOVENT100mcg;  Drug:FLOVENT250mcg\tInterventional\tPhase 4\tIndustry\tNumber of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization Asthma-related Endotracheal Intubation or Asthma-related Death);  Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period;  Number of Participants Experiencing Asthma-related Deaths Over the 6-month Study Treatment Period.;  Number of Participants Experiencing Asthma-related Endotracheal Intubations Over the 6-month Study Treatment Period;  Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period;  Number of Participants Withdrawn From Study Treatment Due to Asthma Exacerbation Over the 6-month Study Treatment Period;  Percentage of Rescue-free Days Over the 6-month Study Treatment Period;  Percentage of Asthma Control Days Over the 6-month Study Treatment Period\t6250\tNCT01462344\tNovember 2011\n4677\tCompleted                  Has Results\tDiscontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia\t\tDrug:Placebo;  Drug:Milnacipran\tInterventional\tPhase 4\tIndustry\tTimetoLossofTherapeuticResponse(LTR);  Time to Worsening in Patient Global Impression of Change (PGIC);  Time to Worsening in Multidimensional Assessment of Fatigue (MAF)\t340\tNCT01014585\tNovember 2009\n"
      },
      "dateCreated": "Dec 4, 2016 1:27:26 PM",
      "dateStarted": "Dec 4, 2016 8:44:28 PM",
      "dateFinished": "Dec 4, 2016 8:44:28 PM",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%sql\n\nselect number_enrolled,status from table_df",
      "dateUpdated": "Dec 4, 2016 6:50:52 PM",
      "config": {
        "colWidth": 6.0,
        "graph": {
          "mode": "pieChart",
          "height": 434.0,
          "optionOpen": false,
          "keys": [
            {
              "name": "status",
              "index": 1.0,
              "aggr": "sum"
            }
          ],
          "values": [
            {
              "name": "status",
              "index": 1.0,
              "aggr": "sum"
            }
          ],
          "groups": [],
          "scatter": {
            "xAxis": {
              "name": "number_enrolled",
              "index": 0.0,
              "aggr": "sum"
            },
            "yAxis": {
              "name": "status",
              "index": 1.0,
              "aggr": "sum"
            }
          }
        },
        "enabled": true,
        "editorMode": "ace/mode/sql",
        "editorHide": true
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "jobName": "paragraph_1480876187700_-17631158",
      "id": "20161204-182947_461973247",
      "result": {
        "code": "SUCCESS",
        "type": "TABLE",
        "msg": "number_enrolled\tstatus\n100\tRecruiting\n150\tRecruiting\n450\tRecruiting\n60\tRecruiting\n35\tNot yet recruiting\n40\tNot yet recruiting\n230\tNot yet recruiting\n500\tNot yet recruiting\n100\tRecruiting\n20\tNot yet recruiting\n80\tNot yet recruiting\n350\tRecruiting\n102\tRecruiting\n120\tRecruiting\n8\tNot yet recruiting\n60\tRecruiting\n60\tRecruiting\n60\tRecruiting\n20\tRecruiting\n75\tNot yet recruiting\n120\tNot yet recruiting\n20\tRecruiting\n99\tNot yet recruiting\n24\tNot yet recruiting\n30\tRecruiting\n40\tRecruiting\n5000\tRecruiting\n60\tNot yet recruiting\n400\tRecruiting\n100\tNot yet recruiting\n100\tRecruiting\n180\tRecruiting\n60\tRecruiting\n100\tNot yet recruiting\n60\tRecruiting\n60\tRecruiting\n60\tNot yet recruiting\n350\tNot yet recruiting\n20\tNot yet recruiting\n32\tNot yet recruiting\n54\tNot yet recruiting\n24\tRecruiting\n300\tNot yet recruiting\n50\tEnrolling by invitation\n100\tRecruiting\n22\tRecruiting\n12\tNot yet recruiting\n60\tRecruiting\n20\tRecruiting\n100\tRecruiting\n120\tNot yet recruiting\n25\tRecruiting\n60\tRecruiting\n50\tNot yet recruiting\n102\tCompleted\n167\tCompleted\n40\tNot yet recruiting\n880\tRecruiting\n36\tRecruiting\n44\tRecruiting\n60\tNot yet recruiting\n7\tRecruiting\n210\tNot yet recruiting\n100\tRecruiting\n32\tRecruiting\n200\tRecruiting\n30\tRecruiting\n164\tRecruiting\n68\tCompleted\n45\tNot yet recruiting\n139\tActive not recruiting\n200\tActive not recruiting\n200\tRecruiting\n50\tNot yet recruiting\n16\tNot yet recruiting\n100\tEnrolling by invitation\n75\tRecruiting\n1000\tRecruiting\n40\tRecruiting\n10\tRecruiting\n20\tNot yet recruiting\n30\tNot yet recruiting\n20\tRecruiting\n40\tRecruiting\n165\tRecruiting\n3000\tRecruiting\n24\tRecruiting\n12\tRecruiting\n60\tEnrolling by invitation\n18\tCompleted\n850\tNot yet recruiting\n40\tRecruiting\n70\tNot yet recruiting\n50\tNot yet recruiting\n250\tNot yet recruiting\n46\tRecruiting\n300\tRecruiting\n200\tEnrolling by invitation\n20\tNot yet recruiting\n400\tRecruiting\n100\tRecruiting\n25\tRecruiting\n250\tNot yet recruiting\n40\tRecruiting\n276\tNot yet recruiting\n25\tRecruiting\n30\tNot yet recruiting\n34\tRecruiting\n40\tRecruiting\n300\tRecruiting\n330\tNot yet recruiting\n28\tNot yet recruiting\n274\tNot yet recruiting\n30\tRecruiting\n\tRecruiting\n350\tRecruiting\n1000\tNot yet recruiting\n24\tActive not recruiting\n40\tRecruiting\n45\tRecruiting\n20\tRecruiting\n2400\tRecruiting\n50\tRecruiting\n30\tRecruiting\n87\tRecruiting\n360\tRecruiting\n40\tRecruiting\n85\tRecruiting\n36\tRecruiting\n24\tRecruiting\n0\tWithdrawn\n60\tRecruiting\n70\tNot yet recruiting\n1520\tRecruiting\n20\tNot yet recruiting\n74\tNot yet recruiting\n98\tRecruiting\n50\tRecruiting\n24\tNot yet recruiting\n100\tNot yet recruiting\n25\tRecruiting\n40\tRecruiting\n200\tRecruiting\n120\tRecruiting\n18\tActive not recruiting\n30\tNot yet recruiting\n432\tRecruiting\n10\tCompleted\n53\tCompleted\n19\tActive not recruiting\n4\tNot yet recruiting\n124\tRecruiting\n54\tTerminated\n15\tRecruiting\n96\tNot yet recruiting\n40\tRecruiting\n5\tRecruiting\n16\tEnrolling by invitation\n120\tRecruiting\n60\tRecruiting\n125\tRecruiting\n40\tNot yet recruiting\n40\tNot yet recruiting\n220\tRecruiting\n250\tRecruiting\n50\tActive not recruiting\n8\tRecruiting\n23\tActive not recruiting\n60\tNot yet recruiting\n12\tRecruiting\n100\tRecruiting\n1000\tRecruiting\n32\tNot yet recruiting\n77\tActive not recruiting\n158\tRecruiting\n1200\tRecruiting\n98\tRecruiting\n80\tRecruiting\n96\tRecruiting\n39\tRecruiting\n31\tRecruiting\n12\tRecruiting\n300\tRecruiting\n65\tActive not recruiting\n105\tRecruiting\n75\tRecruiting\n200\tRecruiting\n70\tRecruiting\n30\tRecruiting\n60\tRecruiting\n120\tRecruiting\n100\tCompleted\n48\tCompleted\n500\tRecruiting\n2310\tRecruiting\n18\tRecruiting\n20\tRecruiting\n210\tRecruiting\n66\tRecruiting\n345\tRecruiting\n100\tRecruiting\n510\tRecruiting\n110\tEnrolling by invitation\n60\tRecruiting\n41\tCompleted\n24\tCompleted\n60\tActive not recruiting\n22\tRecruiting\n30\tRecruiting\n24\tActive not recruiting\n150\tRecruiting\n84\tRecruiting\n60\tRecruiting\n90\tRecruiting\n50\tRecruiting\n30\tRecruiting\n80\tRecruiting\n30\tRecruiting\n10\tRecruiting\n24\tRecruiting\n50\tRecruiting\n50\tRecruiting\n100\tRecruiting\n46\tRecruiting\n160\tRecruiting\n18\tRecruiting\n10\tCompleted\n29\tRecruiting\n22\tRecruiting\n40\tRecruiting\n75\tRecruiting\n64\tRecruiting\n300\tRecruiting\n30\tRecruiting\n2000\tCompleted\n15\tActive not recruiting\n84\tRecruiting\n36\tRecruiting\n375\tNot yet recruiting\n240\tRecruiting\n36\tActive not recruiting\n24\tRecruiting\n75\tRecruiting\n30\tRecruiting\n250\tRecruiting\n27\tRecruiting\n20\tRecruiting\n75\tRecruiting\n60\tNot yet recruiting\n90\tRecruiting\n20\tRecruiting\n222\tActive not recruiting\n30\tRecruiting\n40\tCompleted\n20\tRecruiting\n120\tRecruiting\n100\tRecruiting\n65\tRecruiting\n100\tRecruiting\n50\tRecruiting\n23\tCompleted                  Has Results\n100\tRecruiting\n110\tRecruiting\n48\tRecruiting\n100\tRecruiting\n300\tRecruiting\n30\tRecruiting\n60\tRecruiting\n1656\tActive not recruiting\n248\tRecruiting\n250\tRecruiting\n500000\tActive not recruiting\n120\tRecruiting\n25\tRecruiting\n25\tEnrolling by invitation\n78\tRecruiting\n61\tRecruiting\n240\tRecruiting\n300\tRecruiting\n70\tCompleted\n66\tRecruiting\n80\tRecruiting\n52\tRecruiting\n99\tCompleted\n66\tRecruiting\n26\tRecruiting\n5\tRecruiting\n40\tCompleted\n160\tRecruiting\n400\tRecruiting\n16\tSuspended\n80\tRecruiting\n28\tCompleted\n150\tRecruiting\n260\tEnrolling by invitation\n39\tCompleted\n100\tRecruiting\n40\tCompleted\n13\tActive not recruiting\n50\tRecruiting\n30\tRecruiting\n400\tRecruiting\n550\tRecruiting\n600\tNot yet recruiting\n350\tRecruiting\n360\tActive not recruiting\n130\tRecruiting\n186\tCompleted\n33\tCompleted\n300\tNot yet recruiting\n15\tRecruiting\n50\tRecruiting\n12\tRecruiting\n750\tRecruiting\n15\tCompleted\n15\tEnrolling by invitation\n50\tCompleted\n100\tRecruiting\n40\tRecruiting\n3000\tActive not recruiting\n35\tRecruiting\n10000\tEnrolling by invitation\n6\tCompleted\n40\tNot yet recruiting\n100\tRecruiting\n500\tNot yet recruiting\n0\tWithdrawn\n20\tRecruiting\n0\tWithdrawn\n45\tRecruiting\n20\tActive not recruiting\n200\tNot yet recruiting\n14\tActive not recruiting\n5975\tRecruiting\n200\tRecruiting\n400\tActive not recruiting\n28\tCompleted\n115\tRecruiting\n60\tCompleted\n30\tRecruiting\n115\tRecruiting\n104\tActive not recruiting\n50\tRecruiting\n0\tWithdrawn\n131\tRecruiting\n100\tRecruiting\n100\tRecruiting\n210\tRecruiting\n20\tRecruiting\n315\tRecruiting\n20\tActive not recruiting\n30\tRecruiting\n60\tRecruiting\n84\tActive not recruiting\n60\tRecruiting\n70\tRecruiting\n100\tRecruiting\n0\tWithdrawn\n2\tTerminated\n48\tCompleted\n40\tRecruiting\n472\tRecruiting\n16\tRecruiting\n500\tEnrolling by invitation\n30\tRecruiting\n0\tWithdrawn\n30\tRecruiting\n36\tSuspended\n80\tCompleted\n40\tRecruiting\n11\tCompleted\n131\tCompleted\n41\tCompleted\n50\tRecruiting\n220\tCompleted\n30\tRecruiting\n60\tNot yet recruiting\n30\tRecruiting\n93\tRecruiting\n113\tCompleted\n6\tCompleted\n20\tNot yet recruiting\n500\tActive not recruiting\n60\tActive not recruiting\n80\tCompleted\n150\tRecruiting\n100\tRecruiting\n416\tRecruiting\n30\tCompleted\n260\tRecruiting\n100\tCompleted\n50\tSuspended\n30\tRecruiting\n90\tActive not recruiting\n30\tRecruiting\n20\tCompleted\n570\tRecruiting\n200\tRecruiting\n75\tActive not recruiting\n50\tRecruiting\n32\tCompleted\n116\tRecruiting\n12\tCompleted\n18\tTerminated                  Has Results\n40\tRecruiting\n71\tRecruiting\n440\tRecruiting\n60\tRecruiting\n1017\tCompleted\n24\tCompleted\n25\tActive not recruiting\n34\tCompleted\n90\tRecruiting\n67\tRecruiting\n1\tTerminated\n15\tRecruiting\n68\tRecruiting\n24\tRecruiting\n46\tRecruiting\n150\tRecruiting\n0\tWithdrawn\n90\tRecruiting\n51\tActive not recruiting\n39\tRecruiting\n66\tActive not recruiting\n120\tCompleted\n20\tSuspended\n2160\tActive not recruiting\n302\tActive not recruiting\n100\tRecruiting\n15\tRecruiting\n50\tRecruiting\n200\tRecruiting\n60\tActive not recruiting\n75\tRecruiting\n30\tRecruiting\n25\tTerminated\n50\tNot yet recruiting\n10\tCompleted\n25\tRecruiting\n9\tActive not recruiting\n240\tCompleted\n150\tRecruiting\n33\tActive not recruiting\n350\tActive not recruiting\n20\tCompleted\n50\tRecruiting\n10\tRecruiting\n100\tCompleted\n82\tRecruiting\n100\tRecruiting\n30\tActive not recruiting\n45\tRecruiting\n60\tRecruiting\n21\tActive not recruiting\n161\tCompleted\n40\tRecruiting\n40\tRecruiting\n20\tRecruiting\n150\tCompleted\n88\tCompleted                  Has Results\n275711\tActive not recruiting\n60\tRecruiting\n100\tActive not recruiting\n2000\tRecruiting\n60\tRecruiting\n300\tRecruiting\n203\tCompleted\n45\tCompleted\n100\tRecruiting\n12\tCompleted\n53\tCompleted\n60\tRecruiting\n6484\tEnrolling by invitation\n180\tRecruiting\n22\tCompleted                  Has Results\n10\tCompleted\n200\tRecruiting\n2669\tCompleted\n32\tCompleted\n80\tRecruiting\n0\tWithdrawn\n50\tRecruiting\n50\tRecruiting\n12\tRecruiting\n40\tCompleted\n50\tRecruiting\n10\tCompleted\n24\tRecruiting\n650\tNot yet recruiting\n18\tCompleted\n165\tRecruiting\n37\tCompleted\n7\tTerminated\n120\tActive not recruiting\n100\tRecruiting\n200\tRecruiting\n15\tActive not recruiting\n61\tCompleted\n150\tRecruiting\n1\tTerminated\n200\tRecruiting\n25\tActive not recruiting\n20\tRecruiting\n60\tEnrolling by invitation\n40\tRecruiting\n198\tRecruiting\n30\tRecruiting\n26\tCompleted\n60\tRecruiting\n100\tRecruiting\n24\tRecruiting\n28\tActive not recruiting\n20\tCompleted\n180\tRecruiting\n450\tNot yet recruiting\n33\tCompleted\n500\tUnknown\u0026nbsp;\u0026#8224;\n40\tRecruiting\n72\tRecruiting\n104\tCompleted\n109\tCompleted                  Has Results\n400\tActive not recruiting\n240\tActive not recruiting\n100\tRecruiting\n135\tCompleted\n12\tRecruiting\n10\tCompleted\n40\tActive not recruiting\n73\tCompleted\n82\tCompleted\n60\tCompleted\n250\tCompleted\n20\tRecruiting\n50\tRecruiting\n124\tRecruiting\n79\tCompleted\n60\tActive not recruiting\n9\tCompleted\n90\tRecruiting\n100\tActive not recruiting\n24\tRecruiting\n10\tTerminated                  Has Results\n150\tRecruiting\n40\tRecruiting\n102\tRecruiting\n300\tRecruiting\n100\tActive not recruiting\n175\tCompleted\n39\tCompleted\n60\tEnrolling by invitation\n30\tEnrolling by invitation\n60\tRecruiting\n500\tEnrolling by invitation\n230\tRecruiting\n25\tCompleted\n40\tRecruiting\n60\tRecruiting\n1\tTerminated\n0\tWithdrawn\n14\tRecruiting\n48\tRecruiting\n15\tActive not recruiting\n40\tRecruiting\n17\tActive not recruiting\n50\tRecruiting\n6\tTerminated\n120\tRecruiting\n11\tActive not recruiting\n24\tSuspended\n10\tCompleted\n26\tCompleted\n160\tSuspended\n13\tTerminated                  Has Results\n68\tCompleted\n30\tRecruiting\n27\tCompleted\n30\tRecruiting\n59\tCompleted\n1000\tNot yet recruiting\n2000\tEnrolling by invitation\n13\tTerminated\n15\tTerminated\n60\tNot yet recruiting\n30\tRecruiting\n0\tWithdrawn\n6\tCompleted\n56\tCompleted\n17\tCompleted\n54\tActive not recruiting\n50\tRecruiting\n90\tRecruiting\n220\tRecruiting\n20\tCompleted\n0\tWithdrawn\n6\tCompleted\n10\tRecruiting\n30\tUnknown\u0026nbsp;\u0026#8224;\n14\tCompleted\n50\tNot yet recruiting\n0\tWithdrawn\n6\tCompleted\n30\tCompleted\n50\tRecruiting\n28\tCompleted\n0\tWithdrawn\n30\tActive not recruiting\n30\tRecruiting\n23\tCompleted\n24\tActive not recruiting\n2\tCompleted\n44\tActive not recruiting\n0\tWithdrawn\n156\tUnknown\u0026nbsp;\u0026#8224;\n37\tCompleted\n421\tCompleted                  Has Results\n30\tRecruiting\n64\tCompleted\n60\tUnknown\u0026nbsp;\u0026#8224;\n374\tEnrolling by invitation\n30\tCompleted\n15\tActive not recruiting\n215\tRecruiting\n40\tCompleted\n75\tEnrolling by invitation\n40\tRecruiting\n65\tRecruiting\n132\tSuspended\n23\tCompleted\n6\tCompleted\n51\tCompleted\n46\tCompleted\n9\tCompleted                  Has Results\n30\tCompleted\n60\tCompleted\n\tNo longer available\n30\tEnrolling by invitation\n100\tRecruiting\n24\tCompleted\n85\tRecruiting\n20\tRecruiting\n28\tCompleted\n3\tCompleted\n0\tWithdrawn\n81\tCompleted\n700\tRecruiting\n28\tCompleted\n100\tRecruiting\n1\tTerminated                  Has Results\n34\tEnrolling by invitation\n11\tCompleted\n48\tCompleted\n20\tRecruiting\n0\tWithdrawn\n75\tRecruiting\n0\tWithdrawn\n16400\tUnknown\u0026nbsp;\u0026#8224;\n30\tCompleted\n42\tCompleted\n0\tWithdrawn\n17\tTerminated\n18\tCompleted\n24\tRecruiting\n50\tRecruiting\n30\tRecruiting\n71\tCompleted\n14717\tActive not recruiting\n20\tRecruiting\n25\tRecruiting\n90\tCompleted                  Has Results\n0\tWithdrawn\n34\tCompleted                  Has Results\n9\tCompleted\n8\tTerminated\n45\tCompleted\n57\tCompleted\n1500\tActive not recruiting\n20\tNot yet recruiting\n30\tRecruiting\n1\tTerminated\n32\tCompleted\n4\tTerminated\n6\tCompleted\n1500\tCompleted\n16\tCompleted\n19\tCompleted\n50\tRecruiting\n6\tCompleted\n20\tRecruiting\n30\tCompleted\n80\tActive not recruiting\n450\tActive not recruiting\n400\tRecruiting\n35\tCompleted\n37\tTerminated\n150\tUnknown\u0026nbsp;\u0026#8224;\n17\tTerminated\n20\tActive not recruiting\n250\tUnknown\u0026nbsp;\u0026#8224;\n40\tRecruiting\n80\tActive not recruiting\n28\tCompleted\n60\tRecruiting\n6\tTerminated\n\tNo longer available\n6\tTerminated\n60\tActive not recruiting\n122\tRecruiting\n100\tRecruiting\n6\tCompleted\n25\tCompleted\n60\tCompleted\n100\tRecruiting\n200\tRecruiting\n70\tCompleted                  Has Results\n350\tCompleted\n50\tSuspended\n30\tRecruiting\n153\tRecruiting\n30\tRecruiting\n1\tTerminated\n45\tActive not recruiting\n0\tWithdrawn\n30\tRecruiting\n50\tRecruiting\n0\tWithdrawn\n60\tCompleted\n40\tCompleted\n15\tActive not recruiting\n10\tCompleted\n10\tCompleted\n20\tRecruiting\n210\tCompleted                  Has Results\n36\tRecruiting\n575\tCompleted\n300\tActive not recruiting\n24\tActive not recruiting\n140\tRecruiting\n522\tRecruiting\n140\tRecruiting\n10\tEnrolling by invitation\n364\tCompleted\n15\tCompleted\n8\tTerminated\n101\tCompleted\n9\tTerminated\n250\tRecruiting\n50\tCompleted\n800\tEnrolling by invitation\n17\tTerminated                  Has Results\n1000\tEnrolling by invitation\n20\tRecruiting\n72\tCompleted\n16\tCompleted\n120\tRecruiting\n0\tWithdrawn\n308\tEnrolling by invitation\n0\tWithdrawn\n20\tActive not recruiting\n21\tCompleted\n57\tRecruiting\n120\tUnknown\u0026nbsp;\u0026#8224;\n10\tCompleted\n30\tCompleted\n138\tCompleted                  Has Results\n40\tCompleted\n20\tCompleted\n645\tActive not recruiting\n38\tCompleted\n134\tCompleted\n20\tCompleted                  Has Results\n20\tCompleted\n60\tActive not recruiting\n5000\tUnknown\u0026nbsp;\u0026#8224;\n20\tCompleted\n26\tCompleted\n13\tCompleted\n110\tCompleted\n140\tRecruiting\n1\tCompleted\n300\tUnknown\u0026nbsp;\u0026#8224;\n17\tTerminated\n382\tActive not recruiting\n10\tNot yet recruiting\n0\tWithdrawn\n30\tCompleted\n1000\tUnknown\u0026nbsp;\u0026#8224;\n250\tUnknown\u0026nbsp;\u0026#8224;\n60\tActive not recruiting\n38\tActive not recruiting\n100\tUnknown\u0026nbsp;\u0026#8224;\n38\tCompleted\n41\tCompleted\n2\tTerminated                  Has Results\n459\tCompleted                  Has Results\n28\tRecruiting\n17\tActive not recruiting\n0\tWithdrawn\n202\tActive not recruiting\n20\tRecruiting\n17\tCompleted\n41\tCompleted                  Has Results\n100\tActive not recruiting\n468\tRecruiting\n60\tActive not recruiting\n48\tCompleted\n20\tActive not recruiting\n50\tCompleted\n100\tRecruiting\n110\tCompleted\n20\tCompleted\n239\tCompleted\n50\tEnrolling by invitation\n60\tRecruiting\n13\tCompleted                  Has Results\n6\tCompleted\n120\tCompleted\n59\tCompleted                  Has Results\n18\tCompleted\n19\tTerminated\n13000\tRecruiting\n50\tRecruiting\n100\tActive not recruiting\n34\tCompleted\n36\tCompleted                  Has Results\n28\tCompleted\n320\tEnrolling by invitation\n6\tCompleted\n30\tActive not recruiting\n126\tRecruiting\n99\tCompleted\n10\tRecruiting\n48\tCompleted\n31\tCompleted\n20\tRecruiting\n50\tRecruiting\n78\tCompleted\n30\tRecruiting\n11\tCompleted\n38\tCompleted\n90\tRecruiting\n5\tCompleted\n20\tCompleted\n46\tCompleted                  Has Results\n2003\tCompleted\n25\tCompleted\n36\tCompleted\n21\tCompleted\n1000\tRecruiting\n12\tRecruiting\n41\tCompleted\n26\tCompleted\n35\tCompleted\n60\tActive not recruiting\n102\tCompleted                  Has Results\n16\tActive not recruiting\n200\tRecruiting\n15\tCompleted\n115\tCompleted\n\tAvailable\n15\tCompleted\n17\tCompleted\n30\tRecruiting\n102\tRecruiting\n60\tRecruiting\n500\tCompleted\n100\tRecruiting\n400\tActive not recruiting\n2623\tActive not recruiting\n90\tCompleted\n8\tCompleted\n4344\tCompleted\n14\tCompleted\n30\tCompleted\n81\tCompleted\n25\tCompleted\n95\tRecruiting\n90\tCompleted\n16\tCompleted\n10\tActive not recruiting\n20\tUnknown\u0026nbsp;\u0026#8224;\n107\tCompleted\n80\tRecruiting\n1650\tActive not recruiting\n50\tUnknown\u0026nbsp;\u0026#8224;\n67\tCompleted\n10\tActive not recruiting\n76\tCompleted\n21\tActive not recruiting\n76\tCompleted\n13\tTerminated\n100\tRecruiting\n225\tActive not recruiting\n50\tCompleted\n48\tCompleted\n10\tTerminated                  Has Results\n26\tCompleted\n24\tCompleted                  Has Results\n285\tActive not recruiting\n26\tCompleted                  Has Results\n230\tCompleted\n351\tActive not recruiting\n0\tWithdrawn\n83\tCompleted\n37\tCompleted\n60\tActive not recruiting\n511\tRecruiting\n40\tEnrolling by invitation\n70\tCompleted\n73\tCompleted\n67\tCompleted                  Has Results\n210\tActive not recruiting\n40\tCompleted\n40\tCompleted\n30\tActive not recruiting\n72\tUnknown\u0026nbsp;\u0026#8224;\n29\tTerminated\n150\tRecruiting\n57\tCompleted\n150\tCompleted\n626\tCompleted                  Has Results\n135\tCompleted                  Has Results\n12\tUnknown\u0026nbsp;\u0026#8224;\n20\tCompleted\n0\tWithdrawn\n100\tRecruiting\n20\tCompleted\n18\tCompleted\n28\tCompleted\n48\tCompleted\n57\tCompleted                  Has Results\n100\tActive not recruiting\n243\tActive not recruiting\n63\tCompleted\n25\tCompleted                  Has Results\n569\tCompleted\n12\tActive not recruiting\n100\tRecruiting\n192\tCompleted\n77\tTerminated\n260\tActive not recruiting\n200\tCompleted\n44\tCompleted\n237\tCompleted\n90\tActive not recruiting\n36\tCompleted\n359\tCompleted\n1276\tActive not recruiting\n40\tCompleted\n8\tCompleted\n15\tActive not recruiting\n240\tCompleted\n5\tTerminated\n5\tTerminated                  Has Results\n96\tRecruiting\n18\tCompleted\n7\tTerminated\n10\tRecruiting\n30\tActive not recruiting\n24\tActive not recruiting\n12\tUnknown\u0026nbsp;\u0026#8224;\n130\tCompleted\n690\tRecruiting\n24\tCompleted                  Has Results\n40\tCompleted                  Has Results\n29\tActive not recruiting\n25\tCompleted\n194\tActive not recruiting\n20\tCompleted\n1000\tActive not recruiting\n170\tActive not recruiting\n66\tCompleted\n68\tCompleted                  Has Results\n132\tCompleted\n40\tCompleted\n18\tCompleted                  Has Results\n24\tTerminated\n100\tRecruiting\n58\tCompleted\n16\tCompleted\n18\tEnrolling by invitation\n38\tCompleted\n5\tCompleted                  Has Results\n34\tCompleted\n50\tCompleted                  Has Results\n140\tCompleted\n240\tActive not recruiting\n150\tRecruiting\n34\tCompleted\n100\tRecruiting\n26\tCompleted\n61\tActive not recruiting\n33\tActive not recruiting\n1\tTerminated\n60\tCompleted\n22\tCompleted\n13\tRecruiting\n\tAvailable\n60\tRecruiting\n60\tCompleted\n30\tActive not recruiting\n23\tCompleted                  Has Results\n35\tUnknown\u0026nbsp;\u0026#8224;\n51\tTerminated\n19\tTerminated                  Has Results\n18\tActive not recruiting\n220\tRecruiting\n56\tActive not recruiting\n50\tCompleted\n15\tCompleted\n48\tActive not recruiting\n8\tActive not recruiting\n65\tCompleted\n400\tRecruiting\n35\tCompleted\n23\tCompleted                  Has Results\n65\tCompleted\n7\tCompleted\n100\tRecruiting\n68\tActive not recruiting\n48\tCompleted                  Has Results\n19\tEnrolling by invitation\n2\tTerminated\n15\tCompleted\n40\tCompleted\n12\tCompleted\n125\tCompleted\n17\tActive not recruiting\n50\tCompleted                  Has Results\n18\tCompleted\n1\tTerminated                  Has Results\n\tUnknown\u0026nbsp;\u0026#8224;\n20\tRecruiting\n183\tCompleted\n21\tCompleted\n90\tRecruiting\n7\tTerminated\n300\tActive not recruiting\n30\tRecruiting\n14\tCompleted\n150\tRecruiting\n22\tCompleted\n513\tActive not recruiting\n31\tTerminated\n56\tCompleted\n71\tCompleted\n21\tCompleted\n25\tCompleted\n42\tCompleted\n0\tWithdrawn\n44\tCompleted\n350\tActive not recruiting\n250\tRecruiting\n50000\tRecruiting\n100\tCompleted\n20\tCompleted\n186\tActive not recruiting\n240\tCompleted\n33\tCompleted\n11\tCompleted\n126\tCompleted                  Has Results\n42\tRecruiting\n9587\tCompleted\n775\tCompleted\n18\tUnknown\u0026nbsp;\u0026#8224;\n880\tActive not recruiting\n131\tCompleted\n85\tCompleted\n38\tCompleted                  Has Results\n39\tCompleted\n9000\tCompleted\n40\tCompleted\n12\tTerminated\n45\tActive not recruiting\n3\tSuspended\n496\tRecruiting\n47\tCompleted\n37\tCompleted\n32\tCompleted                  Has Results\n5\tCompleted\n113\tRecruiting\n117\tEnrolling by invitation\n44\tUnknown\u0026nbsp;\u0026#8224;\n418\tCompleted\n78\tUnknown\u0026nbsp;\u0026#8224;\n96\tUnknown\u0026nbsp;\u0026#8224;\n50\tRecruiting\n13\tCompleted\n17\tActive not recruiting\n282\tActive not recruiting\n300\tRecruiting\n44\tRecruiting\n17\tCompleted                  Has Results\n300\tEnrolling by invitation\n1\tCompleted                  Has Results\n264\tActive not recruiting\n39\tActive not recruiting                  Has Results\n30\tRecruiting\n160\tEnrolling by invitation\n36\tCompleted\n372\tCompleted\n891\tActive not recruiting\n92\tCompleted\n250\tRecruiting\n105\tCompleted\n11\tCompleted\n204\tCompleted                  Has Results\n66\tCompleted\n0\tWithdrawn\n10\tCompleted\n103\tActive not recruiting\n7\tCompleted\n10\tCompleted\n12\tActive not recruiting\n48\tRecruiting\n304\tCompleted\n15\tCompleted\n16\tCompleted\n75\tCompleted                  Has Results\n40\tCompleted\n72\tRecruiting\n34\tCompleted\n155\tCompleted\n48\tUnknown\u0026nbsp;\u0026#8224;\n12\tCompleted\n24\tCompleted\n180\tUnknown\u0026nbsp;\u0026#8224;\n225\tCompleted\n40\tRecruiting\n0\tWithdrawn\n715\tCompleted\n400\tCompleted\n200\tUnknown\u0026nbsp;\u0026#8224;\n24\tCompleted\n48\tCompleted\n50\tCompleted\n9\tUnknown\u0026nbsp;\u0026#8224;\n0\tWithdrawn\n49\tActive not recruiting\n3417\tCompleted\n10\tCompleted\n233\tCompleted                  Has Results\n50\tUnknown\u0026nbsp;\u0026#8224;\n15\tCompleted\n200\tActive not recruiting\n3\tTerminated\n0\tWithdrawn\n25\tActive not recruiting\n14\tCompleted\n26\tRecruiting\n30\tCompleted\n160\tCompleted\n424\tCompleted\n160\tActive not recruiting\n60\tRecruiting\n17\tCompleted\n44\tRecruiting\n50\tCompleted\n302\tCompleted\n1167\tActive not recruiting\n141\tCompleted\n15\tCompleted\n64\tActive not recruiting\n270\tCompleted\n1831\tCompleted\n45\tCompleted                  Has Results\n61\tCompleted                  Has Results\n0\tWithdrawn\n244\tCompleted\n20\tCompleted                  Has Results\n18\tCompleted\n30\tCompleted                  Has Results\n6\tCompleted\n60\tCompleted\n24\tRecruiting\n72\tCompleted\n112\tCompleted                  Has Results\n117\tCompleted\n130\tCompleted                  Has Results\n22\tCompleted                  Has Results\n500\tRecruiting\n227\tCompleted\n18\tCompleted                  Has Results\n300\tRecruiting\n20\tUnknown\u0026nbsp;\u0026#8224;\n22\tActive not recruiting\n18\tCompleted                  Has Results\n40\tUnknown\u0026nbsp;\u0026#8224;\n155\tEnrolling by invitation\n120\tCompleted\n20\tUnknown\u0026nbsp;\u0026#8224;\n70\tActive not recruiting\n40\tSuspended\n800\tRecruiting\n123\tCompleted\n8\tTerminated\n83\tCompleted\n20\tCompleted\n20\tCompleted\n40\tEnrolling by invitation\n60\tRecruiting\n25\tActive not recruiting\n100\tActive not recruiting\n20\tCompleted\n20\tCompleted\n5\tTerminated                  Has Results\n5\tTerminated                  Has Results\n48\tCompleted\n6\tCompleted\n0\tWithdrawn\n42\tCompleted\n65\tRecruiting\n33\tActive not recruiting\n1\tTerminated\n22\tCompleted\n375\tActive not recruiting\n145\tActive not recruiting\n43\tCompleted\n50\tActive not recruiting\n70\tCompleted\n2\tTerminated                  Has Results\n30\tActive not recruiting\n0\tWithdrawn\n40\tCompleted\n48\tCompleted\n38\tCompleted\n21\tCompleted\n2\tTerminated                  Has Results\n10\tRecruiting\n15\tCompleted\n62\tCompleted                  Has Results\n24\tCompleted                  Has Results\n6\tCompleted\n200\tCompleted\n22\tCompleted\n162\tCompleted                  Has Results\n50\tUnknown\u0026nbsp;\u0026#8224;\n14\tCompleted\n53\tTerminated\n6\tCompleted\n5000\tRecruiting\n61\tCompleted\n159\tCompleted                  Has Results\n136\tRecruiting\n163\tCompleted                  Has Results\n92\tCompleted                  Has Results\n3\tTerminated                  Has Results\n20\tSuspended\n150\tCompleted\n800\tCompleted\n29\tCompleted\n40\tUnknown\u0026nbsp;\u0026#8224;\n2\tTerminated\n7\tCompleted                  Has Results\n537\tCompleted\n146\tActive not recruiting\n339\tCompleted\n10\tCompleted\n30\tCompleted                  Has Results\n20\tCompleted\n140\tActive not recruiting\n535\tCompleted\n134\tCompleted\n34\tCompleted                  Has Results\n30\tSuspended\n42\tCompleted\n363\tCompleted\n100\tActive not recruiting\n68\tCompleted\n600\tActive not recruiting\n1000\tCompleted\n2329\tActive not recruiting\n10\tCompleted\n75\tCompleted\n89656\tEnrolling by invitation\n60\tUnknown\u0026nbsp;\u0026#8224;\n98\tCompleted\n120\tCompleted\n68\tCompleted\n75\tRecruiting\n400\tActive not recruiting\n40\tActive not recruiting\n99\tCompleted\n60\tCompleted\n80\tRecruiting\n718\tCompleted\n19\tCompleted\n202\tCompleted\n52\tCompleted\n30\tCompleted\n255\tCompleted\n49\tActive not recruiting\n21\tCompleted\n99\tCompleted\n1184\tCompleted\n30\tActive not recruiting\n23\tCompleted\n40\tCompleted\n204\tCompleted\n17\tCompleted\n91\tCompleted\n199\tTerminated\n22\tCompleted\n25\tUnknown\u0026nbsp;\u0026#8224;\n24\tTerminated\n10\tTerminated\n25\tCompleted\n222\tCompleted                  Has Results\n18\tCompleted\n75\tUnknown\u0026nbsp;\u0026#8224;\n183\tCompleted\n30\tActive not recruiting\n97\tCompleted\n21\tCompleted\n0\tWithdrawn\n87\tCompleted\n12\tTerminated\n82\tCompleted\n40\tCompleted\n24\tCompleted\n12\tCompleted\n30\tCompleted\n49\tCompleted\n8\tTerminated\n99\tCompleted\n12\tCompleted\n0\tWithdrawn\n7\tTerminated\n15\tCompleted\n108\tCompleted\n17\tCompleted\n37\tCompleted\n10\tCompleted                  Has Results\n451\tCompleted\n350\tCompleted\n25\tCompleted\n80\tCompleted\n40\tUnknown\u0026nbsp;\u0026#8224;\n100\tUnknown\u0026nbsp;\u0026#8224;\n110\tCompleted                  Has Results\n60\tCompleted                  Has Results\n23\tCompleted                  Has Results\n916\tActive not recruiting\n550\tCompleted\n24\tCompleted\n60\tCompleted\n80\tCompleted                  Has Results\n35\tTerminated\n6\tCompleted\n14\tRecruiting\n50\tCompleted\n4\tCompleted\n55000\tActive not recruiting\n400\tRecruiting\n30\tCompleted\n8\tTerminated\n160\tRecruiting\n0\tWithdrawn\n0\tWithdrawn\n5\tTerminated\n75\tCompleted\n20\tRecruiting\n16\tCompleted                  Has Results\n51\tCompleted\n4\tCompleted                  Has Results\n45\tUnknown\u0026nbsp;\u0026#8224;\n29\tCompleted\n36\tCompleted\n141\tCompleted\n420\tCompleted\n300\tCompleted\n48\tCompleted\n72\tCompleted\n19\tCompleted\n103\tTerminated\n25\tCompleted\n6\tTerminated                  Has Results\n9\tTerminated\n34\tCompleted\n17\tCompleted\n74\tCompleted\n200\tRecruiting\n44\tCompleted\n40\tCompleted\n50\tRecruiting\n10\tCompleted\n22\tCompleted\n2\tTerminated\n306\tCompleted                  Has Results\n157\tCompleted\n9361\tActive not recruiting\n0\tWithdrawn\n0\tWithdrawn\n20\tCompleted\n2\tTerminated\n20\tCompleted\n41\tActive not recruiting                  Has Results\n300\tCompleted\n38\tCompleted\n0\tWithdrawn\n5\tTerminated\n55\tCompleted\n100\tTerminated\n314\tCompleted\n85\tCompleted\n16\tCompleted\n90\tCompleted\n18\tCompleted\n20\tCompleted                  Has Results\n20\tTerminated\n0\tWithdrawn\n107\tCompleted\n11\tTerminated\n10003\tCompleted                  Has Results\n20\tCompleted\n122\tCompleted\n21\tCompleted                  Has Results\n89\tCompleted                  Has Results\n60\tTerminated\n21\tActive not recruiting\n13\tTerminated\n74\tRecruiting\n40\tRecruiting\n157\tCompleted\n62\tCompleted\n6\tTerminated\n60\tCompleted\n67\tCompleted\n207\tCompleted                  Has Results\n18\tCompleted\n7050\tCompleted                  Has Results\n40\tCompleted\n63\tCompleted\n80\tCompleted\n8\tCompleted\n105\tSuspended\n278\tEnrolling by invitation\n67\tEnrolling by invitation\n428\tCompleted                  Has Results\n96\tCompleted\n246\tCompleted\n1\tRecruiting\n15000\tRecruiting\n150\tEnrolling by invitation\n98\tCompleted\n221\tEnrolling by invitation\n18\tCompleted\n26\tCompleted\n26\tCompleted\n24\tCompleted\n26\tCompleted\n300\tCompleted                  Has Results\n15\tCompleted\n11\tCompleted\n10\tCompleted\n1362\tActive not recruiting\n101\tCompleted\n9\tCompleted\n11\tTerminated                  Has Results\n182\tCompleted\n30\tCompleted                  Has Results\n0\tWithdrawn\n38\tCompleted                  Has Results\n201\tCompleted\n256\tCompleted                  Has Results\n25\tActive not recruiting\n36\tCompleted                  Has Results\n54\tCompleted\n20\tCompleted\n140\tCompleted                  Has Results\n5\tTerminated\n15\tTerminated\n50\tCompleted                  Has Results\n24\tCompleted\n10\tEnrolling by invitation\n365\tCompleted\n50\tCompleted\n170\tUnknown\u0026nbsp;\u0026#8224;\n24\tCompleted                  Has Results\n10000\tRecruiting\n31\tCompleted                  Has Results\n3\tTerminated                  Has Results\n484\tRecruiting\n54\tCompleted\n60\tCompleted\n78\tCompleted\n70\tCompleted\n24\tCompleted\n21\tCompleted                  Has Results\n60\tCompleted\n100\tRecruiting\n679\tCompleted\n2000\tActive not recruiting\n601\tCompleted                  Has Results\n60\tActive not recruiting\n320\tCompleted                  Has Results\n147\tCompleted\n69\tCompleted                  Has Results\n14\tCompleted\n0\tWithdrawn\n0\tWithdrawn\n20\tActive not recruiting                  Has Results\n1257\tCompleted\n156\tTerminated\n80\tActive not recruiting\n42\tCompleted\n22\tActive not recruiting\n70\tTerminated\n126\tCompleted\n50\tCompleted\n20\tCompleted                  Has Results\n180\tCompleted\n26\tCompleted                  Has Results\n24\tUnknown\u0026nbsp;\u0026#8224;\n32\tCompleted                  Has Results\n221\tCompleted                  Has Results\n684\tCompleted\n705\tCompleted\n611\tCompleted                  Has Results\n8422\tCompleted\n35\tCompleted\n3\tTerminated                  Has Results\n105\tCompleted                  Has Results\n26\tCompleted\n19\tCompleted\n77\tTerminated                  Has Results\n54\tCompleted\n23\tCompleted                  Has Results\n25\tCompleted\n16\tCompleted\n45\tCompleted\n26\tCompleted\n9\tTerminated\n80\tUnknown\u0026nbsp;\u0026#8224;\n1\tTerminated\n850\tActive not recruiting\n0\tWithdrawn\n35\tCompleted\n38\tActive not recruiting\n45\tCompleted\n350\tRecruiting\n100\tCompleted\n66\tCompleted                  Has Results\n60\tCompleted\n318\tCompleted\n16\tTerminated                  Has Results\n49\tCompleted                  Has Results\n14\tTerminated                  Has Results\n15\tCompleted                  Has Results\n18\tTerminated                  Has Results\n38\tTerminated                  Has Results\n50\tCompleted\n9\tTerminated\n11\tTerminated\n40\tUnknown\u0026nbsp;\u0026#8224;\n0\tWithdrawn\n60\tActive not recruiting\n80\tActive not recruiting                  Has Results\n40\tCompleted\n12\tTerminated\n600000\tActive not recruiting\n75\tActive not recruiting\n413\tCompleted                  Has Results\n25\tUnknown\u0026nbsp;\u0026#8224;\n1000\tUnknown\u0026nbsp;\u0026#8224;\n48\tCompleted\n324\tCompleted\n40\tCompleted\n40\tCompleted\n380\tCompleted                  Has Results\n40\tCompleted\n0\tWithdrawn\n496\tCompleted\n49\tCompleted\n8\tCompleted                  Has Results\n40\tCompleted                  Has Results\n110\tCompleted\n52\tCompleted\n147\tCompleted\n5000\tCompleted\n5\tCompleted\n318\tCompleted\n41\tCompleted                  Has Results\n87820\tCompleted\n377\tCompleted\n50\tTerminated                  Has Results\n3\tTerminated                  Has Results\n300\tCompleted\n35\tCompleted\n60\tCompleted\n53\tActive not recruiting\n33\tCompleted\n44\tUnknown\u0026nbsp;\u0026#8224;\n25\tCompleted\n288\tCompleted\n530\tCompleted                  Has Results\n6\tCompleted\n25\tCompleted                  Has Results\n519\tCompleted                  Has Results\n100\tActive not recruiting\n114\tCompleted\n35\tCompleted\n9\tCompleted\n104\tCompleted                  Has Results\n12\tCompleted\n29\tCompleted                  Has Results\n149\tCompleted\n29\tCompleted                  Has Results\n36\tTerminated                  Has Results\n52\tCompleted\n0\tWithdrawn\n578\tCompleted                  Has Results\n161\tCompleted                  Has Results\n32\tActive not recruiting\n20\tCompleted                  Has Results\n60\tActive not recruiting\n49\tCompleted                  Has Results\n48\tCompleted                  Has Results\n154\tCompleted\n50\tCompleted\n358\tCompleted\n194\tCompleted\n60\tCompleted\n301\tCompleted\n59\tCompleted\n60\tUnknown\u0026nbsp;\u0026#8224;\n16\tCompleted                  Has Results\n21\tTerminated\n60\tActive not recruiting\n8\tCompleted                  Has Results\n48\tCompleted\n11\tCompleted\n40\tCompleted\n15\tNot yet recruiting\n67\tCompleted                  Has Results\n40\tCompleted\n303\tCompleted\n12\tCompleted\n207\tCompleted\n25\tActive not recruiting\n116\tCompleted                  Has Results\n386\tCompleted\n60\tUnknown\u0026nbsp;\u0026#8224;\n63\tCompleted                  Has Results\n61\tCompleted\n160\tRecruiting\n109\tCompleted\n100\tCompleted\n45\tCompleted\n12\tCompleted\n21\tCompleted                  Has Results\n21\tCompleted                  Has Results\n57\tCompleted                  Has Results\n310\tRecruiting\n0\tWithdrawn\n2500\tRecruiting\n40\tCompleted\n1\tTerminated\n30\tTerminated\n48\tActive not recruiting\n2\tTerminated\n80\tActive not recruiting\n606\tCompleted                  Has Results\n50\tCompleted\n228\tCompleted                  Has Results\n13\tCompleted\n30\tCompleted                  Has Results\n372\tCompleted\n101\tCompleted\n120\tUnknown\u0026nbsp;\u0026#8224;\n60\tUnknown\u0026nbsp;\u0026#8224;\n63\tCompleted\n28\tCompleted\n295\tCompleted\n80\tCompleted\n600\tActive not recruiting\n100\tUnknown\u0026nbsp;\u0026#8224;\n16\tCompleted                  Has Results\n64\tCompleted\n16\tCompleted                  Has Results\n190\tCompleted\n10\tCompleted\n0\tWithdrawn\n112\tCompleted\n124\tCompleted\n35\tUnknown\u0026nbsp;\u0026#8224;\n333\tCompleted\n40\tCompleted\n30\tCompleted\n26\tCompleted\n26\tCompleted\n12\tCompleted\n25\tUnknown\u0026nbsp;\u0026#8224;\n2\tTerminated\n20\tCompleted\n112\tCompleted                  Has Results\n13\tCompleted\n34\tCompleted                  Has Results\n72\tTerminated                  Has Results\n4\tTerminated\n25\tCompleted\n46\tCompleted\n30\tCompleted\n200\tActive not recruiting\n40\tCompleted\n11\tCompleted\n32\tCompleted\n26\tTerminated\n25\tCompleted\n133\tCompleted\n31\tCompleted                  Has Results\n13\tTerminated                  Has Results\n100\tRecruiting\n257\tCompleted\n20\tCompleted                  Has Results\n15\tCompleted\n12\tCompleted\n20\tCompleted\n362\tCompleted\n10\tCompleted\n18\tCompleted                  Has Results\n31\tCompleted                  Has Results\n14\tTerminated\n60\tActive not recruiting\n1\tTerminated                  Has Results\n6\tTerminated                  Has Results\n1800\tRecruiting\n154\tActive not recruiting\n18\tCompleted\n16\tTerminated\n13\tCompleted\n125\tCompleted\n100\tTerminated\n5\tCompleted\n5\tCompleted                  Has Results\n60\tCompleted\n5\tCompleted\n19\tCompleted                  Has Results\n84\tCompleted\n68\tCompleted                  Has Results\n51\tCompleted\n8\tCompleted                  Has Results\n37\tCompleted                  Has Results\n6000\tCompleted\n1884\tCompleted                  Has Results\n36\tCompleted                  Has Results\n24\tCompleted\n157\tCompleted\n2\tTerminated                  Has Results\n42\tCompleted\n30\tCompleted\n24\tCompleted\n28\tCompleted\n51\tCompleted\n32\tCompleted\n36\tCompleted\n14\tCompleted\n32\tCompleted\n50\tCompleted\n40\tCompleted\n21\tCompleted                  Has Results\n1\tCompleted\n100\tCompleted\n94\tCompleted\n0\tWithdrawn\n40\tUnknown\u0026nbsp;\u0026#8224;\n12\tCompleted\n1104\tCompleted\n364\tCompleted\n40\tTerminated\n49\tCompleted                  Has Results\n8\tTerminated                  Has Results\n150\tCompleted\n2\tTerminated\n80\tUnknown\u0026nbsp;\u0026#8224;\n42\tCompleted                  Has Results\n7\tCompleted\n2922\tActive not recruiting\n22\tCompleted                  Has Results\n3\tTerminated\n50\tTerminated                  Has Results\n97\tCompleted                  Has Results\n1426\tCompleted\n200\tActive not recruiting\n100\tTerminated\n40\tCompleted\n14\tTerminated\n11\tTerminated                  Has Results\n32\tCompleted                  Has Results\n116\tCompleted\n20\tCompleted                  Has Results\n73\tCompleted                  Has Results\n300\tCompleted\n18\tTerminated                  Has Results\n12\tCompleted                  Has Results\n15\tCompleted                  Has Results\n530\tRecruiting\n115\tCompleted                  Has Results\n0\tWithdrawn\n132\tCompleted\n22\tCompleted                  Has Results\n479\tCompleted                  Has Results\n300\tCompleted\n15\tCompleted                  Has Results\n300\tCompleted                  Has Results\n45\tCompleted                  Has Results\n60\tCompleted\n10\tCompleted\n88\tActive not recruiting\n1\tTerminated\n100\tCompleted\n46\tActive not recruiting\n19\tCompleted\n88\tCompleted                  Has Results\n781\tCompleted                  Has Results\n25\tCompleted                  Has Results\n\tNo longer available\n400\tCompleted                  Has Results\n12\tTerminated\n20\tCompleted\n80\tUnknown\u0026nbsp;\u0026#8224;\n31\tCompleted\n20\tCompleted\n30\tUnknown\u0026nbsp;\u0026#8224;\n30\tUnknown\u0026nbsp;\u0026#8224;\n30\tTerminated                  Has Results\n23\tCompleted\n4\tTerminated\n37\tCompleted\n80\tCompleted                  Has Results\n25\tActive not recruiting\n18\tCompleted                  Has Results\n45\tCompleted\n5\tUnknown\u0026nbsp;\u0026#8224;\n0\tWithdrawn\n0\tWithdrawn\n41\tCompleted\n60\tActive not recruiting\n100\tUnknown\u0026nbsp;\u0026#8224;\n74\tCompleted\n7525\tCompleted\n130\tRecruiting\n117\tCompleted\n75\tCompleted\n150\tCompleted\n110\tCompleted                  Has Results\n13\tCompleted\n102\tCompleted\n86\tCompleted\n3\tCompleted                  Has Results\n124\tCompleted\n137\tCompleted\n64\tCompleted                  Has Results\n31\tCompleted\n12\tCompleted\n8\tTerminated\n62\tCompleted                  Has Results\n32\tCompleted                  Has Results\n1\tTerminated                  Has Results\n8\tTerminated\n57\tCompleted                  Has Results\n855\tCompleted\n40\tTerminated\n420\tCompleted\n30\tCompleted\n29\tCompleted                  Has Results\n11\tCompleted\n24\tCompleted\n610\tCompleted                  Has Results\n66\tCompleted\n112\tCompleted\n16\tTerminated\n614\tCompleted                  Has Results\n100\tUnknown\u0026nbsp;\u0026#8224;\n25\tCompleted\n223\tCompleted\n20\tCompleted\n40\tCompleted\n15\tCompleted                  Has Results\n59\tCompleted\n30\tUnknown\u0026nbsp;\u0026#8224;\n20\tCompleted\n181\tCompleted\n8338\tCompleted                  Has Results\n59\tCompleted                  Has Results\n17\tTerminated\n18\tActive not recruiting\n3\tTerminated\n7\tTerminated                  Has Results\n70\tTerminated\n24\tCompleted                  Has Results\n16\tActive not recruiting\n300\tTerminated\n350\tCompleted\n0\tWithdrawn\n51\tCompleted                  Has Results\n24\tCompleted\n385\tCompleted\n80\tRecruiting\n63\tTerminated                  Has Results\n1350\tCompleted\n21\tCompleted\n30\tCompleted\n56\tTerminated                  Has Results\n23\tCompleted\n10000\tRecruiting\n20\tTerminated                  Has Results\n35\tCompleted\n40\tCompleted\n2\tTerminated                  Has Results\n301\tCompleted\n2303\tUnknown\u0026nbsp;\u0026#8224;\n18\tCompleted\n56\tCompleted\n4\tTerminated\n6\tTerminated                  Has Results\n35\tCompleted                  Has Results\n40\tCompleted\n9\tTerminated\n45\tCompleted                  Has Results\n321697\tCompleted                  Has Results\n18\tActive not recruiting\n16\tCompleted\n87\tCompleted                  Has Results\n54\tCompleted\n7\tCompleted\n30\tCompleted                  Has Results\n74\tCompleted\n7\tCompleted                  Has Results\n0\tWithdrawn\n67\tCompleted                  Has Results\n31\tCompleted\n30\tCompleted                  Has Results\n56\tCompleted\n200\tCompleted\n63\tCompleted\n25\tCompleted                  Has Results\n9\tCompleted                  Has Results\n54\tCompleted\n1\tTerminated                  Has Results\n17\tCompleted                  Has Results\n120\tCompleted\n41\tCompleted\n79\tSuspended\n64\tCompleted                  Has Results\n122\tCompleted\n6\tTerminated                  Has Results\n49\tCompleted\n78\tCompleted\n67\tCompleted\n27\tCompleted\n23\tCompleted                  Has Results\n42\tCompleted\n42\tCompleted                  Has Results\n37\tCompleted\n96\tCompleted\n94\tCompleted                  Has Results\n59\tCompleted                  Has Results\n41\tCompleted                  Has Results\n25\tCompleted\n2\tTerminated\n56\tCompleted                  Has Results\n74\tCompleted\n60\tCompleted\n62\tCompleted\n15\tCompleted\n47\tCompleted\n33\tCompleted                  Has Results\n273\tCompleted\n150\tCompleted\n12\tCompleted\n27\tCompleted\n151\tCompleted\n55\tTerminated\n40\tCompleted\n21\tCompleted                  Has Results\n60\tCompleted\n25\tCompleted\n40\tCompleted\n24\tActive not recruiting\n66\tCompleted\n30\tCompleted\n0\tWithdrawn\n33\tCompleted\n264\tCompleted                  Has Results\n50\tCompleted                  Has Results\n32\tCompleted                  Has Results\n6\tTerminated\n125\tCompleted                  Has Results\n851\tUnknown\u0026nbsp;\u0026#8224;\n20\tTerminated                  Has Results\n302\tCompleted                  Has Results\n18\tTerminated\n52\tActive not recruiting\n25\tTerminated\n62\tCompleted\n13\tCompleted\n13\tCompleted                  Has Results\n21\tCompleted                  Has Results\n47\tCompleted                  Has Results\n123\tCompleted\n216\tCompleted\n56\tCompleted\n61\tTerminated\n45\tCompleted\n5\tCompleted\n176\tCompleted                  Has Results\n15\tActive not recruiting\n28\tActive not recruiting\n343\tCompleted\n7\tTerminated\n48\tCompleted                  Has Results\n16\tCompleted                  Has Results\n29\tCompleted                  Has Results\n9\tCompleted\n21\tTerminated\n39\tActive not recruiting                  Has Results\n795\tCompleted\n28\tActive not recruiting\n26\tActive not recruiting\n127\tCompleted                  Has Results\n170\tCompleted\n31\tCompleted\n40\tCompleted                  Has Results\n11\tTerminated                  Has Results\n144\tCompleted\n34\tCompleted\n500\tUnknown\u0026nbsp;\u0026#8224;\n21\tCompleted\n795\tActive not recruiting\n110\tTerminated\n25\tActive not recruiting\n2\tTerminated                  Has Results\n33\tCompleted\n28\tCompleted                  Has Results\n27\tCompleted\n400\tActive not recruiting\n12\tCompleted                  Has Results\n350\tCompleted\n256\tCompleted                  Has Results\n26\tCompleted\n711\tCompleted\n10\tUnknown\u0026nbsp;\u0026#8224;\n21\tCompleted                  Has Results\n579\tCompleted\n30\tRecruiting\n188\tUnknown\u0026nbsp;\u0026#8224;\n24\tCompleted\n8\tCompleted                  Has Results\n67\tTerminated\n132\tCompleted\n28\tCompleted\n24\tCompleted                  Has Results\n239\tCompleted                  Has Results\n434\tCompleted                  Has Results\n468\tCompleted\n4\tTerminated                  Has Results\n14\tCompleted\n211\tCompleted\n500\tRecruiting\n1000\tRecruiting\n200\tCompleted\n14\tTerminated                  Has Results\n19\tTerminated                  Has Results\n7\tTerminated                  Has Results\n55\tTerminated                  Has Results\n40\tCompleted                  Has Results\n\tUnknown\u0026nbsp;\u0026#8224;\n0\tWithdrawn\n32\tCompleted                  Has Results\n16\tCompleted\n11\tCompleted\n10\tCompleted\n13\tActive not recruiting                  Has Results\n26\tCompleted                  Has Results\n4\tCompleted\n2047\tCompleted\n44\tCompleted\n82\tCompleted                  Has Results\n14\tCompleted                  Has Results\n115\tCompleted\n2\tTerminated\n275\tRecruiting\n4\tCompleted\n123\tCompleted\n0\tWithdrawn\n33\tCompleted\n238\tCompleted\n2800\tRecruiting\n15\tCompleted\n1467\tCompleted                  Has Results\n18\tCompleted\n123\tUnknown\u0026nbsp;\u0026#8224;\n110\tCompleted\n341\tUnknown\u0026nbsp;\u0026#8224;\n53\tCompleted\n60\tCompleted\n8\tCompleted\n71\tCompleted                  Has Results\n295\tCompleted                  Has Results\n44\tCompleted                  Has Results\n120\tCompleted\n54\tCompleted\n16\tCompleted\n30\tTerminated\n290\tCompleted\n66\tCompleted                  Has Results\n14\tTerminated                  Has Results\n30\tUnknown\u0026nbsp;\u0026#8224;\n13\tCompleted\n138\tCompleted\n900\tCompleted\n60\tActive not recruiting\n471\tCompleted                  Has Results\n70\tActive not recruiting\n276\tCompleted\n19\tCompleted\n\tCompleted\n24\tCompleted\n60\tCompleted\n8\tCompleted\n61\tCompleted\n400\tCompleted                  Has Results\n3604\tCompleted\n7\tCompleted\n24\tUnknown\u0026nbsp;\u0026#8224;\n15\tCompleted\n132\tUnknown\u0026nbsp;\u0026#8224;\n90\tCompleted\n16\tCompleted\n140\tTerminated\n101\tCompleted\n24\tCompleted\n278\tCompleted\n23\tCompleted\n36\tCompleted\n30\tCompleted\n1600\tRecruiting\n50\tCompleted\n51\tCompleted\n5\tTerminated                  Has Results\n3\tTerminated                  Has Results\n2040\tRecruiting\n116\tCompleted\n5\tTerminated                  Has Results\n569\tCompleted\n40\tCompleted\n156\tCompleted                  Has Results\n492\tCompleted\n314\tCompleted\n19\tCompleted\n37\tCompleted\n16\tCompleted\n70\tCompleted\n252\tCompleted\n294\tCompleted\n454\tCompleted\n27\tActive not recruiting\n20\tCompleted\n21\tCompleted\n61\tCompleted\n65\tCompleted\n34\tCompleted\n4\tTerminated\n475\tCompleted\n9000\tCompleted\n58\tCompleted                  Has Results\n20108\tCompleted\n52\tCompleted\n21\tCompleted                  Has Results\n2\tTerminated                  Has Results\n65\tCompleted\n600\tCompleted\n20\tCompleted\n40\tCompleted\n93\tCompleted\n60\tCompleted\n29\tTerminated\n62\tActive not recruiting\n516\tCompleted\n2500\tCompleted\n25\tCompleted\n3\tTerminated\n389\tCompleted\n400\tCompleted\n65\tCompleted\n120\tCompleted\n84\tCompleted\n485\tCompleted\n16\tCompleted\n300\tCompleted\n80\tCompleted\n0\tCompleted\n8000\tCompleted\n100\tCompleted\n2000\tCompleted\n106\tActive not recruiting\n0\tWithdrawn\n10\tCompleted\n18\tCompleted                  Has Results\n457\tCompleted\n275\tActive not recruiting\n318\tCompleted\n20\tCompleted\n143\tCompleted                  Has Results\n40\tCompleted\n255\tCompleted                  Has Results\n111\tCompleted\n41\tCompleted\n1354\tCompleted\n4362\tCompleted\n113\tCompleted\n120\tCompleted\n88\tCompleted                  Has Results\n33\tCompleted                  Has Results\n15\tCompleted\n150\tCompleted\n0\tWithdrawn\n89\tCompleted\n14\tTerminated\n34\tCompleted\n262\tTerminated\n48\tActive not recruiting\n201\tCompleted\n45\tCompleted\n29\tCompleted                  Has Results\n28\tCompleted\n4\tTerminated\n18\tCompleted\n46\tCompleted\n27\tCompleted\n113\tCompleted\n412\tCompleted\n37\tCompleted\n101\tCompleted                  Has Results\n60\tCompleted                  Has Results\n12\tTerminated\n400\tTerminated\n0\tWithdrawn\n53\tActive not recruiting\n152\tCompleted\n231\tTerminated                  Has Results\n630\tCompleted                  Has Results\n523\tCompleted                  Has Results\n258\tCompleted\n151\tCompleted\n30\tCompleted\n20\tCompleted\n1\tTerminated\n52\tCompleted\n40\tCompleted\n40\tCompleted                  Has Results\n40\tTerminated\n15\tCompleted\n40\tCompleted\n8\tCompleted                  Has Results\n15\tCompleted\n13\tCompleted\n64\tCompleted\n24\tCompleted\n60\tRecruiting\n75\tCompleted\n30\tCompleted\n65\tCompleted\n225\tCompleted                  Has Results\n261\tCompleted\n24\tCompleted\n150\tUnknown\u0026nbsp;\u0026#8224;\n68\tCompleted\n26\tActive not recruiting\n23\tCompleted\n97\tCompleted\n279\tCompleted\n\tCompleted\n31\tCompleted\n40\tCompleted\n25\tCompleted\n96\tUnknown\u0026nbsp;\u0026#8224;\n400\tUnknown\u0026nbsp;\u0026#8224;\n\tCompleted\n28\tCompleted\n591\tCompleted                  Has Results\n107\tCompleted\n496\tCompleted\n15\tCompleted\n200\tCompleted\n136\tCompleted                  Has Results\n10\tTerminated\n\tCompleted\n\tCompleted\n39\tCompleted\n64\tCompleted\n15\tCompleted\n26\tCompleted\n14\tCompleted                  Has Results\n450\tCompleted\n100\tCompleted\n354\tCompleted\n416\tCompleted\n240\tCompleted\n50\tUnknown\u0026nbsp;\u0026#8224;\n1100\tTerminated\n574\tCompleted\n77\tCompleted\n70\tCompleted\n89\tActive not recruiting\n329\tCompleted\n160\tCompleted\n30\tCompleted\n16\tCompleted\n28\tCompleted                  Has Results\n747\tCompleted\n30\tCompleted\n40\tCompleted\n811\tCompleted\n174\tCompleted\n654\tCompleted\n94\tCompleted\n117\tCompleted\n165\tCompleted\n80\tCompleted                  Has Results\n777\tCompleted\n12\tCompleted\n2364\tTerminated\n3360\tCompleted\n56\tCompleted\n600\tRecruiting\n30\tCompleted                  Has Results\n1500\tCompleted\n146\tCompleted                  Has Results\n\tCompleted\n30\tCompleted\n100\tCompleted\n360\tCompleted\n544\tCompleted\n5\tTerminated\n30\tCompleted\n40\tTerminated\n20\tTerminated\n1800\tCompleted\n18\tCompleted\n15\tCompleted\n76\tCompleted\n154\tCompleted\n33\tCompleted\n55\tCompleted\n45\tCompleted\n101\tTerminated                  Has Results\n15\tTerminated\n\tUnknown\u0026nbsp;\u0026#8224;\n60\tCompleted\n469\tCompleted                  Has Results\n2121\tCompleted\n37\tTerminated\n127\tCompleted\n\tCompleted\n12\tTerminated\n\tCompleted\n221\tCompleted                  Has Results\n60\tCompleted\n107\tCompleted\n43\tCompleted\n18\tCompleted\n40\tCompleted\n84\tTerminated\n300\tCompleted\n4\tCompleted\n600\tCompleted\n60\tCompleted\n8\tCompleted\n\tUnknown\u0026nbsp;\u0026#8224;\n50884\tCompleted\n24\tCompleted\n460\tCompleted\n100\tCompleted\n20\tCompleted\n\tCompleted\n162\tCompleted\n50\tCompleted\n8000\tCompleted\n150\tCompleted\n400\tUnknown\u0026nbsp;\u0026#8224;\n389\tCompleted                  Has Results\n732\tCompleted\n600\tActive not recruiting\n\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n14\tCompleted\n\tUnknown\u0026nbsp;\u0026#8224;\n8\tCompleted\n89\tCompleted\n2136\tCompleted\n3720\tCompleted\n\tCompleted\n176\tCompleted\n\tUnknown\u0026nbsp;\u0026#8224;\n\tCompleted\n271\tCompleted\n260\tCompleted\n\tCompleted\n3\tTerminated\n\tCompleted\n135\tCompleted\n\tCompleted\n1276\tCompleted\n\tCompleted\n\tCompleted\n20\tCompleted\n\tCompleted\n\tCompleted\n\tUnknown\u0026nbsp;\u0026#8224;\n\tCompleted\n\tUnknown\u0026nbsp;\u0026#8224;\n\tUnknown\u0026nbsp;\u0026#8224;\n1500\tCompleted\n19\tCompleted\n6360\tCompleted\n125\tCompleted\n75\tCompleted\n60\tCompleted\n\tCompleted\n150\tCompleted\n3\tCompleted\n\tCompleted\n\tCompleted\n30\tCompleted\n\tCompleted\n0\tWithdrawn\n15\tCompleted\n180\tCompleted\n\tUnknown\u0026nbsp;\u0026#8224;\n6340\tActive not recruiting\n\tCompleted\n300\tUnknown\u0026nbsp;\u0026#8224;\n\tCompleted\n24\tCompleted\n20\tCompleted\n60\tCompleted\n40\tSuspended\n17\tCompleted\n\tCompleted\n216\tCompleted\n21\tCompleted\n10\tCompleted\n68\tCompleted\n60\tCompleted\n50\tCompleted\n20\tCompleted\n\tCompleted\n0\tWithdrawn\n8\tTerminated\n\tCompleted\n4\tTerminated\n\tCompleted\n56\tCompleted\n40\tCompleted\n36\tCompleted\n26\tCompleted\n11\tCompleted\n136\tCompleted\n25\tCompleted\n14\tUnknown\u0026nbsp;\u0026#8224;\n14\tUnknown\u0026nbsp;\u0026#8224;\n20\tUnknown\u0026nbsp;\u0026#8224;\n6\tCompleted\n6\tCompleted\n\tCompleted\n6\tCompleted\n6\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n250\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n30\tCompleted\n30\tCompleted\n\tCompleted\n4400\tCompleted\n\tCompleted\n106\tCompleted\n60\tRecruiting\n300\tRecruiting\n320\tNot yet recruiting\n146\tRecruiting\n24\tRecruiting\n163\tActive not recruiting\n300\tRecruiting\n80\tRecruiting\n80\tRecruiting\n32\tRecruiting\n60\tRecruiting\n153\tCompleted\n40\tRecruiting\n35\tCompleted\n50\tRecruiting\n0\tWithdrawn\n24\tRecruiting\n10\tCompleted\n0\tWithdrawn\n74\tCompleted\n36\tTerminated\n40\tRecruiting\n28\tCompleted\n146\tCompleted\n50\tActive not recruiting\n126\tRecruiting\n42\tCompleted\n20\tCompleted\n23\tTerminated                  Has Results\n26\tCompleted                  Has Results\n1704\tRecruiting\n10\tRecruiting\n11\tCompleted\n522\tCompleted\n63\tCompleted\n15\tActive not recruiting\n805\tCompleted\n200\tCompleted\n80\tCompleted\n92\tCompleted\n240\tCompleted\n240\tCompleted                  Has Results\n33\tActive not recruiting\n628\tCompleted\n30\tActive not recruiting\n113\tCompleted\n200\tCompleted                  Has Results\n10\tSuspended\n19\tTerminated                  Has Results\n91\tCompleted\n30\tActive not recruiting\n25\tCompleted\n282\tCompleted\n300\tCompleted\n682\tCompleted\n41\tCompleted                  Has Results\n6\tTerminated                  Has Results\n84\tRecruiting\n52\tCompleted                  Has Results\n1040\tEnrolling by invitation\n200\tCompleted\n237\tCompleted\n14\tCompleted                  Has Results\n7\tTerminated\n700\tCompleted\n45\tActive not recruiting\n16\tTerminated                  Has Results\n30\tUnknown\u0026nbsp;\u0026#8224;\n598\tCompleted\n13\tCompleted                  Has Results\n11\tActive not recruiting\n12\tActive not recruiting\n1000\tRecruiting\n59\tCompleted\n164\tCompleted\n90\tCompleted\n59\tCompleted                  Has Results\n22\tCompleted\n15\tCompleted\n450\tCompleted\n200\tCompleted                  Has Results\n6\tTerminated\n0\tWithdrawn\n43\tCompleted\n163\tCompleted\n27\tTerminated\n544\tCompleted                  Has Results\n832\tCompleted\n32\tCompleted\n18\tTerminated\n186\tCompleted\n60\tCompleted                  Has Results\n500\tCompleted\n300\tCompleted\n43\tCompleted                  Has Results\n24\tCompleted                  Has Results\n0\tCompleted\n400\tCompleted\n120\tCompleted\n400\tCompleted\n30\tTerminated\n641\tCompleted\n30\tCompleted                  Has Results\n10\tCompleted\n23\tCompleted\n181\tTerminated\n51\tCompleted                  Has Results\n51\tTerminated\n186\tCompleted\n37\tUnknown\u0026nbsp;\u0026#8224;\n105\tCompleted\n60\tCompleted\n85\tCompleted\n10\tCompleted\n90\tRecruiting\n6\tRecruiting\n24\tActive not recruiting\n350\tRecruiting\n60\tRecruiting\n400\tRecruiting\n200\tRecruiting\n60\tRecruiting\n24\tRecruiting\n79\tRecruiting\n50\tRecruiting\n10\tActive not recruiting\n72\tRecruiting\n600\tRecruiting\n50\tRecruiting\n140\tRecruiting\n375\tActive not recruiting\n39\tCompleted                  Has Results\n5\tCompleted                  Has Results\n38\tRecruiting\n38\tCompleted                  Has Results\n30\tRecruiting\n6\tTerminated\n13\tRecruiting\n30\tCompleted\n300\tEnrolling by invitation\n30\tActive not recruiting\n312\tRecruiting\n80\tUnknown\u0026nbsp;\u0026#8224;\n3600\tRecruiting\n1239\tCompleted\n1493\tCompleted\n64\tActive not recruiting\n381\tCompleted\n36\tActive not recruiting\n802\tEnrolling by invitation\n30\tCompleted\n24\tRecruiting\n835\tActive not recruiting\n641\tCompleted\n170\tCompleted                  Has Results\n66\tRecruiting\n280\tCompleted\n5\tTerminated\n210\tRecruiting\n554\tCompleted                  Has Results\n21\tActive not recruiting\n6\tCompleted\n25\tActive not recruiting\n43\tActive not recruiting                  Has Results\n26\tCompleted\n15\tCompleted                  Has Results\n10\tTerminated                  Has Results\n599\tActive not recruiting\n95\tCompleted\n35\tCompleted\n250\tCompleted\n15\tCompleted\n659\tCompleted\n20\tCompleted\n50\tCompleted\n476\tActive not recruiting\n33\tCompleted                  Has Results\n451\tCompleted\n11\tTerminated                  Has Results\n196\tCompleted\n56\tCompleted                  Has Results\n13\tCompleted\n64\tCompleted                  Has Results\n746\tCompleted\n363\tCompleted                  Has Results\n38\tTerminated                  Has Results\n128\tCompleted\n30\tCompleted                  Has Results\n0\tWithdrawn\n40\tActive not recruiting                  Has Results\n482\tCompleted\n62\tTerminated\n22\tTerminated\n120\tCompleted\n1360\tActive not recruiting\n44\tUnknown\u0026nbsp;\u0026#8224;\n756\tCompleted                  Has Results\n75\tCompleted\n80\tCompleted\n80\tCompleted\n1200\tCompleted\n3000\tCompleted\n100\tCompleted                  Has Results\n0\tCompleted\n\tCompleted\n58\tTerminated\n239\tCompleted                  Has Results\n11\tCompleted\n800\tCompleted\n24\tTerminated                  Has Results\n1701\tCompleted\n65\tCompleted\n900\tCompleted\n12\tCompleted\n18\tTerminated\n\tCompleted\n\tCompleted\n20\tCompleted\n30\tCompleted\n300\tCompleted\n100\tCompleted\n\tCompleted\n24\tCompleted\n36\tCompleted\n25\tCompleted\n0\tWithdrawn\n\tCompleted\n820\tRecruiting\n331\tCompleted\n170\tActive not recruiting\n350\tCompleted\n76\tCompleted                  Has Results\n33\tCompleted\n100\tActive not recruiting\n273\tActive not recruiting\n14\tCompleted\n84\tRecruiting\n30\tCompleted\n62\tActive not recruiting\n80\tCompleted                  Has Results\n4100\tRecruiting\n72\tCompleted                  Has Results\n37\tTerminated                  Has Results\n30\tTerminated\n20\tTerminated\n0\tCompleted\n71\tCompleted\n48\tCompleted\n35\tCompleted\n288\tCompleted\n160\tNot yet recruiting\n60\tNot yet recruiting\n110\tRecruiting\n37\tRecruiting\n24\tRecruiting\n150\tNot yet recruiting\n120\tNot yet recruiting\n20\tRecruiting\n90\tNot yet recruiting\n100\tRecruiting\n58\tRecruiting\n1200\tRecruiting\n60\tRecruiting\n40\tEnrolling by invitation\n40\tRecruiting\n60\tNot yet recruiting\n52\tRecruiting\n1\tTerminated\n1820\tCompleted\n30\tUnknown\u0026nbsp;\u0026#8224;\n25\tRecruiting\n4\tCompleted\n24\tCompleted\n56\tRecruiting\n2149\tCompleted\n170\tRecruiting\n100\tEnrolling by invitation\n170\tRecruiting\n75\tRecruiting\n300\tRecruiting\n24\tCompleted\n3\tCompleted                  Has Results\n26\tSuspended\n85\tCompleted\n60\tActive not recruiting\n224\tRecruiting\n52\tCompleted\n108\tCompleted\n167\tCompleted\n32\tCompleted\n600\tCompleted\n23\tActive not recruiting\n1500\tEnrolling by invitation\n55\tRecruiting\n400\tRecruiting\n450\tActive not recruiting\n14\tCompleted\n700\tActive not recruiting\n260\tCompleted\n27\tActive not recruiting\n380\tCompleted\n115\tActive not recruiting\n86\tCompleted\n35035\tCompleted\n100\tCompleted\n16\tCompleted\n90\tActive not recruiting\n24\tCompleted\n10\tRecruiting\n34\tCompleted\n80\tCompleted\n30\tCompleted\n25\tCompleted\n48\tActive not recruiting\n30\tCompleted                  Has Results\n430\tActive not recruiting\n37\tCompleted\n36\tActive not recruiting\n14\tCompleted                  Has Results\n155\tCompleted\n32\tCompleted\n218\tCompleted\n67\tUnknown\u0026nbsp;\u0026#8224;\n2521\tCompleted\n11\tCompleted\n132\tCompleted\n31\tTerminated\n340\tUnknown\u0026nbsp;\u0026#8224;\n269\tTerminated\n2\tCompleted\n16\tCompleted                  Has Results\n42\tCompleted                  Has Results\n50\tActive not recruiting\n14\tTerminated                  Has Results\n206\tRecruiting\n130\tSuspended\n12\tCompleted\n169\tCompleted                  Has Results\n73\tCompleted                  Has Results\n51\tCompleted                  Has Results\n22\tCompleted\n30\tActive not recruiting\n96\tCompleted\n60\tCompleted\n54\tRecruiting\n40\tCompleted                  Has Results\n30\tCompleted                  Has Results\n32\tTerminated                  Has Results\n36\tCompleted                  Has Results\n84\tCompleted                  Has Results\n30\tUnknown\u0026nbsp;\u0026#8224;\n4\tCompleted                  Has Results\n\tCompleted\n11\tCompleted\n721\tCompleted\n40\tCompleted                  Has Results\n10\tCompleted\n13\tCompleted                  Has Results\n0\tWithdrawn\n54\tCompleted\n54\tCompleted\n60\tRecruiting\n185\tCompleted\n\tUnknown\u0026nbsp;\u0026#8224;\n690\tCompleted\n20\tCompleted\n14\tActive not recruiting                  Has Results\n1400\tCompleted\n37\tCompleted                  Has Results\n24\tCompleted                  Has Results\n157\tCompleted\n60\tCompleted\n90500\tActive not recruiting\n0\tCompleted\n131\tCompleted\n12\tCompleted\n480\tSuspended\n5\tCompleted\n35\tUnknown\u0026nbsp;\u0026#8224;\n21\tCompleted\n1686\tCompleted\n50\tCompleted\n16\tCompleted\n21\tCompleted\n18\tCompleted                  Has Results\n270\tTerminated\n24\tCompleted\n24\tTerminated\n20\tCompleted\n50\tCompleted                  Has Results\n24\tTerminated\n268\tCompleted\n280\tCompleted\n74\tCompleted\n\tCompleted\n1490\tUnknown\u0026nbsp;\u0026#8224;\n32\tCompleted\n11\tCompleted\n208\tCompleted\n\tCompleted\n160\tCompleted\n\tCompleted\n50\tUnknown\u0026nbsp;\u0026#8224;\n2\tCompleted                  Has Results\n420\tCompleted\n\tCompleted\n12\tCompleted\n26\tCompleted\n12\tCompleted\n360\tRecruiting\n200\tActive not recruiting\n37\tActive not recruiting\n18\tActive not recruiting\n7\tCompleted\n27\tActive not recruiting\n76\tTerminated                  Has Results\n80\tRecruiting\n20\tCompleted\n38\tActive not recruiting\n265\tCompleted\n960\tRecruiting\n150\tSuspended\n800\tActive not recruiting\n440\tCompleted                  Has Results\n257\tCompleted\n8\tCompleted\n24\tCompleted                  Has Results\n7\tTerminated\n133\tCompleted                  Has Results\n48\tCompleted\n36\tCompleted\n40\tCompleted\n31\tCompleted                  Has Results\n700\tCompleted\n21985\tCompleted\n1200\tUnknown\u0026nbsp;\u0026#8224;\n161\tCompleted\n10\tActive not recruiting\n36\tCompleted                  Has Results\n376\tCompleted                  Has Results\n146\tCompleted                  Has Results\n702\tCompleted                  Has Results\n63\tCompleted\n3988\tCompleted\n128\tCompleted\n130\tCompleted\n41\tCompleted                  Has Results\n40\tActive not recruiting\n39\tCompleted\n304\tCompleted                  Has Results\n622\tCompleted\n32\tTerminated\n496\tCompleted\n20000\tRecruiting\n150\tRecruiting\n100\tRecruiting\n100\tRecruiting\n15\tRecruiting\n114\tRecruiting\n360\tRecruiting\n28\tCompleted\n120\tRecruiting\n43\tCompleted\n60\tRecruiting\n300\tRecruiting\n50\tRecruiting\n20\tActive not recruiting\n9\tActive not recruiting                  Has Results\n677\tCompleted\n56\tRecruiting\n300\tActive not recruiting\n116\tActive not recruiting\n40\tActive not recruiting\n66\tActive not recruiting\n18\tActive not recruiting\n14\tCompleted\n71\tCompleted\n16\tCompleted                  Has Results\n57\tTerminated                  Has Results\n469\tCompleted                  Has Results\n105\tCompleted\n19\tCompleted\n127\tCompleted\n52\tCompleted\n0\tCompleted\n149\tCompleted                  Has Results\n46\tCompleted\n\tTerminated\n124\tCompleted                  Has Results\n119\tCompleted\n36\tRecruiting\n30\tRecruiting\n44\tRecruiting\n300\tRecruiting\n50\tRecruiting\n100\tRecruiting\n20\tCompleted\n358\tCompleted\n200\tSuspended\n400\tRecruiting\n100\tRecruiting\n78\tRecruiting\n27\tCompleted\n36\tRecruiting\n12\tEnrolling by invitation\n0\tWithdrawn\n40\tRecruiting\n30\tActive not recruiting\n500\tEnrolling by invitation\n74\tCompleted\n1\tTerminated\n39\tRecruiting\n44\tActive not recruiting\n61\tTerminated                  Has Results\n50\tRecruiting\n60\tActive not recruiting\n8\tTerminated                  Has Results\n1200\tEnrolling by invitation\n2200\tCompleted\n80\tRecruiting\n37\tCompleted\n0\tWithdrawn\n92\tTerminated\n1260\tCompleted\n2395\tCompleted\n28\tActive not recruiting\n105\tCompleted                  Has Results\n21\tCompleted                  Has Results\n200\tTerminated\n28\tActive not recruiting\n21\tTerminated                  Has Results\n41\tCompleted                  Has Results\n64\tCompleted\n19\tCompleted\n44\tTerminated\n34\tActive not recruiting\n29\tCompleted\n19\tCompleted                  Has Results\n5\tTerminated\n50\tCompleted                  Has Results\n600\tCompleted\n52\tActive not recruiting\n0\tWithdrawn\n406\tCompleted                  Has Results\n140\tTerminated                  Has Results\n37\tCompleted\n24\tUnknown\u0026nbsp;\u0026#8224;\n32\tCompleted\n100\tUnknown\u0026nbsp;\u0026#8224;\n4\tCompleted\n17\tCompleted\n25\tCompleted\n12\tTerminated\n9\tCompleted\n637\tCompleted\n148\tCompleted\n216\tUnknown\u0026nbsp;\u0026#8224;\n131\tCompleted                  Has Results\n6\tCompleted\n0\tWithdrawn\n50\tCompleted                  Has Results\n20\tCompleted                  Has Results\n39\tCompleted                  Has Results\n28\tActive not recruiting\n27\tCompleted                  Has Results\n100000\tCompleted\n40\tTerminated\n12\tTerminated                  Has Results\n16\tCompleted\n24\tCompleted                  Has Results\n120\tCompleted\n828\tCompleted\n8\tCompleted\n709\tCompleted\n50\tActive not recruiting\n268\tCompleted\n100\tActive not recruiting\n120\tCompleted\n80\tCompleted\n65\tCompleted\n62\tCompleted                  Has Results\n\tUnknown\u0026nbsp;\u0026#8224;\n16\tCompleted\n75\tUnknown\u0026nbsp;\u0026#8224;\n30\tTerminated\n\tCompleted\n225\tCompleted\n20\tCompleted\n1000\tCompleted\n12\tCompleted\n\tCompleted\n340\tRecruiting\n12\tNot yet recruiting\n72\tRecruiting\n184\tRecruiting\n232\tRecruiting\n24\tNot yet recruiting\n80\tEnrolling by invitation\n5000\tRecruiting\n36\tActive not recruiting\n100\tRecruiting\n200\tRecruiting\n42\tCompleted\n420\tRecruiting\n34\tCompleted\n63\tRecruiting\n130\tActive not recruiting\n5000\tRecruiting\n1963\tCompleted\n28\tSuspended\n299\tActive not recruiting\n38\tTerminated                  Has Results\n225\tCompleted\n79\tCompleted\n7\tTerminated\n120\tActive not recruiting\n1326\tActive not recruiting\n10\tTerminated\n64\tCompleted\n222\tCompleted\n50\tCompleted\n11816\tCompleted\n10\tCompleted\n6\tTerminated\n24\tCompleted                  Has Results\n52\tUnknown\u0026nbsp;\u0026#8224;\n57\tCompleted\n51\tCompleted\n0\tWithdrawn\n180\tActive not recruiting\n29\tCompleted\n79\tCompleted                  Has Results\n32\tCompleted                  Has Results\n45\tTerminated\n19\tCompleted\n15\tCompleted                  Has Results\n62\tCompleted\n40\tActive not recruiting\n110\tCompleted                  Has Results\n36\tTerminated                  Has Results\n33\tCompleted\n25\tCompleted\n12\tCompleted\n9\tCompleted\n315\tCompleted\n40\tTerminated\n98\tActive not recruiting\n21\tUnknown\u0026nbsp;\u0026#8224;\n120\tCompleted\n259\tCompleted\n33\tCompleted\n29\tCompleted\n48\tCompleted                  Has Results\n300\tCompleted\n31\tActive not recruiting\n40\tCompleted\n42\tCompleted                  Has Results\n93\tCompleted                  Has Results\n18\tTerminated\n45\tCompleted\n300\tUnknown\u0026nbsp;\u0026#8224;\n190\tCompleted\n6\tCompleted                  Has Results\n12\tCompleted\n175\tCompleted\n10\tTerminated\n48\tCompleted\n\tCompleted\n24\tRecruiting\n39\tActive not recruiting\n417\tCompleted\n421\tActive not recruiting\n67\tCompleted\n366\tCompleted\n689\tCompleted                  Has Results\n217\tCompleted\n25\tTerminated\n100\tCompleted\n200\tEnrolling by invitation\n648\tCompleted\n371\tCompleted\n138\tRecruiting\n80\tUnknown\u0026nbsp;\u0026#8224;\n288\tCompleted\n45\tCompleted                  Has Results\n4\tTerminated                  Has Results\n16\tTerminated                  Has Results\n1015\tCompleted\n339\tCompleted\n50\tNot yet recruiting\n90\tRecruiting\n50\tTerminated\n850\tCompleted\n76\tActive not recruiting\n489\tCompleted\n76\tCompleted\n46\tCompleted                  Has Results\n200\tRecruiting\n33\tCompleted\n40\tCompleted\n200\tRecruiting\n43\tActive not recruiting\n480\tRecruiting\n30\tRecruiting\n200\tRecruiting\n111\tCompleted\n1116\tCompleted\n347\tTerminated\n111\tCompleted\n363\tCompleted\n69\tTerminated\n600\tCompleted                  Has Results\n44\tCompleted                  Has Results\n132\tCompleted                  Has Results\n80\tCompleted\n18\tCompleted\n81\tCompleted                  Has Results\n6800\tCompleted\n60\tCompleted\n50\tEnrolling by invitation\n150\tRecruiting\n27\tRecruiting\n35\tCompleted\n1600\tRecruiting\n13\tTerminated\n30\tRecruiting\n7\tCompleted\n300\tRecruiting\n60\tRecruiting\n54\tRecruiting\n85\tRecruiting\n154\tRecruiting\n220\tRecruiting\n9\tCompleted\n19\tCompleted\n0\tWithdrawn\n647\tCompleted\n40\tCompleted\n11\tCompleted\n75\tActive not recruiting\n81\tUnknown\u0026nbsp;\u0026#8224;\n63\tCompleted\n200\tEnrolling by invitation\n45\tActive not recruiting\n51\tCompleted                  Has Results\n51\tCompleted\n40\tCompleted\n37\tCompleted\n187\tCompleted\n18\tCompleted                  Has Results\n45\tCompleted                  Has Results\n40\tCompleted\n144\tActive not recruiting\n10\tTerminated                  Has Results\n64\tCompleted\n9\tCompleted                  Has Results\n25\tCompleted\n32\tActive not recruiting\n40\tCompleted\n10\tCompleted\n71\tCompleted\n1\tCompleted\n100\tCompleted\n424\tCompleted\n25\tCompleted\n11\tCompleted\n116\tCompleted                  Has Results\n68\tCompleted                  Has Results\n46\tCompleted\n\tCompleted\n270\tNot yet recruiting\n48\tRecruiting\n13773\tRecruiting\n60\tRecruiting\n160\tRecruiting\n42\tRecruiting\n49\tCompleted\n48\tRecruiting\n1000\tNot yet recruiting\n100\tCompleted\n40\tRecruiting\n45\tRecruiting\n24\tRecruiting\n60\tRecruiting\n20\tCompleted\n175\tRecruiting\n225\tCompleted\n208\tRecruiting\n1149\tCompleted\n40\tActive not recruiting\n449\tActive not recruiting\n28\tRecruiting\n200\tUnknown\u0026nbsp;\u0026#8224;\n100\tCompleted                  Has Results\n2000\tCompleted\n1300\tRecruiting\n100\tRecruiting\n50\tEnrolling by invitation\n1500\tRecruiting\n120\tRecruiting\n39\tRecruiting\n371\tActive not recruiting\n39\tTerminated\n300\tActive not recruiting\n113\tCompleted\n400\tEnrolling by invitation\n251\tCompleted                  Has Results\n44\tCompleted\n11\tTerminated\n48\tCompleted                  Has Results\n17\tCompleted\n218\tRecruiting\n44\tCompleted\n58\tCompleted                  Has Results\n32\tCompleted                  Has Results\n78\tCompleted\n39\tActive not recruiting\n38\tCompleted\n15\tActive not recruiting\n24\tCompleted\n15\tTerminated\n111\tCompleted\n78\tCompleted                  Has Results\n60\tCompleted\n3\tTerminated\n20\tCompleted\n99\tCompleted                  Has Results\n253\tCompleted                  Has Results\n15\tCompleted\n42\tCompleted\n100\tTerminated\n470\tCompleted\n92\tCompleted\n7\tCompleted                  Has Results\n107\tTerminated\n26\tCompleted                  Has Results\n11\tTerminated                  Has Results\n5\tTerminated\n1028\tCompleted                  Has Results\n58\tCompleted\n600\tCompleted\n20\tCompleted                  Has Results\n25\tTerminated                  Has Results\n69\tCompleted\n50\tCompleted\n17\tCompleted\n22\tCompleted\n64\tCompleted\n25\tCompleted\n46\tCompleted\n\tCompleted\n75\tCompleted\n340\tCompleted\n62\tCompleted\n240\tCompleted\n480\tCompleted\n34\tCompleted\n104\tCompleted\n\tCompleted\n132\tRecruiting\n20\tRecruiting\n300\tEnrolling by invitation\n55\tRecruiting\n51\tActive not recruiting\n36\tRecruiting\n48\tRecruiting\n48\tCompleted\n11\tTerminated\n550\tRecruiting\n0\tWithdrawn\n28\tRecruiting\n87\tCompleted\n110\tActive not recruiting\n800\tRecruiting\n10\tCompleted\n110\tRecruiting\n192\tCompleted\n20\tRecruiting\n60\tCompleted\n90\tUnknown\u0026nbsp;\u0026#8224;\n30\tCompleted\n390\tCompleted\n99\tCompleted\n9\tTerminated\n40\tCompleted\n36\tCompleted                  Has Results\n82\tUnknown\u0026nbsp;\u0026#8224;\n123\tCompleted\n9\tCompleted\n9\tCompleted\n249\tCompleted\n19\tCompleted\n32\tCompleted                  Has Results\n127\tCompleted\n72\tCompleted                  Has Results\n31\tTerminated\n80\tUnknown\u0026nbsp;\u0026#8224;\n371\tCompleted\n51\tCompleted\n42\tCompleted\n62\tCompleted                  Has Results\n84\tTerminated\n50\tCompleted\n30\tCompleted\n45\tCompleted                  Has Results\n73\tCompleted                  Has Results\n69\tCompleted\n39\tCompleted                  Has Results\n605\tCompleted\n305\tCompleted                  Has Results\n40\tActive not recruiting\n100\tCompleted\n33\tCompleted\n6\tCompleted\n\tCompleted\n\tCompleted\n223\tCompleted\n\tCompleted\n\tCompleted\n\tCompleted\n53\tCompleted\n50\tCompleted\n64\tCompleted\n\tCompleted\n40\tUnknown\u0026nbsp;\u0026#8224;\n188\tCompleted\n102\tCompleted\n55\tCompleted\n\tCompleted\n\tCompleted\n39\tCompleted\n56\tCompleted\n402\tActive not recruiting\n77\tCompleted                  Has Results\n48\tCompleted\n90\tCompleted\n36\tCompleted\n51\tCompleted                  Has Results\n57\tCompleted                  Has Results\n7\tTerminated\n7\tCompleted\n450\tActive not recruiting\n250\tActive not recruiting\n1000\tActive not recruiting\n1000\tActive not recruiting\n189\tCompleted\n640\tCompleted\n226\tCompleted\n100\tRecruiting\n25\tCompleted\n81\tCompleted\n41\tActive not recruiting\n2\tCompleted\n400\tRecruiting\n1020\tActive not recruiting\n63\tCompleted\n660\tUnknown\u0026nbsp;\u0026#8224;\n1365\tUnknown\u0026nbsp;\u0026#8224;\n74\tCompleted\n90\tCompleted\n23\tCompleted\n24\tCompleted\n93\tRecruiting\n247\tTerminated\n163\tActive not recruiting\n112\tActive not recruiting\n88\tCompleted\n60\tActive not recruiting\n75\tCompleted\n217\tCompleted\n30\tCompleted\n27\tTerminated                  Has Results\n15\tCompleted                  Has Results\n20\tCompleted                  Has Results\n183\tCompleted                  Has Results\n23\tTerminated\n142\tCompleted\n126\tTerminated\n120\tCompleted                  Has Results\n54\tTerminated\n31\tCompleted\n86\tTerminated                  Has Results\n30\tCompleted\n9\tRecruiting\n154\tCompleted\n200\tCompleted\n61\tCompleted                  Has Results\n33\tCompleted                  Has Results\n56\tCompleted\n7287\tCompleted                  Has Results\n100\tCompleted\n230\tCompleted\n30\tEnrolling by invitation\n6\tTerminated\n40\tCompleted                  Has Results\n30\tActive not recruiting\n24\tCompleted                  Has Results\n0\tWithdrawn\n74\tCompleted                  Has Results\n40\tCompleted\n20\tRecruiting\n\tRecruiting\n24\tRecruiting\n1791\tRecruiting\n308\tRecruiting\n800\tRecruiting\n54\tEnrolling by invitation\n122\tCompleted\n81\tCompleted\n30\tSuspended\n100\tRecruiting\n30\tCompleted\n21\tActive not recruiting\n19\tTerminated\n685\tRecruiting\n80\tActive not recruiting\n108\tCompleted\n8\tCompleted\n130\tRecruiting\n12\tRecruiting\n7000\tRecruiting\n12\tRecruiting\n24\tRecruiting\n1000\tRecruiting\n72\tActive not recruiting\n38\tActive not recruiting\n66\tActive not recruiting\n9\tCompleted                  Has Results\n151\tCompleted                  Has Results\n30\tCompleted\n23\tCompleted\n19\tCompleted\n37\tCompleted\n24\tActive not recruiting\n243\tCompleted                  Has Results\n61\tCompleted                  Has Results\n100\tCompleted                  Has Results\n27\tCompleted                  Has Results\n80\tCompleted                  Has Results\n1100\tUnknown\u0026nbsp;\u0026#8224;\n800\tCompleted\n50\tCompleted                  Has Results\n1267\tCompleted                  Has Results\n80\tActive not recruiting\n75\tCompleted                  Has Results\n54\tTerminated\n40\tCompleted\n31\tCompleted                  Has Results\n100\tUnknown\u0026nbsp;\u0026#8224;\n36\tUnknown\u0026nbsp;\u0026#8224;\n100\tUnknown\u0026nbsp;\u0026#8224;\n\tCompleted\n26\tCompleted\n11811\tCompleted\n3069\tCompleted                  Has Results\n39\tCompleted\n320\tCompleted\n150\tRecruiting\n32\tSuspended\n30\tCompleted\n21395\tCompleted\n37\tActive not recruiting\n89\tCompleted\n501\tUnknown\u0026nbsp;\u0026#8224;\n150\tRecruiting\n60\tCompleted\n158\tRecruiting\n756\tRecruiting\n30\tCompleted\n23\tCompleted\n48\tCompleted\n1370\tCompleted                  Has Results\n0\tWithdrawn\n40\tNot yet recruiting\n40\tNot yet recruiting\n36\tNot yet recruiting\n\tAvailable\n300\tCompleted\n100\tCompleted\n300\tRecruiting\n32\tRecruiting\n30\tRecruiting\n216\tRecruiting\n40\tRecruiting\n0\tWithdrawn\n66\tRecruiting\n25\tEnrolling by invitation\n30\tRecruiting\n363\tCompleted\n7\tCompleted\n180\tCompleted\n26\tCompleted\n20\tTerminated\n1232\tActive not recruiting\n116\tActive not recruiting\n11\tCompleted\n18\tActive not recruiting\n500\tRecruiting\n100\tRecruiting\n25\tCompleted\n1\tTerminated\n26\tCompleted\n92\tCompleted\n70\tActive not recruiting\n342\tCompleted\n40\tRecruiting\n180\tSuspended\n75\tActive not recruiting\n44\tTerminated\n36\tRecruiting\n124\tCompleted\n125\tCompleted\n32\tTerminated\n29\tCompleted\n10\tActive not recruiting\n3342\tCompleted\n30\tActive not recruiting\n51\tCompleted\n79\tCompleted                  Has Results\n272\tCompleted                  Has Results\n27\tCompleted\n100\tCompleted\n43\tCompleted                  Has Results\n230\tCompleted\n329\tCompleted\n150\tCompleted                  Has Results\n16\tCompleted\n10\tCompleted\n23\tTerminated\n80\tUnknown\u0026nbsp;\u0026#8224;\n5\tTerminated                  Has Results\n58\tCompleted\n58\tCompleted\n21\tCompleted\n34\tCompleted                  Has Results\n60\tActive not recruiting\n4\tTerminated                  Has Results\n66\tCompleted\n49\tCompleted                  Has Results\n60\tUnknown\u0026nbsp;\u0026#8224;\n20\tCompleted\n100\tTerminated\n150\tCompleted\n20\tCompleted\n100\tCompleted\n306\tCompleted\n357\tCompleted\n38\tCompleted\n\tCompleted\n\tCompleted\n26\tCompleted\n\tUnknown\u0026nbsp;\u0026#8224;\n101\tTerminated                  Has Results\n101\tActive not recruiting\n14\tCompleted\n100\tRecruiting\n85\tCompleted\n470\tCompleted\n120\tRecruiting\n35\tActive not recruiting\n114\tRecruiting\n622\tRecruiting\n139\tCompleted                  Has Results\n19\tCompleted\n75\tActive not recruiting                  Has Results\n146\tActive not recruiting\n92\tActive not recruiting\n60\tRecruiting\n50\tActive not recruiting\n50\tCompleted\n90\tTerminated\n19\tTerminated                  Has Results\n50\tRecruiting\n709\tCompleted\n125\tEnrolling by invitation\n36\tCompleted\n40\tCompleted\n46\tCompleted\n41\tCompleted\n50\tCompleted                  Has Results\n26\tCompleted\n12\tTerminated                  Has Results\n40\tCompleted                  Has Results\n60\tCompleted\n16\tTerminated\n55\tCompleted                  Has Results\n45\tCompleted\n515\tCompleted\n65\tCompleted\n87\tCompleted                  Has Results\n0\tWithdrawn\n164\tCompleted                  Has Results\n517\tCompleted                  Has Results\n18\tCompleted\n15\tUnknown\u0026nbsp;\u0026#8224;\n384\tActive not recruiting\n120\tCompleted\n0\tWithdrawn\n63\tCompleted\n60\tCompleted\n96\tCompleted\n\tCompleted\n31\tTerminated                  Has Results\n100\tActive not recruiting\n242\tCompleted                  Has Results\n14\tTerminated\n800\tActive not recruiting\n90\tTerminated\n155\tCompleted\n42\tActive not recruiting\n310\tActive not recruiting\n350\tRecruiting\n42\tRecruiting\n59\tRecruiting\n100\tActive not recruiting\n3136\tRecruiting\n112\tRecruiting\n990\tRecruiting\n3000\tRecruiting\n3270\tRecruiting\n94\tRecruiting\n275\tCompleted\n378\tRecruiting\n280\tRecruiting\n8300\tRecruiting\n450\tRecruiting\n106\tActive not recruiting\n10000\tActive not recruiting\n10000\tRecruiting\n600\tRecruiting\n4200\tRecruiting\n540\tSuspended\n519\tActive not recruiting\n330\tRecruiting\n12000\tActive not recruiting\n312\tActive not recruiting\n17000\tActive not recruiting\n4000\tActive not recruiting\n2820\tRecruiting\n1311\tActive not recruiting\n143\tActive not recruiting\n2918\tRecruiting\n523\tActive not recruiting\n756\tRecruiting\n27564\tCompleted\n1900\tRecruiting\n487\tCompleted                  Has Results\n294\tActive not recruiting\n128\tRecruiting\n224\tRecruiting\n230\tActive not recruiting\n1871\tActive not recruiting\n216\tRecruiting\n1060\tRecruiting\n4161\tCompleted\n213\tActive not recruiting\n140\tRecruiting\n1340\tRecruiting\n16568\tCompleted                  Has Results\n3260\tActive not recruiting\n1500\tActive not recruiting\n10000\tRecruiting\n2500\tActive not recruiting\n807\tCompleted\n17183\tCompleted                  Has Results\n1545\tActive not recruiting\n534\tRecruiting\n35895\tCompleted\n480\tActive not recruiting\n500\tActive not recruiting\n55\tUnknown\u0026nbsp;\u0026#8224;\n3900\tActive not recruiting\n799\tActive not recruiting                  Has Results\n2000\tActive not recruiting\n1070\tRecruiting\n1038\tRecruiting\n57000\tRecruiting\n4950\tActive not recruiting\n3966\tActive not recruiting\n8067\tCompleted                  Has Results\n24222\tCompleted\n1500\tActive not recruiting\n11248\tActive not recruiting\n2334\tActive not recruiting\n5652\tCompleted\n1873\tCompleted                  Has Results\n3610\tActive not recruiting\n732\tCompleted\n1200\tCompleted\n3104\tCompleted\n4646\tActive not recruiting\n\tCompleted\n19747\tCompleted\n13000\tRecruiting\n10653\tActive not recruiting\n345\tRecruiting\n150\tActive not recruiting\n168\tActive not recruiting\n13026\tCompleted\n454\tCompleted                  Has Results\n3000\tRecruiting\n1049\tCompleted                  Has Results\n555\tActive not recruiting\n210\tCompleted\n15865\tCompleted\n147494\tCompleted                  Has Results\n400\tActive not recruiting\n488\tCompleted                  Has Results\n1877\tCompleted\n3397\tCompleted                  Has Results\n714\tRecruiting\n562\tRecruiting\n1626\tRecruiting\n19000\tActive not recruiting\n7637\tCompleted\n1636\tRecruiting\n784\tActive not recruiting\n7000\tRecruiting\n1282\tCompleted\n2583\tCompleted                  Has Results\n12776\tCompleted                  Has Results\n1500\tActive not recruiting\n804\tActive not recruiting\n1500\tActive not recruiting\n310\tCompleted                  Has Results\n685\tCompleted                  Has Results\n6000\tActive not recruiting\n1743\tCompleted\n3509\tTerminated\n1206\tActive not recruiting\n295\tActive not recruiting                  Has Results\n2722\tCompleted\n766\tCompleted\n636\tActive not recruiting\n1500\tRecruiting\n2544\tActive not recruiting\n184\tRecruiting\n8250\tRecruiting\n10066\tActive not recruiting\n21379\tCompleted                  Has Results\n6198\tActive not recruiting\n116\tActive not recruiting\n406\tTerminated\n805\tCompleted                  Has Results\n643\tCompleted                  Has Results\n518\tActive not recruiting\n9326\tCompleted                  Has Results\n1792\tActive not recruiting\n596\tCompleted\n18113\tCompleted                  Has Results\n8231\tCompleted                  Has Results\n11000\tActive not recruiting\n1200\tRecruiting\n172\tRecruiting\n8300\tActive not recruiting\n4148\tRecruiting\n16415\tCompleted\n756\tActive not recruiting\n3207\tTerminated                  Has Results\n8910\tTerminated\n11751\tCompleted                  Has Results\n773\tActive not recruiting\n2873\tTerminated\n6068\tCompleted                  Has Results\n14000\tActive not recruiting\n200\tActive not recruiting\n792\tActive not recruiting\n1526\tActive not recruiting\n1546\tActive not recruiting\n1538\tActive not recruiting\n2264\tCompleted\n305\tCompleted                  Has Results\n309\tCompleted                  Has Results\n189\tCompleted                  Has Results\n452\tCompleted                  Has Results\n21105\tCompleted                  Has Results\n305\tActive not recruiting                  Has Results\n939\tTerminated\n1027\tCompleted                  Has Results\n591\tCompleted                  Has Results\n17802\tTerminated                  Has Results\n1038\tCompleted\n520\tCompleted\n1331\tActive not recruiting\n650\tCompleted\n67\tTerminated\n1050\tRecruiting\n8000\tRecruiting\n250\tRecruiting\n2000\tRecruiting\n350\tCompleted\n122\tRecruiting\n951\tCompleted\n332\tRecruiting\n2012\tCompleted                  Has Results\n6115\tActive not recruiting\n950\tRecruiting\n60\tActive not recruiting\n5380\tCompleted                  Has Results\n101\tCompleted                  Has Results\n4000\tEnrolling by invitation\n779\tCompleted                  Has Results\n474\tCompleted                  Has Results\n76\tActive not recruiting\n5067\tCompleted\n1116\tCompleted                  Has Results\n8381\tActive not recruiting                  Has Results\n242\tCompleted\n14269\tCompleted                  Has Results\n34810\tCompleted                  Has Results\n1100\tActive not recruiting\n63\tCompleted                  Has Results\n702\tCompleted\n47\tCompleted\n80\tCompleted\n308\tCompleted\n9000\tActive not recruiting\n39\tCompleted\n41\tCompleted\n9779\tCompleted                  Has Results\n56\tCompleted\n69\tCompleted\n10\tTerminated\n78\tCompleted\n81\tCompleted\n320\tCompleted\n79\tCompleted\n42\tCompleted\n259\tCompleted\n60\tCompleted\n\tCompleted\n91\tCompleted\n391\tCompleted\n280\tCompleted\n75\tCompleted\n109\tCompleted\n854\tActive not recruiting                  Has Results\n270\tCompleted\n5000\tRecruiting\n84\tSuspended\n1800\tRecruiting\n605\tRecruiting\n1471\tCompleted\n400\tRecruiting\n7910\tActive not recruiting\n1223\tCompleted\n4000\tRecruiting\n89\tActive not recruiting\n1394\tCompleted\n2370\tCompleted\n3\tTerminated                  Has Results\n1304\tRecruiting\n460\tCompleted\n2354\tCompleted\n1663\tCompleted\n282\tCompleted\n664\tCompleted                  Has Results\n1053\tCompleted                  Has Results\n10179\tCompleted\n1282\tRecruiting\n3649\tActive not recruiting\n603\tUnknown\u0026nbsp;\u0026#8224;\n886\tCompleted                  Has Results\n1758\tActive not recruiting\n623\tCompleted                  Has Results\n1498\tCompleted\n2500\tCompleted                  Has Results\n394\tActive not recruiting                  Has Results\n2105\tCompleted\n1228\tCompleted                  Has Results\n788\tActive not recruiting\n400\tCompleted\n2278\tCompleted                  Has Results\n525\tCompleted\n720\tActive not recruiting\n534\tCompleted\n4216\tActive not recruiting\n238\tCompleted\n1\tTerminated\n140\tCompleted\n1360\tActive not recruiting\n700\tCompleted\n3066\tActive not recruiting                  Has Results\n546\tActive not recruiting\n633\tCompleted                  Has Results\n571\tCompleted\n49\tCompleted\n143\tRecruiting\n1994\tRecruiting\n53\tRecruiting\n1711\tCompleted\n148\tSuspended\n235\tRecruiting\n500\tRecruiting\n5000\tRecruiting\n1378\tRecruiting\n350\tRecruiting\n825\tActive not recruiting\n1161\tCompleted\n132\tRecruiting\n168\tRecruiting\n796\tCompleted\n15000\tActive not recruiting\n717\tActive not recruiting\n17276\tActive not recruiting\n15000\tRecruiting\n1015\tActive not recruiting\n19000\tRecruiting\n7000\tEnrolling by invitation\n646\tCompleted                  Has Results\n290\tActive not recruiting\n397\tCompleted                  Has Results\n2312\tActive not recruiting\n181\tActive not recruiting\n591\tActive not recruiting\n666\tCompleted                  Has Results\n9340\tCompleted\n180\tRecruiting\n870\tCompleted                  Has Results\n611\tCompleted\n362\tCompleted\n141\tTerminated\n1027\tCompleted\n3000\tCompleted\n712\tCompleted                  Has Results\n338\tCompleted\n646\tCompleted                  Has Results\n873\tTerminated                  Has Results\n418\tUnknown\u0026nbsp;\u0026#8224;\n411\tTerminated\n361\tCompleted                  Has Results\n500\tCompleted\n8037\tActive not recruiting\n760\tCompleted                  Has Results\n420\tCompleted                  Has Results\n361\tActive not recruiting                  Has Results\n541\tCompleted\n612\tActive not recruiting\n755\tCompleted                  Has Results\n244\tCompleted\n545\tActive not recruiting                  Has Results\n78\tCompleted\n406\tActive not recruiting                  Has Results\n743\tActive not recruiting                  Has Results\n3000\tCompleted\n180\tRecruiting\n1064\tRecruiting\n2000\tRecruiting\n680\tRecruiting\n9400\tRecruiting\n2600\tRecruiting\n34\tActive not recruiting\n114\tActive not recruiting\n25\tActive not recruiting\n600\tActive not recruiting\n893\tCompleted\n1847\tCompleted\n2250\tRecruiting\n557\tCompleted\n12116\tCompleted\n18600\tRecruiting\n137\tCompleted                  Has Results\n881\tCompleted\n1150\tCompleted\n2220\tCompleted\n2499\tCompleted                  Has Results\n749\tCompleted\n31989\tCompleted                  Has Results\n812\tCompleted\n262\tCompleted\n2580\tRecruiting\n844\tCompleted                  Has Results\n3080\tCompleted\n990\tCompleted                  Has Results\n130\tActive not recruiting\n394\tActive not recruiting\n846\tCompleted                  Has Results\n700\tActive not recruiting\n140\tActive not recruiting\n234\tCompleted                  Has Results\n63\tActive not recruiting                  Has Results\n18206\tCompleted                  Has Results\n430\tCompleted\n48\tActive not recruiting\n102\tTerminated                  Has Results\n281\tCompleted\n3597\tCompleted                  Has Results\n149\tActive not recruiting\n9172\tTerminated                  Has Results\n242\tCompleted                  Has Results\n626\tCompleted                  Has Results\n275\tCompleted\n637\tActive not recruiting                  Has Results\n3500\tActive not recruiting\n252\tActive not recruiting\n390\tCompleted                  Has Results\n999\tCompleted                  Has Results\n637\tCompleted                  Has Results\n478\tCompleted                  Has Results\n901\tTerminated                  Has Results\n261\tCompleted                  Has Results\n938\tCompleted                  Has Results\n619\tCompleted                  Has Results\n502\tCompleted                  Has Results\n2225\tCompleted\n2269\tCompleted                  Has Results\n651\tActive not recruiting\n1976\tCompleted                  Has Results\n355\tTerminated                  Has Results\n1461\tCompleted                  Has Results\n6228\tCompleted\n317\tCompleted                  Has Results\n1784\tTerminated\n2054\tCompleted                  Has Results\n\tApproved for marketing\n805\tCompleted\n2567\tCompleted\n547\tCompleted                  Has Results\n645\tCompleted\n3600\tCompleted\n1772\tTerminated                  Has Results\n3000\tActive not recruiting\n1150\tTerminated                  Has Results\n5437\tRecruiting\n6500\tRecruiting\n356\tCompleted\n8000\tRecruiting\n450\tRecruiting\n254\tCompleted\n500\tActive not recruiting\n300\tRecruiting\n1972\tCompleted\n2600\tRecruiting\n3000\tRecruiting\n600\tRecruiting\n2168\tRecruiting\n1790\tCompleted                  Has Results\n1400\tRecruiting\n690\tCompleted\n736\tCompleted\n1170\tCompleted\n284\tRecruiting\n420\tCompleted\n718\tCompleted\n2103\tCompleted\n827\tCompleted\n872\tActive not recruiting                  Has Results\n330\tRecruiting\n507\tCompleted\n3000\tRecruiting\n3297\tCompleted\n1137\tCompleted                  Has Results\n593\tCompleted\n872\tCompleted\n75\tActive not recruiting\n607\tCompleted                  Has Results\n105\tTerminated                  Has Results\n373\tCompleted\n480\tCompleted                  Has Results\n642\tTerminated                  Has Results\n490\tTerminated                  Has Results\n219\tTerminated\n233\tCompleted\n165\tActive not recruiting                  Has Results\n808\tCompleted\n575\tRecruiting\n250\tActive not recruiting\n9022\tRecruiting\n80\tActive not recruiting\n1504\tCompleted\n14250\tRecruiting\n841\tCompleted                  Has Results\n354\tTerminated                  Has Results\n123\tRecruiting\n2312\tCompleted                  Has Results\n1656\tCompleted                  Has Results\n421\tCompleted\n702\tCompleted\n894\tCompleted\n2118\tCompleted\n31\tTerminated                  Has Results\n3341\tCompleted\n253\tRecruiting\n25682\tCompleted                  Has Results\n9\tTerminated                  Has Results\n180\tCompleted\n803\tCompleted                  Has Results\n519\tCompleted\n1294\tCompleted\n1500\tRecruiting\n10000\tRecruiting\n529\tActive not recruiting\n5000\tRecruiting\n528\tRecruiting\n2840\tActive not recruiting\n1142\tCompleted                  Has Results\n7484\tTerminated                  Has Results\n5897\tCompleted                  Has Results\n7744\tCompleted                  Has Results\n15828\tCompleted\n407\tCompleted                  Has Results\n1557\tCompleted\n43695\tCompleted                  Has Results\n4485\tRecruiting\n7439\tCompleted                  Has Results\n1189\tCompleted\n1275\tCompleted                  Has Results\n525\tActive not recruiting\n543\tCompleted                  Has Results\n134\tCompleted                  Has Results\n3656\tCompleted\n437\tCompleted                  Has Results\n5077\tCompleted\n242\tActive not recruiting\n500\tActive not recruiting\n80\tActive not recruiting\n30\tCompleted                  Has Results\n1258\tRecruiting\n164\tRecruiting\n1065\tCompleted                  Has Results\n11196\tCompleted\n7141\tCompleted                  Has Results\n742\tCompleted                  Has Results\n300\tActive not recruiting\n1900\tActive not recruiting\n310\tCompleted                  Has Results\n275\tActive not recruiting\n395\tActive not recruiting\n442\tCompleted\n1070\tActive not recruiting                  Has Results\n500\tCompleted\n808\tCompleted\n284\tRecruiting\n294\tCompleted\n630\tCompleted\n660\tTerminated                  Has Results\n493\tCompleted                  Has Results\n805\tCompleted\n48\tCompleted\n1145\tCompleted                  Has Results\n518\tCompleted\n451\tCompleted                  Has Results\n451\tCompleted                  Has Results\n908\tCompleted                  Has Results\n2038\tCompleted                  Has Results\n1159\tCompleted\n378\tTerminated\n1400\tCompleted\n1400\tCompleted\n20332\tCompleted                  Has Results\n1020\tCompleted\n1164\tActive not recruiting\n1462\tCompleted                  Has Results\n62\tCompleted\n109\tCompleted                  Has Results\n684\tActive not recruiting\n55\tCompleted                  Has Results\n5377\tActive not recruiting\n236\tCompleted                  Has Results\n1752\tCompleted\n\tUnknown\u0026nbsp;\u0026#8224;\n4844\tCompleted                  Has Results\n471\tCompleted\n104\tCompleted\n600\tCompleted\n438\tCompleted\n690\tUnknown\u0026nbsp;\u0026#8224;\n3154\tActive not recruiting                  Has Results\n155\tCompleted                  Has Results\n2672\tActive not recruiting                  Has Results\n132\tCompleted\n3200\tCompleted\n33\tCompleted\n170\tCompleted\n1734\tCompleted\n\tCompleted\n399\tCompleted\n138\tCompleted\n31\tActive not recruiting\n32\tCompleted\n21\tCompleted\n31\tCompleted\n77\tCompleted\n253\tCompleted\n125\tCompleted\n67\tCompleted\n254\tCompleted\n120\tCompleted\n968\tActive not recruiting\n573\tCompleted\n483\tCompleted\n69\tCompleted\n3031\tCompleted\n203\tCompleted\n71\tRecruiting\n345\tRecruiting\n12500\tRecruiting\n14535\tRecruiting\n583\tRecruiting\n1500\tRecruiting\n600\tRecruiting\n450\tRecruiting\n645\tActive not recruiting\n629\tActive not recruiting\n51\tRecruiting\n532\tActive not recruiting\n3000\tRecruiting\n1050\tRecruiting\n354\tRecruiting\n1100\tRecruiting\n249\tActive not recruiting\n4600\tRecruiting\n393\tCompleted\n1014\tCompleted\n282\tCompleted\n7764\tRecruiting\n1087\tCompleted\n6000\tRecruiting\n154\tRecruiting\n340\tRecruiting\n1140\tActive not recruiting\n1294\tActive not recruiting\n500\tActive not recruiting\n1082\tCompleted\n1410\tCompleted\n598\tRecruiting\n540\tCompleted\n1380\tActive not recruiting\n248\tCompleted\n910\tRecruiting\n53\tActive not recruiting\n205\tCompleted\n2139\tCompleted\n1200\tRecruiting\n788\tActive not recruiting\n172\tCompleted\n1001\tCompleted\n165\tActive not recruiting\n225\tCompleted\n441\tCompleted                  Has Results\n818\tCompleted\n870\tCompleted                  Has Results\n434\tCompleted\n365\tCompleted                  Has Results\n816\tRecruiting\n7\tTerminated\n800\tRecruiting\n640\tActive not recruiting\n356\tCompleted\n336\tCompleted\n178\tTerminated                  Has Results\n589\tCompleted                  Has Results\n0\tWithdrawn\n282\tActive not recruiting                  Has Results\n610\tCompleted                  Has Results\n8000\tActive not recruiting\n2454\tTerminated                  Has Results\n2648\tCompleted                  Has Results\n650\tEnrolling by invitation\n12463\tCompleted\n641\tCompleted                  Has Results\n780\tRecruiting\n1735\tCompleted                  Has Results\n1750\tRecruiting\n975\tTerminated                  Has Results\n403\tTerminated\n799\tCompleted                  Has Results\n96\tTerminated                  Has Results\n163\tCompleted\n75\tCompleted                  Has Results\n693\tSuspended\n85\tCompleted\n9\tTerminated                  Has Results\n684\tTerminated                  Has Results\n14819\tCompleted\n16166\tCompleted\n5189\tTerminated\n5763\tActive not recruiting\n639\tCompleted                  Has Results\n507\tCompleted                  Has Results\n707\tCompleted                  Has Results\n748\tTerminated                  Has Results\n7226\tCompleted\n8442\tTerminated                  Has Results\n166\tActive not recruiting\n494\tCompleted                  Has Results\n265\tCompleted\n426\tCompleted\n330\tActive not recruiting\n586\tCompleted                  Has Results\n252\tTerminated\n280\tActive not recruiting\n700\tRecruiting\n677\tTerminated\n249\tActive not recruiting\n1068\tCompleted                  Has Results\n963\tCompleted                  Has Results\n188\tCompleted                  Has Results\n1272\tActive not recruiting\n1000\tRecruiting\n3000\tRecruiting\n151\tUnknown\u0026nbsp;\u0026#8224;\n241\tCompleted\n1116\tCompleted                  Has Results\n437\tCompleted\n526\tCompleted                  Has Results\n633\tCompleted                  Has Results\n724\tCompleted                  Has Results\n92\tActive not recruiting\n1144\tActive not recruiting                  Has Results\n723\tCompleted                  Has Results\n543\tCompleted\n829\tCompleted\n1397\tCompleted                  Has Results\n306\tCompleted\n717\tActive not recruiting\n896\tCompleted\n5614\tCompleted                  Has Results\n2711\tCompleted                  Has Results\n376\tCompleted                  Has Results\n272\tTerminated\n306\tActive not recruiting                  Has Results\n1502\tCompleted\n5\tCompleted\n375\tCompleted                  Has Results\n665\tActive not recruiting\n1226\tCompleted                  Has Results\n2492\tCompleted                  Has Results\n5000\tTerminated\n117\tCompleted                  Has Results\n630\tTerminated\n84\tActive not recruiting\n1020\tCompleted\n464\tUnknown\u0026nbsp;\u0026#8224;\n2278\tTerminated\n83\tCompleted                  Has Results\n831\tCompleted\n187\tCompleted                  Has Results\n481\tCompleted\n1897\tTerminated\n156\tActive not recruiting                  Has Results\n981\tCompleted\n1026\tCompleted\n1283\tCompleted                  Has Results\n282\tTerminated                  Has Results\n4500\tActive not recruiting\n560\tCompleted\n18624\tCompleted                  Has Results\n219\tTerminated                  Has Results\n449\tCompleted                  Has Results\n\tCompleted\n481\tActive not recruiting\n109\tActive not recruiting                  Has Results\n244\tTerminated\n588\tUnknown\u0026nbsp;\u0026#8224;\n1000\tCompleted\n484\tCompleted\n947\tCompleted                  Has Results\n390\tCompleted                  Has Results\n2091\tCompleted                  Has Results\n3032\tTerminated                  Has Results\n402\tCompleted\n908\tCompleted                  Has Results\n1109\tCompleted\n1260\tCompleted\n2000\tUnknown\u0026nbsp;\u0026#8224;\n740\tCompleted\n743\tCompleted                  Has Results\n619\tCompleted                  Has Results\n1900\tCompleted\n534\tCompleted\n\tCompleted\n500\tCompleted\n3800\tCompleted\n1100\tCompleted\n6635\tCompleted                  Has Results\n8500\tCompleted\n188\tActive not recruiting                  Has Results\n300\tCompleted\n797\tCompleted\n658\tTerminated\n1440\tCompleted\n479\tCompleted\n233\tCompleted\n170\tCompleted\n1200\tCompleted\n1846\tCompleted\n528\tCompleted\n238\tActive not recruiting                  Has Results\n645\tCompleted                  Has Results\n81\tActive not recruiting\n162\tActive not recruiting                  Has Results\n350\tCompleted\n1302\tCompleted\n84\tCompleted\n501\tCompleted\n129\tCompleted                  Has Results\n265\tCompleted                  Has Results\n440\tCompleted\n172\tCompleted\n\tNo longer available\n377\tCompleted\n336\tCompleted\n57\tCompleted                  Has Results\n1449\tCompleted\n439\tCompleted\n12\tCompleted\n1\tCompleted\n\tCompleted\n59\tCompleted\n587\tCompleted\n\tCompleted\n32\tCompleted\n77\tCompleted\n200\tCompleted\n83\tCompleted\n1076\tCompleted\n838\tCompleted\n219\tCompleted\n\tCompleted\n64\tCompleted\n393\tActive not recruiting                  Has Results\n31\tCompleted\n840\tActive not recruiting\n174\tCompleted\n27\tCompleted\n53\tCompleted\n243\tCompleted\n95\tCompleted\n50\tCompleted\n949\tCompleted\n13\tCompleted\n2108\tTerminated\n313\tCompleted\n333\tCompleted\n156\tCompleted\n1084\tCompleted\n2028\tCompleted\n31\tCompleted\n36\tCompleted\n200\tCompleted\n147\tCompleted\n111\tCompleted\n290\tRecruiting\n1500\tRecruiting\n2420\tRecruiting\n450\tRecruiting\n400\tRecruiting\n150\tRecruiting\n250\tRecruiting\n138\tActive not recruiting\n400\tRecruiting\n1400\tRecruiting\n425\tRecruiting\n563\tActive not recruiting\n55\tRecruiting\n1860\tActive not recruiting\n1953\tRecruiting\n1500\tRecruiting\n552\tCompleted\n56\tRecruiting\n4600\tRecruiting\n1900\tActive not recruiting\n432\tCompleted\n187\tCompleted\n900\tRecruiting\n250\tRecruiting\n296\tActive not recruiting\n1858\tActive not recruiting\n600\tEnrolling by invitation\n240\tActive not recruiting\n356\tRecruiting\n641\tCompleted\n632\tActive not recruiting\n877\tActive not recruiting\n714\tActive not recruiting\n140\tSuspended\n66\tTerminated\n600\tRecruiting\n377\tCompleted\n764\tCompleted\n730\tRecruiting\n660\tRecruiting\n2091\tActive not recruiting\n1375\tActive not recruiting\n366\tTerminated\n800\tRecruiting\n90\tRecruiting\n2026\tCompleted\n328\tTerminated\n432\tActive not recruiting\n34\tRecruiting\n882\tCompleted                  Has Results\n500\tTerminated\n372\tActive not recruiting\n315\tCompleted\n800\tRecruiting\n800\tRecruiting\n2100\tRecruiting\n5000\tRecruiting\n624\tActive not recruiting\n319\tCompleted\n360\tRecruiting\n13307\tCompleted\n8000\tRecruiting\n10\tTerminated                  Has Results\n416\tCompleted\n140\tRecruiting\n158\tCompleted                  Has Results\n255\tTerminated                  Has Results\n11\tTerminated\n499\tActive not recruiting                  Has Results\n2100\tActive not recruiting\n287\tCompleted                  Has Results\n1618\tCompleted\n314\tTerminated                  Has Results\n90\tTerminated                  Has Results\n1443\tActive not recruiting                  Has Results\n872\tActive not recruiting                  Has Results\n304\tCompleted                  Has Results\n350\tCompleted                  Has Results\n1999\tCompleted\n1001\tCompleted                  Has Results\n226\tCompleted                  Has Results\n909\tCompleted\n290\tActive not recruiting\n239\tTerminated\n534\tCompleted                  Has Results\n1017\tActive not recruiting\n1941\tCompleted\n909\tCompleted\n961\tCompleted                  Has Results\n442\tCompleted                  Has Results\n916\tTerminated                  Has Results\n51\tActive not recruiting\n692\tActive not recruiting\n330\tCompleted                  Has Results\n811\tCompleted                  Has Results\n839\tCompleted\n4500\tRecruiting\n1500\tRecruiting\n6250\tCompleted                  Has Results\n421\tCompleted                  Has Results\n1154\tActive not recruiting\n2651\tCompleted                  Has Results\n1692\tCompleted\n450\tCompleted\n183\tCompleted\n722\tCompleted\n302\tCompleted                  Has Results\n14\tTerminated                  Has Results\n376\tCompleted                  Has Results\n160\tCompleted\n430\tCompleted                  Has Results\n1298\tActive not recruiting\n400\tTerminated\n229\tTerminated\n652\tCompleted                  Has Results\n706\tActive not recruiting\n268\tCompleted\n265\tCompleted\n279\tCompleted\n1494\tActive not recruiting\n880\tRecruiting\n1917\tTerminated                  Has Results\n724\tUnknown\u0026nbsp;\u0026#8224;                  Has Results\n2334\tCompleted\n441\tCompleted                  Has Results\n297\tTerminated                  Has Results\n2858\tCompleted                  Has Results\n1000\tTerminated\n165\tCompleted\n196\tTerminated                  Has Results\n149\tActive not recruiting\n36\tTerminated                  Has Results\n417\tTerminated\n698\tCompleted                  Has Results\n708\tCompleted                  Has Results\n12227\tCompleted                  Has Results\n332\tActive not recruiting\n3011\tActive not recruiting\n618\tCompleted                  Has Results\n1635\tCompleted                  Has Results\n340\tCompleted                  Has Results\n106\tCompleted\n190\tCompleted\n600\tActive not recruiting\n"
      },
      "dateCreated": "Dec 4, 2016 6:29:47 PM",
      "dateStarted": "Dec 4, 2016 6:43:55 PM",
      "dateFinished": "Dec 4, 2016 6:43:56 PM",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%sql\n\nselect number_enrolled,phase from table_df where phase !\u003d \"\"",
      "dateUpdated": "Dec 4, 2016 6:50:54 PM",
      "config": {
        "colWidth": 6.0,
        "graph": {
          "mode": "multiBarChart",
          "height": 428.0,
          "optionOpen": false,
          "keys": [
            {
              "name": "phase",
              "index": 1.0,
              "aggr": "sum"
            }
          ],
          "values": [
            {
              "name": "phase",
              "index": 1.0,
              "aggr": "count"
            }
          ],
          "groups": [],
          "scatter": {
            "xAxis": {
              "name": "number_enrolled",
              "index": 0.0,
              "aggr": "sum"
            },
            "yAxis": {
              "name": "phase",
              "index": 1.0,
              "aggr": "sum"
            }
          }
        },
        "enabled": true,
        "editorMode": "ace/mode/sql",
        "editorHide": true
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "jobName": "paragraph_1480876195810_1874563932",
      "id": "20161204-182955_1078852669",
      "result": {
        "code": "SUCCESS",
        "type": "TABLE",
        "msg": "number_enrolled\tphase\n150\tPhase 2\n450\tPhase 2\n60\tPhase 2\n100\tPhase 0\n75\tPhase 2\n120\tPhase 4\n20\tPhase 1 / Phase 2\n99\tPhase 4\n24\tPhase 1 / Phase 2\n40\tPhase 2\n400\tPhase 3\n100\tPhase 1 / Phase 2\n100\tPhase 2\n60\tPhase 4\n350\tPhase 3\n32\tPhase 2\n54\tPhase 2\n300\tPhase 2\n22\tPhase 4\n12\tPhase 1 / Phase 2\n20\tPhase 1\n36\tPhase 4\n60\tPhase 2\n7\tPhase 1\n100\tPhase 1 / Phase 2\n32\tPhase 1\n30\tPhase 4\n68\tPhase 2\n45\tPhase 1\n200\tPhase 2\n50\tPhase 0\n40\tPhase 3\n10\tPhase 2\n40\tPhase 1\n165\tPhase 2\n24\tPhase 4\n12\tPhase 2\n60\tPhase 1\n18\tPhase 2\n70\tPhase 2\n50\tPhase 2\n276\tPhase 3\n25\tPhase 2\n274\tPhase 3\n\tPhase 3\n24\tPhase 1\n36\tPhase 2\n24\tPhase 0\n0\tPhase 1\n74\tPhase 1 / Phase 2\n40\tPhase 4\n18\tPhase 2\n30\tPhase 1\n53\tPhase 4\n4\tPhase 4\n15\tPhase 0\n96\tPhase 2\n60\tPhase 4\n125\tPhase 2\n40\tPhase 2\n50\tPhase 2\n8\tPhase 1\n12\tPhase 1\n100\tPhase 4\n158\tPhase 2\n39\tPhase 2\n31\tPhase 1 / Phase 2\n300\tPhase 4\n65\tPhase 3\n105\tPhase 2\n75\tPhase 2\n70\tPhase 1\n30\tPhase 1 / Phase 2\n48\tPhase 1\n18\tPhase 1\n20\tPhase 4\n66\tPhase 1 / Phase 2\n90\tPhase 1 / Phase 2\n10\tPhase 4\n46\tPhase 2\n160\tPhase 2\n18\tPhase 1\n29\tPhase 2\n40\tPhase 2\n64\tPhase 4\n30\tPhase 1 / Phase 2\n15\tPhase 1\n36\tPhase 1\n240\tPhase 3\n36\tPhase 4\n24\tPhase 1\n30\tPhase 1\n27\tPhase 2\n20\tPhase 2\n90\tPhase 2\n23\tPhase 4\n30\tPhase 3\n25\tPhase 1\n25\tPhase 1 / Phase 2\n78\tPhase 2\n61\tPhase 2\n66\tPhase 1\n80\tPhase 2\n13\tPhase 2 / Phase 3\n600\tPhase 2\n130\tPhase 1 / Phase 2\n33\tPhase 1\n300\tPhase 2\n15\tPhase 4\n50\tPhase 2\n12\tPhase 1\n100\tPhase 2\n40\tPhase 2\n35\tPhase 1\n6\tPhase 2\n40\tPhase 4\n20\tPhase 1\n0\tPhase 1 / Phase 2\n115\tPhase 4\n30\tPhase 1\n115\tPhase 4\n100\tPhase 2\n0\tPhase 4\n48\tPhase 4\n16\tPhase 1\n30\tPhase 2\n0\tPhase 2\n30\tPhase 4\n36\tPhase 1\n30\tPhase 4\n30\tPhase 2\n116\tPhase 2\n40\tPhase 2\n71\tPhase 4\n24\tPhase 1\n25\tPhase 2\n67\tPhase 0\n15\tPhase 4\n24\tPhase 2\n46\tPhase 2\n0\tPhase 1\n51\tPhase 1\n39\tPhase 2\n50\tPhase 2\n50\tPhase 4\n50\tPhase 2\n30\tPhase 0\n45\tPhase 1\n40\tPhase 4\n20\tPhase 1\n150\tPhase 4\n88\tPhase 4\n60\tPhase 2\n60\tPhase 2\n300\tPhase 4\n45\tPhase 4\n60\tPhase 1\n22\tPhase 4\n32\tPhase 1\n50\tPhase 4\n12\tPhase 1\n50\tPhase 2\n120\tPhase 2\n61\tPhase 2\n1\tPhase 1\n20\tPhase 1\n40\tPhase 1\n26\tPhase 1\n60\tPhase 4\n24\tPhase 1\n20\tPhase 4\n500\tPhase 3\n40\tPhase 2\n72\tPhase 1 / Phase 2\n104\tPhase 4\n12\tPhase 1\n60\tPhase 2\n124\tPhase 4\n24\tPhase 1\n39\tPhase 0\n60\tPhase 3\n25\tPhase 1\n40\tPhase 0\n1\tPhase 1\n14\tPhase 1\n40\tPhase 4\n17\tPhase 1\n24\tPhase 2\n160\tPhase 4\n13\tPhase 2\n30\tPhase 4\n27\tPhase 2 / Phase 3\n60\tPhase 3\n10\tPhase 2\n50\tPhase 2\n6\tPhase 1\n50\tPhase 4\n0\tPhase 4\n24\tPhase 1\n44\tPhase 1\n0\tPhase 2\n421\tPhase 3\n30\tPhase 1\n64\tPhase 2\n15\tPhase 1 / Phase 2\n40\tPhase 2\n40\tPhase 2\n132\tPhase 2\n24\tPhase 1\n20\tPhase 2\n3\tPhase 4\n1\tPhase 2\n34\tPhase 2\n20\tPhase 3\n0\tPhase 1\n24\tPhase 4\n50\tPhase 2\n30\tPhase 4\n20\tPhase 2\n90\tPhase 4\n9\tPhase 1 / Phase 2\n30\tPhase 1\n1\tPhase 0\n6\tPhase 1 / Phase 2\n6\tPhase 1\n20\tPhase 1\n400\tPhase 4\n17\tPhase 1\n40\tPhase 4\n28\tPhase 4\n6\tPhase 1\n60\tPhase 2\n100\tPhase 2\n70\tPhase 3\n50\tPhase 2\n30\tPhase 4\n30\tPhase 1\n10\tPhase 4\n36\tPhase 2\n24\tPhase 1\n140\tPhase 4\n364\tPhase 3\n9\tPhase 1\n250\tPhase 2\n17\tPhase 3\n120\tPhase 2\n0\tPhase 2\n40\tPhase 4\n20\tPhase 4\n20\tPhase 1\n60\tPhase 4\n20\tPhase 4\n13\tPhase 2\n140\tPhase 2\n17\tPhase 1\n10\tPhase 1 / Phase 2\n0\tPhase 2\n38\tPhase 4\n41\tPhase 4\n2\tPhase 1 / Phase 2\n28\tPhase 1\n17\tPhase 1 / Phase 2\n20\tPhase 1\n100\tPhase 1\n239\tPhase 1\n13\tPhase 4\n6\tPhase 0\n59\tPhase 4\n28\tPhase 0\n30\tPhase 0\n99\tPhase 2\n10\tPhase 0\n20\tPhase 2\n50\tPhase 2 / Phase 3\n90\tPhase 2 / Phase 3\n5\tPhase 1\n36\tPhase 0\n21\tPhase 2\n12\tPhase 1\n41\tPhase 1\n26\tPhase 1\n35\tPhase 1\n102\tPhase 1 / Phase 2\n16\tPhase 1 / Phase 2\n60\tPhase 2\n8\tPhase 1\n16\tPhase 1\n10\tPhase 1\n20\tPhase 2\n10\tPhase 1\n21\tPhase 1\n10\tPhase 2\n24\tPhase 4\n26\tPhase 3\n83\tPhase 1\n37\tPhase 4\n60\tPhase 4\n30\tPhase 2\n150\tPhase 1\n626\tPhase 3\n12\tPhase 1\n0\tPhase 2\n20\tPhase 2\n48\tPhase 4\n25\tPhase 4\n90\tPhase 2 / Phase 3\n5\tPhase 0\n5\tPhase 4\n7\tPhase 1\n130\tPhase 2 / Phase 3\n20\tPhase 1\n18\tPhase 2\n24\tPhase 2\n18\tPhase 1\n5\tPhase 4\n50\tPhase 0\n61\tPhase 1\n60\tPhase 4\n22\tPhase 1\n13\tPhase 1 / Phase 2\n56\tPhase 1 / Phase 2\n15\tPhase 1\n68\tPhase 2\n48\tPhase 2\n19\tPhase 2\n2\tPhase 1 / Phase 2\n15\tPhase 1\n12\tPhase 1\n17\tPhase 2\n1\tPhase 1 / Phase 2\n20\tPhase 2\n21\tPhase 2\n7\tPhase 0\n14\tPhase 4\n150\tPhase 1\n22\tPhase 0\n42\tPhase 1\n44\tPhase 1\n350\tPhase 3\n250\tPhase 3\n100\tPhase 1 / Phase 2\n126\tPhase 4\n42\tPhase 4\n38\tPhase 2\n12\tPhase 1\n45\tPhase 2\n37\tPhase 1\n32\tPhase 2\n96\tPhase 4\n50\tPhase 1\n282\tPhase 3\n39\tPhase 2\n36\tPhase 4\n250\tPhase 1 / Phase 2\n105\tPhase 1\n11\tPhase 1\n204\tPhase 4\n48\tPhase 1\n15\tPhase 1\n34\tPhase 1\n12\tPhase 1 / Phase 2\n180\tPhase 4\n40\tPhase 2\n0\tPhase 1\n48\tPhase 1\n50\tPhase 1\n9\tPhase 4\n10\tPhase 0\n200\tPhase 4\n3\tPhase 1\n26\tPhase 1\n60\tPhase 1\n17\tPhase 1\n50\tPhase 1\n1167\tPhase 3\n64\tPhase 1\n45\tPhase 2\n61\tPhase 4\n0\tPhase 2\n20\tPhase 2\n30\tPhase 4\n60\tPhase 3\n72\tPhase 1\n112\tPhase 4\n117\tPhase 1\n130\tPhase 2\n18\tPhase 1\n22\tPhase 1\n40\tPhase 0\n20\tPhase 2\n123\tPhase 2\n8\tPhase 4\n20\tPhase 1\n20\tPhase 1\n5\tPhase 2\n48\tPhase 1\n0\tPhase 2\n65\tPhase 1\n33\tPhase 1 / Phase 2\n1\tPhase 1\n375\tPhase 2\n50\tPhase 1\n70\tPhase 1\n38\tPhase 0\n2\tPhase 2\n62\tPhase 2\n14\tPhase 1\n6\tPhase 1\n61\tPhase 1\n136\tPhase 2\n163\tPhase 4\n92\tPhase 4\n3\tPhase 4\n20\tPhase 1\n2\tPhase 1\n339\tPhase 3\n140\tPhase 3\n34\tPhase 2\n30\tPhase 1 / Phase 2\n42\tPhase 2\n10\tPhase 1\n60\tPhase 4\n68\tPhase 1\n60\tPhase 0\n202\tPhase 4\n52\tPhase 4\n30\tPhase 4\n49\tPhase 1 / Phase 2\n21\tPhase 1\n1184\tPhase 4\n30\tPhase 1 / Phase 2\n17\tPhase 1\n22\tPhase 1\n18\tPhase 1\n97\tPhase 0\n21\tPhase 4\n12\tPhase 2 / Phase 3\n82\tPhase 2\n40\tPhase 1\n24\tPhase 1\n12\tPhase 1\n49\tPhase 1\n12\tPhase 4\n0\tPhase 4\n15\tPhase 1\n37\tPhase 1 / Phase 2\n350\tPhase 2 / Phase 3\n25\tPhase 2\n80\tPhase 3\n40\tPhase 3\n110\tPhase 2\n60\tPhase 4\n23\tPhase 4\n916\tPhase 4\n80\tPhase 2\n6\tPhase 1\n14\tPhase 2\n160\tPhase 1\n0\tPhase 2\n0\tPhase 2\n5\tPhase 1 / Phase 2\n20\tPhase 1\n45\tPhase 2\n29\tPhase 1\n36\tPhase 4\n141\tPhase 2\n19\tPhase 1\n6\tPhase 2\n17\tPhase 2\n74\tPhase 1 / Phase 2\n50\tPhase 1 / Phase 2\n10\tPhase 1\n22\tPhase 1\n2\tPhase 1\n0\tPhase 2\n20\tPhase 3\n2\tPhase 1\n41\tPhase 2\n5\tPhase 2\n314\tPhase 3\n18\tPhase 4\n11\tPhase 1\n122\tPhase 1\n21\tPhase 1\n89\tPhase 3\n21\tPhase 1\n62\tPhase 1\n67\tPhase 1 / Phase 2\n18\tPhase 1\n40\tPhase 4\n63\tPhase 2\n80\tPhase 1 / Phase 2\n96\tPhase 1\n246\tPhase 1\n15000\tPhase 1\n18\tPhase 1\n26\tPhase 1\n26\tPhase 1\n24\tPhase 1\n26\tPhase 1\n9\tPhase 1\n11\tPhase 2\n0\tPhase 2\n38\tPhase 2\n36\tPhase 2\n20\tPhase 2\n140\tPhase 2\n5\tPhase 1\n50\tPhase 2\n24\tPhase 1\n365\tPhase 2\n24\tPhase 1\n31\tPhase 2\n3\tPhase 2\n54\tPhase 2\n21\tPhase 2\n100\tPhase 1\n60\tPhase 0\n147\tPhase 1\n14\tPhase 1\n0\tPhase 0\n0\tPhase 4\n20\tPhase 2\n156\tPhase 3\n22\tPhase 1\n70\tPhase 1\n20\tPhase 4\n26\tPhase 4\n24\tPhase 4\n32\tPhase 4\n3\tPhase 2\n26\tPhase 1\n77\tPhase 4\n54\tPhase 2\n25\tPhase 1\n45\tPhase 1\n26\tPhase 4\n9\tPhase 1\n1\tPhase 1\n38\tPhase 1 / Phase 2\n60\tPhase 1 / Phase 2\n16\tPhase 2\n14\tPhase 4\n18\tPhase 4\n38\tPhase 4\n9\tPhase 1\n40\tPhase 1\n0\tPhase 2\n80\tPhase 2\n12\tPhase 4\n48\tPhase 2\n40\tPhase 4\n380\tPhase 3\n40\tPhase 2\n0\tPhase 2\n49\tPhase 2\n52\tPhase 4\n5\tPhase 1\n41\tPhase 2\n50\tPhase 2\n3\tPhase 2\n53\tPhase 2\n530\tPhase 3\n519\tPhase 3\n9\tPhase 1 / Phase 2\n104\tPhase 2\n12\tPhase 1 / Phase 2\n36\tPhase 4\n52\tPhase 4\n0\tPhase 4\n578\tPhase 3\n161\tPhase 3\n32\tPhase 1\n20\tPhase 1\n60\tPhase 2\n49\tPhase 4\n48\tPhase 1 / Phase 2\n301\tPhase 3\n16\tPhase 2\n60\tPhase 1 / Phase 2\n11\tPhase 1 / Phase 2\n15\tPhase 1\n67\tPhase 4\n12\tPhase 1\n25\tPhase 1\n116\tPhase 2\n60\tPhase 2\n63\tPhase 4\n61\tPhase 4\n160\tPhase 4\n12\tPhase 1\n21\tPhase 2\n21\tPhase 2\n57\tPhase 2\n1\tPhase 1 / Phase 2\n606\tPhase 3\n50\tPhase 1\n228\tPhase 4\n13\tPhase 1\n30\tPhase 3\n60\tPhase 3\n80\tPhase 2 / Phase 3\n100\tPhase 2\n16\tPhase 1\n16\tPhase 2\n35\tPhase 2\n333\tPhase 2\n40\tPhase 1\n30\tPhase 1\n26\tPhase 1\n26\tPhase 1\n12\tPhase 2\n20\tPhase 4\n112\tPhase 3\n13\tPhase 1\n34\tPhase 4\n4\tPhase 1\n25\tPhase 1\n11\tPhase 1\n32\tPhase 1\n26\tPhase 1\n25\tPhase 1\n133\tPhase 3\n31\tPhase 2\n13\tPhase 1 / Phase 2\n100\tPhase 4\n257\tPhase 1\n20\tPhase 3\n15\tPhase 1\n20\tPhase 1\n10\tPhase 0\n31\tPhase 1 / Phase 2\n60\tPhase 2\n1\tPhase 2\n6\tPhase 2\n18\tPhase 1\n13\tPhase 1\n125\tPhase 2\n5\tPhase 1\n5\tPhase 1\n68\tPhase 2\n1884\tPhase 3\n24\tPhase 1\n14\tPhase 1\n40\tPhase 0\n100\tPhase 4\n94\tPhase 1\n12\tPhase 1\n364\tPhase 3\n40\tPhase 4\n49\tPhase 4\n150\tPhase 4\n2\tPhase 1\n7\tPhase 1\n22\tPhase 1\n3\tPhase 4\n50\tPhase 4\n14\tPhase 1\n11\tPhase 4\n20\tPhase 2\n300\tPhase 1 / Phase 2\n18\tPhase 2\n12\tPhase 1\n15\tPhase 0\n115\tPhase 4\n0\tPhase 1\n479\tPhase 3\n15\tPhase 1\n45\tPhase 2\n88\tPhase 2\n100\tPhase 1\n46\tPhase 2\n88\tPhase 2\n25\tPhase 2\n400\tPhase 3\n12\tPhase 4\n20\tPhase 4\n80\tPhase 4\n20\tPhase 4\n30\tPhase 4\n30\tPhase 4\n30\tPhase 2\n23\tPhase 1\n4\tPhase 2\n37\tPhase 1\n18\tPhase 2\n5\tPhase 2\n0\tPhase 2\n0\tPhase 2\n41\tPhase 4\n13\tPhase 1\n86\tPhase 0\n3\tPhase 1 / Phase 2\n137\tPhase 4\n12\tPhase 1\n32\tPhase 2\n1\tPhase 1 / Phase 2\n8\tPhase 1\n57\tPhase 2\n855\tPhase 1\n40\tPhase 1\n610\tPhase 3\n16\tPhase 1\n614\tPhase 3\n223\tPhase 2\n20\tPhase 4\n40\tPhase 4\n15\tPhase 4\n30\tPhase 4\n20\tPhase 1\n59\tPhase 1\n17\tPhase 1\n7\tPhase 4\n70\tPhase 1\n16\tPhase 1\n51\tPhase 4\n24\tPhase 1\n63\tPhase 2\n30\tPhase 0\n56\tPhase 2\n20\tPhase 2\n2\tPhase 2\n301\tPhase 3\n18\tPhase 1\n56\tPhase 1\n4\tPhase 1\n35\tPhase 2\n321697\tPhase 4\n18\tPhase 1\n16\tPhase 1\n87\tPhase 0\n54\tPhase 2\n7\tPhase 2\n67\tPhase 4\n30\tPhase 2\n9\tPhase 2\n1\tPhase 2\n17\tPhase 0\n120\tPhase 3\n41\tPhase 2\n64\tPhase 2\n6\tPhase 2\n49\tPhase 1\n78\tPhase 1\n67\tPhase 2\n27\tPhase 1\n23\tPhase 2\n42\tPhase 1\n42\tPhase 1 / Phase 2\n37\tPhase 1\n96\tPhase 1\n94\tPhase 2\n59\tPhase 2\n41\tPhase 2\n25\tPhase 1\n2\tPhase 1\n56\tPhase 2\n74\tPhase 1\n60\tPhase 4\n62\tPhase 1\n15\tPhase 3\n47\tPhase 1\n33\tPhase 2\n12\tPhase 1\n55\tPhase 0\n40\tPhase 1\n21\tPhase 4\n60\tPhase 1\n40\tPhase 1\n24\tPhase 0\n66\tPhase 1\n0\tPhase 2\n264\tPhase 2\n50\tPhase 2\n32\tPhase 2\n6\tPhase 1\n125\tPhase 2\n851\tPhase 3\n20\tPhase 3\n302\tPhase 2 / Phase 3\n52\tPhase 1\n25\tPhase 1\n13\tPhase 1\n13\tPhase 4\n21\tPhase 1\n47\tPhase 1\n56\tPhase 1\n45\tPhase 1\n176\tPhase 2\n15\tPhase 1\n28\tPhase 1 / Phase 2\n7\tPhase 4\n48\tPhase 2\n29\tPhase 1 / Phase 2\n21\tPhase 1\n39\tPhase 2\n28\tPhase 2\n26\tPhase 2\n127\tPhase 4\n31\tPhase 1\n40\tPhase 4\n11\tPhase 4\n25\tPhase 1\n2\tPhase 2\n33\tPhase 4\n12\tPhase 4\n256\tPhase 2 / Phase 3\n711\tPhase 3\n10\tPhase 2\n21\tPhase 4\n30\tPhase 2\n188\tPhase 4\n24\tPhase 1 / Phase 2\n8\tPhase 1 / Phase 2\n67\tPhase 4\n28\tPhase 1 / Phase 2\n24\tPhase 4\n239\tPhase 3\n434\tPhase 3\n468\tPhase 3\n4\tPhase 2\n14\tPhase 2\n19\tPhase 2\n7\tPhase 2\n55\tPhase 3\n40\tPhase 2\n0\tPhase 4\n32\tPhase 2\n13\tPhase 2\n26\tPhase 2\n82\tPhase 4\n14\tPhase 2\n4\tPhase 1\n33\tPhase 2\n15\tPhase 2\n1467\tPhase 3\n18\tPhase 1\n110\tPhase 4\n341\tPhase 3\n8\tPhase 1\n71\tPhase 1\n295\tPhase 3\n44\tPhase 4\n54\tPhase 1\n16\tPhase 1\n30\tPhase 2\n290\tPhase 2\n66\tPhase 2\n14\tPhase 2\n30\tPhase 2\n13\tPhase 1\n60\tPhase 1 / Phase 2\n70\tPhase 2\n276\tPhase 4\n24\tPhase 1\n8\tPhase 1\n61\tPhase 4\n3604\tPhase 3\n24\tPhase 1\n15\tPhase 4\n90\tPhase 4\n16\tPhase 2 / Phase 3\n140\tPhase 2\n24\tPhase 1\n278\tPhase 2 / Phase 3\n23\tPhase 1 / Phase 2\n36\tPhase 2\n1600\tPhase 4\n50\tPhase 2\n51\tPhase 1\n116\tPhase 2\n5\tPhase 2\n569\tPhase 4\n37\tPhase 1\n16\tPhase 1\n454\tPhase 2\n27\tPhase 2\n20\tPhase 1\n61\tPhase 2\n4\tPhase 4\n475\tPhase 2 / Phase 3\n58\tPhase 4\n52\tPhase 2\n21\tPhase 2\n2\tPhase 2\n65\tPhase 1\n20\tPhase 2\n40\tPhase 4\n93\tPhase 4\n29\tPhase 1\n62\tPhase 2\n516\tPhase 4\n65\tPhase 1\n100\tPhase 2\n0\tPhase 4\n10\tPhase 1 / Phase 2\n18\tPhase 2\n457\tPhase 3\n275\tPhase 4\n318\tPhase 3\n20\tPhase 2\n111\tPhase 2 / Phase 3\n41\tPhase 1\n113\tPhase 4\n88\tPhase 4\n33\tPhase 1\n15\tPhase 4\n150\tPhase 3\n89\tPhase 2\n14\tPhase 1\n34\tPhase 1 / Phase 2\n262\tPhase 4\n48\tPhase 1 / Phase 2\n45\tPhase 1\n29\tPhase 2\n4\tPhase 1\n18\tPhase 1\n27\tPhase 2\n113\tPhase 3\n37\tPhase 1\n101\tPhase 3\n60\tPhase 2\n12\tPhase 2 / Phase 3\n53\tPhase 1\n152\tPhase 3\n231\tPhase 2\n20\tPhase 4\n40\tPhase 1\n40\tPhase 4\n40\tPhase 3\n40\tPhase 1\n8\tPhase 1 / Phase 2\n15\tPhase 2\n13\tPhase 1\n64\tPhase 2 / Phase 3\n24\tPhase 2\n75\tPhase 2\n30\tPhase 1\n65\tPhase 1\n261\tPhase 2\n24\tPhase 2\n150\tPhase 2 / Phase 3\n68\tPhase 2\n26\tPhase 2\n23\tPhase 1\n97\tPhase 3\n279\tPhase 3\n\tPhase 3\n31\tPhase 2\n25\tPhase 1\n96\tPhase 4\n400\tPhase 3\n\tPhase 3\n107\tPhase 1 / Phase 2\n496\tPhase 2 / Phase 3\n15\tPhase 2\n200\tPhase 3\n136\tPhase 3\n10\tPhase 1\n\tPhase 2\n\tPhase 3\n64\tPhase 4\n15\tPhase 2 / Phase 3\n26\tPhase 2 / Phase 3\n14\tPhase 2\n354\tPhase 1 / Phase 2\n240\tPhase 2\n574\tPhase 2\n77\tPhase 2\n70\tPhase 2\n89\tPhase 2\n160\tPhase 2 / Phase 3\n30\tPhase 4\n16\tPhase 1\n28\tPhase 0\n40\tPhase 2 / Phase 3\n811\tPhase 3\n174\tPhase 2\n654\tPhase 3\n80\tPhase 3\n12\tPhase 2 / Phase 3\n2364\tPhase 3\n56\tPhase 2 / Phase 3\n600\tPhase 4\n30\tPhase 2\n\tPhase 1\n30\tPhase 1\n5\tPhase 2\n30\tPhase 1\n40\tPhase 2\n20\tPhase 2\n1800\tPhase 3\n18\tPhase 4\n15\tPhase 1 / Phase 2\n76\tPhase 2\n154\tPhase 1 / Phase 2\n33\tPhase 2\n55\tPhase 2\n45\tPhase 1\n101\tPhase 3\n15\tPhase 1\n\tPhase 2\n60\tPhase 1 / Phase 2\n469\tPhase 2 / Phase 3\n37\tPhase 2\n127\tPhase 2 / Phase 3\n\tPhase 2\n12\tPhase 1\n\tPhase 3\n221\tPhase 3\n60\tPhase 1\n107\tPhase 3\n18\tPhase 1\n40\tPhase 2\n84\tPhase 3\n300\tPhase 3\n4\tPhase 1\n8\tPhase 2\n\tPhase 1 / Phase 2\n24\tPhase 1\n460\tPhase 3\n100\tPhase 2\n20\tPhase 1\n162\tPhase 2\n50\tPhase 3\n8000\tPhase 3\n389\tPhase 2\n732\tPhase 3\n\tPhase 3\n\tPhase 3\n\tPhase 2\n\tPhase 3\n14\tPhase 1\n8\tPhase 2\n89\tPhase 2\n2136\tPhase 3\n3720\tPhase 3\n\tPhase 2\n\tPhase 2\n\tPhase 2\n3\tPhase 1\n\tPhase 2\n\tPhase 3\n\tPhase 1\n\tPhase 2\n\tPhase 1\n\tPhase 1\n1500\tPhase 3\n75\tPhase 1\n60\tPhase 1\n\tPhase 1 / Phase 2\n150\tPhase 2\n\tPhase 2\n\tPhase 2\n30\tPhase 1 / Phase 2\n\tPhase 1\n0\tPhase 1\n15\tPhase 1\n\tPhase 2\n\tPhase 2\n300\tPhase 4\n\tPhase 3\n24\tPhase 1\n20\tPhase 1 / Phase 2\n40\tPhase 2\n17\tPhase 1 / Phase 2\n\tPhase 1 / Phase 2\n216\tPhase 3\n21\tPhase 1\n10\tPhase 1 / Phase 2\n68\tPhase 2\n60\tPhase 2\n50\tPhase 2\n20\tPhase 1\n\tPhase 1 / Phase 2\n0\tPhase 1\n8\tPhase 1\n\tPhase 1 / Phase 2\n4\tPhase 1 / Phase 2\n\tPhase 1\n56\tPhase 1\n40\tPhase 1 / Phase 2\n36\tPhase 1\n26\tPhase 1 / Phase 2\n11\tPhase 2\n136\tPhase 3\n25\tPhase 2\n14\tPhase 2\n14\tPhase 2\n20\tPhase 2\n6\tPhase 1\n6\tPhase 1\n\tPhase 1 / Phase 2\n6\tPhase 1 / Phase 2\n6\tPhase 1\n\tPhase 1\n30\tPhase 1\n30\tPhase 1\n4400\tPhase 3\n24\tPhase 1\n300\tPhase 2\n32\tPhase 2\n153\tPhase 0\n0\tPhase 2\n10\tPhase 1\n0\tPhase 2 / Phase 3\n36\tPhase 4\n28\tPhase 2\n23\tPhase 1\n10\tPhase 1 / Phase 2\n63\tPhase 1\n92\tPhase 1\n33\tPhase 4\n30\tPhase 3\n113\tPhase 3\n10\tPhase 2\n19\tPhase 2 / Phase 3\n30\tPhase 1\n282\tPhase 3\n6\tPhase 2\n84\tPhase 1\n52\tPhase 2\n200\tPhase 2\n14\tPhase 1\n7\tPhase 1\n700\tPhase 3\n45\tPhase 2\n30\tPhase 1\n13\tPhase 4\n11\tPhase 1\n12\tPhase 1\n90\tPhase 4\n22\tPhase 2\n15\tPhase 4\n6\tPhase 1\n0\tPhase 4\n43\tPhase 4\n27\tPhase 1 / Phase 2\n18\tPhase 2\n60\tPhase 2\n500\tPhase 3\n43\tPhase 2\n24\tPhase 2\n30\tPhase 4\n641\tPhase 2\n30\tPhase 2\n10\tPhase 2\n23\tPhase 1 / Phase 2\n181\tPhase 4\n51\tPhase 2\n51\tPhase 2\n186\tPhase 3\n37\tPhase 3\n60\tPhase 2\n85\tPhase 2\n10\tPhase 1\n6\tPhase 1\n400\tPhase 3\n60\tPhase 4\n24\tPhase 1\n79\tPhase 1\n50\tPhase 2\n10\tPhase 1\n50\tPhase 2\n39\tPhase 1\n38\tPhase 2\n6\tPhase 1 / Phase 2\n30\tPhase 2\n312\tPhase 3\n64\tPhase 1 / Phase 2\n36\tPhase 2\n24\tPhase 1 / Phase 2\n835\tPhase 2\n641\tPhase 1\n170\tPhase 4\n66\tPhase 2\n5\tPhase 2\n21\tPhase 2\n6\tPhase 2 / Phase 3\n25\tPhase 1\n43\tPhase 1 / Phase 2\n26\tPhase 1\n15\tPhase 2\n10\tPhase 2\n95\tPhase 2\n35\tPhase 1 / Phase 2\n15\tPhase 1\n20\tPhase 2\n50\tPhase 1\n11\tPhase 2\n56\tPhase 2\n13\tPhase 0\n64\tPhase 1\n38\tPhase 2\n30\tPhase 2\n0\tPhase 1\n40\tPhase 2\n62\tPhase 2\n120\tPhase 4\n1360\tPhase 3\n756\tPhase 3\n75\tPhase 3\n80\tPhase 1\n80\tPhase 1\n1200\tPhase 3\n3000\tPhase 3\n100\tPhase 4\n58\tPhase 1\n239\tPhase 3\n11\tPhase 1\n24\tPhase 2\n1701\tPhase 3\n65\tPhase 1\n900\tPhase 2\n12\tPhase 1\n18\tPhase 1\n\tPhase 3\n\tPhase 1\n20\tPhase 2\n30\tPhase 1\n300\tPhase 3\n100\tPhase 2\n\tPhase 1 / Phase 2\n24\tPhase 1\n36\tPhase 1\n25\tPhase 2\n0\tPhase 1\n\tPhase 3\n820\tPhase 3\n331\tPhase 4\n76\tPhase 2\n30\tPhase 2\n80\tPhase 2\n72\tPhase 4\n37\tPhase 2\n30\tPhase 1\n20\tPhase 2\n71\tPhase 2\n48\tPhase 1 / Phase 2\n35\tPhase 2\n110\tPhase 4\n37\tPhase 2\n24\tPhase 1\n150\tPhase 4\n120\tPhase 4\n20\tPhase 2\n90\tPhase 2\n58\tPhase 2\n60\tPhase 4\n40\tPhase 2\n52\tPhase 1 / Phase 2\n1\tPhase 1\n4\tPhase 2\n24\tPhase 2\n56\tPhase 2\n170\tPhase 1 / Phase 2\n75\tPhase 4\n24\tPhase 1\n26\tPhase 2\n60\tPhase 1\n224\tPhase 2\n32\tPhase 4\n23\tPhase 1\n55\tPhase 1 / Phase 2\n400\tPhase 3\n86\tPhase 4\n10\tPhase 1 / Phase 2\n34\tPhase 1\n80\tPhase 2\n25\tPhase 1\n30\tPhase 4\n36\tPhase 1\n14\tPhase 1 / Phase 2\n32\tPhase 1\n67\tPhase 1 / Phase 2\n11\tPhase 1 / Phase 2\n31\tPhase 1\n340\tPhase 3\n16\tPhase 1\n42\tPhase 1 / Phase 2\n50\tPhase 2\n14\tPhase 2\n206\tPhase 4\n12\tPhase 1\n169\tPhase 3\n73\tPhase 3\n51\tPhase 2\n22\tPhase 1\n30\tPhase 1\n54\tPhase 1 / Phase 2\n40\tPhase 4\n30\tPhase 4\n32\tPhase 4\n84\tPhase 2 / Phase 3\n30\tPhase 1 / Phase 2\n4\tPhase 4\n11\tPhase 1\n10\tPhase 2\n0\tPhase 2\n54\tPhase 3\n60\tPhase 2\n\tPhase 3\n20\tPhase 1 / Phase 2\n1400\tPhase 3\n37\tPhase 1 / Phase 2\n24\tPhase 2\n12\tPhase 1\n480\tPhase 3\n5\tPhase 1\n21\tPhase 1\n1686\tPhase 3\n50\tPhase 2\n16\tPhase 1\n21\tPhase 1\n18\tPhase 2\n270\tPhase 2\n24\tPhase 1\n24\tPhase 3\n20\tPhase 2 / Phase 3\n50\tPhase 4\n24\tPhase 1\n268\tPhase 3\n280\tPhase 2\n\tPhase 1\n32\tPhase 1\n11\tPhase 2\n\tPhase 2\n160\tPhase 2 / Phase 3\n\tPhase 1\n2\tPhase 2\n420\tPhase 3\n\tPhase 1\n12\tPhase 1\n26\tPhase 1\n12\tPhase 1\n200\tPhase 3\n37\tPhase 2\n18\tPhase 0\n7\tPhase 2\n27\tPhase 0\n76\tPhase 3\n38\tPhase 2\n440\tPhase 4\n257\tPhase 3\n8\tPhase 1\n24\tPhase 2\n7\tPhase 1\n133\tPhase 1\n48\tPhase 1\n36\tPhase 1\n31\tPhase 2\n161\tPhase 2\n36\tPhase 2\n376\tPhase 2\n146\tPhase 2\n702\tPhase 3\n41\tPhase 2\n40\tPhase 2\n39\tPhase 2\n32\tPhase 1\n100\tPhase 3\n114\tPhase 1\n360\tPhase 3\n28\tPhase 2\n43\tPhase 1\n60\tPhase 1 / Phase 2\n50\tPhase 1\n20\tPhase 1\n56\tPhase 2\n116\tPhase 2\n40\tPhase 2\n66\tPhase 2\n18\tPhase 1\n14\tPhase 1\n71\tPhase 1\n16\tPhase 1 / Phase 2\n57\tPhase 2\n469\tPhase 4\n127\tPhase 3\n52\tPhase 1\n46\tPhase 2\n124\tPhase 3\n36\tPhase 1\n44\tPhase 4\n300\tPhase 1\n50\tPhase 4\n20\tPhase 1\n78\tPhase 1\n27\tPhase 2 / Phase 3\n40\tPhase 2\n30\tPhase 2\n39\tPhase 2\n44\tPhase 3\n61\tPhase 3\n60\tPhase 2\n1200\tPhase 4\n80\tPhase 1 / Phase 2\n37\tPhase 4\n0\tPhase 1\n28\tPhase 1\n105\tPhase 1\n21\tPhase 1\n28\tPhase 0\n21\tPhase 4\n41\tPhase 1 / Phase 2\n64\tPhase 4\n19\tPhase 2\n44\tPhase 1\n29\tPhase 1\n5\tPhase 2\n52\tPhase 2\n406\tPhase 2\n140\tPhase 3\n24\tPhase 2 / Phase 3\n32\tPhase 1\n100\tPhase 4\n4\tPhase 2\n17\tPhase 1\n25\tPhase 1\n12\tPhase 1\n9\tPhase 1 / Phase 2\n148\tPhase 2\n216\tPhase 2 / Phase 3\n131\tPhase 4\n6\tPhase 1\n0\tPhase 2 / Phase 3\n50\tPhase 4\n20\tPhase 1 / Phase 2\n28\tPhase 1 / Phase 2\n27\tPhase 2\n40\tPhase 2\n12\tPhase 4\n24\tPhase 1 / Phase 2\n120\tPhase 3\n8\tPhase 1\n709\tPhase 3\n50\tPhase 2\n100\tPhase 3\n120\tPhase 2\n80\tPhase 2\n65\tPhase 1 / Phase 2\n62\tPhase 1 / Phase 2\n16\tPhase 1 / Phase 2\n75\tPhase 1\n\tPhase 1 / Phase 2\n20\tPhase 2\n12\tPhase 1\n340\tPhase 4\n12\tPhase 1\n72\tPhase 2\n184\tPhase 2\n232\tPhase 4\n24\tPhase 1\n80\tPhase 2\n36\tPhase 1 / Phase 2\n200\tPhase 2\n34\tPhase 0\n63\tPhase 2\n28\tPhase 1\n38\tPhase 3\n225\tPhase 4\n79\tPhase 2\n10\tPhase 4\n64\tPhase 4\n222\tPhase 2\n50\tPhase 1\n10\tPhase 1\n24\tPhase 1\n52\tPhase 4\n51\tPhase 1\n180\tPhase 4\n29\tPhase 1\n32\tPhase 1\n45\tPhase 2\n19\tPhase 1 / Phase 2\n15\tPhase 1 / Phase 2\n40\tPhase 2\n36\tPhase 2\n12\tPhase 1\n9\tPhase 1\n40\tPhase 3\n98\tPhase 3\n21\tPhase 2\n120\tPhase 2 / Phase 3\n259\tPhase 2\n33\tPhase 1\n29\tPhase 1\n48\tPhase 2\n31\tPhase 1\n42\tPhase 2\n93\tPhase 4\n45\tPhase 4\n300\tPhase 3\n190\tPhase 3\n12\tPhase 2\n10\tPhase 1\n48\tPhase 1\n24\tPhase 4\n689\tPhase 3\n217\tPhase 2\n25\tPhase 4\n371\tPhase 2 / Phase 3\n138\tPhase 4\n45\tPhase 2\n4\tPhase 3\n16\tPhase 2\n339\tPhase 3\n50\tPhase 2\n90\tPhase 2\n76\tPhase 2\n76\tPhase 1\n46\tPhase 4\n33\tPhase 3\n200\tPhase 4\n43\tPhase 2\n69\tPhase 1\n600\tPhase 2\n44\tPhase 2\n80\tPhase 1\n18\tPhase 1\n81\tPhase 2\n60\tPhase 2\n50\tPhase 4\n27\tPhase 2\n35\tPhase 3\n13\tPhase 1\n7\tPhase 1 / Phase 2\n60\tPhase 1\n54\tPhase 1\n85\tPhase 1 / Phase 2\n9\tPhase 1 / Phase 2\n19\tPhase 1\n11\tPhase 2\n75\tPhase 1 / Phase 2\n81\tPhase 2\n63\tPhase 1\n51\tPhase 3\n51\tPhase 1\n40\tPhase 2\n37\tPhase 1\n18\tPhase 2\n45\tPhase 3\n10\tPhase 3\n9\tPhase 1\n25\tPhase 1\n32\tPhase 2\n40\tPhase 4\n10\tPhase 2\n71\tPhase 2 / Phase 3\n100\tPhase 1 / Phase 2\n424\tPhase 1 / Phase 2\n25\tPhase 1\n11\tPhase 1\n116\tPhase 4\n68\tPhase 2\n46\tPhase 2\n\tPhase 2\n48\tPhase 1\n60\tPhase 1\n42\tPhase 2\n49\tPhase 2\n48\tPhase 1\n100\tPhase 1\n40\tPhase 2\n45\tPhase 2\n24\tPhase 2\n60\tPhase 2\n20\tPhase 4\n1149\tPhase 1\n40\tPhase 1\n28\tPhase 1\n100\tPhase 2\n100\tPhase 2\n120\tPhase 1\n39\tPhase 2\n39\tPhase 2\n113\tPhase 1\n44\tPhase 1\n11\tPhase 2\n48\tPhase 1\n17\tPhase 1\n44\tPhase 1\n58\tPhase 4\n78\tPhase 1\n39\tPhase 2\n38\tPhase 2\n15\tPhase 1 / Phase 2\n24\tPhase 1\n15\tPhase 1\n60\tPhase 1\n3\tPhase 2\n99\tPhase 2\n15\tPhase 1\n42\tPhase 1\n100\tPhase 2\n92\tPhase 1\n7\tPhase 3\n107\tPhase 2\n26\tPhase 2\n11\tPhase 2\n5\tPhase 4\n58\tPhase 1\n600\tPhase 1 / Phase 2\n20\tPhase 2\n25\tPhase 2\n69\tPhase 2\n50\tPhase 2\n17\tPhase 2 / Phase 3\n22\tPhase 1\n64\tPhase 1 / Phase 2\n25\tPhase 1\n46\tPhase 1 / Phase 2\n\tPhase 2\n75\tPhase 0\n340\tPhase 4\n62\tPhase 1 / Phase 2\n34\tPhase 2\n104\tPhase 2\n\tPhase 3\n132\tPhase 1 / Phase 2\n20\tPhase 1\n55\tPhase 1 / Phase 2\n36\tPhase 1\n48\tPhase 1\n48\tPhase 3\n11\tPhase 4\n0\tPhase 2\n28\tPhase 1\n87\tPhase 3\n10\tPhase 2\n110\tPhase 1 / Phase 2\n192\tPhase 1\n20\tPhase 2\n30\tPhase 1\n390\tPhase 3\n99\tPhase 2\n9\tPhase 1\n40\tPhase 1\n36\tPhase 2\n82\tPhase 2\n9\tPhase 1\n9\tPhase 2\n19\tPhase 1\n32\tPhase 1\n127\tPhase 4\n72\tPhase 1\n31\tPhase 3\n80\tPhase 2\n51\tPhase 1\n42\tPhase 1 / Phase 2\n62\tPhase 4\n84\tPhase 1\n50\tPhase 1\n45\tPhase 2\n73\tPhase 2\n69\tPhase 2\n39\tPhase 1\n305\tPhase 2\n40\tPhase 2\n100\tPhase 4\n33\tPhase 2\n6\tPhase 2\n\tPhase 1\n\tPhase 1\n223\tPhase 3\n\tPhase 2\n\tPhase 2\n53\tPhase 2\n64\tPhase 1\n\tPhase 2\n40\tPhase 1 / Phase 2\n102\tPhase 2\n55\tPhase 2\n\tPhase 2\n\tPhase 2\n39\tPhase 2\n56\tPhase 2\n402\tPhase 3\n77\tPhase 2 / Phase 3\n48\tPhase 1 / Phase 2\n90\tPhase 1\n36\tPhase 2\n51\tPhase 4\n7\tPhase 2\n7\tPhase 4\n226\tPhase 2\n100\tPhase 2\n25\tPhase 2\n2\tPhase 3\n400\tPhase 4\n1365\tPhase 4\n74\tPhase 2\n90\tPhase 2\n23\tPhase 2\n24\tPhase 1\n93\tPhase 1 / Phase 2\n112\tPhase 1\n60\tPhase 2\n75\tPhase 2\n15\tPhase 2\n20\tPhase 4\n183\tPhase 2\n142\tPhase 2\n126\tPhase 1\n120\tPhase 2\n54\tPhase 1 / Phase 2\n86\tPhase 4\n30\tPhase 1\n9\tPhase 4\n154\tPhase 2\n61\tPhase 3\n33\tPhase 2\n56\tPhase 1\n7287\tPhase 3\n100\tPhase 1\n230\tPhase 2\n30\tPhase 2\n6\tPhase 4\n40\tPhase 4\n30\tPhase 1\n24\tPhase 4\n0\tPhase 4\n74\tPhase 2\n40\tPhase 2\n\tPhase 2\n24\tPhase 1\n54\tPhase 1\n122\tPhase 4\n81\tPhase 2\n30\tPhase 1 / Phase 2\n100\tPhase 3\n30\tPhase 2\n21\tPhase 1 / Phase 2\n19\tPhase 1\n108\tPhase 3\n8\tPhase 1\n130\tPhase 1\n12\tPhase 2\n12\tPhase 1\n24\tPhase 2\n38\tPhase 1\n66\tPhase 1 / Phase 2\n151\tPhase 2\n23\tPhase 1\n19\tPhase 1\n37\tPhase 1\n24\tPhase 1\n61\tPhase 3\n100\tPhase 4\n80\tPhase 2\n1100\tPhase 3\n50\tPhase 2\n1267\tPhase 3\n80\tPhase 2\n75\tPhase 1\n54\tPhase 2\n40\tPhase 1\n31\tPhase 1\n100\tPhase 3\n36\tPhase 1\n100\tPhase 3\n\tPhase 2\n26\tPhase 1 / Phase 2\n11811\tPhase 4\n3069\tPhase 3\n150\tPhase 1\n32\tPhase 2\n37\tPhase 2\n89\tPhase 2\n150\tPhase 2\n60\tPhase 3\n158\tPhase 1\n30\tPhase 1\n23\tPhase 1 / Phase 2\n1370\tPhase 3\n0\tPhase 1 / Phase 2\n40\tPhase 1\n40\tPhase 1\n\tPhase 1\n300\tPhase 2\n100\tPhase 2\n300\tPhase 2\n32\tPhase 1 / Phase 2\n30\tPhase 2\n216\tPhase 1 / Phase 2\n40\tPhase 1\n0\tPhase 2\n66\tPhase 1 / Phase 2\n25\tPhase 2\n30\tPhase 1 / Phase 2\n363\tPhase 1\n7\tPhase 2\n180\tPhase 2\n20\tPhase 1\n1232\tPhase 3\n116\tPhase 2\n18\tPhase 2\n100\tPhase 4\n25\tPhase 2\n1\tPhase 1\n26\tPhase 1\n92\tPhase 2\n70\tPhase 1\n342\tPhase 2\n40\tPhase 0\n75\tPhase 1\n44\tPhase 2\n36\tPhase 1\n29\tPhase 1\n10\tPhase 1\n30\tPhase 1\n79\tPhase 2\n27\tPhase 1\n100\tPhase 1\n43\tPhase 2\n230\tPhase 2\n150\tPhase 2\n10\tPhase 1\n23\tPhase 1\n5\tPhase 1 / Phase 2\n58\tPhase 1\n58\tPhase 2\n21\tPhase 3\n34\tPhase 4\n60\tPhase 2\n4\tPhase 1 / Phase 2\n66\tPhase 4\n49\tPhase 1 / Phase 2\n60\tPhase 1 / Phase 2\n20\tPhase 1 / Phase 2\n100\tPhase 2\n150\tPhase 3\n20\tPhase 1\n100\tPhase 2\n306\tPhase 2 / Phase 3\n38\tPhase 2\n\tPhase 1 / Phase 2\n\tPhase 2 / Phase 3\n26\tPhase 2\n101\tPhase 2\n14\tPhase 1\n85\tPhase 2\n470\tPhase 1\n35\tPhase 2\n19\tPhase 1\n75\tPhase 2\n146\tPhase 2\n92\tPhase 2\n60\tPhase 1\n50\tPhase 2\n90\tPhase 2\n19\tPhase 2\n50\tPhase 1 / Phase 2\n36\tPhase 1\n46\tPhase 1\n50\tPhase 2\n26\tPhase 1 / Phase 2\n12\tPhase 2\n40\tPhase 1 / Phase 2\n60\tPhase 2\n16\tPhase 1\n55\tPhase 2\n45\tPhase 2 / Phase 3\n87\tPhase 1 / Phase 2\n0\tPhase 2\n517\tPhase 3\n18\tPhase 1\n15\tPhase 1\n63\tPhase 1 / Phase 2\n60\tPhase 2\n96\tPhase 1\n\tPhase 2\n31\tPhase 2\n100\tPhase 2\n242\tPhase 3\n14\tPhase 2\n800\tPhase 3\n155\tPhase 3\n42\tPhase 2 / Phase 3\n310\tPhase 2 / Phase 3\n350\tPhase 3\n42\tPhase 2 / Phase 3\n59\tPhase 2\n100\tPhase 2\n3136\tPhase 3\n112\tPhase 2\n990\tPhase 3\n3000\tPhase 2\n3270\tPhase 4\n94\tPhase 2\n275\tPhase 3\n378\tPhase 3\n280\tPhase 2\n450\tPhase 3\n106\tPhase 2\n10000\tPhase 3\n10000\tPhase 2 / Phase 3\n600\tPhase 3\n4200\tPhase 3\n540\tPhase 2 / Phase 3\n519\tPhase 3\n330\tPhase 3\n12000\tPhase 4\n312\tPhase 3\n17000\tPhase 3\n4000\tPhase 4\n2820\tPhase 3\n1311\tPhase 3\n143\tPhase 2\n2918\tPhase 3\n523\tPhase 3\n756\tPhase 3\n27564\tPhase 3\n1900\tPhase 3\n487\tPhase 3\n294\tPhase 3\n128\tPhase 3\n224\tPhase 3\n230\tPhase 2\n1871\tPhase 3\n216\tPhase 3\n1060\tPhase 2 / Phase 3\n4161\tPhase 3\n213\tPhase 2\n1340\tPhase 3\n16568\tPhase 3\n3260\tPhase 3\n1500\tPhase 3\n10000\tPhase 3\n2500\tPhase 3\n807\tPhase 2\n17183\tPhase 3\n1545\tPhase 3\n534\tPhase 3\n480\tPhase 3\n500\tPhase 3\n55\tPhase 2\n3900\tPhase 3\n799\tPhase 3\n2000\tPhase 3\n1070\tPhase 3\n1038\tPhase 3\n4950\tPhase 3\n3966\tPhase 3\n8067\tPhase 4\n24222\tPhase 4\n1500\tPhase 3\n11248\tPhase 3\n2334\tPhase 3\n5652\tPhase 4\n1873\tPhase 3\n3610\tPhase 3\n732\tPhase 3\n1200\tPhase 4\n3104\tPhase 3\n4646\tPhase 3\n\tPhase 3\n19747\tPhase 3\n13000\tPhase 3\n10653\tPhase 3\n345\tPhase 2\n150\tPhase 2\n168\tPhase 1 / Phase 2\n13026\tPhase 3\n454\tPhase 2\n3000\tPhase 3\n1049\tPhase 3\n555\tPhase 3\n210\tPhase 3\n15865\tPhase 3\n147494\tPhase 4\n400\tPhase 3\n488\tPhase 3\n1877\tPhase 3\n3397\tPhase 3\n714\tPhase 3\n562\tPhase 3\n1626\tPhase 3\n19000\tPhase 3\n7637\tPhase 3\n1636\tPhase 3\n784\tPhase 3\n7000\tPhase 3\n1282\tPhase 3\n2583\tPhase 3\n804\tPhase 3\n310\tPhase 3\n685\tPhase 3\n1743\tPhase 3\n3509\tPhase 3\n1206\tPhase 3\n295\tPhase 3\n2722\tPhase 3\n766\tPhase 3\n636\tPhase 3\n1500\tPhase 3\n184\tPhase 2\n10066\tPhase 3\n21379\tPhase 3\n6198\tPhase 3\n116\tPhase 1 / Phase 2\n406\tPhase 3\n805\tPhase 3\n643\tPhase 3\n9326\tPhase 3\n1792\tPhase 3\n596\tPhase 2\n18113\tPhase 3\n8231\tPhase 3\n11000\tPhase 4\n172\tPhase 1 / Phase 2\n8300\tPhase 4\n4148\tPhase 3\n16415\tPhase 3\n756\tPhase 3\n3207\tPhase 3\n8910\tPhase 3\n11751\tPhase 4\n773\tPhase 3\n2873\tPhase 3\n6068\tPhase 3\n14000\tPhase 3\n200\tPhase 2\n792\tPhase 3\n1526\tPhase 3\n1546\tPhase 3\n1538\tPhase 3\n305\tPhase 3\n309\tPhase 3\n189\tPhase 2\n452\tPhase 3\n21105\tPhase 3\n305\tPhase 3\n939\tPhase 3\n1027\tPhase 3\n591\tPhase 3\n17802\tPhase 3\n1038\tPhase 3\n520\tPhase 3\n1331\tPhase 3\n650\tPhase 3\n67\tPhase 4\n1050\tPhase 3\n8000\tPhase 3\n250\tPhase 2 / Phase 3\n350\tPhase 2\n122\tPhase 1 / Phase 2\n951\tPhase 2 / Phase 3\n332\tPhase 2\n2012\tPhase 4\n6115\tPhase 3\n950\tPhase 3\n5380\tPhase 3\n101\tPhase 2\n779\tPhase 3\n474\tPhase 3\n76\tPhase 2\n1116\tPhase 3\n8381\tPhase 3\n242\tPhase 3\n14269\tPhase 3\n1100\tPhase 3\n63\tPhase 2\n702\tPhase 3\n47\tPhase 2\n80\tPhase 2\n39\tPhase 2\n41\tPhase 2\n9779\tPhase 3\n56\tPhase 2\n69\tPhase 2\n10\tPhase 3\n78\tPhase 2\n81\tPhase 2\n320\tPhase 2\n79\tPhase 2\n42\tPhase 3\n259\tPhase 2\n60\tPhase 2\n\tPhase 2\n91\tPhase 1 / Phase 2\n280\tPhase 3\n109\tPhase 2\n854\tPhase 3\n270\tPhase 3\n5000\tPhase 3\n84\tPhase 2\n1800\tPhase 3\n605\tPhase 2 / Phase 3\n1471\tPhase 3\n400\tPhase 2 / Phase 3\n7910\tPhase 3\n1223\tPhase 3\n4000\tPhase 4\n89\tPhase 2\n1394\tPhase 3\n2370\tPhase 3\n3\tPhase 2\n1304\tPhase 3\n460\tPhase 3\n2354\tPhase 4\n1663\tPhase 3\n282\tPhase 2\n664\tPhase 4\n1053\tPhase 4\n10179\tPhase 4\n1282\tPhase 3\n3649\tPhase 3\n603\tPhase 3\n886\tPhase 3\n1758\tPhase 3\n623\tPhase 3\n1498\tPhase 3\n2500\tPhase 3\n394\tPhase 3\n1228\tPhase 3\n788\tPhase 3\n400\tPhase 3\n2278\tPhase 3\n525\tPhase 2\n720\tPhase 3\n534\tPhase 3\n4216\tPhase 3\n238\tPhase 2\n1\tPhase 3\n140\tPhase 2\n700\tPhase 3\n3066\tPhase 3\n546\tPhase 3\n633\tPhase 3\n571\tPhase 3\n49\tPhase 2\n143\tPhase 2\n1994\tPhase 4\n53\tPhase 2\n1711\tPhase 4\n148\tPhase 1 / Phase 2\n235\tPhase 2\n500\tPhase 3\n5000\tPhase 3\n1378\tPhase 3\n350\tPhase 3\n825\tPhase 3\n1161\tPhase 3\n132\tPhase 1 / Phase 2\n168\tPhase 2\n796\tPhase 2\n15000\tPhase 3\n717\tPhase 3\n17276\tPhase 3\n15000\tPhase 4\n1015\tPhase 3\n646\tPhase 3\n397\tPhase 3\n2312\tPhase 3\n181\tPhase 2\n591\tPhase 3\n666\tPhase 3\n9340\tPhase 3\n180\tPhase 3\n870\tPhase 4\n611\tPhase 3\n362\tPhase 3\n141\tPhase 3\n1027\tPhase 3\n712\tPhase 3\n338\tPhase 2 / Phase 3\n646\tPhase 3\n873\tPhase 3\n418\tPhase 2\n411\tPhase 3\n361\tPhase 2\n500\tPhase 3\n760\tPhase 3\n420\tPhase 2\n361\tPhase 2\n612\tPhase 3\n755\tPhase 3\n244\tPhase 3\n545\tPhase 3\n78\tPhase 2\n406\tPhase 2\n743\tPhase 3\n3000\tPhase 3\n180\tPhase 2\n1064\tPhase 3\n2000\tPhase 3\n680\tPhase 2 / Phase 3\n9400\tPhase 4\n2600\tPhase 2\n34\tPhase 2\n114\tPhase 3\n25\tPhase 2\n600\tPhase 3\n893\tPhase 3\n1847\tPhase 3\n12116\tPhase 3\n18600\tPhase 3\n137\tPhase 2\n881\tPhase 4\n1150\tPhase 3\n2220\tPhase 3\n2499\tPhase 2\n749\tPhase 3\n31989\tPhase 4\n812\tPhase 3\n262\tPhase 3\n2580\tPhase 3\n844\tPhase 3\n3080\tPhase 4\n990\tPhase 4\n130\tPhase 2\n846\tPhase 3\n700\tPhase 3\n140\tPhase 3\n234\tPhase 3\n63\tPhase 2\n18206\tPhase 4\n430\tPhase 2\n48\tPhase 1 / Phase 2\n102\tPhase 4\n281\tPhase 3\n3597\tPhase 3\n149\tPhase 2\n9172\tPhase 3\n242\tPhase 3\n626\tPhase 3\n637\tPhase 3\n252\tPhase 3\n390\tPhase 3\n999\tPhase 4\n637\tPhase 3\n478\tPhase 2\n901\tPhase 3\n261\tPhase 2\n938\tPhase 3\n619\tPhase 3\n502\tPhase 3\n2225\tPhase 3\n2269\tPhase 3\n651\tPhase 3\n1976\tPhase 4\n355\tPhase 3\n1461\tPhase 3\n6228\tPhase 3\n317\tPhase 2\n1784\tPhase 3\n2054\tPhase 3\n\tPhase 3\n805\tPhase 3\n2567\tPhase 3\n547\tPhase 3\n645\tPhase 3\n3600\tPhase 3\n1772\tPhase 3\n3000\tPhase 3\n1150\tPhase 3\n5437\tPhase 3\n6500\tPhase 3\n356\tPhase 3\n8000\tPhase 3\n450\tPhase 3\n254\tPhase 2\n500\tPhase 3\n300\tPhase 3\n1972\tPhase 3\n2600\tPhase 3\n600\tPhase 3\n2168\tPhase 3\n1790\tPhase 3\n1400\tPhase 3\n690\tPhase 3\n736\tPhase 3\n1170\tPhase 3\n284\tPhase 2 / Phase 3\n420\tPhase 2\n718\tPhase 3\n2103\tPhase 3\n827\tPhase 4\n872\tPhase 3\n330\tPhase 3\n507\tPhase 3\n3297\tPhase 3\n1137\tPhase 3\n593\tPhase 2\n872\tPhase 3\n75\tPhase 2\n607\tPhase 3\n105\tPhase 3\n373\tPhase 2\n480\tPhase 2\n642\tPhase 3\n490\tPhase 3\n219\tPhase 3\n233\tPhase 3\n165\tPhase 2\n808\tPhase 3\n575\tPhase 3\n250\tPhase 3\n9022\tPhase 3\n80\tPhase 1 / Phase 2\n1504\tPhase 3\n841\tPhase 3\n354\tPhase 3\n123\tPhase 2\n2312\tPhase 3\n421\tPhase 2\n702\tPhase 3\n2118\tPhase 3\n31\tPhase 2\n253\tPhase 3\n25682\tPhase 4\n9\tPhase 2\n803\tPhase 3\n519\tPhase 3\n2840\tPhase 3\n1142\tPhase 3\n7484\tPhase 3\n5897\tPhase 3\n7744\tPhase 3\n15828\tPhase 3\n407\tPhase 4\n1557\tPhase 3\n43695\tPhase 3\n1189\tPhase 3\n1275\tPhase 3\n525\tPhase 3\n543\tPhase 3\n134\tPhase 1 / Phase 2\n3656\tPhase 3\n437\tPhase 3\n5077\tPhase 2 / Phase 3\n242\tPhase 3\n500\tPhase 3\n80\tPhase 2\n30\tPhase 2\n1258\tPhase 3\n164\tPhase 2\n1065\tPhase 2 / Phase 3\n7141\tPhase 3\n742\tPhase 3\n1900\tPhase 3\n310\tPhase 2\n275\tPhase 3\n395\tPhase 3\n1070\tPhase 3\n500\tPhase 4\n808\tPhase 3\n284\tPhase 4\n294\tPhase 2\n630\tPhase 4\n660\tPhase 3\n493\tPhase 3\n805\tPhase 4\n48\tPhase 2\n1145\tPhase 3\n518\tPhase 3\n451\tPhase 3\n451\tPhase 3\n908\tPhase 3\n2038\tPhase 3\n1159\tPhase 3\n378\tPhase 2\n1400\tPhase 2\n1400\tPhase 2\n20332\tPhase 4\n1020\tPhase 3\n1164\tPhase 3\n1462\tPhase 3\n62\tPhase 2\n109\tPhase 2\n55\tPhase 2\n5377\tPhase 3\n236\tPhase 3\n1752\tPhase 3\n4844\tPhase 3\n104\tPhase 2\n600\tPhase 3\n438\tPhase 3\n690\tPhase 3\n3154\tPhase 3\n155\tPhase 2\n2672\tPhase 3\n132\tPhase 3\n3200\tPhase 3\n33\tPhase 2\n170\tPhase 2\n1734\tPhase 3\n\tPhase 2\n399\tPhase 3\n138\tPhase 2\n31\tPhase 2\n32\tPhase 1\n21\tPhase 2\n31\tPhase 1\n77\tPhase 2\n253\tPhase 3\n125\tPhase 2\n67\tPhase 3\n254\tPhase 3\n120\tPhase 2\n968\tPhase 3\n573\tPhase 3\n483\tPhase 3\n69\tPhase 2\n3031\tPhase 3\n203\tPhase 3\n71\tPhase 1 / Phase 2\n345\tPhase 2\n12500\tPhase 3\n14535\tPhase 3\n583\tPhase 3\n1500\tPhase 3\n600\tPhase 3\n450\tPhase 3\n645\tPhase 3\n629\tPhase 3\n51\tPhase 2\n532\tPhase 2\n3000\tPhase 3\n1050\tPhase 3\n354\tPhase 3\n1100\tPhase 3\n249\tPhase 2\n4600\tPhase 4\n393\tPhase 2\n1014\tPhase 3\n282\tPhase 3\n7764\tPhase 4\n1087\tPhase 3\n6000\tPhase 3\n154\tPhase 3\n340\tPhase 2 / Phase 3\n1140\tPhase 3\n1294\tPhase 3\n500\tPhase 3\n1082\tPhase 3\n1410\tPhase 3\n598\tPhase 3\n1380\tPhase 3\n248\tPhase 2\n910\tPhase 3\n53\tPhase 3\n205\tPhase 3\n2139\tPhase 3\n1200\tPhase 3\n788\tPhase 3\n172\tPhase 2\n1001\tPhase 4\n165\tPhase 2\n225\tPhase 3\n441\tPhase 3\n870\tPhase 3\n434\tPhase 3\n365\tPhase 3\n816\tPhase 4\n7\tPhase 2\n800\tPhase 3\n640\tPhase 2 / Phase 3\n356\tPhase 2\n178\tPhase 3\n589\tPhase 4\n0\tPhase 3\n282\tPhase 2\n610\tPhase 3\n8000\tPhase 3\n2454\tPhase 3\n2648\tPhase 2\n12463\tPhase 3\n641\tPhase 4\n780\tPhase 3\n1735\tPhase 4\n1750\tPhase 3\n975\tPhase 4\n403\tPhase 3\n799\tPhase 3\n96\tPhase 4\n163\tPhase 2\n75\tPhase 2\n693\tPhase 3\n85\tPhase 2\n9\tPhase 3\n684\tPhase 4\n14819\tPhase 3\n16166\tPhase 3\n5189\tPhase 3\n639\tPhase 4\n507\tPhase 3\n707\tPhase 3\n748\tPhase 3\n7226\tPhase 3\n8442\tPhase 3\n166\tPhase 3\n494\tPhase 2\n265\tPhase 3\n426\tPhase 2\n330\tPhase 2\n586\tPhase 3\n252\tPhase 3\n280\tPhase 3\n700\tPhase 3\n677\tPhase 3\n249\tPhase 3\n1068\tPhase 2\n963\tPhase 4\n188\tPhase 3\n151\tPhase 2\n241\tPhase 3\n1116\tPhase 3\n437\tPhase 3\n526\tPhase 2\n633\tPhase 3\n724\tPhase 3\n92\tPhase 1 / Phase 2\n1144\tPhase 3\n723\tPhase 3\n543\tPhase 4\n829\tPhase 3\n1397\tPhase 3\n306\tPhase 2\n717\tPhase 3\n896\tPhase 4\n5614\tPhase 3\n2711\tPhase 3\n376\tPhase 2\n272\tPhase 3\n306\tPhase 3\n1502\tPhase 3\n5\tPhase 2\n375\tPhase 3\n665\tPhase 3\n1226\tPhase 3\n2492\tPhase 3\n5000\tPhase 3\n117\tPhase 2\n630\tPhase 3\n84\tPhase 3\n1020\tPhase 3\n464\tPhase 3\n2278\tPhase 3\n83\tPhase 2\n831\tPhase 2\n187\tPhase 1 / Phase 2\n481\tPhase 3\n1897\tPhase 4\n156\tPhase 1 / Phase 2\n1026\tPhase 4\n282\tPhase 2 / Phase 3\n4500\tPhase 3\n560\tPhase 3\n18624\tPhase 3\n219\tPhase 2\n449\tPhase 2\n\tPhase 3\n481\tPhase 3\n109\tPhase 3\n244\tPhase 3\n588\tPhase 3\n1000\tPhase 3\n484\tPhase 3\n947\tPhase 3\n390\tPhase 3\n2091\tPhase 4\n402\tPhase 3\n908\tPhase 3\n1109\tPhase 4\n1260\tPhase 2 / Phase 3\n740\tPhase 3\n743\tPhase 3\n619\tPhase 3\n1900\tPhase 3\n534\tPhase 3\n\tPhase 4\n500\tPhase 4\n3800\tPhase 3\n1100\tPhase 3\n6635\tPhase 3\n8500\tPhase 3\n188\tPhase 2\n300\tPhase 2\n797\tPhase 4\n658\tPhase 3\n1440\tPhase 3\n479\tPhase 4\n233\tPhase 2\n170\tPhase 2\n1200\tPhase 3\n1846\tPhase 4\n528\tPhase 3\n238\tPhase 2\n645\tPhase 3\n81\tPhase 2\n162\tPhase 3\n350\tPhase 2\n1302\tPhase 3\n84\tPhase 2\n501\tPhase 4\n129\tPhase 3\n265\tPhase 2\n440\tPhase 3\n377\tPhase 3\n336\tPhase 3\n57\tPhase 2\n1449\tPhase 3\n439\tPhase 3\n12\tPhase 2\n1\tPhase 1\n\tPhase 3\n587\tPhase 3\n\tPhase 3\n32\tPhase 2\n77\tPhase 2\n200\tPhase 2\n83\tPhase 3\n1076\tPhase 3\n838\tPhase 3\n219\tPhase 3\n\tPhase 2\n64\tPhase 1\n393\tPhase 3\n31\tPhase 1\n174\tPhase 3\n27\tPhase 2\n53\tPhase 2\n243\tPhase 3\n95\tPhase 2\n50\tPhase 2\n949\tPhase 3\n13\tPhase 3\n2108\tPhase 3\n313\tPhase 3\n333\tPhase 3\n156\tPhase 2\n1084\tPhase 1 / Phase 2\n2028\tPhase 3\n31\tPhase 2\n36\tPhase 1 / Phase 2\n200\tPhase 3\n147\tPhase 2\n111\tPhase 2\n290\tPhase 2\n1500\tPhase 3\n2420\tPhase 3\n450\tPhase 3\n400\tPhase 3\n150\tPhase 2\n250\tPhase 3\n138\tPhase 3\n400\tPhase 3\n1400\tPhase 3\n425\tPhase 2 / Phase 3\n563\tPhase 2 / Phase 3\n55\tPhase 1\n1860\tPhase 3\n1953\tPhase 1 / Phase 2\n1500\tPhase 3\n552\tPhase 2\n56\tPhase 2\n4600\tPhase 3\n1900\tPhase 2\n432\tPhase 3\n187\tPhase 2\n900\tPhase 3\n250\tPhase 3\n296\tPhase 3\n1858\tPhase 3\n600\tPhase 3\n240\tPhase 3\n356\tPhase 4\n641\tPhase 3\n632\tPhase 3\n877\tPhase 3\n714\tPhase 3\n140\tPhase 2\n66\tPhase 4\n600\tPhase 3\n377\tPhase 3\n764\tPhase 3\n730\tPhase 3\n660\tPhase 3\n2091\tPhase 3\n1375\tPhase 3\n366\tPhase 3\n800\tPhase 4\n90\tPhase 2\n2026\tPhase 3\n328\tPhase 3\n432\tPhase 3\n34\tPhase 2\n882\tPhase 4\n500\tPhase 3\n372\tPhase 3\n315\tPhase 4\n800\tPhase 3\n800\tPhase 3\n624\tPhase 3\n319\tPhase 2\n360\tPhase 3\n13307\tPhase 3\n8000\tPhase 3\n10\tPhase 2\n416\tPhase 3\n140\tPhase 2\n158\tPhase 3\n255\tPhase 2\n11\tPhase 3\n499\tPhase 3\n2100\tPhase 3\n287\tPhase 3\n1618\tPhase 3\n314\tPhase 3\n90\tPhase 3\n1443\tPhase 3\n872\tPhase 3\n304\tPhase 2\n350\tPhase 2\n1999\tPhase 3\n1001\tPhase 3\n226\tPhase 2\n909\tPhase 3\n290\tPhase 2\n239\tPhase 2\n534\tPhase 3\n1941\tPhase 3\n909\tPhase 3\n961\tPhase 3\n442\tPhase 3\n916\tPhase 3\n51\tPhase 2\n330\tPhase 3\n811\tPhase 3\n839\tPhase 3\n6250\tPhase 4\n421\tPhase 3\n2651\tPhase 3\n1692\tPhase 3\n450\tPhase 3\n183\tPhase 2\n722\tPhase 3\n302\tPhase 3\n14\tPhase 3\n376\tPhase 2\n160\tPhase 3\n430\tPhase 3\n1298\tPhase 3\n400\tPhase 3\n229\tPhase 3\n652\tPhase 3\n706\tPhase 3\n268\tPhase 2\n265\tPhase 2\n279\tPhase 2\n880\tPhase 3\n1917\tPhase 3\n724\tPhase 3\n2334\tPhase 3\n441\tPhase 3\n297\tPhase 3\n2858\tPhase 3\n1000\tPhase 3\n165\tPhase 2\n196\tPhase 3\n149\tPhase 2\n36\tPhase 2\n417\tPhase 2\n698\tPhase 3\n708\tPhase 3\n332\tPhase 3\n618\tPhase 3\n1635\tPhase 3\n340\tPhase 4\n106\tPhase 3\n190\tPhase 2\n"
      },
      "dateCreated": "Dec 4, 2016 6:29:55 PM",
      "dateStarted": "Dec 4, 2016 6:44:00 PM",
      "dateFinished": "Dec 4, 2016 6:44:00 PM",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%sql\n\nselect start_date, rank from table_df where length(start_date) \u003e 4",
      "dateUpdated": "Dec 4, 2016 6:50:59 PM",
      "config": {
        "colWidth": 12.0,
        "graph": {
          "mode": "lineWithFocusChart",
          "height": 300.0,
          "optionOpen": false,
          "keys": [
            {
              "name": "start_date",
              "index": 0.0,
              "aggr": "sum"
            }
          ],
          "values": [
            {
              "name": "rank",
              "index": 1.0,
              "aggr": "count"
            }
          ],
          "groups": [],
          "scatter": {
            "xAxis": {
              "name": "start_date",
              "index": 0.0,
              "aggr": "sum"
            },
            "yAxis": {
              "name": "rank",
              "index": 1.0,
              "aggr": "sum"
            }
          },
          "lineWithFocus": true
        },
        "enabled": true,
        "editorMode": "ace/mode/sql",
        "editorHide": true
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "jobName": "paragraph_1480877146371_-1920079317",
      "id": "20161204-184546_464683047",
      "result": {
        "code": "SUCCESS",
        "type": "TABLE",
        "msg": "start_date\trank\nNovember 2015\t1\nNovember 2016\t2\nNovember 2016\t3\nNovember 2016\t4\nNovember 2016\t5\nNovember 2016\t6\nJanuary 2017\t7\nMay 2017\t8\nMay 2016\t9\nNovember 2016\t10\nFebruary 2017\t11\nSeptember 2016\t12\nNovember 2016\t13\nNovember 2016\t14\nNovember 2016\t15\nNovember 2016\t16\nSeptember 2016\t17\nOctober 2016\t18\nDecember 2015\t19\nDecember 2016\t20\nNovember 2016\t21\nOctober 2016\t22\nNovember 2016\t23\nJanuary 2017\t24\nAugust 2016\t25\nNovember 2016\t26\nOctober 2016\t27\nOctober 2016\t28\nSeptember 2016\t29\nNovember 2016\t30\nOctober 2016\t31\nNovember 2016\t32\nMarch 2016\t33\nNovember 2016\t34\nAugust 2016\t35\nSeptember 2016\t36\nDecember 2016\t37\nOctober 2016\t38\nNovember 2016\t39\nSeptember 2016\t40\nNovember 2016\t41\nMay 2016\t42\nSeptember 2016\t43\nOctober 2016\t44\nFebruary 2015\t45\nSeptember 2016\t46\nNovember 2016\t47\nAugust 2016\t48\nJuly 2016\t49\nAugust 2016\t50\nOctober 2016\t51\nAugust 2016\t52\nOctober 2016\t53\nSeptember 2016\t54\nMay 2014\t55\nAugust 2016\t56\nOctober 2016\t57\nAugust 2016\t58\nDecember 2014\t59\nDecember 2016\t60\nMarch 2017\t61\nAugust 2016\t62\nDecember 2016\t63\nAugust 2016\t64\nMay 2016\t65\nOctober 2016\t66\nAugust 2016\t67\nAugust 2016\t68\nJuly 2015\t69\nDecember 2016\t70\nSeptember 2014\t71\nJuly 2015\t72\nNovember 2016\t73\nJuly 2016\t74\nAugust 2016\t75\nJuly 2016\t76\nJuly 2016\t77\nApril 2016\t78\nApril 2016\t79\nFebruary 2016\t80\nAugust 2016\t81\nAugust 2016\t82\nAugust 2016\t83\nOctober 2016\t84\nAugust 2016\t85\nJuly 2016\t86\nJuly 2016\t87\nSeptember 2016\t88\nSeptember 2016\t89\nJune 2012\t90\nAugust 2016\t91\nAugust 2016\t92\nSeptember 2016\t93\nAugust 2016\t94\nJuly 2016\t95\nJanuary 2016\t96\nJuly 2016\t97\nJune 2016\t98\nAugust 2016\t99\nJune 2016\t100\nJune 2016\t101\nJune 2016\t102\nJuly 2016\t103\nJuly 2016\t104\nSeptember 2016\t105\nMay 2016\t106\nJune 2016\t107\nApril 2016\t108\nApril 2016\t109\nSeptember 2016\t110\nJune 2016\t111\nJune 2016\t112\nSeptember 2016\t113\nAugust 2016\t114\nNovember 2016\t116\nApril 2017\t117\nAugust 2016\t118\nNovember 2016\t119\nFebruary 2016\t120\nMay 2016\t121\nMay 2016\t122\nJune 2016\t123\nApril 2016\t124\nMay 2016\t125\nNovember 2016\t126\nApril 2016\t127\nApril 2016\t128\nOctober 2016\t129\nNovember 2015\t130\nJanuary 2016\t131\nJanuary 2016\t132\nMay 2016\t133\nFebruary 2016\t134\nJune 2016\t135\nSeptember 2016\t136\nJanuary 2016\t137\nMay 2016\t138\nMay 2016\t139\nApril 2016\t140\nOctober 2016\t141\nApril 2016\t142\nMarch 2016\t143\nApril 2016\t144\nMarch 2016\t145\nMay 2016\t146\nSeptember 2014\t147\nMarch 2016\t148\nMarch 2016\t149\nApril 2016\t150\nMay 2016\t151\nJuly 2015\t152\nFebruary 2016\t153\nJune 2016\t154\nMay 2016\t155\nAugust 2016\t156\nAugust 2016\t157\nMarch 2016\t158\nMarch 2016\t159\nOctober 2016\t160\nSeptember 2014\t161\nMarch 2016\t162\nMay 2016\t163\nMay 2016\t164\nAugust 2011\t165\nApril 2016\t166\nApril 2016\t167\nMarch 2016\t168\nJune 2017\t169\nMarch 2016\t170\nMarch 2016\t171\nOctober 2016\t172\nMarch 2016\t173\nSeptember 2007\t174\nMay 2016\t175\nMay 2016\t176\nMarch 2016\t177\nFebruary 2016\t178\nApril 2016\t179\nMay 2016\t180\nApril 2016\t181\nMarch 2016\t182\nFebruary 2016\t183\nOctober 2012\t184\nAugust 2016\t185\nFebruary 2016\t186\nDecember 2015\t187\nSeptember 2016\t188\nOctober 2015\t189\nOctober 2015\t190\nMarch 2016\t191\nMay 2014\t192\nDecember 2015\t193\nJanuary 2016\t194\nFebruary 2016\t195\nMarch 2016\t196\nJanuary 2016\t197\nJanuary 2016\t198\nMay 2016\t199\nJuly 2016\t200\nOctober 2015\t201\nApril 2016\t202\nJanuary 2016\t203\nJanuary 2016\t204\nJune 2015\t205\nDecember 2015\t206\nDecember 2015\t207\nApril 2016\t208\nJanuary 2016\t209\nNovember 2015\t210\nMay 2015\t211\nAugust 2015\t212\nApril 2016\t213\nOctober 2015\t214\nMarch 2016\t215\nFebruary 2016\t216\nJuly 2015\t217\nFebruary 2016\t218\nOctober 2015\t219\nDecember 2015\t220\nOctober 2015\t221\nMay 2016\t222\nFebruary 2016\t223\nFebruary 2016\t224\nJanuary 2016\t225\nJanuary 2016\t226\nNovember 2015\t227\nFebruary 2016\t228\nAugust 2015\t229\nJuly 2014\t230\nNovember 2015\t231\nNovember 2015\t232\nOctober 2015\t233\nNovember 2015\t234\nJanuary 2002\t235\nNovember 2015\t236\nFebruary 2016\t237\nMay 2016\t238\nMarch 2017\t239\nFebruary 2016\t240\nFebruary 2014\t241\nFebruary 2016\t242\nOctober 2015\t243\nMarch 2016\t244\nJune 2015\t245\nMarch 2016\t246\nMay 2016\t247\nJuly 2016\t248\nOctober 2015\t249\nApril 2016\t250\nOctober 2015\t251\nSeptember 2015\t252\nMarch 2016\t253\nJune 2013\t254\nSeptember 2015\t255\nJuly 2014\t256\nOctober 2015\t257\nJune 2016\t258\nOctober 2015\t259\nDecember 2015\t260\nMay 2015\t261\nNovember 2013\t262\nOctober 2015\t263\nJuly 2015\t264\nOctober 2015\t265\nOctober 2015\t266\nMarch 2016\t267\nSeptember 2015\t268\nJanuary 2011\t269\nApril 2016\t270\nJuly 2015\t271\nSeptember 2015\t272\nJanuary 2016\t273\nApril 2016\t274\nFebruary 2016\t275\nSeptember 2015\t276\nOctober 2015\t277\nJune 2015\t278\nSeptember 2015\t279\nJuly 2015\t280\nMay 2015\t281\nApril 2016\t282\nSeptember 2015\t283\nMay 2015\t284\nJanuary 2016\t285\nSeptember 2015\t286\nMarch 2016\t287\nJuly 2015\t288\nMay 2016\t289\nJuly 2015\t290\nJanuary 2017\t291\nDecember 2015\t292\nOctober 2015\t293\nDecember 2015\t294\nNovember 2015\t295\nJanuary 2016\t296\nJuly 2015\t297\nDecember 2015\t298\nJuly 2015\t299\nOctober 2015\t300\nApril 2015\t301\nAugust 2015\t302\nJuly 2015\t303\nJuly 2016\t304\nMay 2016\t305\nJuly 2015\t306\nSeptember 2015\t307\nJuly 2015\t308\nJuly 2015\t309\nJanuary 2016\t310\nJune 2015\t311\nSeptember 2015\t312\nOctober 2015\t313\nFebruary 2015\t314\nJune 2015\t315\nMay 2015\t316\nJune 2015\t317\nOctober 2015\t318\nOctober 2015\t319\nJuly 2016\t320\nFebruary 2016\t321\nSeptember 2015\t322\nJuly 2015\t323\nJuly 2015\t324\nJuly 2015\t325\nMay 2015\t326\nJanuary 2016\t327\nApril 2015\t328\nDecember 2015\t329\nJuly 2015\t330\nDecember 2015\t331\nMay 2015\t332\nDecember 2013\t333\nJune 2015\t334\nOctober 2015\t335\nMay 2015\t336\nJanuary 2004\t337\nJune 2015\t338\nMarch 2013\t339\nMay 2015\t340\nJuly 2015\t341\nFebruary 2016\t342\nJuly 2015\t343\nJanuary 2016\t344\nJanuary 2016\t345\nOctober 2014\t346\nJune 2016\t347\nMay 2014\t348\nMay 2015\t349\nJanuary 2016\t350\nMay 2015\t351\nApril 2015\t352\nSeptember 2015\t353\nMay 2015\t354\nSeptember 2015\t355\nOctober 2015\t356\nJanuary 2016\t357\nMay 2015\t358\nAugust 2015\t359\nJune 2015\t360\nMay 2015\t361\nJuly 2015\t362\nApril 2015\t363\nMay 2015\t364\nMay 2015\t365\nOctober 2015\t366\nJune 2015\t367\nSeptember 2015\t368\nJune 2012\t369\nMarch 2015\t370\nSeptember 2014\t371\nMarch 2015\t372\nOctober 2014\t373\nAugust 2015\t374\nMarch 2015\t375\nDecember 2015\t376\nMarch 2015\t377\nMay 2015\t378\nDecember 2014\t379\nAugust 2015\t380\nMarch 2015\t381\nJune 2016\t382\nMay 2013\t383\nApril 2015\t384\nJanuary 2015\t385\nFebruary 2015\t386\nJanuary 2015\t387\nMarch 2015\t388\nMarch 2015\t389\nFebruary 2015\t390\nJanuary 2015\t391\nFebruary 2015\t392\nFebruary 2015\t393\nMarch 2015\t394\nFebruary 2015\t395\nNovember 2014\t396\nSeptember 2015\t397\nFebruary 2015\t398\nDecember 2014\t399\nJanuary 2015\t400\nJune 2015\t401\nSeptember 2015\t402\nJuly 2014\t403\nSeptember 2014\t404\nFebruary 2015\t405\nFebruary 2015\t406\nJanuary 2015\t407\nMay 2015\t408\nApril 2014\t409\nMarch 2015\t410\nFebruary 2015\t411\nMarch 2015\t412\nMay 2015\t413\nMay 2015\t414\nFebruary 2015\t415\nJanuary 2015\t416\nJune 2015\t417\nMay 2015\t418\nJanuary 2015\t419\nJune 2015\t420\nMay 2016\t421\nApril 2015\t422\nMarch 2015\t423\nMay 2015\t424\nJune 2014\t425\nJuly 2008\t426\nMarch 2015\t427\nMarch 2015\t428\nAugust 2013\t429\nOctober 2014\t430\nJune 2014\t431\nDecember 2014\t432\nDecember 2014\t433\nMay 2015\t434\nFebruary 2015\t435\nJanuary 2015\t436\nJanuary 2011\t437\nSeptember 2015\t438\nJune 2016\t439\nJanuary 2015\t440\nNovember 2014\t441\nDecember 2014\t442\nAugust 2015\t443\nMarch 2013\t444\nNovember 2014\t445\nNovember 2014\t446\nMarch 2015\t447\nNovember 2014\t448\nDecember 2014\t449\nJune 2014\t450\nDecember 2014\t451\nDecember 2014\t452\nFebruary 2015\t453\nMay 2015\t454\nDecember 2014\t455\nAugust 2012\t456\nDecember 2014\t457\nDecember 2015\t458\nJune 2015\t459\nJanuary 2014\t460\nDecember 2014\t461\nMay 2013\t462\nAugust 2014\t463\nOctober 2014\t464\nMarch 2014\t465\nOctober 2014\t466\nDecember 2013\t467\nNovember 2014\t468\nDecember 2014\t469\nOctober 2014\t470\nOctober 2014\t471\nOctober 2014\t472\nOctober 2014\t473\nMay 2014\t474\nOctober 2014\t475\nOctober 2014\t476\nSeptember 2014\t477\nJanuary 2015\t478\nSeptember 2014\t479\nOctober 2014\t480\nJune 2008\t481\nSeptember 2014\t482\nSeptember 2014\t483\nOctober 2015\t484\nSeptember 2014\t485\nApril 2015\t486\nJuly 2015\t487\nSeptember 2014\t488\nJanuary 2015\t489\nJanuary 2017\t490\nJanuary 2014\t491\nOctober 2014\t492\nOctober 2014\t493\nNovember 2014\t494\nSeptember 2014\t495\nAugust 2015\t496\nSeptember 2014\t497\nNovember 2014\t498\nJanuary 2015\t499\nOctober 2014\t500\nNovember 2014\t501\nNovember 2014\t502\nNovember 2014\t503\nApril 2015\t504\nFebruary 2015\t505\nDecember 2014\t506\nNovember 2014\t507\nAugust 2014\t508\nAugust 2014\t509\nAugust 2014\t510\nSeptember 2014\t511\nSeptember 2014\t512\nNovember 2014\t513\nOctober 2014\t514\nOctober 2014\t515\nOctober 2014\t516\nAugust 2014\t517\nJuly 2014\t518\nFebruary 2015\t519\nFebruary 2015\t520\nSeptember 2014\t521\nSeptember 2014\t522\nFebruary 2013\t523\nOctober 2010\t524\nAugust 2014\t525\nSeptember 2014\t526\nJanuary 2015\t527\nApril 2014\t528\nJuly 2014\t529\nNovember 2014\t530\nOctober 2014\t531\nJanuary 2012\t532\nJuly 2014\t533\nOctober 2014\t534\nOctober 2014\t535\nFebruary 2015\t536\nApril 2014\t537\nSeptember 2012\t538\nOctober 2009\t539\nAugust 2014\t540\nJuly 2014\t541\nDecember 2015\t542\nAugust 2014\t543\nJune 2014\t544\nJune 2014\t545\nApril 2013\t546\nJune 2014\t547\nOctober 2013\t548\nApril 2009\t549\nJuly 2014\t550\nSeptember 2013\t551\nNovember 2014\t552\nJanuary 2015\t553\nJuly 2009\t554\nOctober 2014\t555\nJune 2014\t556\nDecember 2014\t557\nJune 2014\t558\nDecember 2014\t559\nDecember 2014\t560\nSeptember 2014\t561\nMarch 2014\t562\nJuly 2014\t563\nAugust 2014\t564\nDecember 2014\t565\nJune 2014\t566\nJune 2014\t567\nDecember 2013\t568\nSeptember 2014\t569\nSeptember 2014\t570\nApril 2013\t571\nMay 2010\t572\nNovember 2017\t573\nMay 2006\t574\nMay 2014\t575\nJuly 2014\t576\nMay 2011\t577\nFebruary 2015\t578\nNovember 2011\t579\nMay 2016\t580\nNovember 2013\t581\nNovember 2011\t582\nOctober 2013\t583\nJune 2017\t584\nDecember 2014\t585\nJanuary 2016\t586\nMay 2014\t587\nMay 2011\t588\nMay 2014\t589\nJanuary 2014\t590\nMay 2014\t591\nOctober 2014\t592\nNovember 2014\t593\nJune 2014\t594\nApril 2014\t595\nJune 2014\t596\nApril 2016\t597\nApril 2014\t598\nJune 2014\t599\nNovember 2015\t600\nFebruary 2012\t601\nApril 2014\t602\nApril 2014\t603\nSeptember 2014\t604\nMay 2014\t605\nMay 2014\t607\nApril 2014\t608\nMarch 2014\t609\nAugust 2014\t610\nMarch 2014\t611\nMay 2014\t612\nDecember 2016\t613\nNovember 2011\t614\nDecember 2013\t615\nMarch 2014\t616\nJuly 2014\t617\nApril 2014\t618\nApril 2014\t619\nOctober 2014\t620\nNovember 2013\t621\nJuly 2014\t622\nNovember 2012\t623\nJune 2014\t624\nAugust 2015\t625\nApril 2014\t626\nMarch 2014\t627\nSeptember 2014\t628\nJune 2014\t629\nMarch 2014\t630\nMay 2014\t631\nMarch 2014\t632\nMay 2014\t633\nApril 2014\t634\nJune 2013\t635\nJanuary 2015\t637\nMarch 2014\t638\nMarch 2014\t639\nMarch 2014\t640\nJuly 2015\t641\nFebruary 2014\t642\nNovember 2013\t643\nJune 2014\t644\nFebruary 2014\t645\nMay 2014\t646\nAugust 2014\t647\nFebruary 2014\t648\nFebruary 2014\t649\nFebruary 2014\t650\nFebruary 2014\t651\nApril 2014\t652\nFebruary 2014\t653\nApril 2014\t654\nJanuary 2015\t655\nJanuary 2015\t656\nJanuary 2006\t657\nMarch 2014\t658\nFebruary 2014\t659\nJanuary 2014\t661\nMarch 2014\t662\nAugust 2015\t663\nNovember 2014\t664\nFebruary 2014\t665\nJanuary 2014\t666\nNovember 2013\t667\nJune 2013\t668\nDecember 2013\t669\nFebruary 2014\t670\nJanuary 2014\t671\nJuly 2012\t672\nMay 2014\t673\nJanuary 2013\t674\nJanuary 2014\t675\nJanuary 2014\t676\nAugust 2013\t677\nApril 2015\t678\nJuly 2014\t679\nDecember 2013\t680\nMarch 2011\t681\nFebruary 2014\t682\nMarch 2014\t683\nJanuary 2014\t684\nFebruary 2014\t685\nFebruary 2013\t686\nMarch 2014\t687\nFebruary 2014\t688\nMarch 2014\t689\nDecember 2013\t690\nMarch 2014\t691\nJanuary 2014\t692\nJanuary 2015\t693\nJanuary 2014\t694\nApril 2012\t695\nJanuary 2012\t696\nDecember 2013\t697\nMarch 2014\t698\nDecember 2013\t699\nSeptember 2012\t700\nNovember 2011\t701\nJanuary 2014\t702\nDecember 2013\t703\nMay 2014\t704\nJune 2012\t706\nSeptember 2013\t707\nOctober 2014\t708\nJune 2014\t709\nDecember 2013\t710\nNovember 2011\t711\nAugust 2006\t712\nMarch 2014\t713\nDecember 2013\t714\nDecember 2012\t715\nNovember 2013\t716\nJanuary 2016\t717\nNovember 2012\t718\nJuly 2014\t719\nDecember 2013\t720\nFebruary 2014\t721\nFebruary 2014\t722\nNovember 2011\t723\nJanuary 2014\t724\nDecember 2013\t725\nJanuary 2014\t726\nDecember 2013\t727\nNovember 2013\t728\nSeptember 2013\t729\nApril 2013\t730\nApril 2007\t731\nNovember 2013\t732\nNovember 2013\t733\nJune 2014\t734\nMay 2013\t735\nApril 2014\t736\nNovember 2013\t737\nAugust 2013\t738\nMarch 2014\t739\nNovember 2013\t740\nSeptember 2013\t741\nAugust 2013\t742\nDecember 2013\t743\nMarch 2014\t744\nSeptember 2014\t745\nMay 2014\t746\nFebruary 2014\t747\nSeptember 2011\t748\nJuly 2011\t749\nOctober 2013\t750\nJune 2007\t751\nDecember 2015\t752\nOctober 2013\t753\nSeptember 2011\t754\nNovember 2013\t755\nNovember 2013\t756\nDecember 2014\t757\nNovember 2013\t758\nJune 2013\t759\nOctober 2013\t760\nDecember 2010\t761\nOctober 2013\t762\nNovember 2014\t763\nNovember 2013\t764\nOctober 2013\t765\nDecember 2005\t766\nJanuary 2014\t767\nAugust 2012\t768\nOctober 2013\t769\nAugust 2013\t770\nOctober 2013\t771\nMay 2014\t772\nFebruary 2014\t773\nOctober 2013\t774\nNovember 2008\t775\nSeptember 2013\t776\nFebruary 2014\t777\nApril 2013\t778\nOctober 2013\t779\nJuly 2013\t780\nDecember 2009\t781\nOctober 2013\t782\nJanuary 2013\t783\nNovember 2013\t784\nSeptember 2013\t786\nJune 2007\t787\nSeptember 2005\t788\nDecember 2011\t789\nDecember 2013\t790\nJuly 2008\t791\nDecember 2013\t792\nOctober 2013\t793\nFebruary 2014\t794\nMarch 2014\t795\nSeptember 2014\t796\nSeptember 2013\t797\nSeptember 2013\t798\nJanuary 2010\t799\nNovember 2013\t800\nSeptember 2013\t801\nSeptember 2014\t802\nAugust 2013\t803\nOctober 2013\t804\nSeptember 2013\t805\nAugust 2013\t806\nOctober 2013\t807\nSeptember 2013\t808\nOctober 2013\t809\nJanuary 2013\t810\nJuly 2013\t811\nSeptember 2013\t812\nJuly 2013\t813\nSeptember 2014\t814\nApril 2011\t815\nSeptember 2013\t816\nJune 2010\t817\nJune 2013\t818\nJanuary 2008\t819\nAugust 2013\t820\nJune 2013\t821\nSeptember 2013\t822\nOctober 2013\t823\nAugust 2013\t824\nJuly 2013\t825\nMay 2011\t826\nJanuary 2012\t827\nOctober 2012\t828\nMarch 2013\t829\nOctober 2013\t830\nApril 2001\t831\nSeptember 2012\t832\nAugust 2013\t833\nJuly 2013\t834\nAugust 2013\t835\nDecember 2013\t836\nAugust 2013\t837\nJune 2015\t838\nSeptember 2013\t839\nAugust 2013\t840\nSeptember 2013\t841\nAugust 2013\t842\nAugust 2013\t843\nJuly 2013\t844\nAugust 2013\t845\nJuly 2013\t846\nApril 2004\t847\nApril 2003\t848\nMay 2001\t849\nNovember 2013\t850\nAugust 2002\t851\nMay 2001\t852\nJuly 2001\t853\nJune 2013\t854\nNovember 2011\t855\nJune 2013\t856\nJanuary 2015\t857\nNovember 2012\t858\nJanuary 2008\t859\nAugust 2010\t861\nMay 2014\t862\nAugust 2013\t863\nJuly 2013\t864\nNovember 2013\t865\nJune 2013\t866\nJune 2013\t867\nJanuary 2013\t868\nJuly 2013\t869\nMay 2012\t870\nJune 2012\t871\nNovember 2009\t873\nApril 2013\t874\nMay 2014\t875\nMarch 2013\t876\nApril 2013\t877\nJuly 2013\t878\nApril 2013\t879\nMay 2012\t880\nJuly 2010\t881\nJuly 2013\t882\nApril 2013\t883\nJanuary 2014\t884\nMay 2013\t885\nDecember 2012\t886\nJuly 2013\t887\nMay 2013\t888\nApril 2013\t889\nApril 2013\t890\nAugust 2012\t891\nJanuary 2015\t892\nApril 2013\t893\nSeptember 2013\t894\nFebruary 2014\t895\nMarch 2013\t896\nApril 2013\t897\nApril 2013\t898\nMay 2014\t899\nJuly 2011\t900\nFebruary 2013\t901\nJune 2013\t902\nJanuary 2014\t903\nJuly 2013\t904\nFebruary 2013\t905\nApril 2013\t906\nJune 2014\t907\nMay 2013\t908\nOctober 2010\t909\nMay 2013\t910\nFebruary 2013\t911\nMarch 2013\t912\nMarch 2013\t913\nMarch 2013\t914\nMarch 2013\t915\nMarch 2013\t916\nJune 2014\t917\nJanuary 2013\t918\nJanuary 2013\t919\nApril 2013\t920\nDecember 2012\t921\nJune 2013\t922\nFebruary 2013\t923\nJuly 2011\t924\nMarch 2013\t925\nJuly 2013\t926\nApril 2013\t927\nMarch 2013\t928\nOctober 2012\t929\nDecember 2012\t930\nMarch 2013\t931\nFebruary 2013\t932\nAugust 2012\t933\nSeptember 2012\t934\nJune 2013\t935\nMarch 2013\t936\nJuly 2012\t937\nFebruary 2012\t938\nMarch 2013\t939\nSeptember 2013\t940\nApril 2013\t941\nJanuary 2012\t942\nMarch 2013\t943\nSeptember 2012\t944\nJanuary 2012\t945\nMarch 2012\t946\nMarch 2013\t947\nSeptember 2014\t948\nOctober 2012\t949\nAugust 2013\t950\nJanuary 2013\t951\nSeptember 2012\t952\nAugust 2013\t953\nJanuary 2008\t954\nNovember 2012\t955\nOctober 2012\t956\nOctober 2012\t957\nOctober 2012\t958\nOctober 2012\t959\nFebruary 2013\t960\nAugust 2012\t961\nMarch 2013\t962\nFebruary 2013\t963\nJanuary 2013\t964\nFebruary 2013\t965\nOctober 2012\t966\nJanuary 2013\t967\nSeptember 2012\t968\nJune 2012\t969\nFebruary 2013\t970\nFebruary 2013\t971\nSeptember 2012\t972\nOctober 2012\t973\nJune 2012\t974\nFebruary 2013\t975\nFebruary 2013\t976\nOctober 2013\t977\nNovember 2011\t978\nJanuary 2013\t979\nFebruary 2013\t980\nJune 2012\t981\nOctober 2010\t982\nOctober 2010\t983\nMarch 2012\t984\nDecember 2013\t985\nOctober 2012\t986\nFebruary 2014\t987\nApril 2012\t988\nApril 2012\t989\nJanuary 2013\t990\nAugust 2013\t991\nJanuary 2013\t992\nJanuary 2013\t993\nJuly 2014\t994\nJanuary 2013\t995\nNovember 2012\t996\nMay 2013\t997\nJanuary 2013\t999\nDecember 2012\t1000\nAugust 2013\t1001\nSeptember 2009\t1002\nMarch 2013\t1003\nSeptember 2011\t1004\nDecember 2012\t1005\nOctober 2012\t1006\nFebruary 2013\t1007\nJanuary 2013\t1008\nNovember 2012\t1009\nJuly 2012\t1010\nMay 2013\t1011\nOctober 2012\t1012\nJanuary 2013\t1013\nSeptember 2002\t1014\nJanuary 2013\t1015\nFebruary 2013\t1016\nOctober 2012\t1017\nMay 2012\t1018\nJuly 2012\t1019\nJanuary 2013\t1020\nJanuary 2013\t1021\nSeptember 2013\t1022\nNovember 2012\t1023\nJanuary 2012\t1024\nJuly 2012\t1025\nNovember 2009\t1026\nDecember 2012\t1027\nDecember 2012\t1028\nOctober 2012\t1029\nApril 2011\t1030\nFebruary 2014\t1031\nDecember 2011\t1032\nOctober 2012\t1033\nOctober 2012\t1034\nJanuary 2011\t1035\nFebruary 2012\t1036\nNovember 2012\t1037\nNovember 2013\t1038\nNovember 2012\t1039\nNovember 2012\t1040\nJanuary 2013\t1041\nSeptember 2012\t1042\nDecember 2013\t1043\nJanuary 2013\t1044\nJanuary 2013\t1045\nSeptember 2012\t1046\nMarch 2012\t1047\nNovember 2012\t1048\nOctober 2012\t1049\nOctober 2012\t1050\nSeptember 2009\t1051\nJune 2013\t1052\nFebruary 2013\t1053\nFebruary 2009\t1054\nJuly 2007\t1055\nOctober 2012\t1056\nOctober 2012\t1057\nJanuary 2013\t1058\nOctober 2012\t1059\nDecember 2010\t1060\nOctober 2012\t1061\nOctober 2012\t1062\nAugust 2009\t1063\nSeptember 2012\t1064\nAugust 2012\t1065\nFebruary 2011\t1066\nSeptember 2012\t1067\nMay 2012\t1068\nSeptember 2012\t1069\nApril 2011\t1070\nAugust 2012\t1071\nApril 2012\t1072\nNovember 2012\t1073\nJanuary 2012\t1074\nJuly 2012\t1075\nAugust 2012\t1076\nApril 2009\t1077\nDecember 2007\t1078\nJune 2012\t1079\nFebruary 2014\t1080\nSeptember 2012\t1081\nAugust 2012\t1082\nOctober 2012\t1083\nJune 2013\t1084\nJuly 2012\t1085\nAugust 2012\t1086\nJanuary 2013\t1087\nFebruary 2012\t1088\nAugust 2012\t1089\nSeptember 2012\t1090\nSeptember 2009\t1091\nAugust 2010\t1092\nOctober 2012\t1093\nApril 2012\t1094\nJuly 2012\t1095\nJune 2012\t1096\nFebruary 2005\t1097\nAugust 2012\t1098\nJuly 2012\t1099\nDecember 2011\t1100\nAugust 2012\t1101\nMarch 1991\t1102\nJuly 2012\t1103\nJanuary 2013\t1104\nMarch 2012\t1105\nJune 2012\t1106\nMay 2012\t1107\nFebruary 2009\t1108\nFebruary 2012\t1109\nJuly 2010\t1110\nJune 2012\t1111\nMay 2012\t1112\nJune 2012\t1113\nJune 2012\t1114\nJune 2012\t1115\nAugust 2012\t1116\nJune 2012\t1117\nOctober 2013\t1118\nJanuary 2013\t1119\nJuly 2012\t1120\nMarch 2012\t1121\nJanuary 2013\t1122\nJanuary 2012\t1123\nMarch 2012\t1124\nJune 2012\t1125\nJune 2012\t1126\nDecember 2011\t1127\nJune 2012\t1128\nJune 2012\t1129\nApril 2012\t1130\nSeptember 2011\t1131\nDecember 2012\t1132\nMay 2012\t1133\nMay 2012\t1134\nJanuary 2012\t1135\nMay 2012\t1136\nJune 2012\t1137\nJuly 2012\t1138\nJanuary 2013\t1139\nSeptember 2011\t1140\nMay 2012\t1141\nJune 2012\t1142\nApril 2012\t1143\nJune 2011\t1144\nAugust 2012\t1145\nMarch 2012\t1146\nDecember 2011\t1147\nApril 2012\t1148\nSeptember 2011\t1149\nJune 2012\t1150\nApril 2012\t1151\nApril 2012\t1152\nMarch 2012\t1153\nDecember 2011\t1154\nMarch 2012\t1155\nMay 2012\t1156\nSeptember 2011\t1157\nOctober 2010\t1158\nMay 2012\t1159\nOctober 2010\t1160\nJanuary 2003\t1161\nNovember 2011\t1162\nApril 2007\t1163\nFebruary 2012\t1164\nJuly 2011\t1165\nJuly 2007\t1166\nMarch 2012\t1167\nMarch 2012\t1168\nFebruary 2012\t1169\nOctober 2009\t1170\nFebruary 2012\t1171\nApril 2012\t1172\nJuly 2007\t1173\nFebruary 2008\t1174\nMarch 2012\t1175\nSeptember 2012\t1176\nMarch 2012\t1177\nJanuary 2012\t1178\nAugust 2012\t1179\nAugust 2006\t1180\nJuly 2012\t1181\nMarch 2012\t1182\nFebruary 2012\t1183\nFebruary 2012\t1184\nSeptember 2011\t1185\nFebruary 2012\t1186\nSeptember 2009\t1187\nOctober 2010\t1188\nJanuary 2012\t1189\nOctober 2010\t1190\nJanuary 2012\t1191\nOctober 2012\t1192\nJanuary 2012\t1193\nSeptember 2011\t1194\nJanuary 2012\t1195\nNovember 2011\t1196\nDecember 2011\t1197\nDecember 2002\t1198\nNovember 2002\t1199\nJanuary 2012\t1200\nJanuary 2012\t1201\nOctober 2011\t1202\nOctober 2011\t1203\nDecember 2011\t1204\nJanuary 2012\t1205\nDecember 2011\t1206\nFebruary 2012\t1207\nDecember 2011\t1208\nDecember 2011\t1209\nApril 2012\t1210\nMay 2010\t1211\nJanuary 2012\t1212\nNovember 2011\t1213\nApril 2012\t1214\nDecember 2011\t1215\nMarch 2012\t1216\nJune 2012\t1217\nAugust 2011\t1218\nDecember 2011\t1219\nFebruary 2011\t1220\nMarch 2012\t1221\nJanuary 2012\t1222\nDecember 2011\t1223\nSeptember 2011\t1224\nDecember 2004\t1225\nSeptember 2011\t1226\nApril 2011\t1227\nApril 2012\t1228\nNovember 2011\t1229\nJanuary 2012\t1230\nApril 2012\t1231\nDecember 2011\t1232\nSeptember 2011\t1233\nNovember 2009\t1234\nOctober 2011\t1235\nOctober 2011\t1236\nSeptember 2011\t1237\nNovember 2011\t1238\nJuly 2009\t1239\nJanuary 2011\t1240\nSeptember 2011\t1241\nNovember 2011\t1242\nOctober 2010\t1243\nDecember 2012\t1244\nAugust 2011\t1245\nFebruary 2012\t1246\nSeptember 2011\t1247\nSeptember 2011\t1248\nSeptember 2011\t1249\nMay 2011\t1250\nJune 2009\t1251\nJune 2011\t1252\nSeptember 2011\t1253\nJanuary 2010\t1254\nJuly 2011\t1255\nOctober 2011\t1256\nSeptember 2011\t1257\nAugust 2011\t1258\nAugust 2011\t1259\nSeptember 2011\t1260\nMay 2011\t1261\nSeptember 2011\t1262\nDecember 2010\t1263\nMay 2011\t1264\nMay 2011\t1265\nAugust 2011\t1266\nAugust 2011\t1267\nJanuary 2012\t1268\nOctober 2010\t1269\nApril 2004\t1270\nSeptember 2011\t1271\nJuly 2009\t1272\nAugust 2011\t1273\nSeptember 2010\t1274\nJune 2011\t1275\nJanuary 2010\t1276\nOctober 2007\t1277\nSeptember 2011\t1278\nJuly 2011\t1279\nJuly 2011\t1280\nJuly 2012\t1281\nJune 2011\t1282\nJuly 2011\t1283\nApril 2011\t1284\nJune 2011\t1285\nApril 2007\t1286\nOctober 2011\t1287\nJune 2011\t1288\nJune 2011\t1289\nJune 2011\t1290\nMarch 2011\t1291\nJune 2011\t1292\nJanuary 2012\t1293\nJune 2011\t1294\nOctober 2009\t1295\nApril 2011\t1296\nAugust 2011\t1297\nJune 2011\t1298\nMay 2011\t1299\nOctober 2011\t1300\nFebruary 2011\t1301\nNovember 2010\t1302\nSeptember 2010\t1303\nMay 2010\t1304\nOctober 2010\t1305\nFebruary 2010\t1306\nSeptember 2011\t1307\nAugust 2012\t1308\nMay 2011\t1309\nSeptember 2010\t1310\nApril 2011\t1311\nFebruary 2011\t1312\nApril 2011\t1313\nApril 2011\t1314\nFebruary 2011\t1315\nSeptember 2010\t1316\nMay 2011\t1317\nOctober 2013\t1318\nNovember 2010\t1319\nMay 2010\t1320\nMarch 2011\t1321\nJuly 2009\t1322\nFebruary 2012\t1323\nDecember 2010\t1324\nJanuary 2008\t1325\nOctober 2008\t1326\nApril 2011\t1327\nMarch 2011\t1328\nApril 2011\t1329\nJanuary 2011\t1330\nMarch 2011\t1331\nMarch 2011\t1332\nOctober 2010\t1333\nJuly 2000\t1334\nOctober 2010\t1335\nMarch 2011\t1336\nFebruary 2011\t1337\nOctober 2009\t1338\nDecember 2010\t1339\nMay 2011\t1340\nApril 2006\t1341\nDecember 2010\t1342\nDecember 2011\t1343\nJanuary 2011\t1344\nMarch 2011\t1345\nAugust 2010\t1346\nJanuary 2010\t1347\nApril 2007\t1348\nDecember 2010\t1349\nJuly 2006\t1350\nJanuary 2011\t1351\nJanuary 2011\t1352\nJanuary 2011\t1353\nJuly 2010\t1354\nJanuary 2011\t1355\nFebruary 2011\t1356\nJanuary 2011\t1357\nMay 2011\t1358\nJanuary 2012\t1359\nDecember 2010\t1360\nMay 2009\t1361\nFebruary 2011\t1362\nJanuary 2011\t1363\nDecember 2010\t1364\nOctober 2009\t1365\nJuly 2010\t1366\nJanuary 2011\t1367\nNovember 2010\t1368\nJanuary 2011\t1369\nMarch 2010\t1370\nDecember 2010\t1371\nOctober 2010\t1372\nApril 2010\t1373\nDecember 2010\t1374\nDecember 2010\t1375\nOctober 2010\t1376\nFebruary 2011\t1377\nDecember 2010\t1378\nJanuary 2002\t1379\nOctober 2010\t1380\nFebruary 2010\t1381\nOctober 2010\t1382\nOctober 2004\t1383\nOctober 2004\t1384\nDecember 2010\t1385\nJune 2010\t1386\nMay 2010\t1387\nJanuary 2010\t1388\nDecember 2008\t1389\nSeptember 2010\t1390\nOctober 2010\t1391\nOctober 2010\t1392\nSeptember 2010\t1393\nFebruary 2007\t1394\nAugust 2010\t1395\nJanuary 2011\t1396\nApril 2011\t1397\nJuly 2010\t1398\nDecember 2008\t1399\nOctober 2010\t1400\nMarch 2010\t1401\nAugust 2010\t1402\nJuly 2010\t1403\nDecember 1998\t1404\nMay 2010\t1405\nJanuary 2010\t1406\nSeptember 2008\t1407\nJuly 2010\t1408\nMay 2009\t1409\nNovember 2008\t1410\nMay 2009\t1411\nSeptember 2009\t1412\nJune 2010\t1413\nJuly 2010\t1414\nMarch 2010\t1415\nJune 2010\t1416\nApril 2011\t1417\nOctober 2009\t1418\nMarch 2009\t1419\nJuly 2010\t1420\nSeptember 2010\t1421\nJuly 2010\t1422\nJuly 2010\t1423\nFebruary 2008\t1424\nFebruary 2008\t1425\nDecember 2010\t1426\nJuly 2010\t1427\nJuly 2009\t1428\nMay 2011\t1429\nAugust 2010\t1430\nApril 2010\t1431\nJune 2010\t1432\nJune 2010\t1433\nMay 2009\t1434\nNovember 2009\t1435\nMay 2010\t1436\nMay 2010\t1437\nMay 2010\t1438\nNovember 2011\t1439\nJune 2010\t1440\nJanuary 2010\t1441\nFebruary 1993\t1442\nJuly 2009\t1443\nJuly 2008\t1444\nDecember 2010\t1445\nApril 2010\t1446\nDecember 2008\t1447\nJanuary 2003\t1448\nJanuary 2003\t1449\nAugust 2002\t1450\nOctober 2002\t1451\nAugust 2011\t1452\nJanuary 2010\t1453\nMay 2010\t1454\nMay 2010\t1455\nJune 2009\t1456\nJuly 2009\t1457\nMay 2010\t1458\nApril 2010\t1459\nMay 2010\t1460\nJanuary 2010\t1461\nApril 2010\t1462\nApril 2010\t1463\nJuly 1993\t1464\nMay 2007\t1465\nJune 2010\t1466\nAugust 2010\t1467\nSeptember 2009\t1468\nJune 2010\t1469\nOctober 2010\t1470\nMay 2010\t1471\nJuly 2010\t1472\nMarch 2010\t1473\nMarch 2010\t1474\nNovember 2008\t1475\nNovember 2010\t1476\nDecember 2009\t1477\nDecember 2008\t1478\nMarch 2010\t1479\nFebruary 2010\t1480\nJune 2010\t1481\nFebruary 2010\t1482\nJuly 2009\t1483\nJanuary 2010\t1484\nFebruary 2009\t1485\nJanuary 2009\t1486\nJanuary 2008\t1487\nMarch 2008\t1488\nFebruary 2010\t1489\nAugust 2009\t1490\nApril 2010\t1491\nMarch 2006\t1492\nJune 2009\t1493\nAugust 2010\t1494\nJune 2010\t1495\nFebruary 2011\t1496\nMarch 2009\t1497\nNovember 2009\t1498\nMarch 2010\t1499\nJanuary 2010\t1500\nMarch 2013\t1501\nSeptember 2011\t1502\nAugust 2008\t1503\nNovember 2010\t1504\nApril 2010\t1505\nNovember 2009\t1506\nMarch 2010\t1507\nJanuary 2010\t1508\nFebruary 2010\t1509\nSeptember 2008\t1510\nMarch 2009\t1511\nOctober 2009\t1512\nMarch 2009\t1513\nJanuary 2010\t1514\nJanuary 2010\t1515\nJanuary 2011\t1516\nSeptember 2009\t1517\nSeptember 2008\t1518\nFebruary 2008\t1519\nDecember 2009\t1520\nApril 2009\t1521\nDecember 2009\t1522\nJanuary 2010\t1523\nMarch 2010\t1524\nJanuary 2007\t1525\nDecember 2009\t1526\nAugust 2010\t1527\nSeptember 2009\t1528\nDecember 2009\t1529\nSeptember 2008\t1530\nAugust 2009\t1531\nNovember 2006\t1532\nOctober 2006\t1533\nNovember 2009\t1534\nFebruary 2010\t1535\nApril 2008\t1536\nAugust 2010\t1537\nOctober 2009\t1538\nAugust 2009\t1539\nNovember 2009\t1540\nNovember 2009\t1541\nSeptember 2009\t1542\nNovember 2009\t1543\nNovember 2009\t1544\nMarch 2008\t1545\nFebruary 2010\t1546\nDecember 2009\t1547\nDecember 2009\t1548\nDecember 2009\t1549\nJuly 2009\t1550\nJanuary 2010\t1551\nJune 2007\t1552\nNovember 2006\t1553\nApril 2009\t1554\nOctober 2009\t1555\nOctober 2009\t1556\nAugust 2009\t1557\nDecember 2009\t1558\nJune 2009\t1559\nSeptember 2009\t1560\nJune 2007\t1561\nJanuary 2009\t1562\nMay 2010\t1563\nSeptember 2009\t1564\nFebruary 2009\t1565\nSeptember 2009\t1566\nJuly 2009\t1567\nSeptember 2009\t1568\nJune 2009\t1569\nOctober 2009\t1570\nOctober 2009\t1571\nJanuary 2010\t1572\nJuly 2009\t1573\nSeptember 2009\t1574\nJuly 2009\t1575\nSeptember 2009\t1576\nJanuary 2008\t1577\nJuly 2009\t1578\nMarch 2010\t1579\nSeptember 2009\t1580\nNovember 2009\t1581\nNovember 1997\t1582\nNovember 2009\t1583\nJanuary 1988\t1584\nMay 2008\t1585\nFebruary 2012\t1586\nJuly 2010\t1587\nOctober 2009\t1588\nMay 2009\t1589\nJune 2009\t1590\nAugust 2009\t1591\nAugust 2009\t1592\nOctober 2008\t1593\nJanuary 2010\t1594\nJuly 2009\t1595\nOctober 2009\t1596\nJuly 2009\t1597\nOctober 2009\t1598\nOctober 2009\t1599\nFebruary 2009\t1600\nFebruary 2009\t1601\nFebruary 2009\t1602\nSeptember 2008\t1603\nSeptember 2009\t1604\nJuly 2009\t1605\nOctober 2002\t1606\nFebruary 2009\t1607\nNovember 2009\t1608\nFebruary 2007\t1609\nDecember 2008\t1610\nMarch 2009\t1611\nJuly 2010\t1612\nNovember 2010\t1613\nJanuary 2010\t1614\nJanuary 2010\t1615\nNovember 2009\t1616\nJanuary 2007\t1617\nOctober 2009\t1618\nFebruary 2010\t1619\nMay 2010\t1620\nAugust 2009\t1621\nNovember 2009\t1622\nAugust 2008\t1623\nJune 2009\t1624\nJuly 2009\t1625\nJanuary 2010\t1626\nOctober 2008\t1627\nOctober 2009\t1628\nJune 2009\t1629\nJune 2009\t1630\nAugust 2009\t1631\nJuly 2009\t1632\nApril 2008\t1633\nOctober 2016\t1634\nJuly 2008\t1635\nAugust 2009\t1636\nMay 2008\t1637\nMay 2009\t1638\nJune 2009\t1639\nAugust 2009\t1640\nJune 2009\t1641\nApril 2008\t1642\nMay 2009\t1643\nAugust 2003\t1644\nMarch 2006\t1645\nOctober 2008\t1646\nAugust 2008\t1647\nSeptember 2006\t1648\nAugust 2007\t1649\nMay 2009\t1650\nMay 2009\t1651\nMay 2009\t1652\nAugust 2009\t1653\nMay 2006\t1654\nMay 2009\t1655\nMay 2004\t1656\nJune 2006\t1657\nMay 2009\t1658\nSeptember 2003\t1659\nSeptember 2005\t1660\nMay 2007\t1661\nOctober 2009\t1662\nMay 2009\t1663\nSeptember 2009\t1664\nApril 2009\t1665\nMarch 2009\t1666\nMay 2009\t1667\nJuly 2009\t1668\nNovember 2008\t1669\nMay 2009\t1670\nMarch 2009\t1672\nApril 2008\t1673\nOctober 2006\t1674\nApril 2005\t1675\nAugust 2002\t1676\nMarch 2009\t1677\nMarch 2009\t1678\nDecember 2008\t1679\nAugust 2009\t1680\nMarch 2009\t1681\nSeptember 2008\t1682\nApril 2009\t1683\nAugust 2008\t1684\nMarch 2009\t1685\nJuly 2006\t1686\nJanuary 2009\t1687\nFebruary 2007\t1688\nApril 2007\t1689\nAugust 2006\t1690\nAugust 2006\t1691\nMarch 2009\t1692\nJuly 2007\t1693\nMay 2009\t1694\nJune 2008\t1695\nNovember 2008\t1696\nJuly 2009\t1697\nMarch 2009\t1698\nFebruary 2009\t1699\nJanuary 2003\t1700\nFebruary 2009\t1701\nMay 2007\t1702\nFebruary 2009\t1703\nFebruary 2002\t1704\nMay 2006\t1705\nOctober 2002\t1706\nJanuary 2009\t1707\nAugust 2003\t1708\nDecember 2008\t1709\nDecember 2008\t1710\nAugust 2008\t1711\nJanuary 2009\t1712\nDecember 2008\t1713\nJanuary 2009\t1714\nOctober 2002\t1715\nMarch 2009\t1716\nApril 2007\t1717\nMarch 2009\t1718\nDecember 2008\t1719\nJanuary 2008\t1720\nJune 2008\t1721\nJanuary 2008\t1722\nDecember 2008\t1723\nApril 2009\t1724\nAugust 2008\t1725\nOctober 2008\t1726\nJanuary 2004\t1727\nMarch 2004\t1728\nAugust 2008\t1729\nJanuary 2009\t1730\nNovember 2008\t1731\nJune 2008\t1732\nOctober 2005\t1733\nDecember 2008\t1734\nMarch 2009\t1735\nSeptember 2008\t1736\nOctober 2008\t1737\nOctober 2005\t1738\nNovember 2008\t1739\nOctober 2008\t1740\nAugust 2008\t1741\nSeptember 2008\t1742\nNovember 2008\t1743\nNovember 2008\t1744\nJuly 2009\t1745\nDecember 2008\t1746\nOctober 2008\t1747\nOctober 2008\t1748\nSeptember 2011\t1749\nSeptember 2004\t1750\nOctober 2004\t1751\nNovember 2002\t1752\nOctober 2002\t1753\nOctober 2008\t1754\nJune 2005\t1755\nMay 2005\t1756\nMay 2008\t1757\nJune 2005\t1758\nAugust 2006\t1759\nOctober 2008\t1760\nAugust 2008\t1761\nAugust 2008\t1762\nNovember 2002\t1763\nJanuary 2008\t1764\nOctober 2008\t1765\nOctober 2008\t1766\nJanuary 2007\t1767\nNovember 1998\t1768\nSeptember 2008\t1769\nJanuary 2009\t1770\nFebruary 2009\t1771\nJuly 2008\t1772\nSeptember 2008\t1773\nAugust 2008\t1774\nDecember 2008\t1775\nJanuary 2007\t1776\nSeptember 2008\t1777\nAugust 2008\t1778\nOctober 2008\t1779\nAugust 2008\t1780\nJune 2009\t1781\nSeptember 2006\t1782\nMay 2004\t1783\nJune 2007\t1784\nAugust 2008\t1785\nJune 2005\t1786\nSeptember 2008\t1787\nApril 2009\t1788\nDecember 2007\t1789\nJuly 2008\t1790\nDecember 2007\t1791\nAugust 2007\t1792\nSeptember 2008\t1793\nDecember 2008\t1794\nJuly 2008\t1795\nApril 2008\t1796\nMay 2006\t1797\nSeptember 2007\t1798\nJune 2009\t1799\nJanuary 2006\t1800\nJanuary 2008\t1801\nAugust 2007\t1802\nJanuary 2003\t1803\nJanuary 2008\t1804\nMay 2008\t1805\nJuly 2004\t1806\nAugust 2008\t1807\nAugust 2008\t1808\nDecember 2009\t1809\nJune 2008\t1810\nJune 2007\t1811\nSeptember 2008\t1812\nAugust 2005\t1813\nAugust 2008\t1814\nSeptember 2004\t1815\nJune 2008\t1816\nJune 2008\t1818\nJune 2006\t1819\nApril 2007\t1820\nJune 2006\t1821\nMarch 2006\t1822\nOctober 2006\t1823\nNovember 2006\t1824\nNovember 2006\t1825\nDecember 2007\t1826\nSeptember 2008\t1827\nAugust 2007\t1828\nOctober 2005\t1829\nJune 2005\t1830\nApril 2006\t1831\nAugust 2008\t1832\nMarch 2007\t1833\nMarch 2007\t1834\nAugust 2007\t1837\nApril 2007\t1838\nMay 2008\t1839\nJune 2008\t1840\nJanuary 1996\t1841\nApril 2008\t1842\nFebruary 2008\t1843\nOctober 2006\t1844\nDecember 2004\t1845\nJanuary 2008\t1846\nJune 2007\t1847\nMay 2008\t1848\nApril 2007\t1849\nAugust 2007\t1850\nJuly 2005\t1851\nOctober 2003\t1852\nJune 2008\t1853\nApril 2008\t1854\nJanuary 2008\t1855\nJanuary 2008\t1856\nJanuary 2007\t1857\nApril 2007\t1858\nMarch 2008\t1859\nJune 2007\t1860\nFebruary 2007\t1861\nSeptember 2001\t1862\nOctober 2006\t1863\nMay 2003\t1864\nFebruary 2008\t1865\nJanuary 2008\t1866\nMarch 2008\t1867\nMarch 2008\t1868\nApril 2008\t1869\nSeptember 2006\t1870\nNovember 2002\t1871\nAugust 2007\t1872\nApril 2008\t1873\nFebruary 2008\t1874\nOctober 2007\t1875\nJanuary 2008\t1876\nJuly 2006\t1877\nFebruary 2008\t1878\nMay 2008\t1879\nMay 2008\t1880\nApril 2008\t1881\nOctober 2005\t1882\nJanuary 2007\t1883\nMay 2004\t1884\nMarch 2008\t1885\nSeptember 2007\t1886\nSeptember 2008\t1887\nFebruary 2006\t1888\nMarch 2008\t1889\nApril 2003\t1890\nMarch 2008\t1891\nJanuary 2006\t1892\nAugust 2007\t1893\nJuly 2005\t1894\nSeptember 2009\t1895\nMarch 2008\t1896\nMarch 2008\t1897\nNovember 2004\t1898\nJuly 2007\t1899\nMay 2008\t1900\nSeptember 2009\t1901\nMarch 2006\t1902\nOctober 2002\t1903\nApril 2008\t1904\nDecember 2007\t1905\nMay 1993\t1906\nFebruary 2008\t1907\nJanuary 2007\t1908\nOctober 2007\t1909\nJanuary 2009\t1910\nAugust 2007\t1911\nJuly 1999\t1912\nMay 2008\t1913\nSeptember 2007\t1914\nMay 2008\t1915\nMarch 2008\t1916\nAugust 2005\t1917\nFebruary 2004\t1918\nJune 2007\t1919\nSeptember 2007\t1920\nOctober 2007\t1921\nMarch 2007\t1922\nMarch 2007\t1923\nMay 2008\t1924\nDecember 2007\t1925\nMarch 2004\t1926\nJanuary 2008\t1927\nFebruary 2008\t1928\nNovember 2007\t1929\nJanuary 2008\t1930\nMay 2007\t1931\nMarch 2008\t1932\nJanuary 2006\t1933\nDecember 2005\t1934\nAugust 2004\t1935\nFebruary 2007\t1936\nFebruary 2008\t1937\nJanuary 2007\t1938\nJanuary 2008\t1939\nMarch 2007\t1940\nAugust 2009\t1941\nDecember 2007\t1942\nNovember 2005\t1943\nMay 2007\t1944\nFebruary 2006\t1945\nJune 2004\t1946\nApril 2007\t1947\nFebruary 2008\t1948\nMay 2005\t1949\nOctober 2002\t1950\nNovember 2007\t1951\nApril 2008\t1952\nFebruary 2005\t1953\nJuly 2006\t1954\nOctober 2005\t1955\nJanuary 2005\t1956\nMarch 2008\t1957\nMarch 2007\t1958\nAugust 2007\t1959\nMarch 2008\t1960\nAugust 2005\t1961\nMay 2008\t1962\nMarch 2008\t1963\nJanuary 2002\t1964\nApril 2004\t1965\nOctober 2005\t1966\nJanuary 2008\t1967\nMay 2008\t1968\nJuly 2001\t1969\nJanuary 2007\t1970\nJanuary 2007\t1971\nOctober 2006\t1972\nDecember 2006\t1973\nJanuary 2008\t1974\nSeptember 2005\t1975\nDecember 2007\t1976\nJanuary 2008\t1977\nJanuary 2008\t1978\nJanuary 2008\t1979\nMarch 2008\t1980\nJune 2007\t1981\nJanuary 2006\t1982\nJanuary 2008\t1983\nJanuary 2008\t1984\nFebruary 2008\t1985\nOctober 2007\t1986\nSeptember 2007\t1987\nNovember 2005\t1988\nJuly 2007\t1989\nSeptember 2003\t1990\nSeptember 2007\t1991\nOctober 2008\t1992\nApril 2007\t1993\nJanuary 2008\t1994\nJuly 2008\t1995\nMay 2007\t1996\nJuly 2005\t1997\nSeptember 2007\t1998\nApril 2005\t1999\nMay 2005\t2000\nMay 2005\t2001\nJanuary 2007\t2002\nNovember 2007\t2003\nJanuary 2007\t2004\nSeptember 2005\t2005\nJanuary 2007\t2006\nFebruary 2003\t2007\nJuly 2002\t2008\nMarch 2006\t2009\nMarch 2005\t2010\nJanuary 2009\t2011\nMay 2005\t2012\nJune 2007\t2013\nDecember 2007\t2014\nFebruary 2008\t2015\nNovember 2007\t2016\nJune 2005\t2017\nAugust 2006\t2018\nFebruary 2006\t2019\nNovember 2001\t2020\nSeptember 2006\t2021\nJuly 2005\t2022\nSeptember 2007\t2023\nMarch 2006\t2024\nJanuary 2008\t2025\nOctober 2003\t2026\nDecember 2007\t2027\nNovember 2007\t2028\nSeptember 2006\t2029\nDecember 1995\t2030\nDecember 2007\t2031\nJanuary 2005\t2032\nNovember 2007\t2033\nFebruary 2007\t2034\nJune 2005\t2035\nApril 2006\t2036\nMarch 2007\t2037\nJanuary 2006\t2038\nNovember 2007\t2039\nOctober 2007\t2040\nJuly 2007\t2041\nSeptember 2007\t2042\nJanuary 2007\t2043\nMarch 2004\t2044\nJune 2007\t2045\nJuly 2007\t2046\nSeptember 2007\t2047\nSeptember 2007\t2048\nJanuary 2008\t2049\nNovember 2006\t2050\nDecember 2004\t2051\nSeptember 2007\t2052\nSeptember 2007\t2053\nMarch 2007\t2054\nSeptember 2007\t2055\nOctober 2007\t2056\nJune 2006\t2057\nApril 2002\t2058\nMay 2007\t2059\nAugust 2007\t2060\nJuly 2007\t2061\nJuly 1999\t2062\nJanuary 2007\t2063\nJuly 2006\t2064\nJanuary 2008\t2065\nOctober 2007\t2066\nJuly 2007\t2067\nJune 2006\t2068\nFebruary 2008\t2069\nJuly 2007\t2070\nAugust 2004\t2071\nJune 2007\t2072\nFebruary 2006\t2073\nMay 2007\t2074\nApril 2007\t2075\nJuly 2005\t2076\nJuly 2007\t2077\nJuly 2002\t2078\nJune 2007\t2079\nMarch 2007\t2080\nFebruary 1999\t2081\nDecember 2006\t2082\nMarch 2005\t2083\nFebruary 2006\t2084\nMay 2006\t2085\nAugust 2007\t2086\nOctober 2006\t2087\nMay 2005\t2088\nJune 2006\t2089\nApril 2007\t2090\nJune 2007\t2091\nMarch 2007\t2092\nOctober 2005\t2093\nDecember 2006\t2094\nMarch 2004\t2095\nApril 2007\t2096\nMarch 2007\t2097\nMarch 2007\t2098\nFebruary 2007\t2099\nMay 2007\t2100\nMarch 2007\t2101\nFebruary 2001\t2102\nAugust 2006\t2103\nMarch 2007\t2104\nApril 2006\t2105\nJanuary 2003\t2106\nFebruary 2007\t2107\nDecember 2006\t2108\nFebruary 2007\t2109\nFebruary 2007\t2110\nJuly 2006\t2111\nNovember 2005\t2112\nOctober 2005\t2113\nFebruary 2008\t2114\nNovember 2003\t2115\nJanuary 2007\t2116\nMay 2005\t2117\nFebruary 2007\t2118\nJanuary 2007\t2119\nFebruary 2007\t2120\nMarch 2007\t2121\nJune 2006\t2122\nNovember 2004\t2123\nMarch 2005\t2124\nApril 2006\t2125\nDecember 2014\t2126\nJanuary 2007\t2127\nSeptember 2006\t2128\nJuly 2004\t2129\nNovember 2005\t2130\nDecember 2006\t2131\nJanuary 2007\t2132\nOctober 2006\t2133\nDecember 2000\t2134\nSeptember 2006\t2135\nMay 2003\t2136\nNovember 2006\t2137\nJanuary 1989\t2138\nApril 2003\t2139\nApril 2006\t2140\nDecember 2006\t2141\nSeptember 2006\t2142\nNovember 2006\t2143\nJanuary 2007\t2144\nApril 2005\t2145\nMay 2007\t2146\nOctober 2006\t2147\nJanuary 2007\t2148\nJanuary 2002\t2149\nFebruary 2001\t2150\nFebruary 2006\t2151\nJuly 2005\t2152\nOctober 2006\t2153\nFebruary 2006\t2154\nJuly 2004\t2155\nSeptember 2005\t2156\nOctober 2006\t2157\nMay 2006\t2158\nApril 2006\t2159\nSeptember 2006\t2160\nDecember 2003\t2161\nJune 2006\t2162\nNovember 2006\t2163\nOctober 2006\t2164\nMarch 2006\t2165\nFebruary 2006\t2166\nAugust 2006\t2167\nAugust 2006\t2168\nApril 2004\t2169\nMay 2005\t2170\nJanuary 2006\t2171\nJuly 2004\t2172\nNovember 2002\t2173\nApril 2006\t2174\nJuly 2006\t2175\nSeptember 2006\t2176\nAugust 2004\t2177\nApril 2006\t2178\nOctober 2003\t2179\nDecember 2004\t2180\nMay 2006\t2181\nJanuary 2005\t2182\nDecember 2003\t2183\nJanuary 1999\t2184\nDecember 2001\t2185\nAugust 2004\t2186\nSeptember 2002\t2187\nDecember 2005\t2188\nOctober 2001\t2189\nApril 2004\t2190\nJune 2001\t2191\nJanuary 2005\t2192\nAugust 2002\t2193\nMay 1997\t2194\nJune 2005\t2195\nJune 1998\t2196\nJanuary 2004\t2197\nJune 2006\t2198\nMarch 2006\t2199\nApril 2007\t2200\nAugust 1999\t2201\nFebruary 2005\t2202\nJanuary 2002\t2203\nMay 2006\t2204\nJune 2006\t2205\nFebruary 2006\t2206\nSeptember 2007\t2207\nMay 2006\t2208\nAugust 2006\t2209\nMarch 2004\t2210\nMay 2006\t2211\nApril 2006\t2212\nJune 2003\t2213\nApril 2006\t2214\nApril 2006\t2215\nMarch 2005\t2216\nMay 1996\t2217\nMarch 2005\t2218\nFebruary 2005\t2219\nJune 2006\t2220\nJanuary 2002\t2221\nApril 2006\t2222\nJune 2002\t2223\nFebruary 2001\t2224\nNovember 2003\t2225\nOctober 2002\t2226\nApril 2005\t2227\nOctober 2005\t2228\nAugust 2006\t2229\nApril 2006\t2230\nJanuary 2006\t2231\nAugust 2004\t2232\nJanuary 2004\t2233\nDecember 2004\t2234\nJuly 2006\t2235\nMay 2006\t2236\nNovember 2005\t2237\nJuly 2002\t2238\nJuly 2005\t2239\nFebruary 2005\t2240\nFebruary 2006\t2241\nFebruary 2006\t2242\nOctober 2009\t2243\nOctober 2006\t2244\nMarch 2003\t2245\nFebruary 2005\t2246\nOctober 2005\t2247\nSeptember 2004\t2248\nMarch 2006\t2249\nJanuary 2006\t2250\nMay 2005\t2251\nSeptember 2005\t2252\nJanuary 2006\t2253\nOctober 2005\t2254\nFebruary 2006\t2255\nMarch 2005\t2256\nNovember 2005\t2257\nSeptember 2003\t2258\nJanuary 2005\t2259\nNovember 2003\t2260\nDecember 2003\t2261\nMay 2004\t2262\nJune 2004\t2263\nMarch 2005\t2264\nJanuary 2006\t2265\nMay 2004\t2266\nJuly 2001\t2267\nJanuary 2006\t2268\nMay 2005\t2269\nDecember 2005\t2270\nAugust 2004\t2271\nJanuary 2005\t2272\nDecember 2005\t2273\nDecember 2005\t2274\nJuly 2005\t2275\nJanuary 2005\t2276\nAugust 2003\t2277\nOctober 2005\t2278\nOctober 2005\t2279\nDecember 2004\t2280\nMay 2006\t2281\nMay 2006\t2282\nMay 2001\t2283\nApril 2004\t2284\nMay 2002\t2285\nJanuary 2005\t2286\nJuly 2003\t2287\nSeptember 2005\t2288\nJune 2003\t2289\nApril 2004\t2290\nAugust 2004\t2291\nApril 2004\t2292\nMarch 2004\t2293\nJuly 2005\t2294\nOctober 2004\t2295\nAugust 2004\t2296\nSeptember 2003\t2297\nOctober 2004\t2298\nApril 2003\t2299\nJanuary 1997\t2300\nDecember 2000\t2301\nFebruary 2004\t2302\nFebruary 2004\t2303\nJune 2001\t2304\nSeptember 2001\t2305\nFebruary 2003\t2306\nFebruary 2004\t2307\nFebruary 2005\t2308\nSeptember 2004\t2309\nAugust 2005\t2310\nAugust 2005\t2311\nMarch 2003\t2312\nOctober 2004\t2313\nMarch 2005\t2314\nMay 2005\t2315\nApril 2005\t2316\nOctober 2004\t2317\nOctober 2003\t2318\nSeptember 1999\t2319\nSeptember 1999\t2320\nApril 2005\t2321\nJune 2003\t2322\nSeptember 2002\t2323\nJuly 2005\t2324\nSeptember 2003\t2325\nAugust 2002\t2326\nJanuary 2004\t2327\nDecember 2004\t2328\nFebruary 2004\t2329\nJuly 2004\t2330\nMarch 2005\t2332\nMarch 2002\t2333\nMarch 2004\t2334\nMarch 2002\t2335\nNovember 2004\t2336\nMarch 2004\t2337\nOctober 2004\t2338\nOctober 2004\t2339\nFebruary 2004\t2340\nJanuary 2005\t2341\nNovember 1999\t2342\nSeptember 2001\t2343\nSeptember 2004\t2344\nJanuary 2004\t2345\nJanuary 2004\t2346\nDecember 2003\t2347\nMarch 2003\t2348\nNovember 2003\t2349\nJune 1998\t2350\nSeptember 2003\t2351\nNovember 2003\t2352\nJanuary 2003\t2353\nApril 2003\t2354\nAugust 2001\t2355\nJuly 2003\t2356\nAugust 2003\t2357\nSeptember 1996\t2358\nSeptember 2003\t2359\nSeptember 2003\t2360\nMarch 2003\t2361\nJune 2007\t2362\nJuly 2003\t2363\nOctober 2001\t2364\nAugust 2001\t2365\nJanuary 1999\t2366\nSeptember 2003\t2367\nDecember 2001\t2368\nApril 2001\t2369\nAugust 2002\t2370\nAugust 2003\t2372\nJune 2002\t2373\nJune 2001\t2374\nJune 2001\t2375\nApril 2000\t2376\nJuly 2002\t2377\nSeptember 2001\t2378\nApril 1999\t2379\nAugust 2001\t2380\nMarch 2002\t2381\nDecember 2001\t2383\nJune 2002\t2384\nSeptember 2001\t2385\nApril 2002\t2386\nMay 2002\t2387\nSeptember 2000\t2388\nSeptember 2001\t2389\nJanuary 2002\t2390\nJanuary 2002\t2391\nMay 2001\t2393\nSeptember 2001\t2394\nJanuary 2002\t2395\nJanuary 1997\t2397\nJune 2001\t2398\nJune 2001\t2400\nDecember 2000\t2403\nNovember 2000\t2404\nSeptember 2000\t2405\nJuly 2000\t2406\nJanuary 1998\t2407\nApril 1998\t2408\nJanuary 1998\t2409\nFebruary 1998\t2410\nJune 1998\t2411\nOctober 2000\t2412\nMarch 2001\t2413\nJanuary 2000\t2414\nJanuary 2000\t2415\nJanuary 1997\t2419\nDecember 1999\t2420\nAugust 1999\t2424\nFebruary 2000\t2426\nAugust 2000\t2427\nAugust 2000\t2428\nAugust 2000\t2429\nAugust 2000\t2430\nDecember 1999\t2431\nFebruary 2000\t2432\nFebruary 2000\t2433\nJuly 1998\t2434\nMay 1996\t2435\nAugust 2000\t2436\nSeptember 1996\t2438\nFebruary 1997\t2439\nOctober 1999\t2440\nOctober 1998\t2441\nJuly 1999\t2443\nOctober 2000\t2444\nMarch 1999\t2445\nSeptember 1997\t2446\nOctober 1997\t2447\nJanuary 1998\t2448\nMarch 1998\t2449\nSeptember 1997\t2450\nApril 1998\t2451\nFebruary 1998\t2452\nMay 1998\t2453\nJune 1998\t2454\nJune 1998\t2455\nJune 1998\t2456\nJune 1998\t2457\nMay 1998\t2458\nJanuary 1998\t2459\nApril 1997\t2460\nMarch 1997\t2461\nFebruary 1993\t2462\nJune 1996\t2463\nApril 1995\t2464\nSeptember 1995\t2465\nSeptember 1995\t2466\nSeptember 1995\t2467\nFebruary 1993\t2468\nNovember 1991\t2469\nFebruary 1993\t2470\nJuly 1989\t2471\nDecember 1992\t2472\nJuly 1999\t2493\nMarch 2016\t2494\nNovember 2016\t2495\nJanuary 2017\t2496\nJune 2016\t2497\nAugust 2016\t2498\nMarch 2014\t2499\nJanuary 2016\t2500\nOctober 2014\t2501\nJanuary 2016\t2502\nAugust 2016\t2503\nMarch 2015\t2504\nMay 2015\t2505\nSeptember 2015\t2506\nJanuary 2015\t2507\nDecember 2014\t2508\nDecember 2015\t2509\nSeptember 2014\t2510\nOctober 2013\t2511\nAugust 2015\t2512\nAugust 2014\t2513\nAugust 2014\t2514\nJune 2014\t2515\nMay 2002\t2516\nDecember 2010\t2517\nApril 2014\t2518\nMarch 2014\t2519\nDecember 2013\t2520\nMarch 2012\t2521\nMarch 2014\t2522\nJanuary 2014\t2523\nJuly 2015\t2524\nJanuary 2014\t2525\nJuly 2013\t2526\nAugust 2013\t2527\nMay 2011\t2528\nMay 2014\t2529\nApril 2013\t2530\nMay 2012\t2531\nJanuary 2013\t2532\nSeptember 2013\t2533\nJanuary 2010\t2534\nDecember 2012\t2535\nDecember 2012\t2536\nJuly 2012\t2537\nSeptember 2012\t2538\nOctober 2012\t2539\nJune 2012\t2540\nSeptember 2013\t2541\nMay 2012\t2542\nApril 2011\t2543\nApril 2009\t2544\nAugust 2010\t2545\nJuly 2011\t2546\nJanuary 2010\t2547\nJune 2011\t2548\nMay 2010\t2549\nJanuary 2011\t2550\nAugust 2011\t2551\nDecember 2010\t2552\nMarch 2011\t2553\nApril 2011\t2554\nMay 2010\t2555\nJuly 2010\t2556\nNovember 2009\t2557\nSeptember 2010\t2558\nAugust 2010\t2559\nJanuary 2011\t2560\nJuly 2011\t2561\nMarch 2009\t2562\nAugust 2009\t2563\nJuly 2009\t2564\nOctober 2009\t2565\nDecember 1998\t2566\nOctober 2008\t2567\nSeptember 2009\t2568\nJanuary 2005\t2569\nNovember 2010\t2570\nJuly 2009\t2571\nMarch 2009\t2572\nApril 2009\t2573\nNovember 2008\t2574\nOctober 2008\t2575\nApril 2008\t2576\nJune 2008\t2577\nJuly 2004\t2578\nMarch 2008\t2579\nOctober 2007\t2580\nOctober 2007\t2581\nAugust 2007\t2582\nAugust 2007\t2583\nJune 2007\t2584\nFebruary 2007\t2585\nMay 2004\t2586\nJuly 2003\t2587\nSeptember 2004\t2588\nAugust 2004\t2589\nApril 2001\t2590\nJune 2005\t2591\nJune 2005\t2592\nJune 2005\t2593\nApril 2006\t2594\nDecember 2003\t2595\nJanuary 2006\t2596\nMay 2005\t2597\nAugust 2005\t2598\nJune 2003\t2599\nNovember 2004\t2600\nSeptember 2004\t2601\nDecember 2001\t2602\nJuly 1997\t2603\nFebruary 2003\t2604\nMay 2002\t2605\nDecember 1998\t2606\nMarch 2016\t2608\nMay 2016\t2609\nNovember 2015\t2610\nJanuary 2016\t2611\nJanuary 2016\t2612\nDecember 2015\t2613\nAugust 2015\t2614\nJune 2015\t2615\nJuly 2015\t2616\nMay 2015\t2617\nAugust 2014\t2618\nMay 2015\t2619\nApril 2015\t2620\nAugust 2015\t2621\nDecember 2014\t2622\nJune 2014\t2623\nMay 2014\t2624\nSeptember 2014\t2625\nNovember 2014\t2626\nApril 2014\t2627\nApril 2014\t2628\nMarch 2014\t2629\nApril 2012\t2630\nMay 2014\t2631\nSeptember 2013\t2632\nApril 2013\t2633\nFebruary 2014\t2634\nSeptember 2013\t2635\nMarch 2013\t2636\nNovember 2012\t2637\nJanuary 2013\t2638\nOctober 2012\t2639\nAugust 2012\t2640\nMarch 2012\t2641\nNovember 2011\t2642\nSeptember 2009\t2643\nMarch 2012\t2644\nNovember 2013\t2645\nJuly 2011\t2646\nMay 2012\t2647\nNovember 2010\t2648\nJanuary 2014\t2649\nDecember 2011\t2650\nJanuary 2012\t2651\nApril 2011\t2652\nNovember 2010\t2653\nMay 2011\t2654\nMarch 2011\t2655\nMay 2011\t2656\nDecember 2011\t2657\nMay 2009\t2658\nDecember 2010\t2659\nAugust 2011\t2660\nAugust 2010\t2661\nJuly 2007\t2662\nJune 2010\t2663\nFebruary 2009\t2664\nApril 2005\t2665\nNovember 2010\t2666\nApril 2002\t2667\nDecember 2005\t2668\nJuly 2009\t2669\nJuly 2009\t2670\nJanuary 2004\t2671\nJuly 2009\t2672\nApril 2008\t2673\nJanuary 2009\t2674\nJanuary 2009\t2675\nSeptember 2007\t2676\nAugust 2008\t2677\nMarch 2008\t2678\nSeptember 2008\t2679\nDecember 2007\t2680\nJuly 2006\t2681\nApril 2008\t2682\nSeptember 2007\t2683\nFebruary 2008\t2684\nMarch 2008\t2685\nFebruary 2008\t2686\nJanuary 2002\t2687\nJune 2008\t2688\nDecember 2007\t2689\nDecember 2007\t2690\nJune 2007\t2691\nNovember 2006\t2692\nFebruary 2007\t2693\nJuly 2004\t2694\nNovember 2006\t2695\nAugust 2006\t2696\nJanuary 1994\t2697\nDecember 2000\t2698\nFebruary 2006\t2699\nJune 2006\t2700\nApril 2003\t2701\nFebruary 2003\t2702\nJanuary 2006\t2703\nMay 2005\t2704\nSeptember 2004\t2705\nApril 2004\t2706\nApril 2004\t2707\nDecember 1996\t2709\nDecember 2002\t2710\nJuly 2002\t2711\nJuly 1996\t2713\nMarch 1998\t2714\nJuly 1997\t2715\nSeptember 1997\t2716\nFebruary 1997\t2717\nFebruary 1993\t2718\nMay 1997\t2720\nJanuary 2016\t2721\nMarch 2009\t2722\nJanuary 2014\t2723\nApril 2014\t2724\nSeptember 2013\t2725\nOctober 2012\t2726\nJanuary 2013\t2727\nMarch 2012\t2728\nApril 2009\t2729\nAugust 2010\t2730\nAugust 2011\t2731\nOctober 2010\t2732\nSeptember 2009\t2733\nMay 2009\t2734\nMarch 2009\t2735\nSeptember 2008\t2736\nApril 2007\t2737\nNovember 2005\t2738\nJune 2004\t2739\nJune 1998\t2740\nJanuary 2006\t2741\nOctober 2005\t2742\nAugust 2005\t2743\nDecember 2016\t2744\nAugust 2016\t2745\nSeptember 2016\t2746\nAugust 2016\t2747\nJuly 2016\t2748\nMarch 2016\t2749\nSeptember 2016\t2750\nJune 2016\t2751\nDecember 2015\t2752\nDecember 2015\t2753\nJuly 2015\t2754\nJanuary 2016\t2755\nFebruary 2016\t2756\nJune 2015\t2757\nAugust 2015\t2758\nOctober 2016\t2759\nMay 2015\t2760\nJune 2015\t2761\nMarch 2015\t2762\nDecember 2014\t2763\nNovember 2014\t2764\nSeptember 2014\t2765\nSeptember 2014\t2766\nApril 2015\t2767\nOctober 2014\t2768\nJanuary 2015\t2769\nJuly 2015\t2770\nJanuary 2016\t2771\nJuly 2012\t2772\nJuly 2014\t2773\nJuly 2012\t2774\nDecember 2013\t2775\nApril 2011\t2776\nSeptember 2013\t2777\nNovember 2013\t2778\nDecember 2013\t2779\nJuly 2013\t2780\nSeptember 2009\t2781\nJuly 2013\t2782\nNovember 2011\t2783\nDecember 2012\t2784\nJune 2013\t2785\nSeptember 2009\t2786\nMarch 2013\t2787\nAugust 2014\t2788\nOctober 2014\t2789\nJanuary 2013\t2790\nDecember 2012\t2791\nMay 2012\t2792\nDecember 2010\t2793\nMay 2009\t2794\nAugust 2012\t2795\nSeptember 2011\t2796\nAugust 2012\t2797\nJuly 2012\t2798\nApril 2007\t2799\nJune 2012\t2800\nAugust 2011\t2801\nApril 2012\t2802\nApril 2012\t2803\nDecember 2011\t2804\nDecember 2011\t2805\nJanuary 2012\t2806\nApril 2009\t2807\nMarch 2013\t2808\nJuly 2011\t2809\nJune 2011\t2810\nJune 2011\t2811\nMarch 2011\t2812\nFebruary 2011\t2813\nJanuary 2011\t2814\nDecember 2010\t2815\nJune 2010\t2816\nJanuary 2011\t2817\nNovember 2010\t2818\nApril 2011\t2819\nSeptember 2010\t2820\nAugust 2010\t2821\nApril 2010\t2822\nOctober 2009\t2823\nNovember 2009\t2824\nNovember 2009\t2825\nJanuary 2010\t2826\nMarch 2010\t2827\nSeptember 2009\t2828\nAugust 2009\t2829\nAugust 2009\t2830\nAugust 2009\t2831\nAugust 2009\t2832\nJanuary 2010\t2833\nMay 2009\t2834\nMay 2009\t2835\nMay 2008\t2836\nApril 2009\t2837\nOctober 2013\t2838\nJanuary 2009\t2839\nNovember 2008\t2840\nJanuary 2010\t2841\nDecember 2002\t2842\nAugust 2008\t2843\nAugust 2008\t2844\nOctober 2009\t2845\nAugust 2007\t2847\nOctober 2007\t2848\nOctober 2008\t2849\nMarch 2007\t2850\nFebruary 2003\t2851\nNovember 2007\t2852\nSeptember 1997\t2853\nAugust 2002\t2854\nMarch 2008\t2855\nJanuary 1998\t2856\nSeptember 1992\t2857\nOctober 2006\t2858\nAugust 2006\t2859\nJune 2006\t2860\nAugust 2004\t2861\nFebruary 2007\t2862\nAugust 2006\t2863\nSeptember 2006\t2864\nFebruary 2006\t2865\nApril 1993\t2866\nApril 2006\t2867\nAugust 2001\t2868\nJuly 2006\t2869\nApril 2006\t2871\nMay 2005\t2872\nApril 2005\t2873\nSeptember 2007\t2874\nMarch 2004\t2875\nNovember 2005\t2876\nJuly 2005\t2877\nJuly 2005\t2878\nSeptember 2005\t2880\nAugust 2005\t2881\nJuly 2003\t2882\nFebruary 2004\t2883\nDecember 2003\t2884\nFebruary 2004\t2885\nFebruary 2005\t2886\nFebruary 2002\t2887\nJuly 2003\t2888\nOctober 2002\t2889\nAugust 2002\t2890\nFebruary 2003\t2891\nApril 2001\t2892\nApril 2002\t2893\nMarch 2002\t2894\nAugust 2000\t2895\nJune 1999\t2896\nSeptember 1999\t2897\nJune 1999\t2898\nJuly 1998\t2899\nSeptember 2014\t2903\nMay 2014\t2904\nSeptember 2013\t2905\nSeptember 2012\t2906\nSeptember 2001\t2907\nOctober 2011\t2908\nSeptember 2010\t2909\nJanuary 2015\t2910\nJanuary 2014\t2911\nApril 2014\t2912\nJanuary 2014\t2913\nAugust 2013\t2914\nMay 2013\t2915\nApril 2013\t2916\nSeptember 2012\t2917\nOctober 2012\t2918\nOctober 2011\t2919\nDecember 2011\t2920\nOctober 2011\t2921\nFebruary 2010\t2922\nMarch 2004\t2923\nJanuary 2006\t2924\nSeptember 2007\t2925\nOctober 2007\t2926\nApril 2002\t2927\nJune 2000\t2928\nDecember 2005\t2929\nJanuary 2003\t2930\nOctober 2014\t2931\nJune 2013\t2932\nMarch 2013\t2933\nAugust 2011\t2934\nMarch 2011\t2935\nJuly 2008\t2936\nNovember 2008\t2937\nMarch 2005\t2938\nAugust 2008\t2939\nMay 2007\t2940\nNovember 2010\t2941\nSeptember 2003\t2942\nApril 2010\t2943\nOctober 2010\t2944\nOctober 2008\t2945\nJune 2004\t2946\nNovember 2003\t2947\nJune 2016\t2948\nApril 2015\t2949\nFebruary 2016\t2950\nApril 2016\t2951\nSeptember 2015\t2952\nJune 2016\t2953\nNovember 2015\t2954\nJune 2015\t2955\nMay 2015\t2956\nApril 2015\t2957\nMay 2014\t2958\nJune 2014\t2959\nMay 2013\t2960\nApril 2013\t2961\nNovember 2012\t2962\nFebruary 2013\t2963\nSeptember 2011\t2964\nMay 2009\t2965\nFebruary 2012\t2966\nAugust 2011\t2967\nDecember 2011\t2968\nJuly 2010\t2969\nNovember 2008\t2970\nNovember 2009\t2971\nMay 2009\t2972\nJanuary 2000\t2973\nJune 2007\t2974\nSeptember 2007\t2975\nOctober 2007\t2976\nMarch 2007\t2977\nApril 2001\t2978\nApril 2001\t2979\nJune 2005\t2980\nJune 2003\t2981\nSeptember 2003\t2982\nApril 2000\t2983\nAugust 2016\t2984\nJune 2016\t2985\nSeptember 2016\t2986\nMay 2016\t2987\nSeptember 2016\t2988\nJuly 2015\t2989\nApril 2016\t2990\nMarch 2008\t2991\nMay 2016\t2992\nMarch 2016\t2993\nNovember 2015\t2994\nSeptember 2015\t2995\nAugust 2015\t2996\nSeptember 2015\t2997\nApril 2015\t2998\nJanuary 2016\t2999\nMarch 2015\t3000\nJanuary 2015\t3001\nDecember 2014\t3002\nMarch 2011\t3003\nNovember 2014\t3004\nApril 2014\t3005\nOctober 2013\t3006\nNovember 2013\t3007\nJanuary 2013\t3008\nMarch 2013\t3009\nMay 2013\t3010\nMarch 2014\t3011\nOctober 2012\t3012\nJuly 2012\t3013\nMarch 2012\t3014\nDecember 2011\t3015\nSeptember 2011\t3016\nJune 2011\t3017\nAugust 2006\t3018\nApril 2011\t3019\nDecember 2010\t3020\nJanuary 2011\t3021\nOctober 2010\t3022\nApril 2011\t3023\nSeptember 2010\t3024\nOctober 2010\t3025\nFebruary 2010\t3026\nJune 2010\t3027\nJune 2010\t3028\nFebruary 2010\t3029\nJuly 2010\t3030\nMay 2010\t3031\nFebruary 2009\t3032\nJanuary 2010\t3033\nMarch 2010\t3034\nOctober 2009\t3035\nSeptember 2009\t3036\nAugust 2009\t3037\nOctober 2009\t3038\nJanuary 2009\t3039\nNovember 2008\t3040\nJuly 2009\t3041\nJanuary 2009\t3042\nMay 2009\t3043\nJanuary 2009\t3044\nFebruary 2006\t3045\nApril 2008\t3046\nJanuary 2005\t3047\nNovember 2007\t3048\nSeptember 2008\t3049\nDecember 2008\t3050\nSeptember 2008\t3051\nAugust 2008\t3052\nJuly 2008\t3053\nJune 2009\t3054\nMay 2007\t3055\nJanuary 2008\t3056\nNovember 2007\t3057\nFebruary 2007\t3058\nAugust 2007\t3059\nSeptember 2007\t3060\nOctober 2006\t3061\nJune 2007\t3062\nApril 2007\t3063\nJanuary 2007\t3064\nJune 2002\t3065\nDecember 2006\t3066\nJanuary 2007\t3067\nOctober 2006\t3068\nAugust 2003\t3069\nMarch 1997\t3070\nMarch 2001\t3071\nJuly 2004\t3072\nApril 2004\t3073\nMarch 2005\t3074\nAugust 2002\t3075\nOctober 2003\t3076\nSeptember 2003\t3077\nApril 2003\t3078\nFebruary 2003\t3079\nJune 2000\t3081\nOctober 2016\t3085\nDecember 2016\t3086\nOctober 2016\t3087\nNovember 2016\t3088\nOctober 2016\t3089\nSeptember 2016\t3090\nAugust 2016\t3091\nDecember 2012\t3092\nJuly 2015\t3093\nMay 2015\t3094\nAugust 2015\t3095\nDecember 2014\t3096\nJuly 2016\t3097\nSeptember 2014\t3098\nOctober 2014\t3099\nMay 2014\t3100\nNovember 2014\t3101\nJanuary 2014\t3102\nDecember 2013\t3103\nMay 2013\t3104\nOctober 2013\t3105\nAugust 2013\t3106\nJanuary 2013\t3107\nJanuary 2013\t3108\nJanuary 2013\t3109\nNovember 2012\t3110\nApril 2014\t3111\nMay 2012\t3112\nJune 2012\t3113\nNovember 2011\t3114\nMarch 2012\t3115\nDecember 2010\t3116\nFebruary 2011\t3117\nJanuary 2011\t3118\nAugust 2010\t3119\nOctober 2009\t3120\nFebruary 2010\t3121\nFebruary 2010\t3122\nOctober 2009\t3123\nAugust 2009\t3124\nJuly 2009\t3125\nSeptember 2011\t3126\nJune 2009\t3127\nJune 2009\t3128\nMay 2009\t3129\nJuly 2008\t3130\nMarch 2009\t3131\nJanuary 2007\t3132\nDecember 2008\t3133\nNovember 2007\t3134\nFebruary 2009\t3135\nMay 2008\t3136\nJuly 2008\t3137\nJuly 2007\t3138\nMarch 2008\t3139\nMarch 2008\t3140\nJune 2008\t3141\nNovember 2007\t3142\nApril 2007\t3143\nMarch 2007\t3144\nMay 2000\t3145\nNovember 2008\t3146\nJanuary 2007\t3147\nDecember 2006\t3148\nOctober 2005\t3149\nJune 2006\t3150\nOctober 2005\t3151\nMay 2005\t3152\nApril 2003\t3153\nMarch 2005\t3154\nApril 2004\t3156\nMay 2006\t3157\nDecember 1999\t3159\nDecember 2016\t3162\nMarch 2014\t3163\nOctober 2013\t3164\nJanuary 2013\t3165\nJune 2012\t3166\nJune 2011\t3167\nFebruary 2010\t3168\nMarch 2006\t3169\nApril 2005\t3170\nJanuary 2015\t3171\nJuly 2014\t3172\nApril 2013\t3173\nAugust 2013\t3174\nSeptember 2012\t3175\nOctober 2012\t3176\nFebruary 2010\t3177\nJuly 2009\t3178\nJune 2006\t3179\nMay 2007\t3180\nJune 2006\t3181\nJanuary 2003\t3182\nAugust 2016\t3183\nNovember 2012\t3184\nFebruary 2011\t3185\nJanuary 2010\t3186\nMarch 2011\t3187\nFebruary 2011\t3188\nFebruary 2010\t3189\nOctober 2012\t3190\nJune 2015\t3191\nJanuary 2015\t3192\nFebruary 2015\t3193\nDecember 2014\t3194\nNovember 2011\t3195\nJanuary 2016\t3196\nNovember 2015\t3197\nSeptember 2015\t3198\nMarch 2014\t3199\nJune 2012\t3200\nAugust 2012\t3201\nJuly 2012\t3202\nJanuary 2011\t3203\nDecember 2010\t3204\nOctober 2009\t3205\nOctober 2008\t3206\nApril 2005\t3207\nJanuary 2009\t3208\nMay 2008\t3209\nAugust 2007\t3210\nOctober 2001\t3211\nFebruary 2000\t3212\nOctober 2016\t3213\nAugust 2016\t3214\nJune 2016\t3215\nFebruary 2016\t3216\nApril 2016\t3217\nAugust 2015\t3218\nJanuary 2016\t3219\nSeptember 2015\t3220\nMay 2015\t3221\nMarch 2015\t3222\nDecember 2014\t3223\nMay 2014\t3224\nJuly 2012\t3225\nDecember 2013\t3226\nJanuary 2014\t3227\nJuly 2013\t3228\nJuly 2015\t3229\nSeptember 2011\t3230\nMarch 2011\t3231\nNovember 2010\t3232\nDecember 2010\t3233\nNovember 2010\t3234\nJuly 2010\t3235\nJuly 2009\t3236\nApril 2010\t3237\nJuly 2009\t3238\nJanuary 2010\t3239\nDecember 2002\t3240\nOctober 2009\t3241\nAugust 2009\t3242\nSeptember 2009\t3243\nDecember 2000\t3244\nOctober 2008\t3245\nFebruary 2009\t3246\nSeptember 2008\t3247\nJanuary 2008\t3248\nMarch 2008\t3249\nJanuary 2008\t3250\nDecember 2008\t3251\nDecember 2006\t3252\nFebruary 2006\t3253\nOctober 2008\t3254\nDecember 2005\t3255\nFebruary 2003\t3256\nApril 2004\t3257\nSeptember 2004\t3258\nJuly 2004\t3259\nFebruary 2002\t3260\nSeptember 2002\t3261\nMay 2000\t3262\nOctober 1998\t3263\nNovember 2016\t3264\nAugust 2016\t3265\nAugust 2016\t3266\nNovember 2016\t3267\nMarch 2016\t3268\nNovember 2015\t3269\nMarch 2016\t3270\nApril 2016\t3271\nOctober 2015\t3272\nJune 2015\t3273\nJanuary 2016\t3274\nFebruary 2016\t3275\nNovember 2015\t3276\nMarch 2015\t3277\nSeptember 2015\t3278\nAugust 2015\t3279\nApril 2015\t3280\nNovember 2014\t3281\nJanuary 2015\t3282\nJuly 2014\t3283\nJanuary 2015\t3284\nMay 2014\t3285\nJune 2014\t3286\nApril 2014\t3287\nMarch 2014\t3288\nMarch 2014\t3289\nJune 2014\t3290\nJuly 2016\t3291\nNovember 2013\t3292\nSeptember 2014\t3293\nAugust 2013\t3294\nDecember 2013\t3295\nJune 2013\t3296\nApril 2013\t3297\nFebruary 2013\t3298\nNovember 2012\t3299\nApril 2012\t3300\nJune 2012\t3301\nJune 2002\t3302\nOctober 2011\t3303\nAugust 2011\t3304\nFebruary 2011\t3305\nMarch 2011\t3306\nDecember 2011\t3307\nFebruary 2011\t3308\nDecember 2010\t3309\nOctober 2010\t3310\nNovember 2010\t3311\nJanuary 2010\t3312\nJuly 2010\t3313\nOctober 2010\t3314\nJanuary 2008\t3315\nOctober 2009\t3316\nFebruary 2010\t3317\nJune 2009\t3318\nJuly 2009\t3319\nMarch 2010\t3320\nJuly 2010\t3321\nFebruary 2008\t3322\nDecember 2008\t3323\nAugust 2008\t3324\nJune 2008\t3325\nJuly 2003\t3326\nMay 2008\t3327\nMarch 2008\t3328\nAugust 2007\t3329\nJuly 2007\t3330\nFebruary 2007\t3331\nAugust 2008\t3332\nMay 2005\t3333\nMarch 2006\t3334\nMarch 2006\t3335\nFebruary 2006\t3336\nNovember 2005\t3337\nNovember 2005\t3338\nDecember 2002\t3339\nOctober 2005\t3340\nJanuary 2004\t3341\nJanuary 2003\t3342\nOctober 2003\t3343\nMarch 2004\t3344\nFebruary 2001\t3346\nDecember 2001\t3347\nApril 1999\t3348\nOctober 1998\t3350\nApril 1992\t3352\nDecember 2015\t3353\nDecember 2015\t3354\nSeptember 2015\t3355\nOctober 2015\t3356\nOctober 2014\t3357\nJune 2015\t3358\nApril 2015\t3359\nMay 2014\t3360\nApril 2015\t3361\nSeptember 2014\t3362\nOctober 2014\t3363\nOctober 2013\t3364\nJuly 2013\t3365\nJuly 2013\t3366\nJuly 2009\t3367\nDecember 2012\t3368\nOctober 2012\t3369\nSeptember 2012\t3370\nAugust 2012\t3371\nJanuary 2012\t3372\nJanuary 2012\t3373\nMay 2011\t3374\nJanuary 2011\t3375\nDecember 2010\t3376\nAugust 2010\t3377\nJune 2010\t3378\nApril 2010\t3379\nAugust 2010\t3380\nMarch 2010\t3381\nJune 2009\t3382\nJune 2009\t3383\nSeptember 2006\t3384\nJuly 2009\t3385\nOctober 2009\t3386\nJanuary 2009\t3387\nFebruary 2009\t3388\nJanuary 2009\t3389\nNovember 2008\t3390\nAugust 1998\t3391\nDecember 2007\t3392\nJanuary 2002\t3393\nSeptember 2006\t3394\nSeptember 2007\t3395\nAugust 2007\t3396\nAugust 2007\t3397\nMarch 2007\t3398\nDecember 2006\t3399\nJune 2007\t3400\nAugust 2006\t3401\nMarch 2007\t3402\nNovember 2006\t3403\nMarch 2006\t3404\nNovember 2001\t3405\nJanuary 2000\t3406\nOctober 2004\t3408\nJune 2004\t3409\nJuly 2003\t3410\nSeptember 2002\t3411\nMarch 2001\t3412\nAugust 2000\t3413\nNovember 1996\t3414\nNovember 2001\t3417\nMarch 2012\t3418\nJuly 2008\t3419\nDecember 2004\t3420\nJanuary 2004\t3421\nJanuary 2004\t3422\nNovember 2001\t3423\nMarch 2015\t3424\nOctober 2012\t3425\nDecember 2012\t3426\nOctober 2008\t3427\nSeptember 2008\t3428\nJuly 2007\t3429\nApril 2000\t3430\nAugust 2010\t3431\nJanuary 2008\t3432\nOctober 2009\t3433\nMarch 2003\t3434\nJune 2014\t3435\nSeptember 2011\t3436\nJune 2010\t3437\nMay 2012\t3438\nJanuary 2009\t3439\nDecember 1996\t3440\nJune 2003\t3441\nMay 2014\t3442\nJanuary 1997\t3443\nAugust 2013\t3444\nApril 2012\t3445\nMarch 2004\t3446\nOctober 2016\t3447\nMay 2015\t3448\nFebruary 2013\t3449\nSeptember 2011\t3450\nJuly 2009\t3451\nAugust 2006\t3452\nOctober 2009\t3453\nJanuary 2008\t3454\nJuly 2004\t3455\nNovember 2016\t3456\nSeptember 2014\t3457\nMay 2016\t3458\nApril 2015\t3459\nMay 2014\t3460\nAugust 2014\t3461\nMarch 2014\t3462\nSeptember 2012\t3463\nApril 2010\t3464\nMay 2012\t3465\nMay 2011\t3466\nSeptember 2011\t3467\nSeptember 2010\t3468\nOctober 2009\t3469\nFebruary 2010\t3470\nAugust 2009\t3471\nSeptember 2009\t3472\nOctober 2009\t3473\nMay 2008\t3474\nJanuary 2005\t3475\nFebruary 2009\t3476\nDecember 2008\t3477\nApril 2008\t3478\nFebruary 2006\t3479\nNovember 2007\t3480\nAugust 2007\t3481\nNovember 2006\t3482\nOctober 2003\t3483\nDecember 2001\t3484\nNovember 2005\t3485\nJuly 2016\t3486\nJuly 2014\t3487\nJanuary 2012\t3488\nJune 2011\t3489\nDecember 2004\t3490\nOctober 2003\t3491\nFebruary 2005\t3492\nAugust 2003\t3493\nDecember 2016\t3494\nAugust 2016\t3495\nJuly 2016\t3496\nJanuary 2016\t3497\nJune 2016\t3498\nDecember 2015\t3499\nMarch 2016\t3500\nAugust 2015\t3501\nAugust 2015\t3502\nAugust 2015\t3503\nJuly 2015\t3504\nMay 2015\t3505\nJune 2014\t3506\nJanuary 2015\t3507\nNovember 2013\t3508\nJanuary 2014\t3509\nMarch 2014\t3510\nJune 2014\t3511\nApril 2014\t3512\nSeptember 2013\t3513\nApril 2014\t3514\nOctober 2013\t3515\nJanuary 2013\t3516\nJune 2012\t3517\nSeptember 2012\t3518\nApril 2012\t3519\nJuly 2010\t3520\nAugust 2010\t3521\nNovember 2010\t3522\nJanuary 2010\t3523\nMarch 2010\t3524\nDecember 2009\t3525\nDecember 2009\t3526\nApril 2010\t3527\nApril 2003\t3528\nApril 2009\t3529\nMarch 2009\t3530\nSeptember 2011\t3531\nSeptember 2008\t3532\nFebruary 2009\t3533\nFebruary 2008\t3534\nAugust 2002\t3535\nNovember 2007\t3536\nSeptember 2007\t3537\nJune 2007\t3538\nJanuary 2007\t3539\nSeptember 2005\t3540\nDecember 2004\t3541\nApril 2006\t3542\nOctober 2005\t3543\nJuly 2005\t3544\nJanuary 2004\t3546\nMay 1993\t3547\nOctober 2000\t3548\nMay 2012\t3550\nSeptember 2009\t3551\nJune 2014\t3552\nMarch 2012\t3553\nApril 2012\t3554\nNovember 2010\t3555\nFebruary 2012\t3556\nJune 2008\t3557\nJanuary 2016\t3558\nMay 2015\t3559\nSeptember 2014\t3560\nFebruary 2014\t3561\nJuly 2013\t3562\nJuly 2012\t3563\nJune 2010\t3564\nJuly 2008\t3565\nJuly 2005\t3566\nOctober 2016\t3567\nNovember 2016\t3568\nAugust 2016\t3569\nDecember 2015\t3570\nDecember 2015\t3571\nAugust 2015\t3572\nFebruary 2016\t3573\nJanuary 2016\t3574\nDecember 2015\t3575\nSeptember 2015\t3576\nFebruary 2015\t3577\nJanuary 2015\t3578\nMarch 2015\t3579\nDecember 2014\t3580\nDecember 2014\t3581\nJanuary 2015\t3582\nDecember 2014\t3583\nNovember 2014\t3584\nOctober 2014\t3585\nJune 2014\t3586\nJune 2014\t3587\nJanuary 2014\t3588\nAugust 2013\t3589\nSeptember 2014\t3590\nJanuary 2014\t3591\nMarch 2014\t3592\nNovember 2013\t3593\nDecember 2013\t3594\nJanuary 2014\t3595\nAugust 2013\t3596\nAugust 2013\t3597\nJune 2013\t3598\nSeptember 2013\t3599\nApril 2013\t3600\nApril 2013\t3601\nMarch 2013\t3602\nMarch 2013\t3603\nSeptember 2012\t3604\nMarch 2012\t3605\nDecember 2008\t3606\nJanuary 2013\t3607\nFebruary 2014\t3608\nMay 2012\t3609\nJanuary 2012\t3610\nJuly 2010\t3611\nFebruary 2011\t3612\nFebruary 2011\t3613\nSeptember 2010\t3614\nJuly 2010\t3615\nJuly 2010\t3616\nJune 2009\t3617\nMarch 2009\t3618\nJanuary 2009\t3619\nApril 2008\t3620\nFebruary 2008\t3621\nOctober 2008\t3622\nDecember 2007\t3623\nJune 2008\t3624\nFebruary 2008\t3625\nFebruary 2008\t3626\nSeptember 2001\t3627\nFebruary 2009\t3628\nJuly 2007\t3629\nMarch 2007\t3630\nOctober 2007\t3631\nJuly 2007\t3632\nOctober 2006\t3633\nOctober 2006\t3634\nJune 2006\t3635\nOctober 2005\t3636\nJune 2005\t3637\nMay 2005\t3638\nApril 2005\t3639\nJanuary 2001\t3640\nApril 2003\t3641\nJuly 2003\t3642\nSeptember 2002\t3643\nFebruary 2000\t3644\nAugust 2000\t3645\nMay 2007\t3646\nJune 2012\t3647\nDecember 2015\t3648\nDecember 2015\t3649\nAugust 2015\t3650\nMay 2015\t3651\nApril 2015\t3652\nOctober 2014\t3653\nJune 2014\t3654\nNovember 2013\t3655\nJanuary 2014\t3656\nMarch 2014\t3657\nSeptember 2013\t3658\nAugust 2013\t3659\nJuly 2013\t3660\nOctober 2012\t3661\nMay 2012\t3662\nMay 2012\t3663\nNovember 2011\t3664\nSeptember 2011\t3665\nApril 2010\t3666\nApril 2011\t3667\nJanuary 2011\t3668\nAugust 2010\t3669\nNovember 2009\t3670\nSeptember 2009\t3671\nMarch 2009\t3672\nMarch 2007\t3673\nJune 2008\t3674\nDecember 2007\t3675\nDecember 2007\t3676\nSeptember 2007\t3677\nMay 2006\t3678\nMay 2007\t3679\nNovember 2006\t3680\nJuly 2006\t3681\nMay 2006\t3682\nJanuary 2006\t3683\nSeptember 2005\t3684\nJune 2005\t3685\nJuly 2003\t3686\nMarch 2004\t3687\nAugust 2006\t3688\nFebruary 2002\t3689\nNovember 2000\t3690\nOctober 1995\t3692\nNovember 2001\t3695\nDecember 2007\t3696\nOctober 2013\t3697\nFebruary 2013\t3698\nOctober 2007\t3699\nApril 2014\t3700\nJanuary 2009\t3701\nMarch 2004\t3702\nJune 2014\t3703\nJune 2014\t3704\nDecember 2015\t3705\nJune 2014\t3706\nJune 2014\t3707\nJune 2014\t3708\nAugust 2016\t3709\nOctober 2015\t3710\nJuly 2015\t3711\nAugust 2015\t3712\nJune 2015\t3713\nMarch 2015\t3714\nNovember 2014\t3715\nAugust 2014\t3716\nJuly 2014\t3717\nAugust 2014\t3718\nAugust 2014\t3719\nNovember 2014\t3720\nJune 2014\t3721\nJune 2014\t3722\nMarch 2014\t3723\nFebruary 2014\t3724\nMarch 2014\t3725\nFebruary 2014\t3726\nApril 2014\t3727\nJanuary 2014\t3728\nJanuary 2014\t3729\nOctober 2013\t3730\nOctober 2013\t3731\nDecember 2013\t3732\nJanuary 2014\t3733\nOctober 2013\t3734\nFebruary 2014\t3735\nDecember 2013\t3736\nNovember 2013\t3737\nFebruary 2013\t3738\nApril 2013\t3739\nAugust 2012\t3740\nMay 2013\t3741\nAugust 2012\t3742\nAugust 2013\t3743\nJuly 2012\t3744\nApril 2012\t3745\nJune 2012\t3746\nJanuary 2012\t3747\nJanuary 2012\t3748\nFebruary 2012\t3749\nNovember 2011\t3750\nMarch 2013\t3751\nJanuary 2011\t3752\nJanuary 2011\t3753\nMay 2011\t3754\nJanuary 2011\t3755\nJune 2010\t3756\nMay 2010\t3757\nMay 2010\t3758\nApril 2011\t3759\nApril 2010\t3760\nMarch 2010\t3761\nFebruary 2010\t3762\nJuly 2009\t3763\nDecember 2010\t3764\nMay 2009\t3765\nOctober 2008\t3766\nNovember 2008\t3767\nJune 2012\t3768\nDecember 2007\t3769\nNovember 2006\t3770\nDecember 2009\t3771\nAugust 2006\t3772\nOctober 2006\t3773\nOctober 2006\t3774\nJune 2007\t3775\nApril 2006\t3776\nNovember 2005\t3777\nOctober 2005\t3778\nSeptember 2005\t3779\nAugust 2005\t3780\nOctober 2003\t3781\nAugust 2003\t3782\nJanuary 2003\t3783\nMay 2002\t3784\nAugust 2000\t3785\nMay 1999\t3786\nOctober 2014\t3787\nOctober 2013\t3788\nAugust 2013\t3789\nJuly 2013\t3790\nSeptember 2012\t3791\nDecember 2009\t3792\nMay 2009\t3793\nJuly 2009\t3794\nFebruary 2009\t3795\nMarch 2009\t3796\nJune 2008\t3797\nApril 2008\t3798\nAugust 2007\t3799\nAugust 2008\t3800\nNovember 2006\t3801\nApril 2006\t3802\nFebruary 2004\t3803\nMay 2016\t3804\nApril 2015\t3805\nJune 2014\t3806\nFebruary 2014\t3807\nOctober 2013\t3808\nAugust 2013\t3809\nFebruary 2013\t3810\nApril 2013\t3811\nMay 2012\t3812\nFebruary 2012\t3813\nJune 2011\t3814\nJanuary 2011\t3815\nJune 2009\t3816\nMay 1996\t3817\nJanuary 2009\t3818\nFebruary 2009\t3819\nSeptember 2008\t3820\nSeptember 2008\t3821\nApril 2008\t3822\nNovember 2006\t3823\nSeptember 2006\t3824\nMay 2004\t3825\nJanuary 2004\t3826\nDecember 1999\t3827\nJanuary 2016\t3828\nJuly 2014\t3829\nJuly 2014\t3830\nApril 2013\t3831\nApril 2011\t3832\nOctober 2010\t3833\nApril 2010\t3834\nMarch 2010\t3835\nMarch 2010\t3836\nJuly 2009\t3837\nAugust 2008\t3838\nAugust 2006\t3839\nJune 2008\t3840\nFebruary 2008\t3841\nAugust 2006\t3842\nNovember 2005\t3843\nMarch 2003\t3844\nJune 2015\t3845\nMarch 2015\t3846\nJanuary 2014\t3847\nJuly 2013\t3848\nMay 2013\t3849\nDecember 2012\t3850\nJuly 2012\t3851\nJune 2012\t3852\nJune 2012\t3853\nNovember 2011\t3854\nSeptember 2010\t3855\nSeptember 2010\t3856\nJune 2010\t3857\nJune 2010\t3858\nNovember 2011\t3859\nFebruary 2010\t3860\nJuly 2009\t3861\nJuly 2009\t3862\nSeptember 2009\t3863\nSeptember 2000\t3864\nJanuary 2009\t3865\nJanuary 2009\t3866\nMay 2009\t3867\nApril 2009\t3868\nNovember 2008\t3869\nDecember 2008\t3870\nApril 2006\t3871\nJuly 2007\t3872\nJanuary 2006\t3873\nFebruary 2003\t3874\nAugust 2006\t3875\nAugust 2003\t3877\nOctober 1998\t3878\nJanuary 2016\t3879\nDecember 2014\t3880\nJune 2014\t3881\nFebruary 2014\t3882\nFebruary 2013\t3883\nNovember 2012\t3884\nNovember 2012\t3885\nOctober 2011\t3886\nMay 2012\t3887\nMay 2011\t3888\nOctober 2010\t3889\nNovember 2009\t3890\nDecember 1998\t3891\nSeptember 2009\t3892\nJuly 2009\t3893\nJanuary 2009\t3894\nFebruary 2009\t3895\nNovember 2008\t3896\nMarch 2008\t3897\nSeptember 2007\t3898\nSeptember 2007\t3899\nMay 2007\t3900\nApril 2008\t3901\nDecember 2006\t3902\nMay 2005\t3903\nMarch 2005\t3904\nOctober 2004\t3905\nJune 2003\t3906\nJuly 2003\t3907\nNovember 2002\t3908\nApril 2002\t3909\nJune 1984\t3910\nFebruary 2003\t3911\nJune 2002\t3912\nAugust 2001\t3913\nDecember 2001\t3914\nMarch 2002\t3915\nJanuary 2002\t3916\nFebruary 2002\t3917\nSeptember 2001\t3918\nJuly 2001\t3919\nJune 2001\t3920\nMarch 2004\t3921\nJanuary 2001\t3922\nMarch 2001\t3923\nJuly 2000\t3924\nJuly 2000\t3925\nJune 1999\t3926\nDecember 1999\t3927\nSeptember 1998\t3928\nSeptember 1998\t3929\nApril 1999\t3930\nSeptember 1994\t3931\nSeptember 2016\t3932\nJuly 2015\t3933\nJuly 2015\t3934\nMarch 2015\t3935\nMay 2015\t3936\nSeptember 2015\t3937\nJanuary 2015\t3938\nOctober 2014\t3939\nMarch 2014\t3940\nFebruary 2014\t3941\nNovember 2013\t3942\nAugust 2013\t3943\nJuly 2013\t3944\nMarch 2013\t3945\nMarch 2013\t3946\nSeptember 2011\t3947\nMay 2011\t3948\nMarch 2011\t3949\nOctober 2010\t3950\nAugust 2010\t3951\nJune 2010\t3952\nAugust 2010\t3953\nJuly 2010\t3954\nAugust 2009\t3955\nMay 2009\t3956\nMarch 2009\t3957\nJuly 2008\t3958\nOctober 2001\t3959\nMay 2008\t3960\nMay 2008\t3961\nApril 2006\t3962\nSeptember 2007\t3963\nDecember 2006\t3964\nMay 2006\t3965\nJune 2006\t3966\nDecember 2005\t3967\nNovember 2005\t3968\nJune 2003\t3969\nMarch 2005\t3970\nDecember 2003\t3971\nApril 2004\t3972\nDecember 2003\t3973\nAugust 2003\t3974\nJune 2003\t3975\nAugust 2003\t3976\nDecember 2002\t3977\nSeptember 2001\t3978\nOctober 1998\t3979\nMay 1997\t3980\nSeptember 2016\t3981\nMarch 2016\t3982\nJuly 2016\t3983\nJune 2004\t3984\nNovember 2015\t3985\nJuly 2016\t3986\nAugust 2015\t3987\nApril 2016\t3988\nOctober 2015\t3989\nJune 2015\t3990\nMay 2014\t3991\nDecember 2013\t3992\nFebruary 2014\t3993\nDecember 2013\t3994\nAugust 2013\t3995\nJuly 2013\t3996\nFebruary 2013\t3997\nApril 2013\t3998\nFebruary 2013\t3999\nJanuary 2012\t4000\nNovember 2011\t4001\nApril 2012\t4002\nAugust 2011\t4003\nAugust 2011\t4004\nMay 2011\t4005\nMay 2011\t4006\nFebruary 2011\t4007\nDecember 2010\t4008\nSeptember 2010\t4009\nAugust 2010\t4010\nOctober 2010\t4011\nAugust 2009\t4012\nMay 2010\t4013\nJune 2010\t4014\nMarch 2010\t4015\nJanuary 2010\t4016\nSeptember 2009\t4017\nMarch 2009\t4018\nNovember 2008\t4019\nNovember 2008\t4020\nJuly 2008\t4021\nJanuary 2008\t4022\nJuly 2007\t4023\nApril 2007\t4024\nOctober 2006\t4025\nMay 2005\t4026\nApril 2007\t4027\nApril 2007\t4028\nSeptember 2007\t4029\nApril 2006\t4030\nDecember 2005\t4031\nDecember 2004\t4032\nDecember 2004\t4033\nNovember 2003\t4034\nNovember 2003\t4035\nAugust 2004\t4036\nJuly 2002\t4037\nJuly 2002\t4038\nApril 2016\t4039\nDecember 2015\t4040\nSeptember 2015\t4041\nFebruary 2016\t4042\nJuly 2015\t4043\nJuly 2015\t4044\nApril 2015\t4045\nDecember 2014\t4046\nMay 2015\t4047\nAugust 2014\t4048\nNovember 2013\t4049\nSeptember 2013\t4050\nDecember 2012\t4051\nDecember 2012\t4052\nOctober 2012\t4053\nOctober 2012\t4054\nAugust 2012\t4055\nJune 2012\t4056\nMay 2012\t4057\nJanuary 2012\t4058\nSeptember 2011\t4059\nSeptember 2011\t4060\nSeptember 2011\t4061\nAugust 2011\t4062\nFebruary 2012\t4063\nJuly 2011\t4064\nApril 2011\t4065\nAugust 2011\t4066\nMay 2011\t4067\nApril 2011\t4068\nJuly 2011\t4069\nJune 2011\t4070\nSeptember 2010\t4071\nApril 2011\t4072\nSeptember 2010\t4073\nJune 2010\t4074\nMay 2010\t4075\nApril 2010\t4076\nSeptember 2010\t4077\nNovember 2009\t4078\nNovember 2009\t4079\nOctober 2009\t4080\nApril 2010\t4081\nSeptember 2009\t4082\nNovember 2009\t4083\nMarch 2009\t4084\nJune 1992\t4085\nApril 2009\t4086\nDecember 2008\t4087\nJanuary 2009\t4088\nDecember 2008\t4089\nNovember 2008\t4090\nJuly 2008\t4091\nMay 2008\t4092\nJune 2008\t4093\nMarch 2008\t4094\nNovember 2007\t4095\nOctober 2007\t4096\nJune 2007\t4097\nJune 2004\t4098\nFebruary 2007\t4099\nOctober 2006\t4100\nJuly 2006\t4101\nFebruary 2006\t4102\nApril 2006\t4103\nSeptember 2000\t4104\nDecember 2005\t4105\nJanuary 2006\t4106\nDecember 2005\t4107\nAugust 2005\t4109\nJune 2005\t4110\nFebruary 2003\t4111\nSeptember 2004\t4112\nSeptember 2003\t4113\nOctober 2000\t4114\nMay 2000\t4115\nDecember 1998\t4116\nFebruary 2012\t4117\nAugust 2015\t4118\nJuly 2015\t4119\nJune 2015\t4120\nFebruary 2016\t4121\nOctober 2014\t4122\nAugust 2014\t4123\nJuly 2015\t4124\nSeptember 2014\t4125\nJune 2014\t4126\nJuly 2014\t4127\nMarch 2015\t4128\nJune 2014\t4129\nApril 2014\t4130\nSeptember 2014\t4131\nOctober 2014\t4132\nJanuary 2014\t4133\nFebruary 2014\t4134\nDecember 2013\t4135\nJune 2013\t4136\nNovember 2013\t4137\nMay 2013\t4138\nMay 2013\t4139\nJanuary 2013\t4140\nJune 2013\t4141\nDecember 2012\t4142\nFebruary 2013\t4143\nFebruary 2013\t4144\nSeptember 2012\t4145\nJuly 2012\t4146\nMay 2012\t4147\nJune 2012\t4148\nJanuary 2012\t4149\nJanuary 2012\t4150\nFebruary 2012\t4151\nFebruary 2012\t4152\nDecember 2011\t4153\nDecember 2011\t4154\nNovember 2011\t4155\nAugust 2011\t4156\nNovember 2011\t4157\nMay 2011\t4158\nApril 2011\t4159\nOctober 2010\t4160\nAugust 2010\t4161\nAugust 2010\t4162\nAugust 2010\t4163\nAugust 2010\t4164\nMay 2010\t4165\nJune 2004\t4166\nSeptember 2010\t4167\nMarch 2010\t4168\nJanuary 2008\t4169\nJanuary 2010\t4170\nDecember 2009\t4171\nOctober 2009\t4172\nJanuary 2010\t4173\nOctober 2010\t4174\nJuly 1991\t4175\nSeptember 2009\t4176\nOctober 2009\t4177\nApril 2010\t4178\nFebruary 2009\t4179\nJuly 2009\t4180\nJuly 2009\t4181\nApril 1999\t4182\nMarch 1999\t4183\nNovember 2000\t4184\nJune 2008\t4185\nFebruary 2006\t4186\nSeptember 2006\t4187\nJuly 2009\t4188\nApril 2009\t4189\nMarch 2009\t4190\nNovember 2008\t4191\nDecember 2008\t4192\nDecember 2008\t4193\nNovember 2008\t4194\nOctober 2008\t4195\nSeptember 2008\t4196\nMay 2008\t4197\nAugust 2008\t4198\nJuly 2008\t4199\nJune 2007\t4200\nApril 2008\t4201\nFebruary 2008\t4202\nMarch 2008\t4203\nJanuary 2008\t4204\nAugust 2007\t4205\nNovember 2007\t4206\nJanuary 2008\t4207\nNovember 2007\t4208\nApril 2008\t4209\nJune 2008\t4210\nJune 2007\t4211\nFebruary 2008\t4212\nAugust 2007\t4213\nDecember 2003\t4214\nMay 2007\t4215\nFebruary 2007\t4216\nDecember 2006\t4217\nJanuary 2007\t4218\nNovember 2006\t4219\nMarch 2007\t4220\nFebruary 2007\t4221\nDecember 2006\t4222\nAugust 2006\t4223\nJune 2006\t4224\nOctober 2006\t4225\nJuly 2006\t4226\nJune 2006\t4227\nSeptember 2002\t4228\nFebruary 2004\t4229\nFebruary 2006\t4230\nJuly 2002\t4231\nMay 2006\t4232\nJanuary 2006\t4233\nAugust 2005\t4234\nJanuary 2006\t4235\nJanuary 2006\t4236\nDecember 2005\t4237\nDecember 2005\t4238\nOctober 2003\t4239\nFebruary 2003\t4240\nMay 2004\t4241\nMay 2004\t4242\nAugust 2003\t4243\nApril 2005\t4244\nNovember 2005\t4245\nAugust 2005\t4246\nJune 2005\t4247\nSeptember 2005\t4248\nOctober 2005\t4249\nMay 2005\t4250\nApril 2005\t4251\nAugust 2004\t4252\nFebruary 2004\t4253\nDecember 2004\t4254\nNovember 2003\t4255\nAugust 2004\t4256\nMay 2004\t4257\nApril 2001\t4258\nApril 2004\t4259\nApril 2004\t4260\nDecember 2003\t4261\nDecember 2003\t4262\nAugust 2003\t4263\nJanuary 2004\t4264\nMay 2003\t4265\nApril 2003\t4266\nDecember 2002\t4267\nSeptember 2002\t4268\nMarch 1998\t4269\nMay 2001\t4270\nNovember 2000\t4271\nNovember 2000\t4272\nNovember 2000\t4273\nAugust 2001\t4274\nJanuary 2002\t4275\nSeptember 1999\t4276\nSeptember 1999\t4277\nMay 1999\t4278\nMarch 1999\t4279\nJune 1999\t4280\nMarch 1998\t4281\nMarch 1998\t4282\nMarch 1988\t4283\nAugust 1997\t4284\nApril 1998\t4285\nJuly 1995\t4286\nJanuary 1996\t4287\nDecember 2013\t4288\nMarch 2016\t4289\nApril 2016\t4290\nMarch 2016\t4291\nMarch 2016\t4292\nDecember 2015\t4293\nOctober 2015\t4294\nJanuary 2016\t4295\nNovember 2015\t4296\nNovember 2015\t4297\nNovember 2015\t4298\nOctober 2015\t4299\nJuly 2015\t4300\nJune 2015\t4301\nJuly 2015\t4302\nJuly 2015\t4303\nApril 2015\t4304\nJune 2015\t4305\nJanuary 2015\t4306\nJanuary 2015\t4307\nDecember 2009\t4308\nJanuary 2015\t4309\nOctober 2014\t4310\nNovember 2014\t4311\nJuly 2014\t4312\nJuly 2014\t4313\nJune 2014\t4314\nOctober 2014\t4315\nMay 2014\t4316\nAugust 2014\t4317\nApril 2014\t4318\nDecember 2014\t4319\nMay 2014\t4320\nFebruary 2014\t4321\nMarch 2014\t4322\nMarch 2014\t4323\nApril 2014\t4324\nApril 2014\t4325\nOctober 2013\t4326\nOctober 2013\t4327\nMay 2013\t4328\nAugust 2013\t4329\nJune 2013\t4330\nJune 2013\t4331\nSeptember 2002\t4332\nJanuary 2013\t4333\nDecember 2012\t4334\nSeptember 2012\t4335\nOctober 2012\t4336\nFebruary 2013\t4337\nFebruary 2013\t4338\nJuly 2012\t4339\nAugust 2012\t4340\nJune 2012\t4341\nJuly 2012\t4342\nMarch 2012\t4343\nMarch 2012\t4344\nApril 2012\t4345\nApril 2012\t4346\nMarch 2012\t4347\nDecember 2011\t4348\nNovember 2011\t4349\nJanuary 2012\t4350\nSeptember 2011\t4351\nDecember 2011\t4352\nDecember 2011\t4353\nAugust 2011\t4354\nJanuary 2012\t4355\nJuly 2011\t4356\nJune 2011\t4357\nMay 2011\t4358\nJuly 2011\t4359\nFebruary 2011\t4360\nMay 2011\t4361\nFebruary 2012\t4362\nJanuary 2011\t4363\nNovember 2010\t4364\nOctober 2010\t4365\nAugust 2010\t4366\nAugust 2010\t4367\nAugust 2010\t4368\nAugust 2010\t4369\nMay 2010\t4370\nJune 2007\t4371\nApril 2010\t4372\nMay 2010\t4373\nMarch 2010\t4374\nJanuary 2010\t4375\nFebruary 2010\t4376\nDecember 2009\t4377\nDecember 2009\t4378\nNovember 2009\t4379\nNovember 2009\t4380\nDecember 2009\t4381\nSeptember 2009\t4382\nSeptember 2009\t4383\nAugust 2009\t4384\nJanuary 2010\t4385\nNovember 2009\t4386\nJuly 2009\t4387\nJuly 2009\t4388\nJanuary 2010\t4389\nAugust 2009\t4390\nNovember 2005\t4391\nOctober 2006\t4392\nFebruary 2008\t4393\nMarch 2003\t4394\nMarch 2009\t4395\nFebruary 2009\t4396\nDecember 2008\t4397\nSeptember 2009\t4398\nDecember 2008\t4399\nSeptember 2008\t4400\nJuly 2008\t4401\nApril 2008\t4402\nAugust 2008\t4403\nSeptember 2008\t4404\nMay 2008\t4405\nDecember 2002\t4406\nFebruary 2008\t4407\nApril 2008\t4408\nApril 2008\t4409\nMarch 2004\t4410\nJuly 2008\t4411\nMay 2008\t4412\nFebruary 2008\t4413\nDecember 2007\t4414\nFebruary 2008\t4415\nDecember 2007\t4416\nMarch 2008\t4417\nFebruary 2008\t4418\nNovember 2007\t4419\nNovember 2007\t4420\nJanuary 2008\t4421\nDecember 2007\t4422\nNovember 2007\t4423\nAugust 2007\t4424\nJanuary 2008\t4425\nApril 2007\t4426\nOctober 2007\t4427\nOctober 2007\t4428\nAugust 2007\t4429\nMay 2007\t4430\nJanuary 2006\t4431\nApril 2007\t4432\nJune 2003\t4433\nMarch 2007\t4434\nOctober 2005\t4435\nJanuary 2007\t4436\nApril 2007\t4437\nAugust 2007\t4438\nFebruary 2007\t4439\nNovember 2006\t4440\nOctober 2006\t4441\nFebruary 2007\t4442\nMay 2006\t4443\nJuly 2006\t4444\nDecember 2006\t4445\nJuly 2006\t4446\nMay 2006\t4447\nFebruary 2007\t4448\nJune 2006\t4449\nJune 2006\t4450\nJune 2006\t4451\nFebruary 2006\t4452\nDecember 2005\t4453\nAugust 2005\t4454\nFebruary 2006\t4455\nDecember 2005\t4456\nSeptember 2003\t4457\nMay 2002\t4458\nOctober 2005\t4459\nOctober 2005\t4460\nMay 2004\t4461\nFebruary 2000\t4462\nMay 2005\t4463\nJuly 2003\t4464\nJuly 2004\t4466\nJuly 2004\t4467\nOctober 2003\t4468\nNovember 2004\t4469\nOctober 2004\t4470\nAugust 2005\t4471\nJuly 2005\t4472\nDecember 2004\t4473\nMay 2005\t4474\nAugust 2005\t4475\nNovember 2004\t4476\nOctober 2003\t4477\nNovember 2004\t4478\nNovember 2004\t4479\nMarch 2005\t4480\nApril 2004\t4481\nApril 2004\t4482\nJanuary 2004\t4483\nJune 2003\t4484\nJuly 2002\t4485\nDecember 2003\t4486\nApril 2003\t4487\nApril 2004\t4488\nJune 2001\t4489\nNovember 2003\t4490\nFebruary 2003\t4491\nJune 2003\t4492\nDecember 2002\t4493\nMay 2002\t4494\nFebruary 2002\t4495\nMarch 2002\t4496\nSeptember 2003\t4497\nOctober 2001\t4498\nDecember 2001\t4499\nAugust 2002\t4500\nMarch 1998\t4501\nOctober 2000\t4502\nNovember 2000\t4503\nMay 2001\t4504\nOctober 2000\t4505\nApril 2001\t4506\nDecember 2000\t4507\nJuly 2000\t4508\nSeptember 2000\t4509\nApril 2000\t4510\nApril 2000\t4511\nMarch 1997\t4512\nApril 2000\t4513\nFebruary 1998\t4514\nJune 2000\t4515\nSeptember 1999\t4516\nApril 1999\t4517\nJune 1999\t4518\nApril 2000\t4519\nNovember 1998\t4520\nSeptember 1998\t4521\nSeptember 1998\t4522\nMay 1998\t4523\nFebruary 1998\t4524\nSeptember 2000\t4525\nJune 1997\t4526\nMarch 1997\t4527\nJanuary 1996\t4528\nJanuary 1996\t4529\nMay 1994\t4530\nOctober 1994\t4531\nSeptember 1994\t4532\nJuly 1995\t4533\nFebruary 1994\t4534\nMarch 2006\t4535\nJanuary 2005\t4536\nAugust 2016\t4537\nJuly 2016\t4538\nMay 2016\t4539\nMarch 2016\t4540\nJune 2014\t4541\nJanuary 2016\t4542\nJuly 2016\t4543\nDecember 2015\t4544\nDecember 2015\t4545\nJuly 2016\t4546\nMarch 2016\t4547\nFebruary 2016\t4548\nDecember 2015\t4549\nFebruary 2016\t4550\nNovember 2015\t4551\nNovember 2015\t4552\nSeptember 2015\t4553\nAugust 2015\t4554\nAugust 2015\t4555\nSeptember 2015\t4556\nJuly 2015\t4557\nMay 2015\t4558\nMay 2015\t4559\nDecember 2015\t4560\nApril 2015\t4561\nApril 2015\t4562\nMay 2015\t4563\nMay 2015\t4564\nJanuary 2015\t4565\nFebruary 2015\t4566\nJanuary 2015\t4567\nJanuary 2015\t4568\nJanuary 2015\t4569\nDecember 2014\t4570\nNovember 2014\t4571\nDecember 2014\t4572\nDecember 2014\t4573\nSeptember 2014\t4574\nFebruary 2015\t4575\nJuly 2014\t4576\nJanuary 2015\t4577\nSeptember 2014\t4578\nOctober 2014\t4579\nSeptember 2014\t4580\nJuly 2014\t4581\nJune 2014\t4582\nJune 2014\t4583\nJanuary 2014\t4584\nOctober 2014\t4585\nSeptember 2014\t4586\nMarch 2014\t4587\nAugust 2014\t4588\nFebruary 2014\t4589\nMay 2014\t4590\nApril 2015\t4591\nAugust 2014\t4592\nNovember 2013\t4593\nApril 2014\t4594\nJanuary 2014\t4595\nDecember 2013\t4596\nJanuary 2014\t4597\nNovember 2013\t4598\nOctober 2013\t4599\nDecember 2013\t4600\nNovember 2013\t4601\nSeptember 2013\t4602\nOctober 2013\t4603\nOctober 2013\t4604\nAugust 2013\t4605\nJuly 2013\t4606\nJune 2013\t4607\nJuly 2013\t4608\nApril 2013\t4609\nMay 2013\t4610\nMarch 2013\t4611\nDecember 2012\t4612\nJanuary 2013\t4613\nNovember 2012\t4614\nDecember 2012\t4615\nDecember 2012\t4616\nDecember 2012\t4617\nOctober 2012\t4618\nOctober 2012\t4619\nAugust 2012\t4620\nJune 2012\t4621\nJune 2012\t4622\nMarch 2013\t4623\nApril 2012\t4624\nSeptember 2012\t4625\nJune 2012\t4626\nApril 2012\t4627\nApril 2012\t4628\nMay 2012\t4629\nJanuary 2012\t4630\nDecember 2011\t4631\nNovember 2011\t4632\nNovember 2011\t4633\nOctober 2011\t4634\nNovember 2011\t4635\nNovember 2011\t4636\nJuly 2011\t4637\nOctober 2011\t4638\nSeptember 2011\t4639\nAugust 2011\t4640\nDecember 2011\t4641\nJuly 2011\t4642\nJuly 2011\t4643\nJune 2011\t4644\nAugust 2011\t4645\nMay 2011\t4646\nMarch 2011\t4647\nDecember 2011\t4648\nApril 2011\t4649\nMay 2011\t4650\nMarch 2011\t4651\nJune 2011\t4652\nJuly 2011\t4653\nApril 2011\t4654\nDecember 2010\t4655\nDecember 2010\t4656\nFebruary 2011\t4657\nJanuary 2011\t4658\nOctober 2010\t4659\nNovember 2010\t4660\nOctober 2010\t4661\nNovember 2010\t4662\nAugust 2010\t4663\nMay 2011\t4664\nJune 2010\t4665\nApril 2004\t4666\nMay 2010\t4667\nOctober 2010\t4668\nJuly 2010\t4669\nApril 2010\t4670\nApril 2010\t4671\nMarch 2010\t4672\nOctober 2010\t4673\nSeptember 2009\t4674\nSeptember 2009\t4675\nSeptember 2009\t4676\nNovember 2009\t4677\nNovember 2009\t4678\nNovember 2009\t4679\nOctober 2009\t4680\n"
      },
      "dateCreated": "Dec 4, 2016 6:45:46 PM",
      "dateStarted": "Dec 4, 2016 6:48:30 PM",
      "dateFinished": "Dec 4, 2016 6:48:30 PM",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "title": "Extract Tokens",
      "text": "%pyspark\n\nimport re\nfrom pyspark.sql.functions import udf\nfrom pyspark.sql.types import *\n\ndef parse_text(text):\n    ##############################################################################################\n    #\n    #   Stopwords\n    #   This is a list of common/low-value words that you\u0027d like excluded from the word counts\n    #   You can customize this list and there are many packages out there that has a pre-defined\n    #   list that you can start with (in addition to the short one I have listed below)\n    #\n    ##############################################################################################\n    stopwords_core \u003d [\u0027a\u0027, u\u0027about\u0027, u\u0027above\u0027, u\u0027after\u0027, u\u0027again\u0027, u\u0027against\u0027, u\u0027ain\u0027, u\u0027all\u0027, u\u0027am\u0027, u\u0027an\u0027, u\u0027and\u0027, u\u0027any\u0027, u\u0027are\u0027, u\u0027aren\u0027, u\u0027as\u0027, u\u0027at\u0027, u\u0027be\u0027, u\u0027because\u0027,\n        u\u0027been\u0027, u\u0027before\u0027, u\u0027being\u0027, u\u0027below\u0027, u\u0027between\u0027, u\u0027both\u0027, u\u0027but\u0027, u\u0027by\u0027, u\u0027can\u0027, \u0027come\u0027, u\u0027could\u0027, u\u0027d\u0027, u\u0027did\u0027, u\u0027didn\u0027, u\u0027do\u0027, u\u0027does\u0027, u\u0027doesn\u0027, u\u0027doing\u0027, u\u0027don\u0027,\n        u\u0027down\u0027, u\u0027during\u0027, u\u0027each\u0027, u\u0027few\u0027, u\u0027for\u0027, u\u0027from\u0027, u\u0027further\u0027, u\u0027had\u0027, u\u0027hadn\u0027, u\u0027has\u0027, u\u0027hasn\u0027, u\u0027have\u0027, u\u0027haven\u0027, u\u0027having\u0027, u\u0027he\u0027, u\u0027her\u0027, u\u0027here\u0027, u\u0027hers\u0027, \n        u\u0027herself\u0027, u\u0027him\u0027, u\u0027himself\u0027, u\u0027his\u0027, u\u0027how\u0027, u\u0027i\u0027, u\u0027if\u0027, u\u0027in\u0027, u\u0027into\u0027, u\u0027is\u0027, u\u0027isn\u0027, u\u0027it\u0027, u\u0027its\u0027, u\u0027itself\u0027, u\u0027just\u0027, u\u0027ll\u0027, u\u0027m\u0027, u\u0027ma\u0027, u\u0027me\u0027, u\u0027mightn\u0027,\n        u\u0027more\u0027, u\u0027most\u0027, u\u0027mustn\u0027, u\u0027my\u0027, u\u0027myself\u0027, u\u0027needn\u0027, u\u0027no\u0027, u\u0027nor\u0027, u\u0027not\u0027, u\u0027now\u0027, u\u0027o\u0027, u\u0027of\u0027, u\u0027off\u0027, u\u0027on\u0027, u\u0027once\u0027, u\u0027only\u0027, u\u0027or\u0027, u\u0027other\u0027, u\u0027our\u0027, u\u0027ours\u0027,\n        u\u0027ourselves\u0027, u\u0027out\u0027, u\u0027over\u0027, u\u0027own\u0027, u\u0027re\u0027, u\u0027s\u0027, u\u0027same\u0027, u\u0027shan\u0027, u\u0027she\u0027, u\u0027should\u0027, u\u0027shouldn\u0027, u\u0027so\u0027, u\u0027some\u0027, u\u0027such\u0027, u\u0027t\u0027, u\u0027than\u0027, u\u0027that\u0027, u\u0027the\u0027, u\u0027their\u0027,\n        u\u0027theirs\u0027, u\u0027them\u0027,u\u0027themselves\u0027, u\u0027then\u0027, u\u0027there\u0027, u\u0027these\u0027, u\u0027they\u0027, u\u0027this\u0027, u\u0027those\u0027, u\u0027through\u0027, u\u0027to\u0027, u\u0027too\u0027, u\u0027under\u0027, u\u0027until\u0027, u\u0027up\u0027, u\u0027ve\u0027, u\u0027very\u0027, u\u0027was\u0027,\n        u\u0027wasnt\u0027, u\u0027we\u0027, \u0027without\u0027, u\u0027were\u0027,u\u0027weren\u0027, u\u0027what\u0027, u\u0027when\u0027, u\u0027where\u0027, u\u0027which\u0027, u\u0027while\u0027, u\u0027who\u0027, u\u0027whom\u0027, u\u0027why\u0027, u\u0027will\u0027, u\u0027with\u0027, u\u0027would\u0027, u\u0027y\u0027, u\u0027you\u0027, u\u0027your\u0027,\n        u\u0027yours\u0027, u\u0027yourself\u0027,u\u0027yourselves\u0027]\n    stopwords_custom \u003d [\u0027study\u0027,\u0027subjects\u0027]\n    stopwords \u003d stopwords_core + stopwords_custom\n    stopwords \u003d [word.lower() for word in stopwords]\n    tokens \u003d re.sub(\u0027[^a-zA-Z\\- ]\u0027,\u0027\u0027,text.lower().replace(\"\u0027s\",\"\")).split(\" \")\n    return [token for token in tokens if token not in stopwords]\n\ndata_tokens \u003d  rawdata.filter(lambda x: x not in header)    \\\n                .map(lambda x: x.split(\u0027|\u0027))                \\\n                .map(lambda x: parse_text(x[2]))            \\\n                .flatMap(lambda x: x)                       \\\n                .filter(lambda x: len(x) \u003e 3)               \\\n                .map(lambda x: (x.lower(), 1))              \\\n                .reduceByKey(lambda x,y: x+y)               \\\n                .map(lambda x: (x[1],x[0]))                 \\\n                .sortByKey(ascending\u003dFalse)\n\nfor token in data_tokens.take(100):\n    print token",
      "dateUpdated": "Dec 4, 2016 9:08:26 PM",
      "config": {
        "colWidth": 12.0,
        "graph": {
          "mode": "table",
          "height": 300.0,
          "optionOpen": false,
          "keys": [],
          "values": [],
          "groups": [],
          "scatter": {}
        },
        "enabled": true,
        "editorMode": "ace/mode/scala",
        "title": true,
        "editorHide": true
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "jobName": "paragraph_1480881151089_-1700856764",
      "id": "20161204-195231_1446217384",
      "result": {
        "code": "SUCCESS",
        "type": "TEXT",
        "msg": "(1270, u\u0027patients\u0027)\n(805, u\u0027cancer\u0027)\n(564, u\u0027treating\u0027)\n(464, u\u0027safety\u0027)\n(421, u\u0027therapy\u0027)\n(419, u\u0027treatment\u0027)\n(350, u\u0027efficacy\u0027)\n(270, u\u0027stage\u0027)\n(236, u\u0027disease\u0027)\n(235, u\u0027cell\u0027)\n(235, u\u0027trial\u0027)\n(229, u\u0027chemotherapy\u0027)\n(219, u\u0027breast\u0027)\n(194, u\u0027combination\u0027)\n(189, u\u0027surgery\u0027)\n(181, u\u0027metastatic\u0027)\n(178, u\u0027acute\u0027)\n(170, u\u0027phase\u0027)\n(168, u\u0027radiation\u0027)\n(162, u\u0027lung\u0027)\n(156, u\u0027advanced\u0027)\n(152, u\u0027chronic\u0027)\n(151, u\u0027pain\u0027)\n(137, u\u0027versus\u0027)\n(135, u\u0027evaluation\u0027)\n(135, u\u0027evaluate\u0027)\n(135, u\u0027effect\u0027)\n(128, u\u0027women\u0027)\n(127, u\u0027recurrent\u0027)\n(123, u\u0027diabetes\u0027)\n(121, u\u0027adults\u0027)\n(118, u\u0027effects\u0027)\n(118, u\u0027leukemia\u0027)\n(117, u\u0027children\u0027)\n(112, u\u0027prostate\u0027)\n(110, u\u0027clinical\u0027)\n(104, u\u0027risk\u0027)\n(101, u\u0027intervention\u0027)\n(101, u\u0027syndrome\u0027)\n(98, u\u0027type\u0027)\n(96, u\u0027diagnosed\u0027)\n(95, u\u0027tumors\u0027)\n(93, u\u0027newly\u0027)\n(93, u\u0027blood\u0027)\n(92, u\u0027pilot\u0027)\n(90, u\u0027care\u0027)\n(85, u\u0027using\u0027)\n(84, u\u0027brain\u0027)\n(83, u\u0027vaccine\u0027)\n(82, u\u0027outcomes\u0027)\n(82, u\u0027dose\u0027)\n(81, u\u0027prevention\u0027)\n(81, u\u0027randomized\u0027)\n(79, u\u0027non-small\u0027)\n(79, u\u0027health\u0027)\n(77, u\u0027healthy\u0027)\n(76, u\u0027bevacizumab\u0027)\n(76, u\u0027tolerability\u0027)\n(75, u\u0027lymphoma\u0027)\n(75, u\u0027cardiovascular\u0027)\n(73, u\u0027undergoing\u0027)\n(73, u\u0027severe\u0027)\n(73, u\u0027refractory\u0027)\n(72, u\u0027primary\u0027)\n(71, u\u0027plus\u0027)\n(71, u\u0027response\u0027)\n(70, u\u0027heart\u0027)\n(69, u\u0027disorder\u0027)\n(68, u\u0027receiving\u0027)\n(68, u\u0027older\u0027)\n(67, u\u0027oral\u0027)\n(67, u\u0027comparison\u0027)\n(66, u\u0027system\u0027)\n(65, u\u0027function\u0027)\n(63, u\u0027early\u0027)\n(63, u\u0027exercise\u0027)\n(62, u\u0027solid\u0027)\n(61, u\u0027management\u0027)\n(60, u\u0027paclitaxel\u0027)\n(60, u\u0027moderate\u0027)\n(60, u\u0027registry\u0027)\n(58, u\u0027kidney\u0027)\n(58, u\u0027program\u0027)\n(58, u\u0027pharmacokinetics\u0027)\n(57, u\u0027multiple\u0027)\n(57, u\u0027patient\u0027)\n(57, u\u0027assess\u0027)\n(57, u\u0027hydrochloride\u0027)\n(56, u\u0027evaluating\u0027)\n(56, u\u0027knee\u0027)\n(55, u\u0027carboplatin\u0027)\n(55, u\u0027pulmonary\u0027)\n(55, u\u0027tumor\u0027)\n(55, u\u0027weight\u0027)\n(55, u\u0027malignant\u0027)\n(53, u\u0027relapsed\u0027)\n(53, u\u0027high\u0027)\n(53, u\u0027effectiveness\u0027)\n(52, u\u0027training\u0027)\n(52, u\u0027compared\u0027)\n"
      },
      "dateCreated": "Dec 4, 2016 7:52:31 PM",
      "dateStarted": "Dec 4, 2016 8:17:33 PM",
      "dateFinished": "Dec 4, 2016 8:17:34 PM",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "title": "Extract N-Grams (Common Phrases)",
      "text": "%pyspark\n\ndef find_ngrams(list, n):\n   return zip(*[list[i:] for i in range(n)])\n\nngrams \u003d  rawdata.filter(lambda x: x not in header)     \\\n              .map(lambda x: x.split(\u0027|\u0027)[2])           \\\n              .map(lambda x: x.split(\u0027 \u0027))              \\\n              .flatMap(lambda x: find_ngrams(x, 5))     \\\n              .map(lambda x: (x,1))                     \\\n              .reduceByKey(lambda x,y: x+y)             \\\n              .map(lambda x: [x[1],x[0]])               \\\n              .sortByKey(ascending\u003dFalse)\n\nfor i in ngrams.take(50):\n    print i",
      "dateUpdated": "Dec 4, 2016 9:08:37 PM",
      "config": {
        "colWidth": 12.0,
        "graph": {
          "mode": "table",
          "height": 300.0,
          "optionOpen": false,
          "keys": [],
          "values": [],
          "groups": [],
          "scatter": {}
        },
        "enabled": true,
        "editorMode": "ace/mode/python",
        "editorHide": true,
        "title": true
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "jobName": "paragraph_1480885437318_1481746146",
      "id": "20161204-210357_1520442405",
      "result": {
        "code": "SUCCESS",
        "type": "TEXT",
        "msg": "(81, (u\u0027Therapy\u0027, u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027))\n(65, (u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Stage\u0027))\n(43, (u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Recurrent\u0027))\n(38, (u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Metastatic\u0027))\n(37, (u\u0027Radiation\u0027, u\u0027Therapy\u0027, u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027))\n(34, (u\u0027the\u0027, u\u0027Safety\u0027, u\u0027and\u0027, u\u0027Efficacy\u0027, u\u0027of\u0027))\n(34, (u\u0027the\u0027, u\u0027Efficacy\u0027, u\u0027and\u0027, u\u0027Safety\u0027, u\u0027of\u0027))\n(32, (u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Newly\u0027, u\u0027Diagnosed\u0027))\n(32, (u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Newly\u0027))\n(29, (u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Advanced\u0027))\n(24, (u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Type\u0027, u\u00272\u0027, u\u0027Diabetes\u0027))\n(24, (u\u0027Chemotherapy\u0027, u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027))\n(22, (u\u0027Safety\u0027, u\u0027and\u0027, u\u0027Efficacy\u0027, u\u0027Study\u0027, u\u0027of\u0027))\n(22, (u\u0027Stage\u0027, u\u0027III\u0027, u\u0027or\u0027, u\u0027Stage\u0027, u\u0027IV\u0027))\n(21, (u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Relapsed\u0027))\n(21, (u\u0027Study\u0027, u\u0027to\u0027, u\u0027Evaluate\u0027, u\u0027the\u0027, u\u0027Safety\u0027))\n(21, (u\u0027in\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Type\u0027, u\u00272\u0027))\n(20, (u\u0027Surgery\u0027, u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027))\n(20, (u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Relapsed\u0027, u\u0027or\u0027, u\u0027Refractory\u0027))\n(20, (u\u0027Radiation\u0027, u\u0027Therapy\u0027, u\u0027With\u0027, u\u0027or\u0027, u\u0027Without\u0027))\n(19, (u\u0027Efficacy\u0027, u\u0027and\u0027, u\u0027Safety\u0027, u\u0027Study\u0027, u\u0027of\u0027))\n(19, (u\u0027A\u0027, u\u0027Study\u0027, u\u0027to\u0027, u\u0027Evaluate\u0027, u\u0027the\u0027))\n(18, (u\u0027and\u0027, u\u0027Radiation\u0027, u\u0027Therapy\u0027, u\u0027in\u0027, u\u0027Treating\u0027))\n(18, (u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Young\u0027, u\u0027Patients\u0027, u\u0027With\u0027))\n(17, (u\u0027With\u0027, u\u0027Type\u0027, u\u00272\u0027, u\u0027Diabetes\u0027, u\u0027Mellitus\u0027))\n(17, (u\u0027Bevacizumab\u0027, u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027))\n(17, (u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Relapsed\u0027, u\u0027or\u0027))\n(17, (u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Locally\u0027))\n(16, (u\u0027With\u0027, u\u0027or\u0027, u\u0027Without\u0027, u\u0027Bevacizumab\u0027, u\u0027in\u0027))\n(16, (u\u0027Subjects\u0027, u\u0027With\u0027, u\u0027Type\u0027, u\u00272\u0027, u\u0027Diabetes\u0027))\n(16, (u\u0027or\u0027, u\u0027Without\u0027, u\u0027Bevacizumab\u0027, u\u0027in\u0027, u\u0027Treating\u0027))\n(16, (u\u0027to\u0027, u\u0027Evaluate\u0027, u\u0027the\u0027, u\u0027Safety\u0027, u\u0027and\u0027))\n(16, (u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Recurrent\u0027, u\u0027or\u0027))\n(15, (u\u0027Efficacy\u0027, u\u0027Safety\u0027, u\u0027and\u0027, u\u0027Tolerability\u0027, u\u0027of\u0027))\n(15, (u\u0027Stage\u0027, u\u0027II\u0027, u\u0027or\u0027, u\u0027Stage\u0027, u\u0027III\u0027))\n(15, (u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Locally\u0027, u\u0027Advanced\u0027))\n(15, (u\u0027Combination\u0027, u\u0027Chemotherapy\u0027, u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027))\n(15, (u\u0027Chronic\u0027, u\u0027Obstructive\u0027, u\u0027Pulmonary\u0027, u\u0027Disease\u0027, u\u0027(COPD)\u0027))\n(14, (u\u0027Study\u0027, u\u0027of\u0027, u\u0027the\u0027, u\u0027Safety\u0027, u\u0027and\u0027))\n(14, (u\u0027in\u0027, u\u0027Subjects\u0027, u\u0027With\u0027, u\u0027Type\u0027, u\u00272\u0027))\n(14, (u\u0027Treating\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Stage\u0027, u\u0027III\u0027))\n(14, (u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Advanced\u0027, u\u0027Solid\u0027, u\u0027Tumors\u0027))\n(14, (u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Newly\u0027, u\u0027Diagnosed\u0027, u\u0027Acute\u0027))\n(14, (u\u0027Without\u0027, u\u0027Bevacizumab\u0027, u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027))\n(13, (u\u0027Evaluate\u0027, u\u0027the\u0027, u\u0027Safety\u0027, u\u0027and\u0027, u\u0027Efficacy\u0027))\n(13, (u\u0027of\u0027, u\u0027the\u0027, u\u0027Safety\u0027, u\u0027and\u0027, u\u0027Efficacy\u0027))\n(13, (u\u0027Combination\u0027, u\u0027Chemotherapy\u0027, u\u0027With\u0027, u\u0027or\u0027, u\u0027Without\u0027))\n(13, (u\u0027Vaccine\u0027, u\u0027Therapy\u0027, u\u0027in\u0027, u\u0027Treating\u0027, u\u0027Patients\u0027))\n(13, (u\u0027in\u0027, u\u0027Subjects\u0027, u\u0027With\u0027, u\u0027Moderate\u0027, u\u0027to\u0027))\n(13, (u\u0027in\u0027, u\u0027Patients\u0027, u\u0027With\u0027, u\u0027Newly\u0027, u\u0027Diagnosed\u0027))\n"
      },
      "dateCreated": "Dec 4, 2016 9:03:57 PM",
      "dateStarted": "Dec 4, 2016 9:07:49 PM",
      "dateFinished": "Dec 4, 2016 9:07:50 PM",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "title": "Categorize Study",
      "text": "%pyspark\n\nimport re\nfrom pyspark.sql.functions import udf\nfrom pyspark.sql.types import *\n\ndef categorize_text(text):\n    text \u003d text.lower()\n    if re.search(\"(cancer|chemotherapy|lymphoma|leukemia)\",text):\n        category \u003d \"cancer\"\n    elif re.search(\"(diabete|insulin)\",text):\n        category \u003d \"diabetes\"\n    elif re.search(\"(arthritis)\",text):\n        category \u003d \"arthritis\"\n    elif re.search(\"(asthma)\",text):\n        category \u003d \"asthma\"\n    elif re.search(\"(influenza|flu )\",text):\n        category \u003d \"influenza\"\n    elif re.search(\"(epilepsy)\",text):\n        category \u003d \"epilepsy\"\n    elif re.search(\"(alcohol)\",text):\n        category \u003d \"alcohol\"\n    elif re.search(\"(heart disease|cardiovascular|heart attack|heartattack|stint |cholesterol)\",text):\n        category \u003d \"heart disease\"\n    elif re.search(\"(hepatitis)\",text):\n        category \u003d \"hepatitis\"\n    elif re.search(\"(kidney)\",text):\n        category \u003d \"kidney disease\"\n    elif re.search(\"(tuberculosis)\",text):\n        category \u003d \"tuberculosis\"\n    elif re.search(\"(respiratory)\",text):\n        category \u003d \"respiratory disease\"\n    elif re.search(\"(tumor)\",text):\n        category \u003d \"tumors\"\n    elif re.search(\"(hiv )\",text):\n        category \u003d \"hiv\"\n    elif re.search(\"( burn )\",text):\n        category \u003d \"burns\"\n    elif re.search(\"(dermatitis)\",text):\n        category \u003d \"dermatitis\"\n    elif re.search(\"(fasciitis)\",text):\n        category \u003d \"fasciitis\"\n    elif re.search(\"(elderly)\",text):\n        category \u003d \"elderly\"\n    elif re.search(\"(surgery)\",text):\n        category \u003d \"surgery\"\n    elif re.search(\"(probiotics)\",text):\n        category \u003d \"probiotics\"\n    elif re.search(\"(biometric)\",text):\n        category \u003d \"biometric\"\n    elif re.search(\"(smoker|smoking)\",text):\n        category \u003d \"smoker study\"\n    elif re.search(\"(neuro|brain)\",text):\n        category \u003d \"neurological\"\n    elif re.search(\"(nerve)\",text):\n        category \u003d \"nerve study\"\n    elif re.search(\"(sleep)\",text):\n        category \u003d \"sleep study\"\n    else:\n        category \u003d \"Unclassified\"\n    \n    return category\n\nf \u003d udf(categorize_text, StringType() )\n\ndf_tokens \u003d df.withColumn(\u0027category\u0027, f(df.study)).registerTempTable(\"table_df_tokens\")\n",
      "dateUpdated": "Dec 4, 2016 8:33:12 PM",
      "config": {
        "colWidth": 12.0,
        "graph": {
          "mode": "table",
          "height": 300.0,
          "optionOpen": false,
          "keys": [],
          "values": [],
          "groups": [],
          "scatter": {}
        },
        "enabled": true,
        "editorMode": "ace/mode/python",
        "editorHide": true,
        "title": true
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "jobName": "paragraph_1480881044833_-1508603263",
      "id": "20161204-195044_1559095484",
      "result": {
        "code": "SUCCESS",
        "type": "TEXT",
        "msg": ""
      },
      "dateCreated": "Dec 4, 2016 7:50:44 PM",
      "dateStarted": "Dec 4, 2016 8:30:51 PM",
      "dateFinished": "Dec 4, 2016 8:30:51 PM",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "title": "View / Explore Study Categories",
      "text": "%sql\n\nselect rank,study,phase,category,number_enrolled from table_df_tokens where category !\u003d \"Unclassified\" and category !\u003d \"cancer\"",
      "dateUpdated": "Dec 4, 2016 8:34:20 PM",
      "config": {
        "colWidth": 12.0,
        "graph": {
          "mode": "multiBarChart",
          "height": 300.0,
          "optionOpen": false,
          "keys": [
            {
              "name": "category",
              "index": 3.0,
              "aggr": "sum"
            }
          ],
          "values": [
            {
              "name": "rank",
              "index": 0.0,
              "aggr": "count"
            }
          ],
          "groups": [],
          "scatter": {
            "xAxis": {
              "name": "rank",
              "index": 0.0,
              "aggr": "sum"
            },
            "yAxis": {
              "name": "study",
              "index": 1.0,
              "aggr": "sum"
            }
          }
        },
        "enabled": true,
        "editorMode": "ace/mode/sql",
        "title": true,
        "editorHide": true
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "jobName": "paragraph_1480881388007_-1265969558",
      "id": "20161204-195628_1312482384",
      "result": {
        "code": "SUCCESS",
        "type": "TABLE",
        "msg": "rank\tstudy\tphase\tcategory\tnumber_enrolled\n2\tStudy of the Efficacy Safety \u0026amp; Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury\tPhase 2\tburns\t150\n3\tStudy of the Efficacy Safety and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis\tPhase 2\tdermatitis\t450\n4\tDaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis\tPhase 2\tfasciitis\t60\n10\tA Study Promoting Critical Illness Recovery in the Elderly-- Pilot\t\telderly\t20\n17\tProbiotics in Occupational Shift Workers\t\tprobiotics\t60\n18\tProtein Supplementation Post Bariatric Surgery\t\tsurgery\t60\n23\tOptimal Volume Rate and Interval of Bolus Nerve Catheters for Shoulder Surgery\tPhase 4\tsurgery\t99\n25\tMagnetic Resonance Imaging of Human Biometrics\t\tbiometric\t30\n30\tNeuroimaging Reward Behavioral Treatment and Smoking Cessation\tPhase 1 / Phase 2\tsmoker study\t100\n34\tFeasibility and Smokers\u0026apos; Reactions to DNA Feedback\t\tsmoker study\t100\n37\tTMS Modulation of Insula-related Brain Networks.02\t\tneurological\t60\n42\tA Pilot Study of Nocturnal Hypoglycemia Prevention in Type 1 Diabetes Using the Vigilant Diabetes Management Companion\t\tdiabetes\t24\n43\tCombination Nicotine Patch / Lorcaserin for Smoking Cessation\tPhase 2\tsmoker study\t300\n45\tAn Observational Study of Post-cesarean Delivery Respiratory Patterns Using a Non-invasive Minute Ventilation Monitor (Exspiron \u0026#8482; System)\t\trespiratory disease\t100\n48\tSleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD\t\tneurological\t60\n53\tEffects of Exercise Training Intensity on Fitness and Insulin Sensitivity in African Americans\t\tdiabetes\t60\n57\tSIMT Stereotactic Radiosurgery Outcomes Study\t\tsurgery\t40\n71\tCOMRADE: Collaborative Care Management for Distress and Depression in Rural Diabetes\t\tdiabetes\t139\n83\tEffects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers\t\thiv\t20\n86\tStudy on Smoking Cessation and Cost Outcomes in the Duke Smoking Cessation Program\t\tsmoker study\t3000\n93\tMobile Technology and Online Tools to Improve Asthma Control in Adolescents\tPhase 2\tasthma\t70\n106\tMobile Technology and Online Tools to Improve Asthma Control in Adolescents - Usability\tPhase 2\tasthma\t25\n109\tIntranasal Insulin and Post-stroke Cognition: A Pilot Study\t\tdiabetes\t40\n112\tRespiratory Muscle Training in LOPD\t\trespiratory disease\t28\n125\tBedside Ultrasound to Measure Optic Nerve Sheath Diameter in Pediatric CSF Shunts\t\tnerve study\t87\n138\tQualitative Qualitative and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors\t\ttumors\t50\n142\tAnalgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery\tPhase 4\tsurgery\t40\n144\tThe Effect of Reducing Posttraumatic Stress Disorder Symptoms on Cardiovascular Risk\t\theart disease\t120\n145\tAntagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia\tPhase 2\trespiratory disease\t18\n149\tEfficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis\tPhase 4\tdermatitis\t53\n178\tDietary Acid Load Kidney Function and Disability in Elderly\t\tkidney disease\t80\n182\tTMS Modulation of Insula-related Brain Networks\t\tneurological\t12\n184\tThe Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery\tPhase 3\tsurgery\t65\n186\tContrast-enhanced Ultrasound of the Kidney\tPhase 2\tkidney disease\t75\n190\tProspective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation\t\tneurological\t60\n193\tSafety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage\tPhase 1\tneurological\t48\n200\tSTepped Exercise Program for Knee OsteoArthritis\t\tarthritis\t345\n207\tEfficacy of Neuro+ Attention Training\t\tneurological\t60\n210\tThe Compartmental Biology of HIV in the Male Genital Tract\t\thiv\t24\n212\tExercise Intolerance in Elderly Patients With HFpEF(Heart Failure With Preserved Ejection Fraction)\t\telderly\t84\n213\tStage Ib Trial of mSMART for Smoking Cessation Medication Adherence\t\tsmoker study\t60\n214\tThe KNEEhabilitation Study: Improving Disability in Individuals With Knee Osteoarthritis\tPhase 1 / Phase 2\tarthritis\t90\n230\tAngiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients\tPhase 2\thiv\t40\n231\tVibratory Stimuli A Novel Rehabilitation Method for Preventing Post - Traumatic Knee Osteoarthritis\t\tarthritis\t75\n244\tMuscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery\tPhase 1\tsurgery\t30\n252\tReducing HIV Risk Among Adolescents: Evaluating Project HEART\t\thiv\t222\n254\tEvaluation of Cardiorespiratory Performance After Interval Exercise Training Prior to Hematopoietic Cell Transplantation\t\trespiratory disease\t40\n258\tNeuromodulation Enhanced Cognitive Restructuring: A Proof of Concept Study\t\tneurological\t65\n261\tLazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints\tPhase 4\tnerve study\t23\n265\tPlatelets as Regulators of Inflammation in Cardiac Surgery\t\tsurgery\t100\n270\tPain Coping Skills Training for African Americans With Osteoarthritis\t\tarthritis\t248\n273\tEffects of Smoking Environments on Craving and Smoking (CameraCue2.0)\t\tsmoker study\t120\n274\tIncretin Action in Physiology and Diabetes\tPhase 1\tdiabetes\t25\n279\tStrengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)\t\tsmoker study\t300\n285\tNivolumab With DC Vaccines for Recurrent Brain Tumors\tPhase 1\ttumors\t66\n286\tHigh Intensity Interval Training and Rheumatoid Arthritis\t\tarthritis\t26\n295\tMobile Contingency Management for Smoking Cessation in Returning US Veterans\t\tsmoker study\t260\n301\tVestibular Function After Cochlear Implantation Using Soft Surgery Techniques\t\tsurgery\t30\n305\tTelephone-based Smoking Cessation\t\tsmoker study\t350\n306\tUsing Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement\t\tasthma\t360\n307\tTemporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery\tPhase 1 / Phase 2\tsurgery\t130\n308\tThe Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery\t\tsurgery\t186\n310\tElectronic Nicotine Delivery Systems as a Smoking Cessation Treatment\tPhase 2\tsmoker study\t300\n311\tRejuvenated Washed Packed Red Blood Cells in Pediatric Cardiac Surgery\tPhase 4\tsurgery\t15\n316\tFeasibility of an Interval Exercise and Nutrition Intervention to Reduce Cardiovascular Disease Risk Factors\t\theart disease\t15\n327\tPathways to Improving Functional Capacity in Older Patients With Chronic Kidney Disease and Cardiovascular Disease\t\theart disease\t0\n328\tPredictors of Opioid-Induced Respiratory Depression (OIRD)\tPhase 1\trespiratory disease\t20\n331\tPersonalized Health Planning in Shared Medical Appointments for Individuals With Type II Diabetes Pilot Study\t\tdiabetes\t20\n338\tSystemic Steroids for Peripheral Nerve Blocks\tPhase 4\tnerve study\t115\n340\tStudy of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart\tPhase 1\tdiabetes\t30\n341\tPerineural Steroids for Peripheral Nerve Blocks\tPhase 4\tnerve study\t115\n361\tVIDA Mobile Health Cardiovascular Prevention Program\t\theart disease\t40\n363\tAcid-Base Compensation in Chronic Kidney Disease\tPhase 1\tkidney disease\t16\n372\tIntegrated Population Program for Diabetic Kidney Disease\t\tkidney disease\t131\n373\tEffects of Smoking Environment on Craving and Smoking\t\tsmoker study\t41\n374\tPackHealth: Asthma Engagement Tool\t\tasthma\t50\n375\tClinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders\t\tneurological\t220\n379\tDetermine the Prevalence and Severity of Asthma in HIV (Human Immunodeficiency Virus) Infected Patients\t\tasthma\t93\n386\tObstructive Sleep Apnea in Pregnancy\t\tsleep study\t150\n390\tDoes Physical Therapy Prevent Total Knee Arthroplasty in Patients With End Stage Osteoarthritis\t\tarthritis\t260\n394\tWebsite Application Based Education and Text Messaging in Improving Skin Wound Care in Patients Undergoing Mohs Surgery\t\tsurgery\t90\n397\tTransplant Social Worker Support for Live Kidney Donation in African Americans\t\tkidney disease\t570\n398\tNutrition Education for Cardiovascular Disease Prevention in Spinal Cord Injury\t\theart disease\t200\n406\tPerampanel in Seizure Patients With Primary Glial Brain Tumors\tPhase 4\ttumors\t71\n431\tFLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions\t\tneurological\t15\n433\tNHALES (Natural History of Asthma With Longitudinal Environmental Sampling)\t\tasthma\t200\n443\tCauses of Comorbid Infertility Among Women With Rheumatoid Arthritis\t\tarthritis\t150\n445\tPhysical Therapy Versus Internet-Based Exercise Training for Patients With Knee Osteoarthritis\t\tarthritis\t350\n471\tEffects of Neuromodulation on Verbal Fluency in Post-stroke Aphasia\t\tneurological\t12\n473\tContingency Management Quitting Smoking and ADHD\tPhase 1\tsmoker study\t60\n477\tRelationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome\t\trespiratory disease\t10\n478\tNovel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography\t\tkidney disease\t200\n479\tRespiratory Viral Infections in Pediatric Transplantation\t\trespiratory disease\t2669\n487\tOxytocin Treatment of Alcohol Dependence\tPhase 2\talcohol\t50\n492\tAbstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers\t\tsmoker study\t165\n493\tArthritis Pilot for Preserving Muscle While Losing Weight\t\tarthritis\t37\n498\tFunction and Scoliosis Surgery\t\tsurgery\t15\n500\tStudy of an Emergency Department-based Intervention to Reduce Alcohol Misuse in Older Adults\t\talcohol\t150\n503\tEffects of Chemoradiation and Surgery on Cardiopulmonary Fitness and Tumor Neoplastic Phenotype in Gastrointestinal Malignancies\t\ttumors\t25\n504\tEffect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin\tPhase 1\talcohol\t20\n510\tSurgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain\tPhase 4\tsurgery\t60\n513\tFabrication of a Definitive Cad/Cam Titanium Abutment Prior to Guided Surgery: a Pilot Study.\t\tsurgery\t28\n521\tThe Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine\tPhase 4\tinfluenza\t104\n524\tElectronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy\t\ttumors\t240\n525\tA Validated Necrosis Assay to Determine the Need for Revision Surgery in Metal-on-metal Total Hip Arthroplasty\t\tsurgery\t100\n527\tPhase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy\tPhase 1\thiv\t12\n530\tHydration Monitor Validation in Elderly\t\telderly\t73\n536\tMultimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study\tPhase 4\tsurgery\t124\n543\tTEA vs. PVB vs. PCA in Liver Resection Surgery\t\tsurgery\t10\n547\tAromatherapy Using a Nasal Clip After Surgery\t\tsurgery\t300\n550\tEffects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers\tPhase 0\tinfluenza\t39\n555\tHepatitis C Alcohol Reduction Treatment\t\talcohol\t230\n576\tPain Expectations in Subjects With Osteoarthritis\tPhase 4\tarthritis\t30\n577\tA Double-Blind Placebo-Controlled Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia\tPhase 2 / Phase 3\tsleep study\t27\n578\tInterleukin-2\u0026#8212;Induced Cognitive/Affective/Sleep Symptoms\t\tsleep study\t30\n587\tA Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson\u0026apos;s Disease\t\tneurological\t6\n589\tDetermining Relationships Among Maternity Stress \u0026amp; Sleep\t\tsleep study\t17\n596\tExamining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes\t\tdiabetes\t6\n598\tMultivitamin Adherence Following Bariatric Surgery\t\tsurgery\t30\n601\tExercise Heart Failure and Type 2 Diabetes\t\tdiabetes\t0\n609\tModulation of Insulin Sensitivity by Betaine Upregulation of FGF21\t\tdiabetes\t23\n611\tMobile Sensing of Smoking Behavior\t\tsmoker study\t2\n614\tA Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community\t\tdiabetes\t156\n624\tAnti-thrombin III (ATIII) vs Placebo in Children (\u0026lt;7mo) Undergoing Open Congenital Cardiac Surgery\tPhase 2\tsurgery\t40\n626\tEfficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain\tPhase 2\tneurological\t40\n628\tA Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)\tPhase 2\tneurological\t132\n637\tNonconvulsive Seizure Identification on Quantitative EEG by Neuro ICU Nurses\t\tneurological\t30\n639\tEffects of a Cocoa Shot on the Human Brain 2\tPhase 1\tneurological\t24\n640\tCharacterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)\t\ttumors\t85\n646\tIntegrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis\t\talcohol\t700\n649\tStudy of Tolerability and Efficacy of BVS857 in Severe Burn Subjects\tPhase 2\tburns\t1\n652\tTesting Methods of Self-persuasion Involving Cigarette Smoking\t\tsmoker study\t48\n659\tEfficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study\t\tkidney disease\t42\n660\tUse of Recombinant Hyaluronidase Human is Effective for the Use of Local Blocks for Eyelid\u0026apos;s Surgery\t\tsurgery\t0\n663\tIntravenous Exenatide in Patients With Acute Brain Injury\tPhase 4\tneurological\t24\n669\tImproving Diabetes Outcomes for Persons With Severe Mental Illness\t\tdiabetes\t25\n678\tAirway Inflammatory Response During Illness in Children With Respiratory Failure\t\trespiratory disease\t20\n692\tThree Approaches to Glucose Monitoring in Non-insulin Treated Diabetes\t\tdiabetes\t450\n701\tIsolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method\t\ttumors\t80\n709\tEffects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers\t\tinfluenza\t100\n712\tEffects of Shock Absorbing Insoles on Knee Pain and Walking in Persons With Knee Osteoarthritis\tPhase 2\tarthritis\t60\n728\tEchinacea and Acute Respiratory Illness\t\trespiratory disease\t40\n736\tBrain Connectivity in Age-Related Macular Degeneration\t\tneurological\t300\n739\tBABY STEPS II: SMS Scheduled Gradual Reduction Text Messages to Help Pregnant Smokers Quit\t\tsmoker study\t522\n743\tUse of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD\t\tsmoker study\t15\n747\tPreventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)\tPhase 2\theart disease\t250\n751\tTotal Ankle Replacement for Ankle Arthritis\t\tarthritis\t1000\n755\tEfficacy and Safety of High Dose Baclofen for Alcohol Dependence\tPhase 2\talcohol\t120\n757\tJump Starting Shared Medical Appointments for Diabetes With Weight Management\t\tdiabetes\t308\n760\tNeurocognitive Visual Reaction Training\t\tneurological\t21\n763\tEffect of Tourniquet on Sensory Nerve Conduction Threshold (sNCT) and OxyNeuroGram (ONG) Index- A Volunteer Study\t\tneurological\t10\n774\tStudy of Awareness and Detection of Familial Hypercholesterolemia\t\theart disease\t5000\n779\tComplementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)\tPhase 2\tneurological\t140\n781\tEstablishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases\t\tneurological\t300\n787\tEstablishment of a Tissue Bank (Blood CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND)\t\tneurological\t1000\n796\tBrain Imaging of Intranasal Oxytocin Treatment in Autism\tPhase 1\tneurological\t28\n811\tEvaluation of Efficacy and Accuracy of Aquamantys Device in General Surgery\t\tsurgery\t20\n813\tFluid Intake Application to Reduce Kidney Stone Risks\t\tkidney disease\t50\n816\tEffects of a Cocoa Shot on the Human Brain\tPhase 0\tneurological\t6\n818\tThe Effect of Anticholinergics on Cognitive Function in the Elderly\tPhase 4\telderly\t59\n820\tBlood Pressure Heart Rate Variability \u0026amp; Sleep in Veterans With PTSD\t\tsleep study\t19\n832\tAuditory Brainstem Implantation in Young Children\tPhase 0\tneurological\t10\n836\tCPT and Smoking Cessation\tPhase 2 / Phase 3\tsmoker study\t50\n838\tVirtual Reality for Osteoarthritis Knee Pain Pilot\t\tarthritis\t30\n841\tNeurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans\tPhase 2 / Phase 3\tneurological\t90\n846\tObservational Assessment of Baseline Asthma Control in African-American Children\t\tasthma\t25\n873\tSleep Apnea and Visual Perceptual Skill Learning\t\tsleep study\t14\n874\tAn Evaluation of Neurofeedback Efficacy in Adults With ADHD\t\tneurological\t30\n877\tSuperior Laryngeal Nerve Block For Awake Endotracheal Intubation Study\t\tnerve study\t95\n879\tSulforaphane Supplementation in Atopic Asthmatics\tPhase 1\tasthma\t16\n886\tEnvironments as Smoking Cues: Imaging Brain Substrates Developing New Treatments (CameraCue)\t\tsmoker study\t67\n890\tTranslational Research Evaluating Neurocognitive Memory Processes\t\tneurological\t76\n893\tLatinos Combating Diabetes\t\tdiabetes\t225\n899\tSimultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)\t\tkidney disease\t285\n900\tMilnacipran and Neurocognition Pain and Fatigue in Fibromyalgia : A 13-week Randomized Placebo Controlled Cross Over Trial\tPhase 3\tneurological\t26\n908\tBone Metabolism After Bariatric Surgery\t\tsurgery\t40\n916\tParents and Children Together Preventing Diabetes (PACT PD)\t\tdiabetes\t72\n918\tNicotine Non-Smokers With and Without ADHD and Genetics Study\tPhase 1\tsmoker study\t150\n925\tTrial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery\tPhase 2\tsurgery\t0\n931\tPostoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery\t\tsurgery\t57\n941\tLifestyle Intervention for Treatment of Diabetes\t\tdiabetes\t260\n942\tEmpowering Rural African American Women and Communities to Improve Diabetes Outcomes\t\tdiabetes\t200\n945\tMindfulness: a Novel Approach for the Management of Diabetes-related Distress\tPhase 2 / Phase 3\tdiabetes\t90\n951\tPET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)\t\ttumors\t15\n954\tA Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women\tPhase 4\thiv\t5\n959\tPost-traumatic Arthritis Associated With Joint Injury\t\tarthritis\t30\n963\tCarolina Alcohol and Drug Resources\t\talcohol\t690\n967\tContingency Management for Smoking Cessation in Homeless Smokers\t\tsmoker study\t25\n972\tUnderstanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)\t\telderly\t66\n973\tiCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery\t\tsurgery\t68\n974\tRegulation of Branched-chain Amino Acid Metabolism in Pre-Diabetes\t\tdiabetes\t132\n975\tNeuromuscular Ultrasound in ALS\t\tneurological\t40\n980\tPilot Testing a Patient and Provider Intervention for Managing Osteoarthritis in Hispanic Adults.\t\tarthritis\t16\n985\tAdvanced Comprehensive Diabetes Care for Veterans With Poorly-Controlled Diabetes\tPhase 0\tdiabetes\t50\n994\tCryosurgery and Radiation Therapy in Treating Patients With Painful Bone Metastases\t\tsurgery\t1\n1000\tPhysiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)\t\tneurological\t60\n1001\tNeurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition\t\tneurological\t30\n1014\tDelayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis\t\theart disease\t400\n1029\tStudy to Evaluate the Impact of FeNO Assessments on Asthma Management Decisions in Subject 7 to 60 Years of Age\t\tasthma\t50\n1038\tAbstinence Reinforcement Therapy (ART) for Rural Veteran Smokers\t\tsmoker study\t300\n1048\tExploring Massage Benefits for Arthritis of the Knee for VA Healthcare Users\t\tarthritis\t25\n1055\tEffect Of Acute Inflammatory Mediators On Functional Limitations In Patients With Acute Respiratory Failure\tPhase 1 / Phase 2\trespiratory disease\t100\n1058\tAlmased Multi-Center Diabetes Intervention Trial\t\tdiabetes\t240\n1059\tAssessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera\t\thiv\t33\n1060\tThe Effects of Respiratory Muscle Strength Training (RMST) on Inspiratory and Expiratory Muscle Strength in Adults and Children With Pompe Disease\t\trespiratory disease\t11\n1065\tMRI to Assess the Effects of Dysautonomia and Chronic Nausea on Brain Transmitters\t\tneurological\t18\n1067\tMiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery\t\tsurgery\t131\n1072\tMild Traumatic Brain Injury Registry\t\tneurological\t40\n1088\tAdvanced Image Guidance Utilized in Liver Surgery\t\tsurgery\t13\n1092\tGene Expression Variation and Implant Wound Healing Among Smokers and Diabetics\t\tsmoker study\t44\n1094\tSurgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery\t\tsurgery\t300\n1099\tVisceral (Kidney and Abdominal Organ) Function After Fenestrated and Branched Endovascular Aneurysm Repair (FEVAR/BEVAR) of Thoracoabdominal Aortic Aneurysms\t\tkidney disease\t160\n1100\tStudy of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics\tPhase 4\tdiabetes\t36\n1109\tThe Effects of Smoking Withdrawal On Resting State Functional Connectivity\t\tsmoker study\t0\n1112\tNeurostimulation Device for Treatment of Migraine Headache\t\tneurological\t7\n1116\tHIV Prevention Among Latino MSM: Evaluation of a Locally Developed Intervention\t\thiv\t304\n1119\tEffects of Tai Chi Chuan on Psychobiological Indicators of Anxiety and Sleep Quality in Young Adults\t\tsleep study\t75\n1122\tVentilatory Heterogeneity in Participants With Asthma (MK-0476-513)\tPhase 1\tasthma\t34\n1123\tEvaluation of DVD and Internet Decision Aids for Hip and Knee Osteoarthritis: Focus on Health Literacy\t\tarthritis\t155\n1129\tMultimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery\tPhase 2\tsurgery\t40\n1137\tCombinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding\tPhase 4\tdiabetes\t9\n1141\tMindful Movement and Breathing to Improve Outcomes of Gynecologic Surgery\tPhase 0\tsurgery\t10\n1142\tStudy of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery\t\tsurgery\t233\n1154\tENLIGHTEN: Exercise and NutritionaL Interventions for coGnitive and Cardiovascular HealTh ENhancement\t\theart disease\t160\n1158\tTo Compare the Safety Tolerability and Pharmacokinetics of QBX258 in Patients With Asthma\tPhase 1\tasthma\t50\n1170\tTherapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery\tPhase 2\tsurgery\t20\n1173\tCardiovascular Effects of Incremental Diesel Exhaust Inhalation in Middle-Aged Healthy GSTM1 Null Human Volunteers\t\theart disease\t6\n1182\tMapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease\t\tkidney disease\t227\n1186\tA Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901\tPhase 1\ttumors\t22\n1195\tEffect of Blueberries on Cognition and Body Composition in Elderly With Mild Cognitive Decline\tPhase 2\telderly\t123\n1197\tEating Disorders in Type 1 Diabetes: Mechanisms of Comorbidity\t\tdiabetes\t83\n1200\tStudy to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)\t\talcohol\t40\n1206\tNeurostimulation in Temporomandibular Disorders (TMD) Patients\t\tneurological\t5\n1216\tStrength Training for ARthritis Trial\tPhase 2\tarthritis\t375\n1226\tTrivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors\tPhase 0\tinfluenza\t38\n1229\tEfficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis\t\tdermatitis\t10\n1233\tVasospasm in Pediatric Traumatic Brain Injury\t\tneurological\t6\n1234\tObesity in HIV After Antiretroviral Therapy\t\thiv\t200\n1241\tDevelopment of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions\t\ttumors\t5000\n1242\tStudy to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants\tPhase 1\telderly\t61\n1255\tPatient and Provider Interventions for Managing Osteoarthritis in Primary Care\t\tarthritis\t537\n1261\tMindfulness-based Personalized Health Planning for Reducing Risk of Heart Disease and Diabetes\tPhase 3\tdiabetes\t140\n1268\tNeural Markers and Rehabilitation of Executive Functioning in Veterans With Traumatic Brain Injury and Posttraumatic Stress Disorder\t\tneurological\t100\n1270\tEarly Brain Development in Twins\t\tneurological\t600\n1278\tNeuromuscular Ultrasound for Focal Neuropathies\t\tneurological\t120\n1280\tPain and Function After Orthopedic Surgery\t\tsurgery\t75\n1282\tPediatric Atopic Dermatitis (AD) Internet Survey\t\tdermatitis\t40\n1284\tStrategies for Enhancing Mucosal Immunity to Influenza Vaccine\tPhase 0\tinfluenza\t60\n1287\tPersonalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes\t\tkidney disease\t19\n1297\tFamilies and Pediatric Cardiac Surgery Multidisciplinary Teams: How Well Do We Communicate\t\tsurgery\t23\n1304\tEffect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome\t\tneurological\t25\n1307\tBrain Connectivity in Neurodevelopmental Disorders in Response to Treatment\t\tneurological\t25\n1316\tStress Reduction Training to Improve Sleep Quality Stress Physiology \u0026amp; Cardiovascular Disease (CVD) Risk Markers\t\theart disease\t87\n1318\tNeuroactive Steroids and Traumatic Brain Injury (TBI) in OEF/OIF Veterans\tPhase 2\tneurological\t82\n1324\tEarly Intervention for Morbidly Obese Patients After Roux-en-Y Gastric Bypass (RYGB) Surgery\t\tsurgery\t8\n1328\tPatient Positioning in Lumbar Fusion Surgery and Its Impact on Spinal Sagittal Balance and Surgeon Satisfaction\t\tsurgery\t7\n1331\tCardiovascular Effects in Psoriasis Patients Treated With Adalimumab.\t\theart disease\t17\n1332\tThe Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART\tPhase 1 / Phase 2\thiv\t37\n1333\tMeasurement of Kidney Blood Flow and Oxygen Levels by MRI\t\tkidney disease\t10\n1341\tTissueLink Study During Multi-Level Spine Surgery\tPhase 4\tsurgery\t60\n1347\tSweet Preference and Alcohol Craving\tPhase 2\talcohol\t80\n1351\tClinical Assessment of Nonin 7600 Near Infrared Spectroscopy (NIRS) Tissue Oximetry During Cardiovascular Surgery\t\theart disease\t50\n1355\tFeasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures\t\tsurgery\t30\n1364\tEffects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers\t\tinfluenza\t51\n1372\tEffect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study\t\tdiabetes\t48\n1376\tA Study of FolateScan in Patients With Knee Osteoarthritis\t\tarthritis\t25\n1377\tBenazepril Hydrochloride Lisinopril Ramipril or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors\tPhase 2\ttumors\t6\n1378\tYoga Therapy in Treating Patients With Malignant Brain Tumors\t\ttumors\t9\n1379\tAtypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI\t\tneurological\t34\n1380\tEfficacy and Tolerability Study of Device RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults\tPhase 2\tdermatitis\t17\n1381\tWe Can Prevent Diabetes: A Behavioral Intervention to Reduce Diabetes Risk in African Americans\tPhase 1 / Phase 2\tdiabetes\t74\n1390\tDischarge Planning for Elderly Patients in the Emergency Department: Use of a Brief Phone Call After Discharge to Improve Medication Utilization and Physician Follow-up\t\telderly\t157\n1396\tEhealth: Second Life Impacts Diabetes Education \u0026amp; Self-Management\t\tdiabetes\t20\n1398\tUnderstanding of Genetic Risk Information for Type 2 Diabetes\t\tdiabetes\t300\n1400\tStatin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery\t\tsurgery\t0\n1403\tIncidence of Respiratory Depression in Cesarean Section\t\trespiratory disease\t100\n1412\tReusable Versus Disposable Draping System in Breast Reconstruction Surgery\t\tsurgery\t107\n1422\tEvaluation of Continuous Saphenous Nerve Block to Supplement a Continuous Sciatic Nerve Block After Ankle Surgery\t\tsurgery\t74\n1430\tPioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors\tPhase 1\ttumors\t18\n1439\tCardiovascular Intervention Improvement Telemedicine Study\t\theart disease\t428\n1445\tPersonalized Cardiovascular Risk Information to Initiate and Maintain Health Behavior Changes\t\theart disease\t98\n1452\tPatient and Provider Interventions for Managing Osteoarthritis in Primary Care\t\tarthritis\t300\n1457\tNeuroimaging of Smokers With and Without Attention Deficit Hyperactivity Disorder (ADHD)\t\tsmoker study\t101\n1462\tA Panobinostat Presurgery\tPhase 2\tsurgery\t0\n1463\tEvaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection\tPhase 2\trespiratory disease\t38\n1468\tFast Spectral Imaging Device for Tumor Margin Mapping\t\ttumors\t54\n1472\tA Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)\t\tsleep study\t15\n1494\tGenetic Testing for Type 2 Diabetes\t\tdiabetes\t601\n1495\tTransoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Lesions Using Da Vinci Robotic Surgical System\tPhase 0\tsurgery\t60\n1496\tGroup Physical Therapy for Knee Osteoarthritis\t\tarthritis\t320\n1497\tNeurobiology of Nicotine and Non-nicotine Components of Tobacco Addiction\tPhase 1\tneurological\t147\n1498\tSupplemental Nicotine Administration for Smoking Cessation in Posttraumatic Stress Disorder (PTSD)\t\tsmoker study\t69\n1499\tSafety Study of Bevacizumab Everolimus and LBH589 (BEL) for Advanced Solid Tumors\tPhase 1\ttumors\t14\n1503\tManaging Chronic Kidney Disease in Eastern North Carolina\t\tkidney disease\t1257\n1511\tA Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis\tPhase 4\tdermatitis\t20\n1512\tInvestigating Fitness Interventions in the Elderly (INFINITE)\t\telderly\t180\n1514\tPilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery\tPhase 4\tsurgery\t24\n1515\tReducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)\tPhase 4\tkidney disease\t32\n1518\tEn Pareja: A Latino Couples Intervention to Help Expectant Fathers Quit Smoking\t\tsmoker study\t705\n1521\tp16 Methylation for Smoking Cessation\t\tsmoker study\t35\n1527\tArmodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors\tPhase 2\ttumors\t54\n1532\tPilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects\tPhase 4\tsleep study\t26\n1538\tIntensive Computerized Brain Training (ICBT) in Youth With Early Onset Psychosis (EOP)\t\tneurological\t35\n1542\tDietary Patterns and Cardiovascular (CVD) Risk in Spinal Cord Injury (SCI) Factors In Individuals With Chronic Spinal Cord Injury\t\theart disease\t100\n1544\tSafety Metabolism and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C\tPhase 1 / Phase 2\thepatitis\t60\n1547\tOptimal Planning Target Volume With Stereotactic Radiosurgery\t\tsurgery\t49\n1549\tRadiosurgery and Avastin for Recurrent Malignant Gliomas\t\tsurgery\t15\n1550\tDexmedetomidine Sedation With Third Molar Surgery\tPhase 4\tsurgery\t18\n1551\tModerate to Persistent Asthma in the Obese Subject\tPhase 4\tasthma\t38\n1563\tInternet-Based Smoking Cessation for Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans\t\tsmoker study\t413\n1582\tThe Arthritis Diet and Activity Promotion Trial\t\tarthritis\t318\n1585\tTailored Case Management for Diabetes and Hypertension\t\tdiabetes\t377\n1588\tStandardized Rehabilitation for Intensive Care Unit (ICU) Patients With Acute Respiratory Failure\t\trespiratory disease\t300\n1589\tLowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial\t\tkidney disease\t35\n1595\tExercise Dose-Response Effects in Prediabetes\t\tdiabetes\t288\n1600\tExercise Intolerance in Elderly Patients With Diastolic Heart Failure\t\telderly\t100\n1628\tFunctional Imaging of Tumor and Normal Tissue\t\ttumors\t21\n1638\tA Study of Inhalation of 20000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers\tPhase 1\tsmoker study\t12\n1641\tSafety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C\tPhase 2\thepatitis\t116\n1642\tPreventing Postpartum Return to Smoking\t\tsmoker study\t386\n1651\tA Controlled Laboratory Study of the Effects on Cue-Induced Craving in Dependent Smokers\tPhase 2\tsmoker study\t21\n1656\tCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors\t\ttumors\t2500\n1662\tPrevalence of Sleep Disturbances in Psoriasis\t\tsleep study\t80\n1663\tEvaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype\tPhase 3\tsmoker study\t606\n1664\tVaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme\tPhase 1\tsurgery\t50\n1666\tSafety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors\tPhase 1\ttumors\t13\n1667\tTreatment Effects of Escitalopram (Lexapro\u0026#174;) on Generalized Anxiety Disorder in Patients With HIV and AIDS\tPhase 3\thiv\t30\n1668\tMindfulness Emotional Well-being and Sleep Quality\t\tsleep study\t372\n1674\tSex Differences in Early Brain Development; Brain Development in Turner Syndrome\t\tneurological\t295\n1675\tEfficacy and Tolerability of Baclofen for Alcohol Dependence\tPhase 2 / Phase 3\talcohol\t80\n1682\tStudy of Massage Therapy Within a Brain Tumor Setting\t\ttumors\t10\n1683\tBTC Neuropsychological Database\t\tneurological\t0\n1699\tValidation of Brain Oxygenation Monitor on Pediatric Patients\t\tneurological\t72\n1702\tCompatibility of a Mild Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis\t\tdermatitis\t46\n1703\tBronchoscopy Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects\t\trespiratory disease\t30\n1706\tEffect of a 10000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults\tPhase 1\tasthma\t11\n1707\tA Study of Inhalation of 20000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals\tPhase 1\tasthma\t32\n1709\tIn Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics\tPhase 1\tasthma\t25\n1710\tImproving Neurologic Outcomes in People With Diabetes Who Are Undergoing Heart Surgery\tPhase 3\tdiabetes\t133\n1711\tEffectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes\tPhase 2\tdiabetes\t31\n1715\tRole of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma\tPhase 3\tasthma\t20\n1718\tRapid Administration of Insulin in Sepsis\tPhase 1\tdiabetes\t20\n1719\tCholesterol Hypertension and Glucose Education Study\t\theart disease\t362\n1721\tValidation of Brain Oxygenation Monitor\t\tneurological\t18\n1725\tStereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases\tPhase 2\tsurgery\t1\n1726\tStereotactic Radiosurgery in Treating Patients With Brain Metastases\tPhase 2\tsurgery\t6\n1730\tAmantadine and Temporal Discrimination in Patients With Traumatic Brain Injury (TBI)\t\tneurological\t16\n1732\tPharmacokinetics of NRL972 in Patients With Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)\tPhase 2\talcohol\t125\n1739\tImpact of GBS on CVD in Type 2 Diabetes Mellitus\t\tdiabetes\t84\n1745\tEffectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)\tPhase 3\tsurgery\t1884\n1774\tRange of Neutrophil Response to 20000 EU of Clinical Center Reference Endotoxin in Otherwise Healthy Smokers\tPhase 1\tsmoker study\t2\n1783\tEvaluating the Effects of Hormone Replacement Therapy on Brain Function (The WHIMS-MRI Study)\t\tneurological\t1426\n1788\tMetformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)\tPhase 4\talcohol\t11\n1789\tAttention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study\t\tsmoker study\t32\n1791\tA Study to Determine if Carbon Dioxide Lavage During Total Knee Surgery Reduces Intraoperative Embolic Events\tPhase 2\tsurgery\t20\n1797\tAn Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients\t\ttumors\t530\n1801\tTreating Co-Morbid Sleep Difficulties in Veterans With Posttraumatic Stress Disorder (PTSD): A Pilot Study\t\tsleep study\t22\n1802\tConcurrent Nicotine Patch / Denicotinized Cigarette Therapy for Smoking Cessation II\tPhase 3\tsmoker study\t479\n1814\tA Multicenter Randomized Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy Safety and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery\tPhase 2\tsurgery\t88\n1818\tLoteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery\tPhase 3\tsurgery\t400\n1819\tEffects of Capsaicin on the Structure Distribution and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin\tPhase 4\tnerve study\t12\n1822\tComprehensive Investigation of Opiates Neuropeptides Barrier Function Scratching and Sleep Physiology\t\tneurological\t31\n1824\tAdherence to Topical Hydrocortisone 17-Butyrate 0.1% (Locoid\u0026#174;) Using Different Vehicles in Adults With Atopic Dermatitis\tPhase 4\tdermatitis\t30\n1830\tNeuroimaging Attentional Impairment During Abstinence\t\tneurological\t80\n1833\tComprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis\t\tdermatitis\t45\n1837\tEfficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis\tPhase 4\tdermatitis\t41\n1845\tSupplemental Choline and Brain Development in Humans\t\tneurological\t150\n1855\tImmunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells\tPhase 1\ttumors\t12\n1857\tNeuroimaging Decision Making and Response Inhibition During Smoking Abstinence\t\tsmoker study\t62\n1862\tRole of TLR4 in Environmental Asthma\tPhase 1\tasthma\t855\n1864\tNitric Oxide LPS and the Pathogenesis of Asthma Phase 1\t\tasthma\t420\n1869\tEfficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis\tPhase 3\tarthritis\t610\n1873\tEfficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis\tPhase 3\tarthritis\t614\n1875\tThe Effect of Visual Stimuli on Itch Perception Intensity in Healthy and Atopic Dermatitis Patients\t\tdermatitis\t25\n1876\tPhase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis\tPhase 2\thiv\t223\n1881\tMeasuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit\tPhase 4\tdermatitis\t30\n1886\tGenetics of Asthma - Bronchoscopy Studies\tPhase 1\tasthma\t17\n1890\tNitric Oxide LPS and the Pathogenesis of Asthma Phase II\tPhase 1\tasthma\t70\n1891\tGroup Physical Therapy for Knee Osteoarthritis\t\tarthritis\t24\n1895\tThe Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression\t\ttumors\t0\n1899\tInsulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study\t\tdiabetes\t80\n1911\tHealthy Living Partnership to Prevent Diabetes\tPhase 3\tdiabetes\t301\n1915\tSafety Study of 20000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma\tPhase 1\tasthma\t4\n1916\tFeasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors\t\ttumors\t6\n1918\tInnohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients\t\ttumors\t40\n1920\tCoronary Heart Disease as Measured by Coronary Calcium Score Among Individuals With Chronic Traumatic Spinal Cord Injury\t\theart disease\t45\n1924\tNicotine Patch Pretreatment for Smoking Cessation in PTSD\tPhase 0\tsmoker study\t87\n1928\tCarbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression\t\tneurological\t74\n1939\tEffects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With \u0026amp; Without Allergies\t\tinfluenza\t54\n1942\tStudy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)\tPhase 3\tsurgery\t120\n1947\tMK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection\tPhase 2\thiv\t6\n1963\tEverolimus Fluorouracil Leucovorin Panitumumab and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment\tPhase 1\ttumors\t74\n1969\tGIOP Prevention Among People With Rheumatoid Arthritis\t\tarthritis\t273\n1972\tBrain Imaging of Psychotherapy for Depression\t\tneurological\t27\n1976\tU-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod\tPhase 4\tdiabetes\t21\n1990\tChronic Hepatitis Intervention Project for Drug Users\tPhase 3\thepatitis\t851\n1993\tAlcohol in the Treatment of Obesity\t\talcohol\t18\n2005\tA Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors\tPhase 1\ttumors\t45\n2011\tExenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy\tPhase 4\tdiabetes\t7\n2018\tDuke Conte Center for the Neuroscience of Depression in Late Life\t\tneurological\t795\n2022\tPathogenesis and Genetics of Environmental Asthma Ozone Study\t\tasthma\t170\n2023\tSorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors\tPhase 1\ttumors\t31\n2024\tA Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy\tPhase 4\tneurological\t40\n2026\tENCORE: Exercise and Nutritional Interventions for Cardiovascular Health\t\theart disease\t144\n2028\tIsolation and Culture of Circulating Tumor Cells From Peripheral Blood\t\ttumors\t500\n2029\tRetisert and Cataract Surgery in Patients With Severe Uveitis\t\tsurgery\t21\n2030\tNeurocognitive Outcomes of Depression in the Elderly\t\telderly\t795\n2031\tUtility of Exercise-induced N-terminal (NT) Pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis\t\tneurological\t110\n2049\tPrecedex Versus Propofol-Awakening for Reducing Brain Injury Expansion\tPhase 1 / Phase 2\tneurological\t8\n2056\tEvaluation of Walk With Ease in Arthritis\tPhase 3\tarthritis\t468\n2065\tNICardipine Neuroprotection in AortiC Surgery (NICNACS)\tPhase 2\tsurgery\t7\n2067\tKetamine In Thoracic Surgery (KITS) Trial\tPhase 2\tsurgery\t40\n2071\tChanges in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed Progressive or Recurrent Primary Malignant Brain Tumors\t\ttumors\t16\n2079\tEffect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery\tPhase 4\tsurgery\t82\n2085\tUse of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery\t\tsurgery\t123\n2092\tAngiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors\tPhase 1\ttumors\t18\n2094\tImproving Care for Primary Care Patients With Diabetes and Poor Literacy and Numeracy Skills\tPhase 4\tdiabetes\t110\n2095\tSafety and Efficacy Study of Re-treatment With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Respond Poorly to Anti-TNF\u0026#945; Therapies\tPhase 3\tarthritis\t341\n2097\tEffect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients\t\tburns\t60\n2101\tThe Treatment of Insomnia in Patients With HIV Disease\tPhase 4\thiv\t44\n2111\tCigarette Smoke and Susceptibility to Influenza Infection\t\tinfluenza\t138\n2112\tDevelopment and Evaluation of A Mailed Arthritis Self-Management Program\t\tarthritis\t900\n2114\tFamily-supported Smoking Cessation for Chronically Ill Veterans\t\tsmoker study\t471\n2129\tLifestyle Modification for Obesity-Related Type 2 Diabetes\tPhase 4\tdiabetes\t90\n2132\tOvercoming Psychiatric Barriers to the Treatment of Hepatitis C\t\thepatitis\t101\n2148\tSleep Specialty Consultation: Improving Management of Sleep Disorders\t\tsleep study\t156\n2150\tImproving Drug Use for Elderly Heart Failure Patients\t\telderly\t314\n2153\tSafety Study of a Vitamin E Supplement in Normal Volunteers and Those With Both Allergy and Asthma\tPhase 1\tasthma\t16\n2157\tIntensive Diet and Exercise for Improving Knee Osteoarthritis in Obese and Overweight Older Adults\tPhase 2\tarthritis\t454\n2161\tZinc Supplements in Lowering Cadmium Levels in Smokers\tPhase 2\tsmoker study\t61\n2163\tEffects of an Alternative Treatment for Military Sexual Trauma on PTSD Symptoms Neurosteroids and Brain Function\t\tneurological\t34\n2164\tFunctional Brain Imaging of Medication Treatment Response in Mild Alzheimer\u0026apos;s Disease Patients\tPhase 4\tneurological\t4\n2193\tExposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis\t\tneurological\t0\n2198\tEffect of Dexmedetomidine Upon Sleep Postoperatively\tPhase 4\tsleep study\t0\n2202\tStudy of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation\tPhase 4\tkidney disease\t275\n2204\tLevetiracetam for Cramps Spasticity and Neuroprotection in Motor Neuron Disease\tPhase 2\tneurological\t20\n2205\tStudy of an Intervention to Improve Use of Life-saving Medications for Heart Disease\t\theart disease\t143\n2207\tA Patient-Spouse Intervention for Self-Managing High Cholesterol\t\theart disease\t255\n2209\tVinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors\tPhase 1\ttumors\t41\n2211\tExamining the Link Between Trace Elements and Cardiovascular Disease Risk Factors in Young Adults\t\theart disease\t4362\n2213\tThe Impact of Patient Involvement in Decision-Making About Heart Disease Prevention\t\theart disease\t120\n2220\tStudy of Valproic Acid to Treat HIV Infected Adults\tPhase 1\thiv\t14\n2223\tExtracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors\tPhase 1 / Phase 2\ttumors\t48\n2224\tA Church Based Intervention to Improve Diabetes Care\t\tdiabetes\t201\n2229\tPaclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors\tPhase 1\ttumors\t18\n2233\tWeight Management and Coping Skills Training For Patients With Knee Osteoarthritis\t\tarthritis\t412\n2234\tVatalanib and Everolimus in Treating Patients With Advanced Solid Tumors\tPhase 1\ttumors\t37\n2235\tExercise to Treat Depression in Individuals With Coronary Heart Disease\tPhase 3\theart disease\t101\n2244\tSelf-Management of Osteoarthritis\t\tarthritis\t523\n2247\tMeasuring Cholesterol in the Fasting and Postmeal State in Patients With Type 2 Diabetes\t\tdiabetes\t30\n2248\tSleep Disorders and Gastroesophageal Reflux Disease (GERD)\tPhase 4\tsleep study\t20\n2249\tEffect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab\t\tasthma\t1\n2250\tGenetic Susceptibility to Ozone in Mild Asthmatic Volunteers\t\tasthma\t52\n2263\tA Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors\tPhase 1\ttumors\t30\n2264\tBevacizumab Everolimus and Erlotinib in Treating Patients With Advanced Solid Tumors\tPhase 1\ttumors\t65\n2266\tEffects of Resistance and Aerobic Exercise on Cardiovascular Health\tPhase 2\theart disease\t261\n2276\tPolicosanol for the Treatment of Hypercholesterolemia\t\theart disease\t40\n2277\tImatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors\tPhase 1\ttumors\t25\n2278\tImproving Sleep and Psychological Functioning in People With Depression and Insomnia\tPhase 4\tsleep study\t96\n2284\tA Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy\tPhase 2 / Phase 3\tneurological\t496\n2299\tComparing ASHC and CDSMP Outcomes In Arthritis\t\tarthritis\t416\n2303\tInterventions to Improve Hypertension Control and Reduce Cardiovascular Disease Risk\tPhase 2\theart disease\t574\n2310\tThe Role of Vitamins E and C in Maintaining Lung Health in People With Asthma\tPhase 1\tasthma\t16\n2314\tComparing Paroxetine and Duloxetine on Cardiovascular Measures\tPhase 2 / Phase 3\theart disease\t40\n2317\tTrial to Assess the Efficacy and Safety of SPM 927 (200 400 and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy\tPhase 3\tneurological\t654\n2321\tPIE II: Pharmacological Intervention in the Elderly II\tPhase 3\telderly\t80\n2331\tTumor RNA Transfected Dendritic Cell Vaccines\tPhase 1\ttumors\t\n2344\tSafety of KAI-9803 for Injection With Angioplasty Following Heart Attack\tPhase 1 / Phase 2\theart disease\t154\n2351\tPainful HIV Neuropathy and Alpha-Lipoic Acid\tPhase 1 / Phase 2\thiv\t60\n2355\tAssessing the Results of Lip Surgery in Patients With Cleft Lip and Palate\tPhase 2 / Phase 3\tsurgery\t127\n2358\tHIV Symptom Management Program for African American Mothers\tPhase 3\thiv\t\n2363\tImaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma\tPhase 1\tsurgery\t18\n2364\tStudy of Karenitecin (BNP1350) in Patients With Brain Tumors\tPhase 2\ttumors\t40\n2366\tReduced Manipulation of the Aorta and Neurobehavioral Outcome Trial\tPhase 3\tneurological\t300\n2373\tPhase 1 Study OF CDC-501 in Patients With Solid Tumors\tPhase 1\ttumors\t24\n2382\tScreening Adolescents for Type 2 Diabetes Mellitus in a Community Clinic\t\tdiabetes\t400\n2383\tEffects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery\tPhase 2\tsurgery\t389\n2384\tImatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery\tPhase 3\ttumors\t732\n2394\tImatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery\tPhase 2\ttumors\t89\n2396\tAntibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission\tPhase 3\thiv\t3720\n2397\tTreatment to Quit Smoking\tPhase 2\tsmoker study\t\n2398\tThe Genetics of Environmental Asthma\t\tasthma\t176\n2399\tIntensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen\t\ttuberculosis\t\n2407\tTo Determine the Prevalence of HIV and Other Related Infections Such as Hepatitis C Along With Associated Risk Behaviors in Patients With Severe Mental Illness (SMI).\t\thepatitis\t\n2408\tFinding Diabetes Mellitus Among Veterans\t\tdiabetes\t1276\n2415\tAcute Glycemic Effects of a Very Low Fat Diet in Type 2 Diabetes\t\tdiabetes\t\n2416\tActive Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA\tPhase 1\ttumors\t\n2417\tA Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA\tPhase 1\ttumors\t\n2418\tEffectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns\tPhase 3\thiv\t1500\n2419\tGenetic Study in Patients Receiving Treatment for Hodgkin\u0026apos;s Disease or Childhood Brain Tumor\t\ttumors\t19\n2427\tTemozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors\tPhase 2\ttumors\t\n2428\tTemozolomide in Treating Patients With Brain Metastases\tPhase 2\tneurological\t\n2429\tTemozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors\tPhase 1 / Phase 2\ttumors\t30\n2437\tEffectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment\tPhase 4\thiv\t300\n2442\tPhase II Study of Stereotypes and Mental Retardation: Neurobiological Basis\tPhase 2\tneurological\t40\n2445\tMelphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg\tPhase 3\ttumors\t216\n2446\tRadiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors\tPhase 1\ttumors\t21\n2447\tRadiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors\tPhase 1 / Phase 2\ttumors\t10\n2451\tIntrathecal Busulfan in Treating Patients With Recurrent Refractory or Metastatic Leptomeningeal Tumors\tPhase 1\ttumors\t20\n2452\tRadiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors\tPhase 1 / Phase 2\ttumors\t\n2458\tCarmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain\tPhase 1\tneurological\t56\n2468\tMonoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors\tPhase 1\ttumors\t6\n2471\tMonoclonal Antibody Therapy in Treating Patients With Brain Metastases\tPhase 1 / Phase 2\tneurological\t6\n2476\tA Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus\t\thiv\t\n2478\tA Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS\t\thiv\t\n2483\tA Prospective Double-Blind Study of Retrovir in Early HIV Infection\t\thiv\t\n2484\tA Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases\t\tneurological\t\n2485\tAn Oral Dose-Ranging Finding Study in Patients With HIV Disease CDC Classification Groups IIB III and IV-C2\t\thiv\t\n2490\tA Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus\t\thiv\t\n2491\tA Study of Nonoxynol-9 (N-9) and HIV Infection\tPhase 3\thiv\t4400\n2492\tA Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease\t\thiv\t\n2494\tiOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes\t\tdiabetes\t60\n2501\tTo Determine the Measurement Properties of the ACT in an African American Adolescent Population With Persistent Asthma\t\tasthma\t80\n2502\tTo Determine the Validity of the ACT in an Adolescent Population With Persistent Asthma\t\tasthma\t80\n2506\tSafety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection\t\thiv\t40\n2507\tBiomarkers of Aging as Predictors of Kidney Transplant Function\t\tkidney disease\t35\n2515\tRespiratory Event-Related Potentials in Patients With Spinal Cord Injury\t\trespiratory disease\t40\n2521\tPatient Self-management and Gene Guided Therapy for Chronic Hepatitis C\t\thepatitis\t20\n2531\tOptimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants\t\tdiabetes\t200\n2535\tCholesterol Medication Packaging Study\t\theart disease\t240\n2536\tDonepezil Compared to Placebo in Patients With Chronic Neuropathic Pain\tPhase 4\tneurological\t33\n2538\tTreatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet\tPhase 3\thiv\t30\n2539\tInternet-Based Osteoarthritis Pain Coping Skills Intervention\tPhase 3\tarthritis\t113\n2542\tTailored Smoking Cessation Treatment for LIVE FOR LIFE\u0026#174; Participants\tPhase 2 / Phase 3\tsmoker study\t19\n2544\tSafety Efficacy and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases\tPhase 1\tsurgery\t30\n2546\tMechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation\tPhase 3\tsmoker study\t282\n2553\tTitle: Comparative Effectiveness of Asthma Interventions Within an AHRQ PBRN\t\tasthma\t1040\n2556\tOxytocin Treatment of Alcohol Withdrawal\tPhase 1\talcohol\t14\n2557\tTemsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma Bone Sarcoma or Soft Tissue Sarcoma\tPhase 1\tneurological\t7\n2560\tPacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial)\t\theart disease\t16\n2561\tCollaborative Study Of Neurofeedback Training Of 6-18 Year Olds With Autism\tPhase 1\tneurological\t30\n2562\tProject POWER Adapting Project SAFE: Reducing STD/HIV Risk in Women Prisoners\t\thiv\t598\n2563\tFMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders\tPhase 4\tneurological\t13\n2569\tTreatment of Acute HIV With Emtricitabine Tenofovir and Efavirenz (CID 0805)\tPhase 4\thiv\t90\n2571\tThe Effects of One-Time Pregnenolone Dehydroepiandrosterone (DHEA) or Placebo Administration On Withdrawal Symptoms Mood Craving And Cigarette Evaluation Ratings In Male Smokers\tPhase 2\tsmoker study\t22\n2572\tStudy to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Na\u0026#239;ve Patients Treated With Darunavir/Ritonavir and Etravirine\tPhase 4\thiv\t15\n2573\tEffect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes\t\tdiabetes\t450\n2574\tCognitive Effects of Inhalational Versus Intravenous General Anesthesia in the Elderly\t\telderly\t200\n2577\tRaltegravir as Early Therapy in African-Americans Living With HIV Study\tPhase 4\thiv\t43\n2580\tFeasibility of Cocooning Immunization Strategy With Influenza Vaccine\t\tinfluenza\t544\n2582\tErythropoietin Resistance in Anemia of Chronic Kidney Disease\t\tkidney disease\t32\n2584\tEvaluating a Web-Based Educational Program for Adults at Risk for Coronary Heart Disease (The Heart to Heart Feasibility Study)\t\theart disease\t186\n2588\tClonidine-induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain\tPhase 2\tneurological\t43\n2589\tClonidine Versus Adenosine to Treat Neuropathic Pain\tPhase 2\tneurological\t24\n2594\tFunctional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal\tPhase 4\tneurological\t30\n2599\tTesting Pharmacological Therapies for Pregnant Smokers\tPhase 4\tsmoker study\t181\n2602\tSensory Re-Training Following Facial Surgery for Correction of Facial Skeletal Disharmony\tPhase 3\tsurgery\t186\n2604\tCoping Skills Training for Early Rheumatoid Arthritis\t\tarthritis\t105\n2611\tEffects of Nicotine Reduction on Smoking Behavior in ADHD Smokers\t\tsmoker study\t350\n2623\tDouble-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD\t\tneurological\t140\n2625\tStudy To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.\tPhase 1\tdiabetes\t39\n2641\tEvaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX\t\thiv\t381\n2642\tStudy of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)\tPhase 2\tdiabetes\t36\n2643\tIntraoperative OCT Guidance of Intraocular Surgery\t\tsurgery\t802\n2646\tSchool Support as Structural HIV Prevention for Adolescent Orphans in Kenya\tPhase 2\thiv\t835\n2652\tA Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins\t\ttumors\t210\n2668\tCP-868596 And CP-868596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors\tPhase 1\ttumors\t50\n2669\tLidocaine For Neuroprotection During Cardiac Surgery\t\tsurgery\t476\n2680\tPhysical Activity Following Surgery Induced Weight Loss\t\tsurgery\t128\n2686\tThree Way Interaction Between Gabapentin Duloxetine and Donepezil in Patients With Diabetic Neuropathy\t\tneurological\t22\n2696\tStudy of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic\tPhase 4\talcohol\t100\n2699\tComparison Of Molecular Targets In Mild To Severe Asthmatics And Healthy Subjects\tPhase 1\tasthma\t58\n2700\tCan Group Visits Improve Outcomes of Veterans With Diabetes\tPhase 3\tdiabetes\t239\n2706\tMEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)\tPhase 2\tsurgery\t900\n2710\tGW786034 in Treating Patients With Advanced Solid Tumors\tPhase 1\ttumors\t\n2715\tVaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal\tPhase 1 / Phase 2\ttumors\t\n2719\tA Study of Zidovudine in HIV-Infected Patients With Kidney Problems\tPhase 1\tkidney disease\t0\n2721\tWeight Loss and Exercise for Communities With Arthritis in North Carolina\tPhase 3\tarthritis\t820\n2725\tEvaluation of Moclobemide a Reversible MAO-A Inhibitor as an Adjunct to Nicotine Replacement Therapy in Female Smokers\tPhase 2\tsmoker study\t76\n2733\tEvaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection\tPhase 2\thiv\t80\n2739\tEffects of Anti-HIV Therapy on Red Blood Cells of HIV-infected Mothers and Their Infants\t\thiv\t0\n2769\tTreatment for Teens With Alcohol Abuse and Depression\t\talcohol\t170\n2773\tDiabetes Self-Management \u0026amp; Support LIVE\t\tdiabetes\t300\n2775\tCardioneuroablation for Neurocardiogenic Syncope\t\tneurological\t3\n2778\tHigh-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors\tPhase 1\tinfluenza\t60\n2781\tMechanisms and Functional Outcomes of Exercise Progression Models in the Elderly\t\telderly\t108\n2785\tA Prospective Evaluation of the Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors.\tPhase 1\ttumors\t23\n2786\tDeployment Related Mild Traumatic Brain Injury (mTBI)\t\tneurological\t1500\n2791\tSevere Asthma Research Program - Wake Forest University\t\tasthma\t700\n2798\tSymptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery\t\tsurgery\t100\n2812\tStudy to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma\tPhase 1 / Phase 2\tasthma\t14\n2823\tProspective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR\t\tkidney disease\t2\n2828\tLymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection\tPhase 4\tsurgery\t206\n2854\tGlucose/Insulin Responses:Subjects With Type 2 Diabetes Consuming Diabetes-Specific vs Standard Nutritional Formulas\tPhase 3\tdiabetes\t54\n2855\tInduction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion\tPhase 2\tkidney disease\t60\n2858\tArthritis Self-Management Education Program\t\tarthritis\t690\n2860\tDonepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain\t\ttumors\t14\n2868\tEffect of Brain Lesion Severity on Treatment Response in Late-Life Depression\t\tneurological\t131\n2886\tPain and Stress Management for People With Rheumatoid Arthritis\tPhase 2\tarthritis\t280\n2888\tImmunotoxin Therapy in Treating Patients With Advanced Solid Tumors\tPhase 1\ttumors\t\n2900\tA Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time\tPhase 1\thiv\t12\n2915\tEarly Mobility for the Critically Injured Burn Patient\t\tburns\t150\n2922\tSafety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults\tPhase 1\tinfluenza\t133\n2925\tAutomated Chest Physiotherapy to Improve Outcomes in Neuro\t\tneurological\t40\n2932\tProof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate\tPhase 2\tsmoker study\t36\n2933\tCombination Bupropion / Varenicline for Smoking Cessation in Male Smokers\tPhase 2\tsmoker study\t376\n2934\tMeclizine as a Potential Smoking Cessation Treatment\tPhase 2\tsmoker study\t146\n2935\tConcurrent Bupropion / Varenicline for Smoking Cessation\tPhase 3\tsmoker study\t702\n2943\tTrial of Collaborative Depression Care Management for HIV Patients\t\thiv\t304\n2952\tSafety Study of MGD009 in B7-H3-expressing Tumors\tPhase 1\ttumors\t114\n2956\tStudy to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT\u0026#174; DISKUS\u0026#174; and ADVAIR\u0026#174; DISKUS\u0026#174; in Patients With Persistent Asthma 12 Years of Age and Older\tPhase 1\tasthma\t43\n2957\tPhase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors\tPhase 1 / Phase 2\ttumors\t60\n2959\tFirst in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors\tPhase 1\ttumors\t50\n2962\tClinical Performance Study of the Ultra Influenza A\u0026amp;B Test Using Nasal Swabs for Identifying Subjects Who Are Infected With the Influenza Virus Strain Type A or Type B\t\tinfluenza\t677\n2965\tSurgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix\tPhase 2\ttumors\t116\n2970\tSafety and Efficacy of LCL161 in Patients With Solid Tumors\tPhase 1\ttumors\t71\n2981\tEfficacy of Seprapack Sinus Dressing Versus No Dressing in the Prevention of Intranasal Adhesions Following Sinus Surgery\t\tsurgery\t\n2984\tStudy to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors\tPhase 1\ttumors\t36\n2990\tA Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma\tPhase 1\tasthma\t20\n3003\tStudy of A Cell-Phone System to Improve Health of Youth With Diabetes\t\tdiabetes\t74\n3004\tPharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients\t\tneurological\t1\n3008\tThe Pathogenesis of Hepatitis C Virus Vertical Transmission\t\thepatitis\t50\n3009\tEfficacy and Safety of Beta-adrenoceptor Inverse Agonist Nadolol in Mild Asthma\tPhase 2\tasthma\t60\n3014\tNAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness\tPhase 4\tsleep study\t37\n3028\tA Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors\tPhase 1\ttumors\t44\n3032\tTrial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)\tPhase 2\ttumors\t5\n3034\tCollection and Extraction of Respiratory Specimens\t\trespiratory disease\t600\n3037\tSanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations\tPhase 2\tinfluenza\t406\n3041\tSafety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.\tPhase 1\ttumors\t32\n3045\tStudy of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy\tPhase 1\ttumors\t25\n3055\tStudy of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet\tPhase 1 / Phase 2\ttumors\t20\n3083\tSafety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy\tPhase 1\thiv\t12\n3089\tA Multicenter 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar\u0026#174; Gel in Subjects With Rheumatoid Arthritis\tPhase 4\tarthritis\t232\n3091\tOpen-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder\tPhase 2\tsleep study\t80\n3113\tExploring Massage Benefits for Arthritis of the Knee\tPhase 2\tarthritis\t222\n3144\tA Phase 1 Double-Blind Randomized Single Dose Escalation Safety Study of Intra-articular OP-1 in Subjects With Osteoarthritis of the Knee\tPhase 1\tarthritis\t33\n3154\tFibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy\tPhase 3\thepatitis\t300\n3157\tSafety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People\tPhase 2\thiv\t12\n3160\tA Study of 141W94 in Combination With Other Anti-HIV Drugs\tPhase 1\thiv\t48\n3173\tSoutheastern Diabetes Initiative Clinical Intervention\t\tdiabetes\t648\n3181\tRisk of Developing Antibodies to Heparin-PF4 After Heart Surgery\t\tsurgery\t1015\n3183\tA Study of Autologous Neo-Kidney Augment\u0026#8482; (NKA) in Type 2 Diabetics With Chronic Kidney Disease\tPhase 2\tkidney disease\t50\n3188\tHeart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk\t\theart disease\t489\n3191\tEarly Weight Bearing on Supracondylar Distal Femur Fractures in Elderly Patients\t\telderly\t200\n3204\tStudy to Investigate the Safety Pharmacokinetics Pharmacodynamics and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.\tPhase 1\ttumors\t69\n3205\tA Study of Influenza Virus Vaccines in Children and Adults\tPhase 2\tinfluenza\t600\n3211\tEarly Life Factors and Respiratory Health in Mexico City Children\t\trespiratory disease\t6800\n3213\tInfluenza Vaccine Feasibility Study in Children With Persistent Asthma\tPhase 4\tasthma\t50\n3222\tPTC596 in Patients With Advanced Solid Tumors\tPhase 1\ttumors\t60\n3227\tSafety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C\tPhase 1 / Phase 2\thepatitis\t9\n3228\tA Study to Evaluate the Safety Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis\tPhase 1\tarthritis\t19\n3230\tRESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol\t\tsurgery\t647\n3232\tStudy of SCY-635 Pegasys and Copegus in Hepatitis C\tPhase 2\thepatitis\t11\n3235\tBioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors\tPhase 1\ttumors\t63\n3241\tStudy of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma\tPhase 1\ttumors\t37\n3254\tAffect Recognition: Enhancing Performance of Persons With Acquired Brain Injury (ABI)\tPhase 2 / Phase 3\tneurological\t71\n3261\tEffects of Treating Obstructive Sleep Apnea in Epilepsy\tPhase 2\tepilepsy\t68\n3264\tRisk Evaluation and Education for Alzheimer\u0026apos;s Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)\t\tneurological\t270\n3284\tEvaluating the Impact of Year Long Augmented Diabetes Self Management Support\t\tdiabetes\t449\n3288\tThe Tobacco Alcohol Prescription Medication and Other Substances Tool\t\talcohol\t2000\n3317\tBioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors\tPhase 1\ttumors\t60\n3320\tSafety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation\tPhase 2\tkidney disease\t99\n3329\tPharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors\tPhase 2\ttumors\t26\n3333\tA Study of R547 in Patients With Advanced Solid Tumors.\tPhase 1\ttumors\t58\n3342\tDose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors\tPhase 1\ttumors\t25\n3344\tDonepezil or EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases\tPhase 2\ttumors\t\n3345\tOmega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients\tPhase 0\tkidney disease\t75\n3347\tSingle Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients\tPhase 1 / Phase 2\tdiabetes\t62\n3349\tImproving Diabetes Care Via Telephone Assessment and Patient Education\t\tdiabetes\t480\n3352\tTrial of Nonpharmacologic Interventions in Elderly (TONE)\tPhase 3\telderly\t\n3359\tSafety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)\tPhase 1\trespiratory disease\t48\n3363\tDovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors\tPhase 2\ttumors\t0\n3373\tCardiovascular Effects of Exposure to Ozone\t\theart disease\t90\n3374\tA Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors\tPhase 1\ttumors\t30\n3382\tDosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors\tPhase 1\ttumors\t9\n3383\tStudy to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)\tPhase 2\thiv\t9\n3385\tSafety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors\tPhase 1\ttumors\t19\n3396\tSafety and Tolerability Study of SNS-314 for Advanced Solid Tumors\tPhase 1\ttumors\t50\n3407\tA Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy\tPhase 2\thiv\t6\n3408\tSafety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors\tPhase 1\ttumors\t\n3409\tInitial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.\tPhase 1\ttumors\t\n3412\tNBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme\tPhase 2\tsurgery\t\n3422\tRadiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases\tPhase 2\tneurological\t\n3444\tA Non-Invasive Neuromodulation Device for Treatment of Migraine Headache\t\tneurological\t81\n3448\tA Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation\t\tsmoker study\t1020\n3455\tIL13-PE38QQR Infusion After Tumor Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma\tPhase 1\ttumors\t24\n3468\t2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women\tPhase 2\tinfluenza\t183\n3473\tCombination Study of BMS-754807 and Erbitux\u0026#174; in Subjects With Advanced or Metastatic Solid Tumors\tPhase 1 / Phase 2\ttumors\t54\n3478\tPhase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment\tPhase 2\thepatitis\t154\n3480\tEfficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients\tPhase 3\tburns\t61\n3486\tAutologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)\tPhase 2\tdiabetes\t30\n3490\tA Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition\tPhase 4\tneurological\t24\n3502\tA Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee\tPhase 2\tarthritis\t81\n3505\tStudy of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to \u0026lt;17 Years of Age\tPhase 2\tsurgery\t30\n3507\tSafety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors\tPhase 1\ttumors\t19\n3517\tGenetic Studies of Non-Alcoholic Fatty Liver Disease\t\talcohol\t1000\n3530\tComparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis\tPhase 4\tdermatitis\t100\n3531\tA Clinical Demonstration of EEG Brain-computer Interface for ALS Patients\t\tneurological\t27\n3534\tFLU A+B Nasal Swab Clinical Study\t\tinfluenza\t800\n3543\tStudy of XTL6865 in Patients With Chronic Hepatitis C Virus Infection\tPhase 1\thepatitis\t36\n3544\tThe Effects of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy\tPhase 3\tneurological\t100\n3558\tTradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis\tPhase 2\tdermatitis\t150\n3563\tSafety Tolerability and PK of AN2728 in Adolescents With Atopic Dermatitis\tPhase 1 / Phase 2\tdermatitis\t23\n3575\tStudy of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to \u0026lt;17 Years of Age\tPhase 2\tsurgery\t30\n3576\tA Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.\tPhase 1 / Phase 2\ttumors\t216\n3581\tAutologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery\tPhase 1 / Phase 2\tsurgery\t30\n3589\tTumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC\t\ttumors\t11\n3590\tA Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers\tPhase 2\ttumors\t18\n3593\tA Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults\tPhase 2\tsurgery\t25\n3594\tA Phase 1 Open-label Safety Study of NKA in Patients With Type 2 Diabetes\tPhase 1\tdiabetes\t1\n3597\tA First-in-Human Double Blind Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.\tPhase 1\tasthma\t70\n3612\tHyperbaric Oxygen Therapy (HBO2) for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (mTBI)\tPhase 2\tneurological\t79\n3613\tCollection and Testing of Respiratory Samples\t\trespiratory disease\t272\n3614\t1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors\tPhase 1\ttumors\t27\n3619\tA Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients\tPhase 2\tsurgery\t150\n3626\tPhase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients\tPhase 2\tkidney disease\t58\n3631\tInfluenza Vaccine in Premature Infants\tPhase 4\tinfluenza\t66\n3640\tRegistry for African Americans With Early Rheumatoid Arthritis\t\tarthritis\t357\n3643\tStudy of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients\tPhase 2 / Phase 3\thiv\t\n3648\tOpen Label Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)\tPhase 1\tdermatitis\t14\n3666\tVaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor\tPhase 1 / Phase 2\ttumors\t50\n3669\tSafety Tolerability Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness\tPhase 1\tsleep study\t36\n3671\tSafety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors\tPhase 1\ttumors\t46\n3672\tAn Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy\t\tdiabetes\t41\n3680\tEfficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma\tPhase 2 / Phase 3\tasthma\t45\n3683\tStudy to Assess Steady-State Trough Concentrations Safety and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)\tPhase 1 / Phase 2\tarthritis\t87\n3691\tEvaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication\t\thiv\t0\n3698\tMethod-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects\tPhase 3\theart disease\t242\n3717\tDabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery\tPhase 2\tsurgery\t280\n3724\tEvaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy\tPhase 3\theart disease\t4200\n3728\tA Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors\tPhase 4\tdiabetes\t12000\n3730\tThe Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects\tPhase 3\theart disease\t17000\n3731\tEvaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.\tPhase 4\theart disease\t4000\n3738\tFurther Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk\tPhase 3\theart disease\t27564\n3746\tGemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery\tPhase 3\tsurgery\t216\n3754\tIpilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery\tPhase 3\tsurgery\t1500\n3778\tComparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes\tPhase 4\tdiabetes\t5652\n3788\tThe Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects\tPhase 3\theart disease\t10653\n3795\tEfficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes\tPhase 3\tdiabetes\t1049\n3798\tA Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome\tPhase 3\theart disease\t15865\n3799\tA Study to Describe Pediatric Influenza Vaccine Coverage\tPhase 4\tinfluenza\t147494\n3807\tA Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus\tPhase 3\tdiabetes\t19000\n3808\tA Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events\tPhase 3\tdiabetes\t7637\n3811\tCardiovascular Inflammation Reduction Trial\tPhase 3\theart disease\t7000\n3818\tSafety and Efficacy of Albiglutide in Type 2 Diabetes\tPhase 3\tdiabetes\t310\n3819\tA Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes\tPhase 3\tdiabetes\t685\n3832\tCardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)\tPhase 3\theart disease\t10066\n3833\tPrevention of Cardiovascular Events (eg Death From Heart or Vascular Disease Heart Attack or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin\tPhase 3\theart disease\t21379\n3834\tCardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities\tPhase 3\theart disease\t6198\n3848\tCardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)\tPhase 4\tdiabetes\t8300\n3850\tA Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease\tPhase 3\theart disease\t16415\n3851\tStrategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease\tPhase 3\tkidney disease\t756\n3852\tStudy of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease\tPhase 3\tdiabetes\t3207\n3853\tCardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)\tPhase 3\theart disease\t8910\n3854\tSAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.\tPhase 4\tasthma\t11751\n3857\tEvaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)\tPhase 3\tdiabetes\t6068\n3858\tExenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus\tPhase 3\tdiabetes\t14000\n3866\tSafety and Efficacy Study of Albiglutide in Type 2 Diabetes\tPhase 3\tdiabetes\t309\n3874\tJUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events\tPhase 3\theart disease\t17802\n3879\tNaltrexone/Bupropion Cardiovascular Outcomes Study\tPhase 4\theart disease\t67\n3889\tCAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes\tPhase 3\tdiabetes\t6115\n3892\tCardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome\tPhase 3\tdiabetes\t5380\n3895\tA Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes\tPhase 3\tdiabetes\t779\n3896\tSafety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (\u0026quot;Bad Cholesterol\u0026quot;) and Triglycerides\tPhase 3\theart disease\t474\n3899\tStudy Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine\tPhase 3\tinfluenza\t1116\n3929\tDocetaxel in Treating Patients With Solid Tumors\tPhase 2\ttumors\t109\n3932\tFurther Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension\tPhase 3\theart disease\t5000\n3933\tNivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery\tPhase 2\tsurgery\t84\n3937\tNivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery\tPhase 2 / Phase 3\tsurgery\t400\n3940\tSafety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis\tPhase 4\tarthritis\t4000\n3944\tAfatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence\tPhase 2\tsurgery\t3\n3946\tA Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes\tPhase 3\tdiabetes\t460\n3948\tDual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes\tPhase 3\tdiabetes\t1663\n3956\tA Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)\tPhase 3\tarthritis\t886\n3972\tCisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors\tPhase 3\ttumors\t1\n3982\tEfficacy in Controlling Glycaemia With Victoza\u0026#174; (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes\tPhase 4\tdiabetes\t1994\n3989\tHigh-Dose Recombinant Interferon Alfa-2B Ipilimumab or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery\tPhase 3\tsurgery\t1378\n3992\tPhase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults\tPhase 3\tinfluenza\t1161\n3994\tIpilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery\tPhase 2\tsurgery\t168\n3998\tMulticenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events\tPhase 3\theart disease\t17276\n4005\tSafety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients\tPhase 3\tarthritis\t397\n4010\tLiraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation\tPhase 3\tdiabetes\t9340\n4015\tSafety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone\tPhase 3\tdiabetes\t141\n4017\tAn Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants\t\trespiratory disease\t3000\n4019\tEfficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes\tPhase 2 / Phase 3\tdiabetes\t338\n4023\tEfficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia\tPhase 3\theart disease\t411\n4024\tOut-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only\tPhase 2\tdiabetes\t361\n4026\tA Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis\t\tdermatitis\t8037\n4043\tEffect of Albiglutide When Added to Standard Blood Glucose Lowering Therapies on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus\tPhase 4\tdiabetes\t9400\n4048\tNon-inferiority Study to Compare the Efficacy and Safety of Mylan\u0026apos;s Insulin Glargine With Lantus\u0026#174; in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)\tPhase 3\tdiabetes\t600\n4054\tODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab\tPhase 3\theart disease\t18600\n4058\tA Study of Dalcetrapib in Patients With Stable Coronary Heart Disease With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease\tPhase 3\theart disease\t2220\n4061\tA Study of Fluzone\u0026#174; High-Dose Vaccine Compared With Fluzone\u0026#174; Vaccine In Elderly Adults\tPhase 4\telderly\t31989\n4066\tA Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors\tPhase 4\tarthritis\t3080\n4070\tEffect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE\u0026#8482; - Diabetes\tPhase 3\tdiabetes\t846\n4073\tEfficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study\tPhase 3\tdiabetes\t234\n4075\tDoes Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications\tPhase 4\tdiabetes\t18206\n4078\tA Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain\tPhase 4\tinfluenza\t102\n4082\tMulti-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone\u0026#174; Vaccine in Adults Aged 65 Years and Older\tPhase 3\tinfluenza\t9172\n4085\tCollecting Tumor Samples From Patients With Gynecological Tumors\t\ttumors\t275\n4096\tA Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis\tPhase 3\tarthritis\t619\n4101\tExubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety\tPhase 4\theart disease\t1976\n4106\tA Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.\tPhase 3\theart disease\t1784\n4123\tNon-inferiority Study to Compare the Efficacy and Safety of Mylan\u0026apos;s Insulin Glargine With Lantus\u0026#174; in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)\tPhase 3\tdiabetes\t500\n4125\tEvaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects\tPhase 3\theart disease\t1972\n4126\tSafety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD) Not on Dialysis\tPhase 3\tkidney disease\t2600\n4132\tRandomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events\tPhase 3\theart disease\t690\n4133\tEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes\tPhase 3\tdiabetes\t736\n4134\tEfficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM\tPhase 3\tdiabetes\t1170\n4137\tA Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate in Participants With Moderate to Severe Active Rheumatoid Arthritis\tPhase 3\tarthritis\t718\n4139\tStudy of Safety of Foradil in Patients With Persistent Asthma\tPhase 4\tasthma\t827\n4144\tTrial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes\tPhase 3\tdiabetes\t3297\n4148\tBevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors\tPhase 2\ttumors\t75\n4150\tEfficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes\tPhase 3\tdiabetes\t105\n4156\tLong-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients\tPhase 3\tarthritis\t233\n4168\tA Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children\tPhase 3\tinfluenza\t2312\n4169\tPROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-na\u0026#239;ve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b\t\thepatitis\t1656\n4170\tSafety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy\tPhase 2\tdiabetes\t421\n4172\tNovel Influenza A (H1N1) Surveillance Registry\t\tinfluenza\t894\n4173\tA Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease\tPhase 3\tdiabetes\t2118\n4184\tBiomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma\t\ttumors\t10000\n4186\tStudy of Kidney Tumors in Younger Patients\t\tkidney disease\t5000\n4196\tTrial to Evaluate the Efficacy of GSK Biologicals\u0026apos; Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older\tPhase 3\tinfluenza\t43695\n4199\tA Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Thiazolidinedione or a Combination of Both.\tPhase 3\tdiabetes\t1189\n4206\tA Long-Term Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee\tPhase 2 / Phase 3\tarthritis\t5077\n4216\tA Comparison of SYMBICORT\u0026#174; pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.\tPhase 3\tasthma\t742\n4225\tVincristine Dactinomycin and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I Stage II or Stage III Wilms\u0026apos; Tumor\tPhase 3\ttumors\t808\n4228\tRosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin\tPhase 4\tdiabetes\t630\n4230\tStudy of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus\tPhase 3\tdiabetes\t493\n4256\tDNA Variations in the Gene in Young Patients With Wilms\u0026apos; Tumor\t\ttumors\t471\n4269\tLobradimil and Carboplatin in Treating Children With Brain Tumors\tPhase 2\ttumors\t\n4282\tSurgery in Treating Children With Neuroblastoma\tPhase 3\tsurgery\t968\n4289\tRadiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery\tPhase 2\tsurgery\t345\n4293\tA Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate\tPhase 3\tarthritis\t1500\n4300\tLong Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee\tPhase 3\tarthritis\t3000\n4304\tChronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma\tPhase 2\tasthma\t249\n4305\tA Study of Apixaban in Patients With Atrial Fibrillation Not Caused by a Heart Valve Problem Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event Such as a Heart Attack or a Procedure to Open the Vessels of the Heart\tPhase 4\theart disease\t4600\n4307\tComparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications\tPhase 3\tdiabetes\t1014\n4312\t24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension\tPhase 3\tdiabetes\t154\n4314\tA Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma\tPhase 3\tasthma\t1140\n4317\tEfficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-na\u0026#239;ve Subjects With Type 2 Diabetes\tPhase 3\tdiabetes\t1082\n4326\tRandomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events\tPhase 3\theart disease\t2139\n4331\tPazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors\tPhase 2\ttumors\t165\n4337\tComparison Study of the Glycemic Effects Safety and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus\tPhase 3\tdiabetes\t365\n4342\tMonthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin\tPhase 2\theart disease\t356\n4349\tA Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.\tPhase 3\theart disease\t8000\n4350\tEfficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes\tPhase 3\tdiabetes\t2454\n4353\tA 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents\tPhase 3\tasthma\t12463\n4358\tStudy to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes\tPhase 4\tdiabetes\t975\n4361\tA Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor\tPhase 4\tarthritis\t96\n4373\tA Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.\tPhase 3\tdiabetes\t507\n4376\tA Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus\tPhase 3\tdiabetes\t7226\n4379\tEfficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes\tPhase 2\tdiabetes\t494\n4381\tEfficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus\tPhase 2\tdiabetes\t426\n4383\tA Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine\tPhase 3\tdiabetes\t586\n4384\tSafety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone\tPhase 3\tdiabetes\t252\n4387\tSafety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin\tPhase 3\tdiabetes\t677\n4393\tCollecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma\t\ttumors\t1000\n4406\tSafety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia\tPhase 3\telderly\t829\n4408\tA Double-blind Parallel Group Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep\tPhase 2\tsleep study\t306\n4413\tA Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)\tPhase 2\tneurological\t376\n4414\tEarly Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)\tPhase 3\trespiratory disease\t272\n4419\tComparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma\tPhase 3\tneurological\t665\n4426\tEfficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee\tPhase 3\tarthritis\t1020\n4436\tA Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)\tPhase 4\tarthritis\t1026\n4437\tAirway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath\t\tsmoker study\t1283\n4439\tLong-Term Effectiveness And Safety Of CP-690550 For The Treatment Of Rheumatoid Arthritis\tPhase 3\tarthritis\t4500\n4440\tEffect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes\tPhase 3\tdiabetes\t560\n4452\tEfficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.\tPhase 3\tdiabetes\t390\n4453\tThe DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)\tPhase 4\tdiabetes\t2091\n4461\tExtension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness\tPhase 3\tsleep study\t743\n4462\tEfficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.\tPhase 3\tarthritis\t619\n4467\tA Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol\tPhase 3\theart disease\t3800\n4468\tA Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease\tPhase 3\theart disease\t1100\n4469\tStudy of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children\tPhase 3\trespiratory disease\t6635\n4470\tTrivalent Live Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6\u0026#8211;59 Months of Age\tPhase 3\tinfluenza\t8500\n4474\tA Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack\tPhase 3\theart disease\t658\n4475\tStudy of Muraglitazar Versus Pioglitazone in Type 2 Diabetes\tPhase 3\tdiabetes\t1440\n4476\tStudy Of Asthma In Patients Of African Descent\tPhase 4\tasthma\t479\n4489\tEffect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension\tPhase 4\tdiabetes\t501\n4494\tAtazanavir for HIV Infected Individuals: An Early Access Program\t\thiv\t\n4495\tEvaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea\tPhase 3\tdiabetes\t377\n4496\tEvaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin\tPhase 3\tdiabetes\t336\n4498\tIsotretinoin With or Without Dinutuximab Aldesleukin and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma\tPhase 3\tneurological\t1449\n4503\tEvaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases\t\tneurological\t59\n4528\tRadiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases\tPhase 3\tsurgery\t333\n4540\tA Study to Compare ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs\tPhase 3\tarthritis\t450\n4544\tExtension Study to Assess Safety and Efficacy of Mylan\u0026apos;s Insulin Glargine and Lantus\u0026#174; in Type 1 Diabetes Mellitus Patients\tPhase 3\tdiabetes\t138\n4550\tEfficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes\tPhase 3\tdiabetes\t1860\n4554\tA Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas\tPhase 2\ttumors\t56\n4557\tA Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis\tPhase 3\tkidney disease\t432\n4562\tEvaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)\tPhase 3\tasthma\t1858\n4563\t\u0026quot;A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA\u0026quot;\tPhase 3\tsleep study\t600\n4564\t\u0026quot;Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy\u0026quot;\tPhase 3\tsleep study\t240\n4579\tA Study of Evacetrapib (LY2484595) in Participants With High Cholesterol\tPhase 3\theart disease\t366\n4581\tBGJ398 for Patients With Tumors With FGFR Genetic Alterations\tPhase 2\ttumors\t90\n4586\tConcomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.\tPhase 4\tinfluenza\t882\n4589\tA Study to Examine Patient Characteristics Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir\tPhase 4\thepatitis\t315\n4590\tA Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors\tPhase 3\ttumors\t800\n4598\tCardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease The VERTIS CV Study (MK-8835-004)\tPhase 3\tdiabetes\t8000\n4600\tUNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects\tPhase 3\thepatitis\t416\n4604\tA Golimumab Phase 3b Multicenter Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE\u0026#174;)\tPhase 3\tarthritis\t11\n4607\tStudy of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee\tPhase 3\tarthritis\t287\n4610\tTAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes\tPhase 3\tdiabetes\t90\n4615\tA Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities\tPhase 3\theart disease\t1999\n4617\tA Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy\tPhase 2\tdiabetes\t226\n4620\tA Trial of NNC0109-0012 an Anti-IL-20 Biologic in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics\tPhase 2\tarthritis\t239\n4623\tSafety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza\tPhase 3\tinfluenza\t1941\n4626\tA Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone\tPhase 3\tdiabetes\t442\n4627\tComparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes\tPhase 3\tdiabetes\t916\n4631\tComparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy\tPhase 3\tdiabetes\t811\n4633\tHCV-TARGET- Hepatitis C Therapeutic Registry and Research Network\t\thepatitis\t4500\n4636\tComparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes\tPhase 3\tdiabetes\t421\n4658\tEvaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)\tPhase 3\tarthritis\t1917\n4666\tSafety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase\tPhase 3\tarthritis\t196\n4669\tA Study in Participants With Diabetic Kidney Disease\tPhase 2\tkidney disease\t417\n"
      },
      "dateCreated": "Dec 4, 2016 7:56:28 PM",
      "dateStarted": "Dec 4, 2016 8:34:16 PM",
      "dateFinished": "Dec 4, 2016 8:34:17 PM",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%md\n\n\u003ch3\u003eWhat can we do with these results?\u003c/h3\u003e\n\u003cb\u003eEnhance Search:  \u003c/b\u003eCategories (and enriched variables) can be fed into SOLR to enhance search\n\u003cb\u003ePredictive Modeling:  \u003c/b\u003eCategories, flags, and variables can be fed in to a predictive model (ie. What factors/variables influence what studies make it to Phase 4)\n\u003cb\u003eUnsupervised Learning:  \u003c/b\u003eExtract data-driven topics (text mining), used to uncover unknown patterns in textual data (can also be applied to structred data as clustering)\n\u003cb\u003eSend to Hive:  \u003c/b\u003eWrite to Hive as an enriched table and for use with other operational systems.",
      "dateUpdated": "Dec 4, 2016 9:00:17 PM",
      "config": {
        "colWidth": 12.0,
        "graph": {
          "mode": "table",
          "height": 300.0,
          "optionOpen": false,
          "keys": [],
          "values": [],
          "groups": [],
          "scatter": {}
        },
        "enabled": true,
        "editorMode": "ace/mode/markdown",
        "editorHide": true
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "jobName": "paragraph_1480883455595_1367424293",
      "id": "20161204-203055_2038648891",
      "result": {
        "code": "SUCCESS",
        "type": "HTML",
        "msg": "\u003ch3\u003eWhat can we do with these results?\u003c/h3\u003e\n\u003cp\u003e\u003cb\u003eEnhance Search:  \u003c/b\u003eCategories (and enriched variables) can be fed into SOLR to enhance search\n\u003cbr  /\u003e\u003cb\u003ePredictive Modeling:  \u003c/b\u003eCategories, flags, and variables can be fed in to a predictive model (ie. What factors/variables influence what studies make it to Phase 4)\n\u003cbr  /\u003e\u003cb\u003eUnsupervised Learning:  \u003c/b\u003eExtract data-driven topics (text mining), used to uncover unknown patterns in textual data (can also be applied to structred data as clustering)\n\u003cbr  /\u003e\u003cb\u003eSend to Hive:  \u003c/b\u003eWrite to Hive as an enriched table and for use with other operational systems.\u003c/p\u003e\n"
      },
      "dateCreated": "Dec 4, 2016 8:30:55 PM",
      "dateStarted": "Dec 4, 2016 9:00:15 PM",
      "dateFinished": "Dec 4, 2016 9:00:15 PM",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "title": "Send Data to Hive",
      "text": "",
      "dateUpdated": "Dec 4, 2016 9:03:23 PM",
      "config": {
        "colWidth": 12.0,
        "graph": {
          "mode": "table",
          "height": 300.0,
          "optionOpen": false,
          "keys": [],
          "values": [],
          "groups": [],
          "scatter": {}
        },
        "enabled": true,
        "title": false
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "jobName": "paragraph_1480884502008_-1644706971",
      "id": "20161204-204822_981926615",
      "dateCreated": "Dec 4, 2016 8:48:22 PM",
      "status": "READY",
      "progressUpdateIntervalMs": 500
    }
  ],
  "name": "ClinicalAnalysis",
  "id": "2C2QHC919",
  "angularObjects": {
    "2C35SAQUV:shared_process": [],
    "2C1SVJQKC:shared_process": [],
    "2BZCYSBP1:shared_process": [],
    "2C3QWZMH9:shared_process": [],
    "2C2VCMDMA:shared_process": [],
    "2C2DNH7EH:shared_process": [],
    "2C2J776HS:shared_process": [],
    "2C24HD65R:shared_process": [],
    "2C33UV8C1:shared_process": []
  },
  "config": {
    "looknfeel": "default"
  },
  "info": {}
}